var images_info;if (!images_info) images_info =[]; images_info["95"]={"95000":{"type":"graphic_figure","displayName":"Sickle cell trait PI","title":"Sickle cell trait","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sickle cell trait</div><div class=\"cntnt\"><img style=\"width:446px; height:506px;\" src=\"images/PI/95000_Sickle_cell_trait_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sickle cell&nbsp;trait happens in people who get the sickle cell gene from&nbsp;one parent and the normal gene from the other parent. Sickle cell anemia happens in people who get the sickle cell gene from both parents. The gene affects a protein called hemoglobin, whose job it is to carry oxygen in the&nbsp;blood. Other types of sickle cell disease can happen in people who get one sickle cell gene plus another abnormal hemoglobin gene.</div><div id=\"graphicVersion\">Graphic 95000 Version 2.0</div></div></div>"},"95001":{"type":"graphic_table","displayName":"Diagnostic criteria FASD","title":"Compilation of diagnostic criteria for fetal alcohol spectrum disorders*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Compilation of diagnostic criteria for fetal alcohol spectrum disorders*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">&nbsp;FASD</td> <td class=\"subtitle1_left\" colspan=\"2\">Diagnostic criteria</td> </tr> <tr> <td colspan=\"2\">&nbsp;Fetal alcohol syndrome</td> <td colspan=\"2\"> <p>At least two&nbsp;characteristic facial features</p> <p>Growth retardation</p> <p>Clear evidence of brain&nbsp;involvement</p> <p>Neurobehavioral impairment</p> With or without documented&nbsp;prenatal alcohol exposure</td> </tr> <tr> <td rowspan=\"2\" colspan=\"2\">Partial fetal alcohol syndrome</td> <td colspan=\"2\"> <p><strong>With documented prenatal alcohol exposure:</strong>&nbsp;&nbsp;</p> <ul> <li>At least two characteristic&nbsp;facial features </li> <li>Neurobehavioral impairment </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <p><strong>Without documented prenatal alcohol exposure:</strong></p> <ul> <li>At least two characteristic facial features </li> <li>Growth retardation&nbsp;<strong>or</strong> clear evidence of brain involvement </li> <li>Neurobehavioral impairment </li> </ul> </td> </tr> <tr> <td colspan=\"2\">Alcohol-related neurodevelopmental disorder</td> <td colspan=\"2\"> <p>Documented prenatal alcohol exposure</p> <p>Neurobehavioral impairment</p> <p>(This diagnosis cannot be definitively diagnosed in children &#60;3 years of age)</p> </td> </tr> <tr> <td colspan=\"2\">Alcohol-related birth defects</td> <td colspan=\"2\"> <p>Documented prenatal alcohol exposure</p> <p>At least one specific major malformation associated with prenatal alcohol exposure</p> </td> </tr> <tr> <td colspan=\"2\">Neurobehavioral disorder associated with prenatal alcohol exposure<sup>&#182;</sup></td> <td colspan=\"2\"> <p>Documented prenatal alcohol exposure&nbsp;</p> <p>Neurobehavioral impairment&nbsp;and onset in childhood</p> <p>Facial features, growth retardation, and clear evidence of brain involvement not necessary (but may be present)</p> <p>Not better explained by other teratogens, genetic or medical conditions, or environmental neglect</p> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">&nbsp;Definition of clinical features</td> </tr> <tr> <td colspan=\"2\">&nbsp;Characteristic facial features</td> <td colspan=\"2\"> <p>Short palpebral fissures<sup>&#916;</sup></p> <p>Thin vermillion border (University of Washington Lip-Philtrum rank 4 or 5)</p> Smooth philtrum (University of Washington Lip-Philtrum rank 4 or 5)</td> </tr> <tr> <td colspan=\"2\">&nbsp;Growth retardation</td> <td colspan=\"2\">Height and/or weight (adjusted for gestational age) &#8804;10<sup>th</sup> percentile for age, sex, race/ethnicity at any point of time (eg, prenatal or postnatal)</td> </tr> <tr> <td rowspan=\"3\">&nbsp;CNS involvement</td> <td rowspan=\"2\">Clear evidence of brain involvement</td> <td class=\"subtitle2_left\">For FAS and pFAS</td> <td class=\"subtitle2_left\">For ND-PAE</td> </tr> <tr> <td>Structural&nbsp;or neurologic involvement&nbsp;(one of the following): <ul class=\"decimal_heading\"> <li>Head circumference &#8804;10<sup>th</sup> percentile for age and sex, or, if weight and height are &#60;10<sup>th</sup> percentile, head circumference &#8804;3<sup>rd</sup> percentile </li> <li>Significant structural abnormalities on neuroimaging </li> <li>Hard or soft neurologic signs<sup>&#9674;</sup> </li> <li>Recurrent seizures that are not due to postnatal insult or fever </li> </ul> </td> <td>NA</td> </tr> <tr> <td>Neurobehavioral impairment</td> <td>Functional abnormalities (one of the following): <ul> <li>Significant global cognitive or intellectual deficits </li> <li>Significant developmental delay<sup>&#167;</sup> </li> <li>Functional deficits<sup>&#165;</sup> in at least three of the following domains: <ul> <li>Cognitive or developmental deficits or discrepancies </li> <li>Executive functioning deficits </li> <li>Motor functioning delays </li> <li>Problems with attention or hyperactivity </li> <li>Social skills </li> <li>Other, such as sensory problems, pragmatic language problems, memory deficits, etc </li> </ul> </li> <li>Evidence of significant impairment of self-regulation in at least one of the following domains: <ul> <li>Mood or behavioral regulation impairment </li> <li>Attention deficit </li> <li>Impulse control </li> </ul> </li> </ul> </td> <td>Functional impairments/deficits in each of the following domains: Neurocognitive (at least one): <ul class=\"decimal_heading\"> <li>Intellectual disability </li> <li>Executive functioning </li> <li>Learning </li> <li>Memory </li> <li>Visual-spatial reasoning </li> </ul> Self-regulation (at least one): <ul class=\"decimal_heading\"> <li>Mood or behavioral regulation </li> <li>Attention </li> <li>Impulse control </li> </ul> Adaptive function (at least two): <ul class=\"decimal_heading\"> <li>Communication </li> <li>Social communication and interaction </li> <li>Daily living skills </li> <li>Motor skills </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FASD: fetal alcohol spectrum disorder; CNS: central nervous system; FAS: fetal alcohol syndrome; pFAS: partial FAS; ND-PAE: neurobehavioral disorder associated with prenatal alcohol exposure; NA: not applicable.<br />* Diagnostic criteria may vary geographically. Refer to UpToDate content on diagnosis of fetal alcohol spectrum disorder for details. <br />¶ Sometimes called \"neurodevelopmental disorder associated with prenatal alcohol exposure.\" This category is similar to alcohol-related neurodevelopmental disorder, but does not overlap completely.<br />Δ The definition of short palpebral fissures varies according to the diagnostic schema.<br /><FONT class=lozenge>◊</FONT> \"Hard\" neurologic signs include abnormal reflexes, abnormal tone, cranial nerve deficits; \"soft\" neurologic signs include poor coordination or balance, visual-motor difficulties, nystagmus, difficulty with motor sequencing or rapid successive movements, right-left confusion.<br />§ The definition of significant developmental delay varies according to the diagnostic criteria.<br />¥ The definition of functional deficit varies according to the diagnostic criteria.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Psychiatric Association. Neurobehavioral disorder associated with prenatal alcohol exposure. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013. p.798.</LI>&#xD;&#xA;<LI>Astley SJ. Diagnosis of Fetal Alcohol Spectrum Disorders (FASD): The 4-Digit Diagnostic Code, 3<SUP>rd</SUP> edition. University of Washington Publication Services, Seattle, 2004.</LI>&#xD;&#xA;<LI>Bertrand J, Floyd RL, Weber MK, et al. National Task Force on Fetal alcohol syndrome and fetal alcohol effect. Fetal alcohol syndrome: Guidelines for referral and diagnosis. Center for Disease Control and Prevention; Atlanta, GA, 2004. Available at: <A href=\"http://www.cdc.gov/ncbddd/fasd/documents/fas_guidelines_accessible.pdf\" target=_blank>www.cdc.gov/ncbddd/fasd/documents/fas_guidelines_accessible.pdf</A> (Accessed on February 24, 2014).</LI>&#xD;&#xA;<LI>Hoyme HE, May PA, Kalberg WO, et al. A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: Clarification of the 1996 institute of medicine criteria. Pediatrics 2005; 115:39. </LI>&#xD;&#xA;<LI>Hoyme HE, Kalberg WO, Elliot AJ, et al. Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders. Pediatrics 2016; 138.</LI>&#xD;&#xA;<LI>Hagan JF Jr, Balachova T, Bertrand J, et al. Neurobehavioral Disorder Associated With Prenatal Alcohol Exposure. Pediatrics 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 95001 Version 7.0</div></div></div>"},"95002":{"type":"graphic_table","displayName":"Spiritual distress","title":"Categories of spiritual distress","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of spiritual distress</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnoses (primary)</td> <td class=\"subtitle1\">Key feature from history</td> <td class=\"subtitle1\">Example statements</td> </tr> <tr class=\"divider_bottom\"> <td>Existential concerns</td> <td> <p>Lack of meaning</p> <p>Questions meaning about one's own existence</p> <p>Concern about afterlife</p> <p>Questions the meaning of suffering</p> Seeks spiritual assistance</td> <td> <p>\"My life is meaningless.\"</p> \"I feel useless.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Abandonment by God or others</td> <td> <p>Lack of love, loneliness</p> <p>Not being remembered</p> No sense of relatedness</td> <td> <p>\"God has abandoned me.\"</p> <p>\"No one comes by anymore.\"</p> \"I am so alone.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Anger at God or others</td> <td> <p>Displaces anger toward religious representatives or others</p> Inability to forgive</td> <td>\"Why would God take my child...it's not fair.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Concerns about relationship with deity</td> <td>Desires closeness to God, deepening relationship</td> <td> <p>\"I want to have a deeper relationship with God.\"</p> \"I want to understand my spirituality more.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Conflicted or challenged belief systems</td> <td> <p>Verbalizes inner conflicts or questions about beliefs of faith</p> <p>Conflicts between religious beliefs and recommended treatments</p> <p>Questions moral or ethical implications of therapeutic regimen</p> Expresses concern with life/death or belief system</td> <td> <p>\"I am not sure if God is with me anymore.\"</p> \"I question all that I used to hold as meaningful.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Despair/hopelessness</td> <td> <p>Hopelessness about future health, life</p> <p>Despair as absolute hopelessness</p> No hope for value of life</td> <td> <p>\"Life is being cut short.\"</p> \"There is nothing left for me to live for.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Grief/loss</td> <td>The feeling and process associated with the loss of a person, health, relationship</td> <td> <p>\"I miss my loved one so much.\"</p> \"I wish I could run again.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Guilt/shame</td> <td> <p>Feeling that one has done something wrong or evil</p> Feeling that one is bad or evil</td> <td>\"I do not deserve to die pain free.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Reconciliation</td> <td>Need for forgiveness or reconciliation from self or others</td> <td> <p>\"I need to be forgiven for what I did.\"</p> \"I would like my wife to forgive me.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Isolation</td> <td>Separated from religious community or other community</td> <td> <p>\"Since moving to the assisted living, I am not able to go to my church anymore.\"</p> \"I have moved and no longer can go to my usual 12-step meeting.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Religious specific</td> <td> <p>Ritual needs</p> Unable to perform usual religious practices</td> <td>\"I just can't pray anymore.\"</td> </tr> <tr> <td>Religious/spiritual struggle</td> <td> <p>Loss of faith or meaning</p> Religious or spiritual beliefs or community not helping with coping</td> <td>\"What if all that I believe is not true?\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Puchalski C, Ferrell B, Virani R, et al. Improving the Quality of Spiritual Care as a Dimension of Palliative Care: The Report of the Consensus Conference. J Palliat Med 2009; 12:885. Copyright &copy; 2009 Mary Ann Liebert, Inc. Publishers.</div><div id=\"graphicVersion\">Graphic 95002 Version 2.0</div></div></div>"},"95013":{"type":"graphic_table","displayName":"Spiritual treatment plan","title":"The biopsychosocial and spiritual assessment and treatment plan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The biopsychosocial and spiritual assessment and treatment plan</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Patient: Ronda is a 52-year-old with end stage ovarian cancer.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><strong>Physical</strong></td> <td> <p>Assessment: Pain is well controlled.</p> Plan: Continue with current medication regimen.</td> </tr> <tr> <td> <p>Assessment: Nausea; still has episodes of nausea and vomiting, likely secondary to partial small bowel obstruction (SBO).</p> Plan: Add octreotide to current regimen.</td> </tr> <tr> <td class=\"indent1\"><strong>Psychological</strong></td> <td> <p>Assessment: Grief reaction that \"fight is over.\" Tearful at times in visit but denies depression, no suicidal ideation, some difficulty sleeping but able to manage the sleep with music tapes. Reaction appropriate for her situation.&nbsp;Patient has strong coping skills and good support system.</p> Plan: Supportive counseling, continue monitoring for worsening of hopelessness, ability to enjoy things, guilt.</td> </tr> <tr> <td class=\"indent1\"><strong>Social</strong></td> <td> <p>Assessment: Ronda concerned about how to tell her family that she is dying. While her relationships with her family are strong, Ronda is fearful of causing pain to her family. Patient has strong family support.</p> Plan: Work with social work to arrange family meeting.</td> </tr> <tr> <td class=\"indent1\"><strong>Spiritual</strong></td> <td> <p>Assessment: Hopelessness, main source of meaning in \"winning the fight\", active in ovarian cancer alliance and seen as inspiration. This has been a source of hope. She has strong spiritual coping skills in past when husband died unexpectedly. Though not religious, she now wants to learn how \"Jewish patients die?\"</p> Plan: Dream List, legacy building, encourage talking with Ovarian Cancer Alliance, referral to chaplain and to Rabbi.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is a patient-based example of the biopsychosocial assessment and treatment plan, which incorporates the psychosocial and spiritual components.</div><div id=\"graphicVersion\">Graphic 95013 Version 3.0</div></div></div>"},"95022":{"type":"graphic_table","displayName":"CAP uterine sarcoma classific","title":"College of American Pathologists classification system for uterine sarcomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">College of American Pathologists classification system for uterine sarcomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Histologic type (more than one may apply)</td> </tr> <tr> <td class=\"indent1\">Leiomyosarcoma</td> </tr> <tr> <td class=\"indent1\">Low-grade endometrial stromal sarcoma*</td> </tr> <tr> <td class=\"indent1\">Low-grade endometrial stromal sarcoma with: <ul class=\"decimal_heading\"> <li>Smooth muscle differentiation</li> <li>Sex cord elements</li> <li>Glandular elements</li> <li>Other (specify)</li> </ul> </td> </tr> <tr> <td class=\"indent1\">High-grade endometrial stromal sarcoma</td> </tr> <tr> <td class=\"indent1\">Undifferentiated uterine/endometrial sarcoma</td> </tr> <tr> <td class=\"indent1\">Adenosarcoma</td> </tr> <tr> <td class=\"indent1\">Adenosarcoma with: <ul class=\"decimal_heading\"> <li>Rhabdomyoblastic differentiation</li> <li>Cartilaginous differentiation</li> <li>Osseous differentiation</li> <li>Other heterologous element (specify)</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Adenosarcoma with sarcomatous overgrowth</td> </tr> <tr> <td class=\"indent1\">Other (specify)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Low-grade endometrial sarcoma is distinguished from benign endometrial stromal nodule by infiltration into the surrounding myometrium and/or lymphovascular invasion. Minor marginal irregularity in the form of tongues &lt;3 mm (up to three) is allowable for an endometrial stromal nodule. This protocol does not apply to endometrial.</div><div class=\"graphic_reference\">Source:<br /><ol>&#xD;&#xA;    <li>Tavassoli FA, Devilee P. World Health Organization Classification of Tumors, Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2003. </li>&#xD;&#xA;    <li>Otis C, Ocampo A. Protocol for the Examination of Specimens From Patients With Sarcoma of the Uterus, 2013. College of American pathologists, 2013. Available at: <a href=\"http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/UterineSarcomaProtocol_3000.pdf\" target=\"_blank\">http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/UterineSarcomaProtocol_3000.pdf</a> (Accessed on April 29, 2014).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 95022 Version 1.0</div></div></div>"},"95023":{"type":"graphic_table","displayName":"WHO uterine tumor classific","title":"WHO Classification of tumors of the uterine corpus*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO Classification of tumors of the uterine corpus*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Epithelial tumors and precursors</td> </tr> <tr> <td class=\"subtitle2_single\">Precursors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hyperplasia without atypia </li> <li>Atypical hyperplasia/endometrioid intraepithelial neoplasia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Endometrial carcinomas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Endometrioid carcinoma <ul> <li>Squamous differentiation </li> <li>Villoglandular </li> <li>Secretory </li> </ul> </li> <li>Mucinous carcinoma </li> <li>Serous endometrial intraepithelial carcinoma </li> <li>Serous carcinoma </li> <li>Clear cell carcinoma </li> <li>Neuroendocrine tumors <ul> <li>Low-grade neuroendocrine tumor <ul> <li>Carcinoid tumor </li> </ul> </li> <li>High-grade neuroendocrine tumor <ul> <li>Small cell neuroendocrine carcinoma </li> <li>Large cell neuroendocrine carcinoma </li> </ul> </li> </ul> </li> <li>Mixed cell adenocarcinoma </li> <li>Undifferentiated carcinoma </li> <li>Dedifferentiated carcinoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Tumor-like lesions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Polyp </li> <li>Metaplasias </li> <li>Arias-Stella reaction </li> <li>Lymphoma-like lesion </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mesenchymal tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Leiomyoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Cellular leiomyoma </li> <li>Leiomyoma with bizarre nuclei </li> <li>Mitotically active leiomyoma </li> <li>Hydropic leiomyoma </li> <li>Apoplectic leiomyoma </li> <li>Lipomatous leiomyoma (lipoleiomyoma) </li> <li>Epithelioid leiomyoma </li> <li>Myxoid leiomyoma </li> <li>Dissecting (cotyledonoid) leiomyoma </li> <li>Diffuse leiomyomatosis </li> <li>Intravenous leiomyomatosis </li> <li>Metastasizing leiomyoma </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_single\">Smooth muscle tumor of uncertain malignant potential</td> </tr> <tr> <td class=\"subtitle2_single\">Leiomyosarcoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Epithelioid leiomyosarcoma </li> <li>Myxoid leiomyosarcoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Endometrial stromal and related tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Endometrial stromal nodule </li> <li>Low-grade endometrial stromal sarcoma </li> <li>High-grade endometrial stromal sarcoma </li> <li>Undifferentiated uterine sarcoma </li> <li>Uterine tumor resembling ovarian sex cord tumor </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous mesenchymal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Rhabdomyosarcoma </li> <li>Perivascular epithelioid cell tumor <ul> <li>Benign </li> <li>Malignant </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_single\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Mixed epithelial and mesenchymal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adenomyoma </li> <li>Atypical polypoid adenomyoma </li> <li>Adenofibroma </li> <li>Adenosarcoma </li> <li>Carcinosarcoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adenomatoid </li> <li>Neuroectodermal tumors </li> <li>Germ cell tumors </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Lymphoid and myeloid tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Lymphomas </li> <li>Myeloid neoplasms </li> </ul> </td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\"><strong>Secondary tumors</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization.<br />* The classification is modified from the previous WHO classification of tumors, taking into account changes in our understanding of these lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Kurman RJ, Carcangiu ML, Herrington S, Young RH. World Health Organization Classification of Tumours of the Female Reproductive Organs. IARC, Lyon, 2014. Copyright &copy; 2014.</div><div id=\"graphicVersion\">Graphic 95023 Version 2.0</div></div></div>"},"95024":{"type":"graphic_figure","displayName":"Grain taxonomy","title":"Grain taxonomy","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Grain taxonomy</div><div class=\"cntnt\"><img style=\"width:754px; height:370px;\" src=\"images/ALLRG/95024_Grain_taxonomy.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 95024 Version 1.0</div></div></div>"},"95025":{"type":"graphic_picture","displayName":"Granuloma faciale nose","title":"Granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95025_Granuloma_faciale_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown plaque with follicular prominence on the nose. A biopsy site of a smaller lesion is adjacent to the plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95025 Version 1.0</div></div></div>"},"95026":{"type":"graphic_picture","displayName":"Granuloma faciale on nose","title":"Granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95026_Granuloma_faciale_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown plaque with telangiectasias on the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95026 Version 1.0</div></div></div>"},"95027":{"type":"graphic_picture","displayName":"Granuloma faciale forehead","title":"Granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95027_Granuloma_faciale_forehead.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smooth, red-brown plaque on the forehead.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95027 Version 1.0</div></div></div>"},"95028":{"type":"graphic_picture","displayName":"Granuloma faciale papules","title":"Granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95028_Granuloma_faciale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple smooth, red-brown papules on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95028 Version 1.0</div></div></div>"},"95029":{"type":"graphic_picture","displayName":"Pseudolymphoma","title":"Pseudolymphoma (cutaneous lymphoid hyperplasia)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pseudolymphoma (cutaneous lymphoid hyperplasia)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95029_Pseudolymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodule on the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95029 Version 2.0</div></div></div>"},"95030":{"type":"graphic_table","displayName":"Fetal soft markers of aneuploidy on second trimester ultrasound ","title":"Fetal soft markers of aneuploidy on second trimester ultrasound examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal soft markers of aneuploidy&nbsp;on second trimester ultrasound examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Soft marker</td> <td class=\"subtitle1\">Imaging criteria</td> <td class=\"subtitle1\">Aneuploidy association</td> <td class=\"subtitle1\">Management</td> </tr> <tr class=\"divider_bottom\"> <td>First trimester: enlarged nuchal translucency</td> <td>Certified ultrasonography measurement &#8805;3.0 mm or above the 99<sup>th</sup> percentile for the CRL</td> <td> <ul> <li>Aneuploidy risk increases with size of NT </li> <li>Also associated with Noonan syndrome, multiple pterygium syndrome, skeletal dysplasias, congenital heart disease, and other anomalies </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Genetic counseling </li> <li>Offer cfDNA or CVS </li> <li>Second-trimester detailed anatomic survey and fetal cardiac ultrasonography </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>First trimester: cystic hygroma</td> <td>Large single or multilocular fluid-filled cavities, in the nuchal region and can extend the length of the fetus</td> <td> <ul> <li>If septate, approximately 50% are aneuploid </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Genetic counseling </li> <li>Offer CVS </li> <li>Second-trimester detailed fetal anatomic survey and fetal cardiac ultrasonography </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Second trimester: echogenic intracardiac foci</td> <td>Echogenic tissue in one or both ventricles of the heart seen on standard four-chamber view</td> <td> <ul> <li>LR 1.4 to 1.8 for Down syndrome </li> <li>Seen in 15 to 30% of Down syndrome and 4 to 7% euploid fetuses </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>If isolated finding, aneuploidy screening should be offered if not done previously </li> <li>If aneuploidy screen result is negative, no further evaluation is required </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Second trimester: pyelectasis</td> <td>Renal pelvis measuring &#8805;4 mm in anteroposterior diameter up to 30 weeks of gestation (&#62;7 mm after 30 weeks)</td> <td> <ul> <li>LR 1.5 to 1.6 for Down syndrome </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>If isolated finding, aneuploidy screening should be offered if not performed previously </li> <li>Repeat ultrasonography in third trimester for potential urinary tract obstruction </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Second trimester: echogenic bowel</td> <td>Fetal small bowel as echogenic as bone</td> <td> <ul> <li>LR 5.5 to 6.7 for Down syndrome </li> <li>Associated with aneuploidy, intra-amniotic bleeding, CF, CMV </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Further counseling </li> <li>Offer CMV, CF, and aneuploidy screening or diagnostic testing </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Second trimester: thickened nuchal fold</td> <td>&#8805;6 mm from outer edge of the occipital bone to outer skin in the midline</td> <td> <ul> <li>LR 11 to 18.6 with 40 to 50% sensitivity and &#62;99% specificity for Down syndrome </li> <li>Most powerful second-trimester marker </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Detailed anatomic survey </li> <li>Further detailed genetic counseling and aneuploidy screening or diagnostic testing </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Second trimester: mild ventriculomegaly</td> <td>Lateral ventricular atrial measurement between 10 to 15 mm</td> <td> <ul> <li>Associated with aneuploidy </li> <li>LR 25 for Down syndrome </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Genetic counseling </li> <li>Second-trimester detailed anatomic ultrasound evaluation </li> <li>Consider diagnostic testing for aneuploidy and CMV </li> <li>Repeat ultrasound in third trimester </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Second trimester: choroid plexus cysts</td> <td>Discrete cyst(s) in one or both choroid plexus(es)</td> <td> <ul> <li>In isolation, no aneuploidy association </li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Second-trimester detailed anatomic survey&nbsp;including fetal cardiac ultrasound (echocardiogram not required) </li> <li>No further follow-up if isolated </li> <li>Consider aneuploidy screening or diagnostic testing if other markers are present </li> </ol> </td> </tr> <tr> <td>Second trimester: short femur length</td> <td>Measurement &#60;2.5<sup>th</sup> percentile for gestational age</td> <td> <ul> <li>LR 1.2 to 2.2 for Down syndrome; can be associated with aneuploidy, IUGR, short limb dysplasia</li> </ul> </td> <td> <ol class=\"numbers_to_nine\"> <li>Second-trimester detailed fetal anatomic evaluation for short limb dysplasia </li> <li>Further detailed counseling </li> <li>Consider repeat ultrasonography in third trimester for fetal growth </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There is some controversy as to whether cystic hygroma and&nbsp;enlarged nuchal translucency are the same or different entities, but the work-up is the same. Criteria for short femur length vary; there is no universal standard.</div><div class=\"graphic_footnotes\">CRL: crown-rump length; NT: nuchal translucency; cfDNA: cell-free DNA; CVS: chorionic villus sampling; LR: likelihood ratio; CMV: cytomegalovirus; CF: cystic fibrosis; IUGR: intrauterine growth restriction.</div><div class=\"graphic_reference\">Adapted from: American College of Obstetricians and Gynecologists. Practice Bulletin No. 163: Screening for fetal aneuploidy. Obstet Gynecol 2016; 127:e123. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2016&amp;issue=05000&amp;article=00041&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000001406</A>. Copyright © 2016 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95030 Version 4.0</div></div></div>"},"95031":{"type":"graphic_picture","displayName":"Cutaneous B-cell lymphoma","title":"Cutaneous B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Cutaneous B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95031_Cutaneous_B-cell_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodule on the preauricular skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95031 Version 1.0</div></div></div>"},"95035":{"type":"graphic_table","displayName":"Contraindications to thrombolysis","title":"Contraindications to fibrinolytic therapy for deep venous thrombosis or acute pulmonary embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to fibrinolytic therapy for deep venous thrombosis or acute pulmonary embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute contraindications</td> </tr> <tr> <td class=\"indent1\">Prior intracranial hemorrhage</td> </tr> <tr> <td class=\"indent1\">Known structural cerebral vascular lesion</td> </tr> <tr> <td class=\"indent1\">Known malignant intracranial neoplasm</td> </tr> <tr> <td class=\"indent1\">Ischemic stroke within three months (excluding stroke within three hours*)</td> </tr> <tr> <td class=\"indent1\">Suspected aortic dissection</td> </tr> <tr> <td class=\"indent1\">Active bleeding or bleeding diathesis (excluding menses)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Significant closed-head trauma or facial trauma within three months</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td class=\"indent1\">History of chronic, severe, poorly controlled hypertension</td> </tr> <tr> <td class=\"indent1\">Severe uncontrolled hypertension on presentation (SBP &#62;180 mmHg or DBP &#62;110 mmHg)</td> </tr> <tr> <td class=\"indent1\">History of ischemic stroke more than three months prior</td> </tr> <tr> <td class=\"indent1\">Traumatic or prolonged (&#62;10 minute) CPR or major surgery less than three weeks</td> </tr> <tr> <td class=\"indent1\">Recent (within two to four weeks) internal bleeding</td> </tr> <tr> <td class=\"indent1\">Noncompressible vascular punctures</td> </tr> <tr> <td class=\"indent1\">Recent invasive procedure</td> </tr> <tr> <td class=\"indent1\">For streptokinase/anistreplase - Prior exposure (more than five days ago) or prior allergic reaction to these agents</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Active peptic ulcer</td> </tr> <tr> <td class=\"indent1\">Pericarditis or pericardial fluid</td> </tr> <tr> <td class=\"indent1\">Current use of anticoagulant (eg, warfarin sodium) that has produced an elevated international normalized ratio (INR) &#62;1.7 or prothrombin time (PT) &#62;15 seconds</td> </tr> <tr> <td class=\"indent1\">Age &#62;75 years</td> </tr> <tr> <td class=\"indent1\">Diabetic retinopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SBP: systolic blood pressure; DBP: diastolic blood pressure; CPR: cardiopulmonary resuscitation.<br />* The American College of Cardiology suggests that select patients with stroke may benefit from thrombolytic therapy within 4.5 hours of the onset of symptoms.</div><div class=\"graphic_reference\">Reproduced with permission from the American College of Chest Physicians. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 95035 Version 4.0</div></div></div>"},"95037":{"type":"graphic_table","displayName":"Weekly paclitaxel for unresectable angiosarcoma","title":"Weekly paclitaxel for unresectable angiosarcoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weekly paclitaxel for unresectable angiosarcoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline or 5% dextrose in water (D5W)* and administer over one hour; special tubing needed.<sup>&#182;</sup></td> <td>Days 1, 8, and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW (10 to 30% frequency of emesis).</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not generally warranted except in highest risk patients. In the original publication, febrile neutropenia was observed in only 2 of 30 patients during the first two cycles.<sup>[1]</sup></li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential prior to treatment weekly during each cycle.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess serum electrolytes prior to treatment weekly during each cycle.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess renal and liver function prior to treatment weekly during each cycle.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess for neurologic toxicity prior to each treatment.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, new cycles were not started unless granulocyte count was &#62;1500 cells/microL and platelets &#62;100,000/microL.<sup>[1]</sup> For grade 3 or 4 toxicity, the weekly paclitaxel dose was reduced to 70 mg/m<sup>2</sup>, and then to 60 mg/m<sup>2</sup> for a second episode of toxicity.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Peripheral neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>The development of severe symptomatic peripheral neuropathy requires a dose reduction of 20% for all subsequent courses of paclitaxel or may be cause for discontinuation of paclitaxel therapy.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For any other grade 3 or 4 toxicity, paclitaxel dose was reduced to 70 mg/m<sup>2</sup> and then to 60 mg/m<sup>2</sup> for a second episode of that toxicity.<sup>[1]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte-colony stimulating factors; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />¶ Paclitaxel can be administered in normal saline, D5W, or normal saline/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Penel N, et al. J Clin Oncol 2008; 26:5269.</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed May 20, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 95037 Version 5.0</div></div></div>"},"95038":{"type":"graphic_algorithm","displayName":"Cervical cancer in pregnancy management","title":"Approach to invasive cervical cancer diagnosed in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Approach to invasive cervical cancer diagnosed in pregnancy</div><div class=\"cntnt\"><img style=\"width:591px; height:457px;\" src=\"images/ONC/95038_Appr_inv_cerv_cancer_pregn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Stage based on International Federation of Gynecologic Oncology (FIGO) system.<br />&para; Due to the risks associated with disease progression, patients should be offered termination of pregnancy and definitive treatment as an alternative option to neoadjuvant chemotherapy.</div><div id=\"graphicVersion\">Graphic 95038 Version 2.0</div></div></div>"},"95039":{"type":"graphic_picture","displayName":"Villitis of unknown etiology","title":"Villitis of unknown etiology","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Villitis of unknown etiology</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/OBGYN/95039_Villitis_unknown_etiology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy mild villitis of unknown etiology.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 95039 Version 1.0</div></div></div>"},"95041":{"type":"graphic_diagnosticimage","displayName":"Brain MRI showing PRES","title":"Brain MRI images showing posterior reversible encephalopathy syndrome in AIP","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Brain MRI images showing posterior reversible encephalopathy syndrome in AIP</div><div class=\"cntnt\"><img style=\"width:566px; height:635px;\" src=\"images/HEME/95041_MRI_of_AIP_with_PRES.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Brain MRI with axial FLAIR sequences showing hyperintensities scattered in the subcortical white matter of the frontal and parietal lobes and prominent geographic subcortical hyperintensities in bilateral occipital lobes.<br />(C, D) These FLAIR lesions recovered after one year. May be due to vasospasm.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; AIP: acute intermittent porphyria; PRES: posterior reversible encephalopathy syndrome; FLAIR: fluid attenuated inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Kuo HC, Huang CC, Chu CC, et al. Neurological complications of acute intermittent porphyria. Eur Neurol 2011; 66:247. Copyright © 2011 Karger Publishers, Basel, Switzerland. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95041 Version 3.0</div></div></div>"},"95066":{"type":"graphic_picture","displayName":"Angiokeratoma-male","title":"Angiokeratoma involving the scrotum of a male patient","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Angiokeratoma involving the scrotum of a male patient</div><div class=\"cntnt\"><img style=\"width:600px; height:480px;\" src=\"images/ONC/95066_Angiokeratoma_male.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Curtis A Pettaway, MD.</div><div id=\"graphicVersion\">Graphic 95066 Version 1.0</div></div></div>"},"95067":{"type":"graphic_picture","displayName":"Scrotal extramammary Paget disease","title":"Scrotal extramammary Paget's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scrotal extramammary Paget's disease</div><div class=\"cntnt\"><img style=\"width:392px; height:590px;\" src=\"images/ONC/95067_Scrotal_extramammary_Paget.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Curtis A. Pettaway, MD.</div><div id=\"graphicVersion\">Graphic 95067 Version 2.0</div></div></div>"},"95068":{"type":"graphic_table","displayName":"ASCO recommendations for prevention and management of CIPN","title":"ASCO recommendations for prevention and management of chemotherapy-induced peripheral neuropathy (CIPN) from the American Society of Clinical Oncology (ASCO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASCO recommendations for prevention and management of chemotherapy-induced peripheral neuropathy (CIPN) from the American Society of Clinical Oncology (ASCO)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Prevention of CIPN</td> </tr> <tr> <td>There are no established agents recommended for the prevention of CIPN in patients with cancer undergoing treatment with neurotoxic agents. This is based on the paucity of high-quality, consistent evidence and a balance of benefits versus harms.</td> </tr> <tr> <td>Clinicians should <strong>not</strong> offer the following agents for the prevention of CIPN to patients with cancer undergoing treatment with neurotoxic agents:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Acetyl-L-carnitine (ALC) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Amifostine </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Amitriptyline </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>CaMg for patients receiving oxaliplatin-based chemotherapy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Diethyldithio-carbamate (DDTC) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Glutathione (GSH) for patients receiving paclitaxel/carboplatin chemotherapy </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Nimodipine </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Org 2766 </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>All-<em>trans</em>-retinoic acid </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Recombinant human leukemia inhibitory factor (rhuLIF) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Vitamin E </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Venlafaxine is not recommended for routine use in clinical practice. Although the venlafaxine data support its potential utility, the data were not strong enough to recommend its use in clinical practice, until additional supporting data become available. </li> <li>No recommendations can be made on the use of <em>N</em>-acetylcysteine, carbamazepine, glutamate, GSH for patients receiving cisplatin or oxaliplatin-based chemotherapy, goshajinkigan (GJG), omega-3 fatty acids, or oxycarbazepine for the prevention of CIPN at this time. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of CIPN</td> </tr> <tr> <td>For patients with cancer experiencing CIPN, clinicians may offer duloxetine.</td> </tr> <tr> <td>No recommendations can be made on the use of:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>ALC, noting that a positive phase III abstract supported its value, but this work has not yet been published in a peer-reviewed journal, and a prevention trial suggested that this agent was associated with worse outcomes. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Tricyclic antidepressants; however, based on the limited options that are available for this prominent clinical problem and the demonstrated efficacy of these drugs for other neuropathic pain conditions, it is reasonable to try a tricyclic antidepressant (eg, nortriptyline or desipramine) in patients suffering from CIPN after a discussion with the patients about the limited scientific evidence for CIPN, potential harms, benefits, cost, and patient preferences. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Gabapentin, noting that the available data were limited regarding its efficacy for treating CIPN. However, the panel felt that this agent is reasonable to try for selected patients with CIPN pain given that only a single negative randomized trial for this agent was completed, the established efficacy of gabapentin and pregabalin for other forms of neuropathic pain, and the limited CIPN treatment options. Patients should be informed about the limited scientific evidence for CIPN, potential harms, benefits, and costs. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>A topical gel treatment containing baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 mg), noting that a single trial indicated that this product did decrease CIPN symptoms. Given the available data, the panel felt that this agent is reasonable to try for selected patients with CIPN pain. Patients should be informed about the limited scientific evidence for the treatment of CIPN, potential harms, benefits, and costs. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Hershman D, et al: J Clin Oncol 2014. DOI: 10.1200/JCO.2013.54.0914. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95068 Version 2.0</div></div></div>"},"95072":{"type":"graphic_table","displayName":"Neuropsychiatric symptoms of dementia","title":"Neuropsychiatric symptoms of dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuropsychiatric symptoms of dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Delusions</td> </tr> <tr> <td>Hallucinations</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Anxiety</td> </tr> <tr> <td>Euphoria</td> </tr> <tr> <td>Aggression</td> </tr> <tr> <td>Apathy</td> </tr> <tr> <td>Irritability</td> </tr> <tr> <td>Disinhibition</td> </tr> <tr> <td>Wandering or pacing</td> </tr> <tr> <td>Sleep disturbances</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95072 Version 1.0</div></div></div>"},"95079":{"type":"graphic_algorithm","displayName":"Strategies rhythm control paroxysmal persistent AF","title":"Strategies for rhythm control in patients with paroxysmal* and persistent AF<SUP>¶</SUP>","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Strategies for rhythm control in patients with paroxysmal* and persistent AF<SUP>¶</SUP></div><div class=\"cntnt\"><img style=\"width:587px; height:267px;\" src=\"images/CARD/95079_Stratrhythmcontrolparoxy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AF: atrial fibrillation; CAD: coronary artery disease; HF: heart failure; LVH: left ventricular hypertrophy; AV: atrioventricular.<br />* Catheter ablation is only recommended as first-line therapy for patients with paroxysmal AF (Class IIa recommendation).<br />¶ Drugs are listed alphabetically.<br />Δ Depending on patient preference when performed in experienced centers.<br /><FONT class=lozenge>◊</FONT> Not recommended with severe LVH (wall thickness &gt;1.5 cm).<br />§ Should be used with caution in patients at risk for torsades de pointes ventricular tachycardia.<br />¥ Should be combined with AV nodal blocking agents.</div><div class=\"graphic_reference\">Reproduced from: January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014. DOI: 10.1016/j.jacc.2014.03.021. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95079 Version 3.0</div></div></div>"},"95082":{"type":"graphic_table","displayName":"SLIT-tablet labeling differences","title":"Sublingual immunotherapy (SLIT) tablets: Labeling differences among United States products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sublingual immunotherapy (SLIT) tablets: Labeling differences among United States products</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Grastek</td> <td class=\"subtitle1\">Odactra</td> <td class=\"subtitle1\">Oralair</td> <td class=\"subtitle1\">Ragwitek</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Components</strong></td> <td>Timothy grass pollen extract. Cross-reactive with: <ul class=\"decimal_heading\"> <li>Timothy</li> <li>Orchard</li> <li>Kentucky Blue</li> <li>Perennial Rye</li> <li>Sweet Vernal</li> <li>Fescue</li> <li>Redtop</li> </ul> </td> <td>House dust mite allergen extract from <em>Dermatophagoides farinae</em> and <em>D. pteronyssinus</em></td> <td>Pollen extracts of five grasses: <ul class=\"decimal_heading\"> <li>Timothy</li> <li>Orchard</li> <li>Kentucky Blue</li> <li>Perennial Rye</li> <li>Sweet Vernal</li> </ul> </td> <td>Short ragweed pollen extract</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Indications</strong></td> <td>Grass pollen-induced allergic rhinitis with or without conjunctivitis</td> <td>Dust mite-induced allergic rhinitis with or without conjunctivitis</td> <td>Grass pollen-induced allergic rhinitis with or without conjunctivitis</td> <td>Short ragweed pollen-induced allergic rhinitis with or without conjunctivitis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Approved for ages</strong></td> <td>5 to 65 years</td> <td>18 to 65 years</td> <td>10 to 65 years</td> <td>18 to 65 years</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Required testing</strong></td> <td>Positive skin test <strong>or</strong> in vitro testing for IgE antibodies to Timothy grass <strong>or</strong> any of the cross-reactive grass species</td> <td>Positive skin test with a house dust mite extract <strong>or</strong> in vitro testing for IgE antibodies to <em>Dermatophagoides farinae</em> or <em>D. pteronyssinus</em></td> <td>Positive skin test <strong>or</strong> in vitro testing for IgE antibodies to <strong>any</strong> of the 5-grass species in the tablet</td> <td>Positive skin test <strong>or</strong> in vitro testing for IgE antibodies to short ragweed</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dose</strong></td> <td>2800 BAU single dose tablet, daily</td> <td>12 SQ-HDM unit single dose tablet, daily</td> <td> <ul> <li>300 IR in adults (ages: 18 to 65)</li> <li>In children (ages: 10 to 17) step-up over three days, as tolerated: <ul class=\"decimal_heading\"> <li>Day 1: 100 IR</li> <li>Day 2: 2x 100 IR</li> <li>Day 3: 300 IR</li> </ul> </li> </ul> </td> <td>12 Amb a 1 unit single dose tablet, daily</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Method of administration</strong></td> <td>Place tablet under the tongue until it completely dissolves; do <strong>not</strong> swallow for at least one minute</td> <td>Place tablet under the tongue until it completely dissolves; do <strong>not</strong> swallow for at least one minute</td> <td>Place tablet under tongue for at least one minute or until completely dissolved, and then swallow</td> <td>Place tablet under the tongue until it completely dissolves; do <strong>not</strong> swallow for at least one minute</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Initiation</strong></td> <td>12 weeks prior to grass season</td> <td>Can be started anytime</td> <td>16 weeks prior to grass season</td> <td>12 weeks prior to ragweed season</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration</strong></td> <td>Prior to and through relevant grass season; may be continued on a perennial basis over three years for sustained effectiveness</td> <td>Year-round</td> <td>Prior to and through relevant grass season</td> <td>Prior to and through relevant ragweed season</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Data on safety of reinitiating treatment after a missed dose</strong></td> <td>In clinical trials, treatment interruptions for up to seven days were allowed</td> <td>In clinical trials, treatment interruptions for up to seven days were allowed</td> <td>Data not available</td> <td>In clinical trials, treatment interruptions for up to seven days were allowed</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Contraindications</strong></td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Inactive ingredients</strong></td> <td>Gelatin (fish source), mannitol, sodium hydroxide</td> <td>Gelatin (fish source), mannitol, sodium hydroxide</td> <td>Mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, lactose monohydrate</td> <td>Gelatin (fish source), mannitol, sodium hydroxide</td> </tr> <tr> <td><strong>Asthma patients included in clinical trials</strong></td> <td>Not studied in patients with moderate or severe asthma or in patients who require daily medication to treat asthma</td> <td>Trials allowed patients with mild-to-moderate asthma that required, at most, a medium daily dose of an inhaled glucocorticoid to treat asthma</td> <td>Not studied in patients with moderate or severe asthma or in any subjects who require daily medication to treat asthma</td> <td>Trials allowed patients who required daily low doses of inhaled glucocorticoids to treat asthma</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table highlights differences in the product labeling among tablet products for SLIT. Several important safety issues, which are the same for all products, are not included. Please refer to the accompanying UpToDate topic on sublingual immunotherapy for allergic rhinitis for a discussion of additional safety issues, use in patients with asthma, recommendations for administration of initial dose, data on safety of initiating treatment during pollen season, and evaluation of patients with asthma exacerbations or recurrent asthma episodes while receiving SLIT.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; BAU: biologic allergy units; SQ-HDM: standardized units of potency for house dust mite allergen extract; IR: index of reactivity.</div><div id=\"graphicVersion\">Graphic 95082 Version 4.0</div></div></div>"},"95084":{"type":"graphic_algorithm","displayName":"Algorithmic approach to malignant bowel obstruction pall care","title":"An algorithmic approach to clinical management of malignant bowel obstruction in palliative care patients","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">An algorithmic approach to clinical management of malignant bowel obstruction in palliative care patients</div><div class=\"cntnt\"><img style=\"width:662px; height:781px;\" src=\"images/PALC/95084_Malignant_bowel_obstruction.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SBO: small bowel obstruction; LBO: large bowel obstruction.<br />* If evidence of perforation or ischemia is present on plain radiography, cross-sectional imaging may not be necessary.<br />Δ Symptomatic care may include one or more of the following: glucocorticoids, antiemetics (typically haloperidol, not metoclopramide or constipating 5HT3 receptor antagonists), octreotide, anticholinergics, analgesics, +/– gastrointestinal decompression.<br /><FONT class=lozenge>◊</FONT> Stenting is not an option when perforation or ischemia is present.<br />§ Depending upon the location and suspected etiology of the obstruction, immediate surgery or stenting should be considered. Some etiologies, such as closed loop SBO, and most LBO leading to complete obstruction are not likely to resolve with conservative management.<br />¥ Gastrograffin may be more useful for partial SBO related to adhesions. Colorectal obstruction is less likely to respond.<br />‡ Conservative care can continue, as long as there is no clinical deterioration. The duration of conservative management is generally shorter for complete versus partial obstruction, but is highly variable.<br />† Sites amenable to stenting include large bowel, distal ileum, proximal jejunum.</div><div id=\"graphicVersion\">Graphic 95084 Version 1.0</div></div></div>"},"95085":{"type":"graphic_picture","displayName":"Seatbelt sign","title":"Seatbelt sign","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Seatbelt sign</div><div class=\"cntnt\"><img style=\"width:582px; height:430px;\" src=\"images/EM/95085_Seatbelt_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Presence of a seat belt sign is closely associated with significant intra-abdominal injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Nishijima DK, Simel DL, Wisner DH, Holmes JF. Does this adult patient have a blunt intra-abdominal injury? JAMA 2012; 307:1517. Copyright © 2012 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95085 Version 4.0</div></div></div>"},"95109":{"type":"graphic_table","displayName":"Opioid use disorder meds PI","title":"Medicines to treat opioid use disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines to treat opioid use disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medicine name</td> <td class=\"subtitle1\">How used</td> <td class=\"subtitle1\">How it works</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Buprenorphine combined with naloxone<br /> (brand names: Suboxone, Zubsolv)</td> <td> <p>Suboxone: Film that melts under your tongue (lime flavor)</p> Zubsolv: Tablet that melts under your tongue (menthol flavor)</td> <td>This medicine eases drug cravings and helps prevent withdrawal symptoms. It also blocks the effects of opioids, so you cannot get high even if you use drugs.</td> <td> <p>May cause burning or tingling under tongue.</p> Contains naloxone, which prevents misuse of the drug.</td> </tr> <tr class=\"divider_bottom\"> <td>Buprenorphine<br /> (brand name: Probuphine)</td> <td>Implant placed under skin on the inside of the upper arm. One implant gives you a daily dose for 6 months.</td> <td>This medicine eases drug cravings and helps prevent withdrawal symptoms. It also blocks the effects of opioids, so you cannot get high even if you use drugs.</td> <td>The implant can be helpful for people who might stop taking a daily drug.</td> </tr> <tr class=\"divider_bottom\"> <td>Methadone<br /> (brand names: Dolophine, Methadose)</td> <td> <p>Tablet or liquid that you swallow</p> Dissolving tablet is added to fruit juice or water before swallowing.</td> <td>This medicine eases drug cravings and helps prevent withdrawal symptoms. It also makes it less likely that you can get high.</td> <td>People taking methadone must go to a clinic every day or every few days to get their medicine. This medicine comes in different strength pills and liquids. Taking too much can be dangerous. Make sure you know what the medicine looks like and what dose you are supposed to take.</td> </tr> <tr> <td>Naltrexone<br /> (brand names: ReVia, Vivitrol)</td> <td>Pill that you swallow or shot that you get each month</td> <td> <p>This medicine blocks the effects of opioids, so you cannot get high even if you use drugs.</p> It helps people who have completely stopped using drugs to stay off of them.</td> <td>Naltrexone can also help reduce cravings for alcohol. It should not be started until the person has been free of opioids for a while.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Methadone and buprenorphine are strong medicines that can cause harm if taken differently than directed. Never take more than the prescribed dose. Do not share your medicines and do not take medicines not prescribed to you. Keep these medicines away from children and pets. If you or someone else begins breathing slowly or cannot be woken-up easily after taking these medicines, it could be a sign of a dangerous reaction. Get emergency medical help right away. Carefully read the patient guide that comes with each of these medicines.</div><div id=\"graphicVersion\">Graphic 95109 Version 4.0</div></div></div>"},"95110":{"type":"graphic_table","displayName":"Summary of urine drug testing assays","title":"Summary of urine drug testing assays","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of urine drug testing assays</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup width=\"12%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Time frame for&nbsp;positive urine assay with acute exposure*<br /> (time frame for chronic exposure in parentheses)</td> <td class=\"subtitle1\">Substance detected</td> <td class=\"subtitle1\">False positives<br /> (false positivity varies by assay)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Amphetamine</td> <td>1 to 2 days (2 to 4 days)</td> <td>Amphetamine molecule</td> <td> <p>Amphetamine assays have poor specificity due to structural similarity of many drugs, herbal supplements, and medications.</p> <p>False positives result from structurally similar substances, drugs that are metabolized to structurally similar molecules in vivo, and structurally dissimilar molecules.</p> Nasal decongestants, including l-methamphetamine, phenylephrine, pseudoephedrine; herbal products, including ephedrine, synephrine; amphetamine analogues; medications including bupropion, selegiline, propranolol, atenolol.</td> <td> <p>Many assays include MDMA and methamphetamine, but this varies by manufacturer. Refer to manufacturer's literature.</p> <p>Over 100 \"designer\" amphetamines exist, dozens of which are widely available for purchase on the internet. These may not be detected by routine screening.</p> Atomoxetine and methylphenidate are not detected by routine screening.</td> </tr> <tr class=\"divider_bottom\"> <td>Benzodiazepines</td> <td> <p>1 to 5 days (most)</p> <p>2 to 30 days for diazepam</p> Chronic use does not significantly alter window of detection</td> <td> <p>Oxazepam (most common)</p> Various benzodiazepine metabolites</td> <td>Oxaprozin</td> <td> <p>Due to poor sensitivity of assays, not recommended as a urine immunoassay in the emergency setting.</p> <p>No single assay is known to detect all benzodiazepines. Depending on metabolites detected, commonly used benzodiazepines such as alprazolam and lorazepam might not be detected.</p> <p>\"Z\" drugs (eszopiclone, zaleplon, zolpidem, zopiclone) are not detected by benzodiazepine screening.</p> Detection depends on half-life of metabolites, which is generally several days, but for diazepam and chlordiazepoxide may be &#62;1 week.</td> </tr> <tr class=\"divider_bottom\"> <td>Cocaine</td> <td>2 days (7 days)</td> <td>Benzoylecgonine (cocaine metabolite)</td> <td>Coca tea, Coca leaves</td> <td>Cocaine assays have high specificity and overall accuracy.</td> </tr> <tr class=\"divider_bottom\"> <td>GHB</td> <td> <p>&#60;24 hours</p> Chronic use does not significantly alter detection</td> <td>GHB</td> <td>Endogenous neurotransmitter naturally present in minute quantities.</td> <td> <p>Detection is difficult because of brief half-life and technical problems.</p> <p>GHB detection is possible but requires specific assay. Congeners GBL and 1,4 butanediol are detected by GHB screening.</p> Often included as part of date rape screening panel.</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine</td> <td>1 to 3 days</td> <td>Ketamine, norketamine</td> <td>&nbsp;</td> <td>Not detected by routine screening assays, must be ordered as a standalone test.</td> </tr> <tr class=\"divider_bottom\"> <td>LSD</td> <td>1 to 3 days</td> <td>2-oxo-3-hydroxyLSD (LSD metabolite)</td> <td>&nbsp;</td> <td>Not commonly used in clinical settings.</td> </tr> <tr class=\"divider_bottom\"> <td>Marijuana</td> <td>1 to 3 days (&#62;1 month)</td> <td>11-nor-9-carboxy-delta9-THC (THC metabolite)</td> <td> <p>Hemp-containing foods.</p> Early, rare reports of false positives from NSAIDs associated with assays that are no longer in use.</td> <td> <p>False positive urine testing due to secondhand smoke exposure is considered impossible.</p> <p>Consumption of hemp-containing foods is extremely unlikely to cause a positive test. Differentiation between positive tests from marijuana use and hemp oil is generally not possible.</p> <p>No longer recommended as a required urine immunoassay due to the extended time frame for a positive test and lack of evidence of relevant acute adverse effects.</p> Synthetic cannabinoids that are widely abused are not detected by routine urine assays.</td> </tr> <tr> <td class=\"sublist1_start\">Opioids</td> <td class=\"sublist_other_start\">1 to 3 days</td> <td class=\"sublist_other_start\">Codeine or morphine</td> <td class=\"sublist_other_start\">Poppy seeds</td> <td class=\"sublist_other_start\"> <p>After recognition that poppy seed consumption may cause positive tests, the threshold for detection in urine was substantially raised. Using this recommended threshold, it is unlikely that poppy seed consumption could trigger positive results.</p> <p>Routine opioid screening does not detect synthetic opioids, such as buprenorphine, fentanyl, methadone, meperidine, pentazocine, propoxyphene, tramadol, and loperamide.</p> Oxycodone is poorly detected by many routine opioid screening assays. Specific assays are required.</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Methadone </li> </ul> </td> <td class=\"sublist_other\">1 to 5 days</td> <td class=\"sublist_other\"> <p>Methadone</p> EDDP (methadone metabolite)</td> <td class=\"sublist_other\">Doxylamine</td> <td class=\"sublist_other\"> <p>Due to problems with noncompliance and diversion, assays detect both methadone and the methadone metabolite EDDP.</p> Noncompliant patients who are diverting their methadone to other abusers commonly try to add methadone to their urine samples to demonstrate compliance.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <ul> <li>Propoxyphene </li> </ul> </td> <td class=\"sublist_other\">3 to 10 days</td> <td class=\"sublist_other\">Norpropoxyphene (propoxyphene metabolite)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td>PCP</td> <td>4 to 7 days</td> <td>PCP</td> <td>Dextromethorphan, diphenhydramine, doxylamine, ketamine, tramadol, and venlafaxine</td> <td> <p>Dozens of congeners of PCP with similar clinical effects exist, and these are variably detected or not detected by PCP screening.</p> Many causes of false-positive screening exist, and due to the low prevalence of PCP use in most settings, the likelihood of a true positive test is low.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GHB: gamma-hydroxybutanoic acid; GBL: gamma-butyrolactone; LSD: lysergic acid diethylamide; THC: tetrahydrocannabinol; NSAIDs: nonsteroidal antiinflammatory drugs; PCP: phencyclidine.<br />*Generally, screening tests for particular drugs become positive within minutes to hours once the drug becomes bioavailable.</div><div class=\"graphic_reference\">Courtesy of Robert J Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 95110 Version 7.0</div></div></div>"},"95112":{"type":"graphic_table","displayName":"DDx of undifferentiated arthritis","title":"Differential diagnosis and potential diagnostic outcomes of undifferentiated inflammatory arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis and potential diagnostic outcomes of undifferentiated inflammatory arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"12%\"></colgroup><colgroup width=\"52%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Sex</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Lab tests</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Undifferentiated inflammatory arthritis</td> <td>F &#62; M</td> <td>35 to 65</td> <td> <p>10 to 15% RF+</p> less frequent ACPA+</td> <td>Chronic, usually seronegative, inflammatory arthritis, atypical of RA or fails to meet classification criteria for RA. Up to 50% may evolve into RA; up to 25% will go into remission.</td> </tr> <tr class=\"divider_bottom\"> <td>Rheumatoid arthritis</td> <td>F &#62; M</td> <td>35 to 65</td> <td> <p>70 to 80% RF+</p> 70 to 80% ACPA+</td> <td>Chronic inflammatory polyarthritis, typically meets classification criteria for RA. RA often begins insidiously with vague constitutional and musculoskeletal symptoms that may last up to months before synovitis is evident.</td> </tr> <tr class=\"divider_bottom\"> <td>Undifferentiated peripheral spondyloarthritis</td> <td>M &#62; F</td> <td>15 to 45</td> <td>&#62; 50% HLA-B27+</td> <td>Most often presents as asymmetric large joint involvement with predominantly lower extremity involvement, and often with enthesitis or occasionally dactylitis, as in several forms of SpA. May involve only a few joints. Often \"silent\" urogenital tract infection (eg, chlamydia).</td> </tr> <tr class=\"divider_bottom\"> <td>Psoriatic arthritis</td> <td>M = F</td> <td>30 to 55</td> <td>&#60;20% RF+</td> <td>Some patients have asymmetric large joint involvement, similar to other SpA. 50% of those with psoriatic arthritis will have an RA-like distribution (MCPs, PIPs, wrists). Cutaneous psoriasis will be evident in the vast majority of cases.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Tophaceous gout</td> <td>M &#62; F</td> <td>M: 25 to 70 </td> <td>Usually&nbsp;RF&ndash;</td> <td class=\"divider_bottom\" rowspan=\"2\">Intermittent inflammatory arthritis during the onset, with evolution of tophi and chronic inflammatory polyarthritis. Elevated serum urate and tophi help distinguish from RA.</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>F: &#62;45 </td> <td>&#62;95% &#8593; serum urate</td> </tr> <tr class=\"divider_bottom\"> <td>Erosive inflammatory osteoarthritis</td> <td>F &#62; M</td> <td>&#62;60</td> <td>Usually RF&ndash; (but normally slight increase in RF-positivity with increasing&nbsp;age)</td> <td>Chronic polyarthritis with intermittent or sustained inflammation affecting PIP and DIP joints. Radiographs demonstrate distinctive erosions and evidence of OA.</td> </tr> <tr class=\"divider_bottom\"> <td>Pseudogout</td> <td>F = M</td> <td>&#62;60</td> <td>Usually RF&ndash; (but normally slight increase in RF-positivity with increasing&nbsp;age)</td> <td>5% of patients will have \"rheumatoid-like\" inflammatory arthritis with stiffness, fatigue, synovitis, and elevated ESR, often lasting four weeks to several months.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Reactive arthritis</p> (formerly known as Reiter's syndrome)</td> <td>M &#62; F</td> <td>16 to 50</td> <td>Usually RF&ndash;; 50 to 80% HLA-B27+</td> <td>Post-infectious SpA; often associated with low back pain, ocular, genitourinary, or GI symptoms and enthesitis (heel pain).</td> </tr> <tr class=\"divider_bottom\"> <td>Enteropathic arthritis</td> <td>M = F</td> <td>All ages</td> <td>Usually RF&ndash;</td> <td>Up to 20% of patients with Crohn's disease or ulcerative colitis will develop peripheral arthritis. Diagnosis may be difficult until GI involvement becomes apparent. Associated with oral ulcerations, GI symptoms or other features of SpA.</td> </tr> <tr class=\"divider_bottom\"> <td>Systemic lupus erythematosus</td> <td>F &#62; M</td> <td>15 to 40</td> <td>10 to 15% RF+; &#62;95% ANA+ (&#62;80% anti-dsDNA-positive; other characteristic ANA subsets)</td> <td>Chronic non-deforming inflammatory polyarthritis associated with ANA positivity and other features of SLE.</td> </tr> <tr class=\"divider_bottom\"> <td>Polymyositis/ dermatomyositis</td> <td>F &#62; M</td> <td>30 to 60</td> <td>95% RF&ndash;; &#62;50% ANA+ (characteristic ANA subsets); &#62;70% &#8593; CK</td> <td>Chronic inflammatory arthritis uncommonly occurs early in course of PM/DM. Features of proximal muscle weakness, bulbar dysphagia, muscle enzyme elevation, or skin involvement (ie, Gottron's papules) should be sought.</td> </tr> <tr class=\"divider_bottom\"> <td>Scleroderma</td> <td>F &#62; M</td> <td>30 to 50</td> <td>95% RF&ndash;; &#62;90% ANA+ (characteristic ANA subsets)</td> <td>Chronic inflammatory polyarthritis may predominate over skin changes early in the disease. Associated with Raynaud's phenomenon, sclerodactyly, dysphagia, hypertension, or renal abnormalities.</td> </tr> <tr class=\"divider_bottom\"> <td>Sarcoid arthritis</td> <td>F &#62; M</td> <td>20 to 40</td> <td>Usually RF&ndash;</td> <td>15% of patients with sarcoidosis will develop arthritis. Early in the disease a chronic inflammatory oligo or polyarthritis lasting weeks to months may develop and typically involve the ankles and knees. Other features of sarcoidosis (ie, erythema nodosum, hilar adenopathy) are usually apparent.</td> </tr> <tr> <td>Parvovirus B19-associated arthritis</td> <td>F &#62; M</td> <td>Any age</td> <td>&#60;10% RF+; &#62;80% anti-B19 IgM antibodies (acutely)</td> <td>Adults manifest a flu-like picture, seldom develop the \"slapped-cheek\" rash; arthralgias are more common than arthritis. Arthritis is an acute inflammatory polyarthritis with an RA-like distribution mostly lasting about two weeks. Less than 10% develop a chronic inflammatory arthritis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RF: rheumatoid factor; ACPA: anti-citrullinated peptide antibody; RA: rheumatoid arthritis; HLA: human leukocyte antigen; SpA: spondyloarthritis; MCP: metacarpophalangeal; PIP: proximal interphalangeal; DIP: distal interphalangeal; OA: osteoarthritis; ESR: erythrocyte sedimentation rate; GI: gastrointestinal; dsDNA: double-stranded DNA; ANA: antinuclear antibody; SLE: systemic lupus erythematosus; CK: creatine kinase; IgM: immunoglobulin M.</div><div class=\"graphic_reference\">Data adapted from: Lipsky P. Algorithms for the diagnosis and management of musculoskeletal complaints: A new tool for the primary-care provider.</div><div id=\"graphicVersion\">Graphic 95112 Version 2.0</div></div></div>"},"95115":{"type":"graphic_table","displayName":"Classification of scars","title":"Classification of scars ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of scars </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Scar type</td> <td class=\"subtitle1\">Characteristics*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </td> <td class=\"subtitle1\">Maturation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td><strong>&nbsp;Mature</strong></td> <td> <ul> <li>Light in color </li> <li>Flat </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;<strong>Immature</strong></td> <td> <ul> <li>Red </li> <li>Pruritic </li> <li>Painful </li> <li>Slightly elevated, indicating remodeling </li> </ul> </td> <td> <ul> <li>Many mature in time </li> <li>Become flat </li> <li>Pigmentation generally similar to surrounding skin </li> <li>Pigmentation may be paler or darker than skin </li> </ul> </td> </tr> <tr> <td> <p><strong>Linear, hypertrophic</strong></p> <p>Example: Surgical or traumatic scar</p> </td> <td> <ul> <li>Red </li> <li>Raised </li> <li>Pruritic </li> <li>Confined to the border of the original scar </li> <li>Generally matures to an elevated, slightly rope-like appearance </li> <li>Mature scar has increased width (variable) </li> </ul> </td> <td> <ul> <li>Increases in size rapidly for first&nbsp;three to&nbsp;six months </li> <li>After a static phase, regresses&nbsp; </li> <li>Full maturation in approximately&nbsp;two years </li> </ul> </td> </tr> <tr> <td> <p><strong>Widespread, hypertrophied</strong>&nbsp;</p> <p>Example: Burn</p> </td> <td> <ul> <li>Widespread </li> <li>Red </li> <li>Raised </li> <li>Pruritic </li> <li>Remains within the borders of the burn injury&nbsp; </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td><strong>Minor keloid</strong></td> <td> <ul> <li>Focally raised </li> <li>Pruritic </li> <li>Extends beyond burn borders </li> <li>May have genetic component for keloid development </li> <li>Typical site: Earlobes </li> </ul> </td> <td> <ul> <li>May develop&nbsp;one year after burn </li> <li>Does&nbsp;not regress spontaneously </li> <li>Recurrence generally follows surgical excision&nbsp; </li> </ul> </td> </tr> <tr> <td><strong>Major keloid</strong></td> <td> <ul> <li>Large (&#62;0.5 cm) </li> <li>Painful </li> <li>Pruritic </li> <li>Extends beyond burn borders over normal tissue </li> <li>Can result even from minor trauma </li> </ul> </td> <td> <ul> <li>Does not spontaneously regress&nbsp; </li> <li>Can continue to progress in size over years </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Characteristics may be variable in symptoms (eg, pruritus, pain) for each patient.</div><div class=\"graphic_reference\">From: Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110:560. Adapted with permission from Lippincott Williams &amp; Wilkins. Copyright © 2002 American Society of Plastic Surgeons, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95115 Version 5.0</div></div></div>"},"95116":{"type":"graphic_table","displayName":"Treatment of burn scars","title":"Treatment of burn scars","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of burn scars</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Diagnosis</td> <td class=\"subtitle1\" colspan=\"4\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">First-line</td> <td class=\"subtitle2\">Second-line</td> <td class=\"subtitle2\">Third-line</td> <td class=\"subtitle2\">Management after favorable treatment response</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Fresh burn scar (preventive measures)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td> <ul> <li>Silicone gel/sheet or onion extract formulations </li> <li>Begin two weeks after injury (eg, in combination with pressure therapy) </li> <li>Continue for three months </li> </ul> </td> <td> <ul> <li>Pulsed-dye laser (PDL) therapy for persisting erythema </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Immature scar, erythematous hypertrophic scar, minor keloid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td> <ul> <li>Triamcinolone acetonide (TAC) injections <ul> <li>Men 20 to 40 mg/mL </li> <li>Women 10 to 40 mg/mL </li> </ul> </li> <li>Use in combination with silicone gel or sheet </li> <li>Intralesional corticosteroidal injection with silicone gel or sheeting </li> </ul> </td> <td> <ul> <li>Cryotherapy (10 to 15 seconds) </li> <li>Directly followed by TAC injections until scar has flattened over time </li> </ul> </td> <td> <ul> <li>5- fluorouracil (5-FU; topical) with TAC injections <ul> <li>Administer every other week </li> </ul> </li> </ul> <p>Or:</p> <ul> <li>Intralesional cryotherapy </li> <li>Ultimo ratio excision and appropriate prophylactic therapy (NTA) </li> </ul> </td> <td> <ul> <li>PDL to reduce erythema </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Widespread hypertrophic burn scar</td> </tr> <tr> <td class=\"indent1\">Tension present</td> <td> <ul> <li>Surgical release <ul> <li>Z-plasty </li> <li>W-plasty </li> <li>Excision and reconstructive flaps </li> </ul> </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No tension present</td> <td> <ul> <li>Silicone gel preparations </li> <li>Compression therapy </li> <li>Onion extract formulations </li> </ul> </td> <td> <ul> <li>Individual counseling </li> <li>Ablative fractional laser </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>PDL to reduce erythema </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Major keloid</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td> <ul> <li>Cryotherapy (10 to 15 seconds) </li> <li>Directly followed by TAC injections until scar has flattened </li> </ul> </td> <td> <ul> <li>Combination every other week of <ul> <li>5-FU and </li> <li>TAC </li> </ul> </li> <li>Intralesional cryotherapy </li> </ul> </td> <td> <ul> <li>Combination of <ul> <li>Surgical excision </li> <li>Radiation therapy </li> <li>TAC </li> </ul> </li> </ul> </td> <td> <ul> <li>PDL to reduce erythema </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Fresh burn scar is considered hypertrophic scar.</div><div class=\"graphic_reference\">Adapted with permission from: Gauglitz G. Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol 2013; 6:103. Copyright &copy; 2013 Gerd G Gauglitz, MMS, MD.</div><div id=\"graphicVersion\">Graphic 95116 Version 4.0</div></div></div>"},"95118":{"type":"graphic_table","displayName":"Refined DRI for survival after allo-HCT","title":"Refined disease risk index for survival after allogeneic hematopoietic cell transplantation (HCT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Refined disease risk index for survival after allogeneic hematopoietic cell transplantation (HCT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Disease type and stage</td> <td class=\"subtitle1_left\">Risk group</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"21\">Leukemia/MDS/MPN</td> <td rowspan=\"2\" colspan=\"2\">CLL/SLL</td> <td>CR or PR</td> <td>Low</td> </tr> <tr> <td>Stable or progressive</td> <td>Intermediate</td> </tr> <tr> <td rowspan=\"3\" colspan=\"2\">CML</td> <td>Chronic phase</td> <td>Low</td> </tr> <tr> <td>Accelerated phase</td> <td>Intermediate</td> </tr> <tr> <td>Blast crisis</td> <td>Very high</td> </tr> <tr> <td rowspan=\"6\">AML</td> <td rowspan=\"2\">Favorable cytogenetics</td> <td>CR</td> <td>Low</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td rowspan=\"2\">Intermediate cytogenetics</td> <td>CR</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td rowspan=\"2\">Adverse cytogenetics</td> <td>CR</td> <td>High</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>Very high</td> </tr> <tr> <td rowspan=\"3\" colspan=\"2\">ALL</td> <td>First CR</td> <td>Intermediate</td> </tr> <tr> <td>Second or third CR</td> <td>High</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>Very high</td> </tr> <tr> <td rowspan=\"3\">Low-risk MDS (&#60;5 percent blasts)</td> <td>Intermediate cytogenetics</td> <td>Any stage</td> <td>Intermediate</td> </tr> <tr> <td rowspan=\"2\">Adverse cytogenetics</td> <td>Early stage</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td rowspan=\"3\">High-risk MDS (&#8805;5 percent blasts)</td> <td rowspan=\"2\">Intermediate cytogenetics</td> <td>Early stage</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td>Adverse cytogenetics</td> <td>Any stage</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">MPN</td> <td>Any stage</td> <td>Intermediate</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"11\">Lymphoma</td> <td colspan=\"2\">Hodgkin lymphoma</td> <td>CR</td> <td>Low</td> </tr> <tr> <td rowspan=\"3\" colspan=\"2\">Mantle cell lymphoma</td> <td>CR</td> <td>Low</td> </tr> <tr> <td>PR</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td colspan=\"2\">Clinically indolent B cell NHL</td> <td>CR or PR</td> <td>Low</td> </tr> <tr> <td rowspan=\"2\" colspan=\"2\">Clinically aggressive B cell NHL</td> <td>CR or PR</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>Very high</td> </tr> <tr> <td rowspan=\"2\" colspan=\"2\">Burkitt lymphoma</td> <td>CR</td> <td>High</td> </tr> <tr> <td>PR, induction failure, or active relapse</td> <td>Very high</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\" colspan=\"2\">T cell NHL</td> <td>CR or PR</td> <td>Intermediate</td> </tr> <tr class=\"divider_bottom\"> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\" colspan=\"3\">Multiple myeloma</td> <td>CR or PR</td> <td>Intermediate</td> </tr> <tr class=\"divider_bottom\"> <td>Relapsed/refractory disease</td> <td>High</td> </tr> <tr> <td class=\"subtitle1_left\">Risk group</td> <td class=\"subtitle1_left\" colspan=\"2\">Percentage of cases</td> <td class=\"subtitle1_left\" colspan=\"2\">Estimated two-year overall survival (95% CI)</td> </tr> <tr> <td class=\"indent1\">Low</td> <td colspan=\"2\">14</td> <td colspan=\"2\">66 percent (63 to 68 percent)</td> </tr> <tr> <td class=\"indent1\">Intermediate</td> <td colspan=\"2\">63</td> <td colspan=\"2\">51 percent (50 to 52 percent)</td> </tr> <tr> <td class=\"indent1\">High</td> <td colspan=\"2\">20</td> <td colspan=\"2\">33 percent (31 to 35 percent)</td> </tr> <tr> <td class=\"indent1\">Very high</td> <td colspan=\"2\">4</td> <td colspan=\"2\">23 percent (20 to 27 percent)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A refined disease risk index (DRI) was created by the Center for International Blood and Marrow Transplant Research (CIBMTR) based on data from 13,131 patients who underwent myeloablative, nonmyeloablative, or reduced intensity conditioning followed by allogeneic HCT between 2008 and 2010. The DRI combines information on disease type and status in order to identify \"low\", \"intermediate\", \"high\", and \"very high\" risk patient populations with significantly different estimated overall survival at two years. For AML, t(8;21), inv(16), and t(15;17) were classified as favorable cytogenetics, complex karyotype (4+ abnormalities) as adverse cytogenetics, and all others as intermediate; for MDS, abnormal chromosome 7 and complex karyotype (≥4 abnormalities) were classified as adverse cytogenetics, and all others as intermediate.</div><div class=\"graphic_footnotes\">MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasms; CLL: chronic lymphocytic leukemia; SLL: small lymphocytic lymphoma; CR: complete remission; PR: partial remission; CML: chronic myeloid leukemia; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; HCT: hematopoietic cell transplantation.</div><div class=\"graphic_reference\">Data from: Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. Blood 2014; 123:3664.</div><div id=\"graphicVersion\">Graphic 95118 Version 1.0</div></div></div>"},"95119":{"type":"graphic_table","displayName":"Dust mite control PI","title":"Ways to reduce dust mite allergy symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to reduce dust mite allergy symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First: Bedrooms</td> </tr> <tr> <td class=\"indent1\">Cover pillows and mattresses with zippered covers that trap in mites and mite allergens. These covers are made of special, tightly-woven material and should be labeled as specifically designed to block dust mites.</td> </tr> <tr> <td class=\"indent1\">Wash sheets, pillowcases, and blankets in hot or warm water with detergent or dry in an electric dryer on the hot setting every week. If needed, replace blankets with ones that can be washed. If you must use comforters (or duvets), cover them with tightly-woven covers.</td> </tr> <tr> <td class=\"indent1\">Use washable, vinyl, or roll-type window covers.</td> </tr> <tr> <td class=\"indent1\">Remove clutter, soft toys, and upholstered furniture.</td> </tr> <tr> <td class=\"indent1\">Where possible, remove carpets or replace them with area rugs that can be cleaned or washed.</td> </tr> <tr> <td class=\"subtitle1_single\">Second: Rest of house</td> </tr> <tr> <td class=\"indent1\">Reduce upholstered furniture, especially old sofas.</td> </tr> <tr> <td class=\"indent1\">Where possible, replace carpets with polished flooring. Carpets on concrete slabs or stuffy crawl spaces are a problem. Those carpets especially should be replaced with polished flooring.</td> </tr> <tr> <td class=\"indent1\">Vacuum weekly using a cleaner with a high-efficiency particulate air (HEPA) filter.</td> </tr> <tr> <td class=\"indent1\">Window coverings should be washable, vinyl, or roll-type.</td> </tr> <tr> <td class=\"indent1\">Control humidity to less than 50% relative humidity at normal temperatures (between 68 to 72&#176;F). To check humidity levels, you can buy a humidity monitor at a hardware store. If it is too humid, you can lower humidity by using an air conditioner.</td> </tr> <tr> <td class=\"subtitle1_single\">Third: Changing houses*</td> </tr> <tr> <td class=\"indent1\">If you have bad allergies and live in a basement or very damp home, think about moving.</td> </tr> <tr> <td class=\"indent1\">People who are allergic to mites (or molds) often do much better if they live in an apartment (second floor or higher) or a house with second floor bedrooms and wooden floors.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The average family in the United States moves approximately every four years.</div><div id=\"graphicVersion\">Graphic 95119 Version 3.0</div></div></div>"},"95120":{"type":"graphic_diagnosticimage","displayName":"Fetal VCI cyst","title":"Fetal VCI cyst at 21 and 27 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal VCI cyst at 21 and 27 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:437px; height:597px;\" src=\"images/OBGYN/95120_Fetal_VCI_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Median section of the fetal brain at 21 4/7 weeks with a VCI cyst (arrow) measuring 0.46 x 0.37 cm.<br />(B) Same fetus at 27 weeks. VCI cyst has not enlarged and measures 0.5 x 0.3 cm.</div><div class=\"graphic_footnotes\">VCI: cavum veli interpositi.</div><div id=\"graphicVersion\">Graphic 95120 Version 1.0</div></div></div>"},"95121":{"type":"graphic_diagnosticimage","displayName":"Fetal VCI cyst 3-D ultrasound","title":"Fetal VCI cyst 3-D ultrasound","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Fetal VCI cyst 3-D ultrasound</div><div class=\"cntnt\"><img style=\"width:598px; height:417px;\" src=\"images/OBGYN/95121_Fetal_VCI_cyst_3D_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional ultrasound showing the VCI (arrow) in all three scanning planes.</div><div class=\"graphic_footnotes\">VCI: cavum veli interpositi; 3-D ultrasound: three-dimensional ultrasound examination.</div><div id=\"graphicVersion\">Graphic 95121 Version 1.0</div></div></div>"},"95124":{"type":"graphic_figure","displayName":"Severity domains in COPD","title":"COPD Foundation guide to assessment of COPD severity","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">COPD Foundation guide to assessment of COPD severity</div><div class=\"cntnt\"><img style=\"width:629px; height:396px;\" src=\"images/PULM/95124_Severity_domains_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity; SG: spirometry grade; PaO<SUB>2</SUB>: arterial tension of oxygen; CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted with permission from the COPD Foundation. Slight modifications were made. (Thomashow B, Crapo J, Yawn B, et al. The COPD Foundation Pocket Consultant Guide. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2014; 1(1): 83-87). Copyright &copy; 2014 Informa Plc.</div><div id=\"graphicVersion\">Graphic 95124 Version 1.0</div></div></div>"},"95125":{"type":"graphic_picture","displayName":"Ulerythema ophryogenes cheek","title":"Ulerythema ophryogenes (keratosis pilaris atrophicans faciei)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ulerythema ophryogenes (keratosis pilaris atrophicans faciei)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95125_Ulerythema_ophriogene_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and tiny keratotic follicular papules involving the cheeks in a boy with keratosis pilaris atrophicans faciei.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95125 Version 1.0</div></div></div>"},"95126":{"type":"graphic_picture","displayName":"Solar lentigines chest","title":"Solar lentigines","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Solar lentigines</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95126_Solar_lentigines_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous small solar lentigines on the photodamaged skin of the upper chest.</div><div id=\"graphicVersion\">Graphic 95126 Version 2.0</div></div></div>"},"95127":{"type":"graphic_figure","displayName":"Variant anatomy of the vagus nerve","title":"Variant anatomy of the vagus nerve","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Variant anatomy of the vagus nerve</div><div class=\"cntnt\"><img style=\"width:535px; height:511px;\" src=\"images/SURG/95127_Variant_anatomy_of_the_vagus_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn from: Dragstedt LR, Fournier HJ, Woodward ER, et al. Transabdominal gastric vagotomy; a study of the anatomy and surgery of the vagus nerves at the lower portion of the esophagus. Surg Gynecol Obstet 1947; 85:461.</div><div id=\"graphicVersion\">Graphic 95127 Version 1.0</div></div></div>"},"95135":{"type":"graphic_movie","displayName":"Color Doppler echocardiogram of a moderate PDA in a neonate","title":"Echocardiogram image with color flow mapping of a moderate patent ductus arteriosus in a neonate","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiogram image with color flow mapping of a moderate patent ductus arteriosus in a neonate</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/95135_ColorDoppmoderatePDAvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:590px; height:485px;\" src=\"images/PEDS/95135_ColorDoppmoderatePDAimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram still frame and movie clip demonstrate a moderately large patent ductus arteriosus (PDA) in a neonate with pulmonary hypertension. There is bidirectional shunting within the PDA (arrow in still frame) coursing between the descending aorta (DAo), seen in cross section, and the main pulmonary artery (MPA). Flow is left to right in diastole, and right to left in systole.</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; RA: right atrium; LA: left atrium; RPA: right pulmonary artery; LPA: left pulmonary artery.</div><div id=\"graphicVersion\">Graphic 95135 Version 1.0</div></div></div>"},"95136":{"type":"graphic_movie","displayName":"Color Doppler echocardiogram of small PDA in a neonate","title":"Two dimensional echocardiogram images with color flow mapping of a small patent ductus arteriosus in a neonate using the parasternal short axis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Two dimensional echocardiogram images with color flow mapping of a small patent ductus arteriosus in a neonate using the parasternal short axis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/95136_ColorDopplersmallPDAvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:590px; height:435px;\" src=\"images/PEDS/95136_ColorDopplersmallPDAimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram still frame and movie clip of&nbsp;the parasternal short axis view in a neonate displays a small patent ductus arteriosus (PDA), highlighted by color flow mapping, coursing between the descending aorta (DAo) in cross section and main pulmonary artery (MPA).</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; Ao: ascending aorta in cross section; RPA: right pulmonary artery; LPA: left pulmonary artery.</div><div id=\"graphicVersion\">Graphic 95136 Version 1.0</div></div></div>"},"95137":{"type":"graphic_diagnosticimage","displayName":"Continuous wave Doppler calculation of PA pressure in PDA","title":"Estimation of pulmonary artery pressure using continuous wave Doppler echocardiogram interrogation in a patient with a patent ductus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Estimation of pulmonary artery pressure using continuous wave Doppler echocardiogram interrogation in a patient with a patent ductus arteriosus</div><div class=\"cntnt\"><img style=\"width:591px; height:441px;\" src=\"images/PEDS/95137_Wave_Dopp_calc_PA_press_PDA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doppler echocardiogram interrogation is directed into the jet of continuous left-to-right flow in the short axis view of a patient with a patent ductus arteriosus (PDA). The maximum velocity (V) of 2.8 m/sec through the ductus arteriosus is noted by continuous wave Doppler. The peak gradient between the aorta and pulmonary artery is 4 x V<SUP>2</SUP> or 32 mmHg. The estimated pulmonary artery pressure of 36 mmHg is the difference between the measured systolic blood pressure of 68 mmHg and the peak gradient of 32 mmHg between the aorta and pulmonary artery.</div><div class=\"graphic_footnotes\">PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 95137 Version 1.0</div></div></div>"},"95138":{"type":"graphic_movie","displayName":"Echocardiogram images of a PDA from the suprasternal notch view","title":"Echocardiogram images with color flow mapping of a patent ductus arteriosus in an infant from the suprasternal notch view","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiogram images with color flow mapping of a patent ductus arteriosus in an infant from the suprasternal notch view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/95138_EchoPDAsuprastnotchvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:590px; height:451px;\" src=\"images/PEDS/95138_EchoPDAsuprastnotchimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram still frame and movie clip from the suprasternal notch imaging window show a small patent ductus arteriosus (PDA) in an infant, which is highlighted by color flow mapping.</div><div class=\"graphic_footnotes\">MPA: main pulmonary artery; DAo: descending aorta.</div><div id=\"graphicVersion\">Graphic 95138 Version 1.0</div></div></div>"},"95144":{"type":"graphic_movie","displayName":"Vestibular-ocular motor screening exam","title":"Vestibular-ocular motor screening exam (VOMS)","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Vestibular-ocular motor screening exam (VOMS)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/95144_Vestocularmotorexamvid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:521px; height:251px;\" src=\"images/EM/95144_Vestocularmotorexamimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vestibular and oculomotor examinations demonstrated in this video are an important part of the assessment of the patient with a possible concussion.</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH, CAQSM.</div><div id=\"graphicVersion\">Graphic 95144 Version 2.0</div></div></div>"},"95155":{"type":"graphic_table","displayName":"Physiologic effects of sleep stage","title":"Physiologic effects of sleep stage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic effects of sleep stage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">NREM sleep</td> <td class=\"subtitle1\">REM sleep</td> </tr> <tr> <td><strong>Autonomic nervous system</strong></td> <td>Increased parasympathetic tone</td> <td>Unstable, brief surges in sympathetic and parasympathetic activity</td> </tr> <tr> <td><strong>Cardiovascular system</strong></td> <td> <p>Heart rate is slow and regular</p> Blood pressure is lower</td> <td> <p>Heart rate is irregular</p> Transient increases in blood pressure</td> </tr> <tr> <td><strong>Respiratory system</strong></td> <td> <p>Mild decrease in ventilatory drive in response to hypoxia and hypercapnia</p> Decreased respiratory rate</td> <td> <p>Significant decrease in ventilatory drive in response to hypoxia and hypercapnia</p> Increased respiratory rate</td> </tr> <tr> <td><strong>Temperature regulation</strong></td> <td>Decreased hypothalamic temperature set point</td> <td>Reduced thermoregulatory mechanisms</td> </tr> <tr> <td><strong>Reproductive system</strong></td> <td>&nbsp;</td> <td> <p>Penile erections</p> Increased vaginal blood flow</td> </tr> <tr> <td><strong>Dreaming</strong></td> <td>Less vivid</td> <td>More vivid, visually intense</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: rapid eye movement; NREM: non-REM.</div><div class=\"graphic_reference\">Data from: Benca R. Sleep Disorders: The Clinician's Guide to Diagnosis and Management. Oxford University Press, New York. 2012.</div><div id=\"graphicVersion\">Graphic 95155 Version 3.0</div></div></div>"},"95156":{"type":"graphic_picture","displayName":"Kidney biopsy showing anticoagulant-associated nephropathy","title":"Kidney biopsy showing histologic findings of anticoagulant-associated nephropathy","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Kidney biopsy showing histologic findings of anticoagulant-associated nephropathy</div><div class=\"cntnt\"><img style=\"width:598px; height:514px;\" src=\"images/NEPH/95156_Kidney_biop_anticoag_nephro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">RBCs in different compartments of the kidney in patients on warfarin therapy with acute kidney injury.<br />(A) Numerous RBCs and RBC occlusive casts were noticed in tubules and Bowman space (Hematoxylin and eosin stain; original magnification x200).<br />(B) Immunohistochemical stain for Tamm-Horsfall protein shows that most RBC casts do not contain Tamm-Horsfall protein. Positively stained thick ascending loop of Henle (arrow).<br />(C) Immunohistochemical stain for cytokeratin AE1/AE3 (arrows, dark brown) highlights distal tubules with occlusive RBC casts (counterstain with hematoxylin/eosin; original magnification x200).<br />(D) Dysmorphic RBCs were noticed in several tubules by means of electron microscopy (uranyl acetate, lead citrate stain; original magnification x3000).</div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div class=\"graphic_reference\">Reproduced from: Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: A report of nine cases. Am J Kidney Dis 2009; 54:1121. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95156 Version 1.0</div></div></div>"},"95157":{"type":"graphic_figure","displayName":"Hypnogram","title":"Hypnogram of a 36-year-old man in a sleep laboratory","html":"<div class=\"graphic\"><div style=\"width: 957px\" class=\"figure\"><div class=\"ttl\">Hypnogram of a 36-year-old man in a sleep laboratory</div><div class=\"cntnt\"><img style=\"width:937px; height:186px;\" src=\"images/PULM/95157_Hypnogram_36_man_sleep_lab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This hypnogram represents the movement of a patient through various sleep cycles over the course of a single night; from approximately 10:37 pm to 5:36 am. The stages are listed as W (wake), R (REM sleep, stage R), and N1-N3 (NREM stages N1, N2, and N3). The patient starts by transitioning from wake into light NREM sleep, then to deep NREM sleep, back to light NREM sleep and then into REM sleep. This pattern generally repeats itself with blocks of NREM and REM sleep approximately every 90 minutes.</div><div class=\"graphic_footnotes\">REM: rapid eye movement; NREM: non-REM.</div><div id=\"graphicVersion\">Graphic 95157 Version 5.0</div></div></div>"},"95158":{"type":"graphic_figure","displayName":"Definition of PICS and PICSF","title":"Definition of post-intensive care unit syndrome (PICS) and post-intensive care unit syndrome-family (PICS-F)","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Definition of post-intensive care unit syndrome (PICS) and post-intensive care unit syndrome-family (PICS-F)</div><div class=\"cntnt\"><img style=\"width:486px; height:207px;\" src=\"images/PULM/95158_DefinitionPICSPICSF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-intensive care syndrome (PICS) conceptual diagram.</div><div class=\"graphic_footnotes\">PTSD: posttraumatic stress disorder; ASD: acute stress disorder.</div><div class=\"graphic_reference\">From: Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med 2012; 40:502. DOI: <a href=\"http://journals.lww.com/ccmjournal/pages/articleviewer.aspx?year=2012&amp;issue=02000&amp;article=00020&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/CCM.0b013e318232da75</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2012 Society of Critical Care Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95158 Version 3.0</div></div></div>"},"95159":{"type":"graphic_table","displayName":"Risk factors and natural history of PICS","title":"Risk factors and natural history of post-intensive care unit syndrome (PICS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors and natural history of post-intensive care unit syndrome (PICS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Selected risk factors</td> <td class=\"subtitle1\">Natural history</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Patient outcomes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pulmonary</td> <td>Impairment in spirometry, lung volumes, and diffusion capacity</td> <td>Diffusion capacity: duration of mechanical ventilation</td> <td>Generally mild impairment with improvement during first year, but can persist five years or more</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"5\">Neuromuscular/ICU-acquired weakness</td> <td rowspan=\"4\">Includes critical illness polyneuropathy and myopathy</td> <td>Hyperglycemia</td> <td class=\"divider_bottom\" rowspan=\"5\">Polyneuropathy may recover more slowly than myopathy; can extend to five years</td> </tr> <tr> <td>Systemic inflammatory response syndrome</td> </tr> <tr> <td>Sepsis</td> </tr> <tr> <td>Multiorgan dysfunction</td> </tr> <tr class=\"divider_bottom\"> <td>Disuse atrophy</td> <td>Immobility/bed rest</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"5\">Physical function</td> <td class=\"divider_bottom\" rowspan=\"5\">Impairment in activities of daily living (ADL/IADL) and six-minute walk distance</td> <td>Systemic corticosteroids</td> <td rowspan=\"3\">Some improvement in ADL within months, but impairments may be seen in ADL at one year and in IADL at two years</td> </tr> <tr> <td>ICU-acquired illnesses</td> </tr> <tr> <td>Slow resolution of lung injury</td> </tr> <tr> <td>Age</td> <td class=\"divider_bottom\" rowspan=\"2\">Long-lasting impairment in six-minute walk distance versus population norms</td> </tr> <tr class=\"divider_bottom\"> <td>Preexisting IADL impairment</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"4\">Psychiatric</td> <td>Depression</td> <td>Traumatic/delusional memories of ICU, sedation, psychiatric symptoms at discharge, impairment of physical function</td> <td>May decrease over first year</td> </tr> <tr> <td>Posttraumatic stress disorder</td> <td>Sedation, agitation, physical restraints, traumatic/delusional memories</td> <td>Little improvement in first year</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Anxiety</td> <td>Unemployment, duration of mechanical ventilation</td> <td class=\"divider_bottom\" rowspan=\"2\">May persist past first year</td> </tr> <tr class=\"divider_bottom\"> <td>Overall risk factors: female gender, younger age, less education, pre-ICU psychiatric symptoms, and personality</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"5\">Cognitive</td> <td class=\"divider_bottom\" rowspan=\"5\">Impairments in memory, attention, executive function, mental processing speed, visuo-spatial ability</td> <td>Lower pre-ICU intelligence</td> <td class=\"divider_bottom\" rowspan=\"5\">Significant improvement during first year, with residual deficits up to six years later</td> </tr> <tr> <td>ICU delirium</td> </tr> <tr> <td>Sedation</td> </tr> <tr> <td>Hypoxia</td> </tr> <tr class=\"divider_bottom\"> <td>Glucose dysregulation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Family outcomes</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Psychiatric</td> <td>Depression</td> <td>Overall risk factors: female gender, younger age, less education, pre-ICU psychiatric symptoms, and personality, distance to hospital, restricted visiting</td> <td>Depression and anxiety decrease over time, but are higher than population norms at six months</td> </tr> <tr> <td>Posttraumatic stress disorder</td> <td>Dissatisfaction with communication, ICU physician perceived as \"uncaring,\" passive preference for decision-making, mismatch between involvement in decision-making and preference</td> <td rowspan=\"4\">Posttraumatic stress disorder and complicated grief can persist four years or more after death or discharge and may not decrease over time</td> </tr> <tr> <td>Anxiety</td> <td>Severity of illness not associated with development of symptoms</td> </tr> <tr> <td rowspan=\"2\">Complicated grief</td> <td>Complicated grief is worse when family does not have knowledge of patient's wishes</td> </tr> <tr> <td>In pediatric ICU, paternal stress after discharge is associated with child stress in pediatric ICU</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADL: activities of daily living; IADL: instrumental activities of daily living; ICU: intensive care unit.</div><div class=\"graphic_reference\">From: Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med 2012; 40:502. DOI: <a href=\"http://journals.lww.com/ccmjournal/pages/articleviewer.aspx?year=2012&amp;issue=02000&amp;article=00020&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/CCM.0b013e318232da75</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2012 Society of Critical Care Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95159 Version 3.0</div></div></div>"},"95161":{"type":"graphic_movie","displayName":"Echocardiogram images of PDA in patient with TGA","title":"Two dimensional echocardiogram images with color flow mapping showing patent ductus arteriosus in a neonate with transposition of the great arteries","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Two dimensional echocardiogram images with color flow mapping showing patent ductus arteriosus in a neonate with transposition of the great arteries</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/95161_EchocardiogramPDATGAvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:590px; height:483px;\" src=\"images/PEDS/95161_EchocardiogramPDATGAimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram still frame and movie clip show the relationship between the aortic arch and main pulmonary artery (MPA) in a patient with a patent ductus arteriosus (PDA) and transposition of the great arteries (TGA). The image is a longitudinal view from the suprasternal notch showing the PDA.</div><div class=\"graphic_footnotes\">TAo: transverse aorta; DAo: descending aorta; RA: right atrium; LA: Left atrium.</div><div id=\"graphicVersion\">Graphic 95161 Version 1.0</div></div></div>"},"95162":{"type":"graphic_movie","displayName":"Echocardiography of PDA using high parasternal view","title":"Echocardiogram images of a patent ductus arteriosus in a neonate using the high parasternal view","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiogram images of a patent ductus arteriosus in a neonate using the high parasternal view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/95162_EchoPDAhighparasternvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:590px; height:437px;\" src=\"images/PEDS/95162_EchoPDAhighparasternimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram still frame and movie clip of right-to-left shunting through a patent ductus arteriosus (PDA) in a neonate with pulmonary hypertension, and high pulmonary vascular resistance using&nbsp;the high parasternal view. Color flow mapping shows only antegrade flow (blue per color flow map) in the PDA.</div><div class=\"graphic_footnotes\">MPA: main pulmonary artery; Ao: ascending aorta; RA: right atrium; LA: left atrium; RPA: right pulmonary artery; LPA: left pulmonary artery.</div><div id=\"graphicVersion\">Graphic 95162 Version 1.0</div></div></div>"},"95163":{"type":"graphic_diagnosticimage","displayName":"Pulsed wave Doppler interrogation II of PDA with L to R shunting","title":"Pulsed wave Doppler interrogation in a patient with a patent ductus arteriosus and significant left-to-right shunting with retrograde diastolic flow","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pulsed wave Doppler interrogation in a patient with a patent ductus arteriosus and significant left-to-right shunting with retrograde diastolic flow</div><div class=\"cntnt\"><img style=\"width:590px; height:446px;\" src=\"images/PEDS/95163_Puls_Dopp_intII_PDA_LRshunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with a patent ductus arteriosus (PDA) and significant left-to-right shunting, pulsed Doppler echocardiography shows retrograde diastolic flow in the descending aorta (arrows) towards the PDA.</div><div class=\"graphic_footnotes\">L: left; R: right.</div><div id=\"graphicVersion\">Graphic 95163 Version 1.0</div></div></div>"},"95164":{"type":"graphic_diagnosticimage","displayName":"Pulsed wave Doppler interrogation of PDA with L to R shunting","title":"Pulsed wave Doppler interrogation in a patient with patent ductus arteriosus and significant left-to-right shunting with continuous diastolic run off","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pulsed wave Doppler interrogation in a patient with patent ductus arteriosus and significant left-to-right shunting with continuous diastolic run off</div><div class=\"cntnt\"><img style=\"width:590px; height:415px;\" src=\"images/PEDS/95164_Puls_Dopp_inter_PDA_LRshunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with a patent ductus arteriosus (PDA) and significant left-to-right shunting, pulsed Doppler echocardiography shows flow in the descending aorta proximal to the PDA. Note the continuous diastolic run off pattern of flow toward the ductus (arrows).</div><div class=\"graphic_footnotes\">L: left; R: right.</div><div id=\"graphicVersion\">Graphic 95164 Version 1.0</div></div></div>"},"95165":{"type":"graphic_diagnosticimage","displayName":"Pulsed wave Doppler interrogation of PDA with systemic PAP","title":"Pulsed wave Doppler interrogation in a patient with patent ductus arteriosus and systemic pulmonary artery pressure","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pulsed wave Doppler interrogation in a patient with patent ductus arteriosus and systemic pulmonary artery pressure</div><div class=\"cntnt\"><img style=\"width:590px; height:423px;\" src=\"images/PEDS/95165_Puls_Dopp_int_PDA_syst_pulm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with patent ductus arteriosus (PDA) and systemic pulmonary artery pressure (PAP), pulsed Doppler echocardiography&nbsp;(using&nbsp;the short axis&nbsp;view)&nbsp;shows systolic flow (arrows) is directed away from the pulmonary artery, across the PDA, and into the descending aorta. In diastole, flow reverses and is left to right, directed toward the pulmonary artery.</div><div id=\"graphicVersion\">Graphic 95165 Version 1.0</div></div></div>"},"95166":{"type":"graphic_table","displayName":"Estimated oxygen uptakes","title":"Estimated oxygen uptake for various activities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated oxygen uptake for various activities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Activity</td> <td class=\"subtitle1\">Estimated [VO<sub>2</sub> (mL/kg/min)]</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Basic postures</td> </tr> <tr> <td>Sitting only (desk work, writing, driving a car)</td> <td class=\"centered\">4.25</td> </tr> <tr> <td>Standing only (bartending)</td> <td class=\"centered\">8.75</td> </tr> <tr> <td>Walking 3.0 mph</td> <td class=\"centered\">10.5</td> </tr> <tr class=\"divider_bottom\"> <td>Walking 3.5 mph</td> <td class=\"centered\">14</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Standing: Moderate work</td> </tr> <tr> <td>Light assembly at slow pace</td> <td class=\"centered\">8.75</td> </tr> <tr> <td>Scrubbing, waxing, polishing (floors, walls)</td> <td class=\"centered\">9.45</td> </tr> <tr> <td>Stocking shelves (light objects)</td> <td class=\"centered\">10.5</td> </tr> <tr> <td>Janitorial work</td> <td class=\"centered\">10.5</td> </tr> <tr> <td>Assembly line with light or medium parts at moderate pace</td> <td class=\"centered\">12.25</td> </tr> <tr class=\"divider_bottom\"> <td>Masonry, painting, paperhanging</td> <td class=\"centered\">14</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Walking: Moderate work</td> </tr> <tr> <td>Carrying trays, dishes</td> <td class=\"centered\">14.7</td> </tr> <tr> <td>Light interior repair (tile laying)</td> <td class=\"centered\">14</td> </tr> <tr> <td>Service station mechanical work (changing tires, etc)</td> <td class=\"centered\">15.75</td> </tr> <tr> <td>Building and finishing interior</td> <td class=\"centered\">15.75</td> </tr> <tr class=\"divider_bottom\"> <td>Exterior remodeling (hammering, sawing)</td> <td class=\"centered\">21</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Heavy work: Lifting and carrying</td> </tr> <tr> <td>20 to 44 lb</td> <td class=\"centered\">15.75</td> </tr> <tr> <td>45 to 64 lb</td> <td class=\"centered\">21</td> </tr> <tr> <td>65 to 84 lb</td> <td class=\"centered\">26.25</td> </tr> <tr> <td>85 to 100 lb</td> <td class=\"centered\">29.75</td> </tr> <tr> <td>Jackhammers, pneumatic drills</td> <td class=\"centered\">21</td> </tr> <tr> <td>Shovel, pick</td> <td class=\"centered\">28</td> </tr> <tr> <td>Pushing objects of 75 lb or more (desks, file cabinets)</td> <td class=\"centered\">28</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Wasserman K, Hansen JE, Sue DY, et al. Physiology of exercise. In: Principles of exercise testing and interpretation: Including pathophysiology and clinical applications, 5th ed, Lippincott Williams &amp; Wilkins, 2011.</div><div id=\"graphicVersion\">Graphic 95166 Version 1.0</div></div></div>"},"95167":{"type":"graphic_table","displayName":"SSA disability criteria based on ABG","title":"Social Security Administration disability criteria based on arterial blood gas analysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Social Security Administration disability criteria based on arterial blood gas analysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Testing &#8804;3000 feet<br /> (&#8804;914.4 meters)</td> <td class=\"subtitle1\" colspan=\"2\">Testing at 3000 to 6000 feet<br /> (914.4 to 1828.8 meters)</td> <td class=\"subtitle1\" colspan=\"2\">Testing &#62;6000 feet<br /> (&#62;1228.8 meters)</td> </tr> <tr> <td class=\"subtitle2\">Arterial PCO<sub>2</sub><br /> (mmHg)</td> <td class=\"subtitle2\">Arterial PO<sub>2</sub> equal to or less than<br /> (mmHg)</td> <td class=\"subtitle2\">Arterial PCO<sub>2</sub><br /> (mmHg)</td> <td class=\"subtitle2\">Arterial PO<sub>2</sub> equal to or less than<br /> (mmHg)</td> <td class=\"subtitle2\">Arterial PCO<sub>2</sub><br /> (mmHg)</td> <td class=\"subtitle2\">Arterial PO<sub>2</sub> equal to or less than<br /> (mmHg)</td> </tr> <tr> <td class=\"centered\">30 or below</td> <td class=\"centered\">65</td> <td class=\"centered\">30 or below</td> <td class=\"centered\">60</td> <td class=\"centered\">30 or below</td> <td class=\"centered\">55</td> </tr> <tr> <td class=\"centered\">31</td> <td class=\"centered\">64</td> <td class=\"centered\">31</td> <td class=\"centered\">59</td> <td class=\"centered\">31</td> <td class=\"centered\">54</td> </tr> <tr> <td class=\"centered\">32</td> <td class=\"centered\">63</td> <td class=\"centered\">32</td> <td class=\"centered\">58</td> <td class=\"centered\">32</td> <td class=\"centered\">53</td> </tr> <tr> <td class=\"centered\">33</td> <td class=\"centered\">62</td> <td class=\"centered\">33</td> <td class=\"centered\">57</td> <td class=\"centered\">33</td> <td class=\"centered\">52</td> </tr> <tr> <td class=\"centered\">34</td> <td class=\"centered\">61</td> <td class=\"centered\">34</td> <td class=\"centered\">56</td> <td class=\"centered\">34</td> <td class=\"centered\">51</td> </tr> <tr> <td class=\"centered\">35</td> <td class=\"centered\">60</td> <td class=\"centered\">35</td> <td class=\"centered\">55</td> <td class=\"centered\">35</td> <td class=\"centered\">50</td> </tr> <tr> <td class=\"centered\">36</td> <td class=\"centered\">59</td> <td class=\"centered\">36</td> <td class=\"centered\">54</td> <td class=\"centered\">36</td> <td class=\"centered\">49</td> </tr> <tr> <td class=\"centered\">37</td> <td class=\"centered\">58</td> <td class=\"centered\">37</td> <td class=\"centered\">53</td> <td class=\"centered\">37</td> <td class=\"centered\">48</td> </tr> <tr> <td class=\"centered\">38</td> <td class=\"centered\">57</td> <td class=\"centered\">38</td> <td class=\"centered\">52</td> <td class=\"centered\">38</td> <td class=\"centered\">47</td> </tr> <tr> <td class=\"centered\">39</td> <td class=\"centered\">56</td> <td class=\"centered\">39</td> <td class=\"centered\">51</td> <td class=\"centered\">39</td> <td class=\"centered\">46</td> </tr> <tr> <td class=\"centered\">40 or above</td> <td class=\"centered\">55</td> <td class=\"centered\">40 or above</td> <td class=\"centered\">50</td> <td class=\"centered\">40 or above</td> <td class=\"centered\">45</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Arterial blood gas values obtained in paired measurements, such that at &le;3000 feet, an arterial PO<sub>2</sub> &le;65 mmHg would meet criteria for disability when the associated arterial PCO<sub>2</sub> is &le;30.</div><div class=\"graphic_footnotes\">Arterial PO<sub>2</sub>: arterial tension of oxygen; Arterial PCO<sub>2</sub>: arterial tension of carbon dioxide.</div><div class=\"graphic_reference\">Adapted from: Disability evaluation under Social Security, US Department of Health and Human Services <a href=\"http://www.ssa.gov/disability/professionals/bluebook/3.00-Respiratory-Adult.htm#3_01\" target=\"_blank\">http://www.ssa.gov/disability/professionals/bluebook/3.00-Respiratory-Adult.htm#3_01</a> (Accessed on February 4, 2014).</div><div id=\"graphicVersion\">Graphic 95167 Version 1.0</div></div></div>"},"95168":{"type":"graphic_table","displayName":"SSA disability criteria based on PFTs","title":"Social Security Administration disability criteria based on pulmonary function tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Social Security Administration disability criteria based on pulmonary function tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Height without shoes<br /> (centimeters)</td> <td class=\"subtitle1\">Height without shoes<br /> (inches)</td> <td class=\"subtitle1\">FEV<sub>1</sub> equal to or less than<br /> (L, BTPS)</td> <td class=\"subtitle1\">FVC equal to or less than<br /> (L, BTPS)</td> </tr> <tr> <td class=\"centered\">154 or less</td> <td class=\"centered\">60 or less</td> <td class=\"centered\">1.05</td> <td class=\"centered\">1.25</td> </tr> <tr> <td class=\"centered\">155 to 160</td> <td class=\"centered\">61 to 63</td> <td class=\"centered\">1.15</td> <td class=\"centered\">1.35</td> </tr> <tr> <td class=\"centered\">161 to 165</td> <td class=\"centered\">64 to 65</td> <td class=\"centered\">1.25</td> <td class=\"centered\">1.45</td> </tr> <tr> <td class=\"centered\">166 to 170</td> <td class=\"centered\">66 to 67</td> <td class=\"centered\">1.35</td> <td class=\"centered\">1.55</td> </tr> <tr> <td class=\"centered\">171 to 175</td> <td class=\"centered\">68 to 69</td> <td class=\"centered\">1.45</td> <td class=\"centered\">1.65</td> </tr> <tr> <td class=\"centered\">176 to 180</td> <td class=\"centered\">70 to 71</td> <td class=\"centered\">1.55</td> <td class=\"centered\">1.75</td> </tr> <tr> <td class=\"centered\">181 or more</td> <td class=\"centered\">72 or more</td> <td class=\"centered\">1.65</td> <td class=\"centered\">1.85</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; FVC: forced vital capacity; BTPS: body temperature, ambient pressure, saturated (with water vapor).</div><div class=\"graphic_reference\">Adapted from: Disability evaluation under Social Security, US Department of Health and Human Services <a href=\"http://www.ssa.gov/disability/professionals/bluebook/3.00-Respiratory-Adult.htm#3_01\" target=\"_blank\">http://www.ssa.gov/disability/professionals/bluebook/3.00-Respiratory-Adult.htm#3_01</a> (Accessed on February 4, 2014).</div><div id=\"graphicVersion\">Graphic 95168 Version 1.0</div></div></div>"},"95184":{"type":"graphic_table","displayName":"Scale for impairment related to lung cancer","title":"Scale for determining impairment in subjects with lung cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scale for determining impairment in subjects with lung cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\">0</td> <td>Fully active; able to carry on all predisease activities without restrictions</td> </tr> <tr> <td class=\"centered\">1</td> <td>Restricted in physically strenuous activity, but ambulatory and able to carry out light tasks such as light work in home or office</td> </tr> <tr> <td class=\"centered\">2</td> <td>Requires occasional to considerable care for most needs and frequent medical care</td> </tr> <tr> <td class=\"centered\">3</td> <td>Capable only of limited self-care and confined to bed or chair at least half of waking hours</td> </tr> <tr> <td class=\"centered\">4</td> <td>Almost totally impaired; cannot care for self and totally confined to bed or chair</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Moosa AR, Robson MC, Schimpff SC (eds). Comprehensive Textbook of Oncology. Williams and Wilkins, Baltimore, MD 1986.</div><div id=\"graphicVersion\">Graphic 95184 Version 1.0</div></div></div>"},"95189":{"type":"graphic_picture","displayName":"Dowling-Degos antecubital","title":"Dowling-Degos disease (reticulate pigmented anomaly of flexures)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dowling-Degos disease (reticulate pigmented anomaly of flexures)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95189_DowlingDegosantecubital.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented macules in a net-like distribution in the antecubital folds in a patient with Dowling-Degos disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95189 Version 1.0</div></div></div>"},"95193":{"type":"graphic_table","displayName":"Risk factors for CIPN by neurotoxic drug classification","title":"Risk factors for chemotherapy-induced peripheral neuropathy by neurotoxic drug classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for chemotherapy-induced peripheral neuropathy by neurotoxic drug classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Sites of peripheral nerve damage</td> </tr> <tr> <td>Cisplatin</td> <td>Dorsal root ganglion</td> </tr> <tr> <td>Oxaliplatin</td> <td>Dorsal root ganglion; ion channels</td> </tr> <tr> <td>Paclitaxel</td> <td>Dorsal root ganglion; microtubules; nerve terminals</td> </tr> <tr> <td>Docetaxel</td> <td>Dorsal root ganglion; microtubules; mitochondria; nerve terminals</td> </tr> <tr> <td>Epothilones</td> <td>Dorsal root ganglion; microtubules; nerve terminals</td> </tr> <tr> <td>Bortezomib</td> <td>Microtubules; mitochondrial and endoplasmic reticulum; dysregulation of neurotrophins</td> </tr> <tr> <td>Thalidomide</td> <td>Dorsal root ganglion; nerve blood supply; dysregulation of neurotrophins</td> </tr> <tr> <td>Lenalidomide</td> <td>Dorsal root ganglion; nerve blood supply; dysregulation of neurotrophins</td> </tr> <tr> <td>Pomalodomide</td> <td>Dorsal root ganglion; nerve blood supply; dysregulation of neurotrophins</td> </tr> <tr> <td>Vincristine</td> <td>Dorsal root ganglion; microtubules; nerve terminals</td> </tr> <tr> <td>Suramin</td> <td>Inhibition of growth factors in dorsal root ganglion</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Republished with permission of Dove Press Ltd. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 2014; 6:135. Copyright &copy; 2014; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 95193 Version 1.0</div></div></div>"},"95194":{"type":"graphic_picture","displayName":"Generalized pustular psoriasis","title":"Generalized pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Generalized pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95194_General_pustular_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema, numerous pustules, and scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95194 Version 1.0</div></div></div>"},"95195":{"type":"graphic_table","displayName":"Individual water contamination symptoms in HD patients","title":"Individual symptoms associated with water contaminants among hemodialysis patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Individual symptoms associated with water contaminants among hemodialysis patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom of toxicity</td> <td class=\"subtitle1\">Contaminants</td> </tr> <tr> <td>Abdominal pain</td> <td>Lead</td> </tr> <tr> <td>Anemia</td> <td>Aluminum, chloramine, copper, zinc</td> </tr> <tr> <td>Bone disease</td> <td>Aluminum, fluoride (chronic exposure)</td> </tr> <tr> <td>Cardiac arrest</td> <td>Fluoride (acute exposure to high concentrations)</td> </tr> <tr> <td>Chest pain</td> <td>Fluoride</td> </tr> <tr> <td>Chills</td> <td>Copper</td> </tr> <tr> <td>Cognitive changes</td> <td>Lead</td> </tr> <tr> <td>Death</td> <td>Aluminum, bacteria, chloramine, endotoxin, fluoride</td> </tr> <tr> <td>Encephalopathy</td> <td>Aluminum</td> </tr> <tr> <td>Fever</td> <td>Bacteria, endotoxin</td> </tr> <tr> <td>Hemolysis</td> <td>Chloramine, copper, nitrates</td> </tr> <tr> <td>Hypertension</td> <td>Calcium, sodium</td> </tr> <tr> <td>Hypotension</td> <td>Bacteria, endotoxin, nitrates</td> </tr> <tr> <td>Metabolic acidosis</td> <td>Low pH, sulfate</td> </tr> <tr> <td>Methemoglobinemia</td> <td>Chloramine, nitrates</td> </tr> <tr> <td>Muscle weakness</td> <td>Calcium, lead, magnesium</td> </tr> <tr> <td>Nausea and vomiting</td> <td>Bacteria, calcium, copper, endotoxin, fluoride, low pH, magnesium, nitrates, sulfate, zinc</td> </tr> <tr> <td>Neurologic deterioration</td> <td>Aluminum</td> </tr> <tr> <td>Peripheral neuropathy</td> <td>Lead</td> </tr> <tr> <td>Pruritus</td> <td>Fluoride</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Dialysis water pre-treatment for in-centre and satellite haemodialysis units in NSW: A set of guidelines. NSW Renal Services Network 2008.</div><div id=\"graphicVersion\">Graphic 95195 Version 2.0</div></div></div>"},"95197":{"type":"graphic_figure","displayName":"Prevalence of T1DM and T2DM in youth","title":"Prevalence of type 1 and type 2 diabetes in children and adolescents in the United States, 2001 and 2009","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Prevalence of type 1 and type 2 diabetes in children and adolescents in the United States, 2001 and 2009</div><div class=\"cntnt\"><img style=\"width:628px; height:362px;\" src=\"images/PEDS/95197_Prevalence_T1DM_T2DM_youth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence&nbsp;of type 1 diabetes is for children and adolescents 0 to 19 years. Prevalence&nbsp;of type 2 diabetes is for youth 10 to 19 years.</div><div class=\"graphic_reference\">Data from: Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311:1778.</div><div id=\"graphicVersion\">Graphic 95197 Version 2.0</div></div></div>"},"95200":{"type":"graphic_table","displayName":"Juvenile systemic sclerosis severity score","title":"Juvenile systemic sclerosis severity score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Juvenile systemic sclerosis severity score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">0 (normal)</td> <td class=\"subtitle1\">1 (mild)</td> <td class=\"subtitle1\">2 (moderate)</td> <td class=\"subtitle1\">3 (severe)</td> <td class=\"subtitle1\">4 (end-stage)</td> <td class=\"subtitle1\">Maximum possible score</td> </tr> <tr class=\"divider_bottom\"> <td><strong>General*</strong></td> <td> <p>BMI &#8805; baseline</p> Hgb &#62;11.5 g/dL</td> <td> <p>BMI &#60;1st centile</p> Hgb 10 to 11.4 g/dL</td> <td> <p>BMI &#60;2nd centile</p> Hgb 9 to 9.9 g/dL</td> <td> <p>BMI &#60;3rd centile</p> Hgb 7 to 8.9 g/dL</td> <td> <p>BMI &#60;4th centile</p> Hgb &#60;7 g/dL</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vascular</strong></td> <td>No Raynaud</td> <td>Raynaud requiring vasodilators</td> <td>Digital tip scars</td> <td>Digital tip ulcerations</td> <td>Digital gangrene</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Skin</strong></td> <td>MRSS 0</td> <td>MRSS 1 to 14</td> <td>MRSS 15 to 29</td> <td>MRSS 30 to 39</td> <td>MRSS &#62;40</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Osteoarticular<sup>&#182;</sup></strong></td> <td>No articular involvement</td> <td>&nbsp;</td> <td>Presence of limited range of motion</td> <td>&nbsp;</td> <td>Presence of arthritis and/or tendon friction rub</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Muscle<sup>&#182;</sup></strong></td> <td>Normal proximal muscle strength</td> <td>CMAS 39 to 51</td> <td>CMAS 26 to 38</td> <td>CMAS 13 to 25</td> <td>CMAS 0 to 12</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td><strong>GI*</strong></td> <td>Normal results of proximal GI tract investigations</td> <td> <p>GI symptoms</p> <p>Distal esophageal hypomotility</p> GERD on 24-hour Ph-metry or scintiscan</td> <td>Medium and/or high esophageal hypomotility</td> <td>Malabsorption syndrome</td> <td>Hyperalimentation</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Respiratory<sup>&#916;</sup></strong></td> <td> <p>DLco &#62;80%</p> <p>FVC &#62;80%</p> <p>Normal HRCT</p> sPAP &#60;30 mmHg</td> <td> <p>DLco 70 to 79%</p> <p>FVC 70 to 79%</p> <p>Ground glass changes on HRCT</p> sPAP 31 to 45 mmHg</td> <td> <p>DLco 50 to 69%</p> <p>FVC 50 to 69%</p> <p>Honeycomb changes on HRCT</p> sPAP 46 to 75 mmHg</td> <td> <p>DLco &#60;50%</p> <p>FVC &#60;50%</p> <p>Fibrosis on radiography</p> sPAP &#62;75 mmHg</td> <td>O<sub>2</sub> dependence</td> <td>8</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cardiac<sup>&#916;</sup></strong></td> <td> <p>Normal ECG</p> LVEF &#62;50%</td> <td> <p>ECG conduction defect</p> LVEF 45 to 49%</td> <td> <p>Arrhythmia</p> LVEF 40 to 44%</td> <td> <p>Arrhythmia requiring treatment</p> LVEF 30 to 39%</td> <td> <p>Congestive heart failure</p> LVEF &#60;30%</td> <td>8</td> </tr> <tr> <td><strong>Renal<sup>&#9674;</sup></strong></td> <td>GFR &#62;90 mL/minute</td> <td>GFR 75 to 89 mL/minute</td> <td>GFR 50 to 74 mL/minute</td> <td>GFR 10 to 49 mL/minute</td> <td>End-stage renal failure</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; HgB: hemoglobin; MRSS: modified Rodnan skin thickness score; CMAS: Childhood Myositis Assessment Scale; GI: gastrointestinal; GERD: gastroesophageal reflux disease; DLco: diffusing capacity for carbon monoxide; FVC: forced vital capacity; HRCT: high-resolution computed tomography; sPAP: estimated systolic pulmonary artery pressure by Doppler echocardiography; ECG: electrocardiogram; LVEF: left ventricular ejection fraction; GFR: glomerular filtration rate.<br />* Any of the parameters defines the score.<br />&para; Each score should be multiplied by 0.5 to obtain the final score.<br />&Delta; Any of the parameters defines the score. Each score should be multiplied by 2 to obtain the final score.<br /><span class=\"lozenge\">&loz;</span> The GFR was used to measure creatinine clearance. Values are calculated as follows: for males ages 0 to 12 years, 0.55 x height (cm)/creatinine (mg/dL); for males ages 12 to 18 years, 0.7 x height (cm)/creatinine (mg/dL); for females age 0 to 18 years, 0.55 x height (cm)/creatinine (mg/dL); for males older than age 18 years, (140 - age) x weight (kg)/(72 x creatinine [mg/dL]); for females older than age 18 years, (140 - age) x weight (kg)/(72 x creatinine [mg/dL]) x 0.85.</div><div class=\"graphic_reference\">From: La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum 2012; 64:4143. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/art.34652/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/art.34652/abstract</a>. Copyright &copy; 2012 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 95200 Version 1.0</div></div></div>"},"95201":{"type":"graphic_picture","displayName":"BT-Cath","title":"BT-Cath","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">BT-Cath</div><div class=\"cntnt\"><img style=\"width:514px; height:769px;\" src=\"images/OBGYN/95201_BT_cath.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Permission for use granted by Utah Medical Products Inc, Midvale, Utah. www.utahmed.com.</div><div id=\"graphicVersion\">Graphic 95201 Version 3.0</div></div></div>"},"95209":{"type":"graphic_picture","displayName":"Dyskeratosis congenita teeth","title":"Dyskeratosis congenita","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dyskeratosis congenita</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95209_Dyskeratosiscongenteeth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormal teeth in a child with dyskeratosis congenita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95209 Version 1.0</div></div></div>"},"95211":{"type":"graphic_picture","displayName":"Dyskeratosis congenita tongue","title":"Dyskeratosis congenita","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Dyskeratosis congenita</div><div class=\"cntnt\"><img style=\"width:612px; height:459px;\" src=\"images/DERM/95211_Dyskeratosiscongentongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive leukoplakia on the lateral aspect of the tongue in a child with dyskeratosis congenita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95211 Version 1.0</div></div></div>"},"95215":{"type":"graphic_table","displayName":"Water treatment system component and distribution monitoring","title":"Suggested monitoring of water treatment system components and distribution systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested monitoring of water treatment system components and distribution systems</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item to monitor</td> <td class=\"subtitle1\">What to monitor</td> <td class=\"subtitle1\">Typical range of values*</td> <td class=\"subtitle1\">Typical interval<sup>&#182;</sup></td> </tr> <tr> <td>Sediment filter</td> <td>Pressure drop across the filter</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Daily</td> </tr> <tr> <td>Sediment filter backwashing cycle</td> <td>Backwash cycle timer setting</td> <td>&nbsp;</td> <td>Daily</td> </tr> <tr> <td>Cartridge filter</td> <td>Pressure drop across the filter</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Daily</td> </tr> <tr> <td>Water softener</td> <td>Residual hardness of product water</td> <td>Hardness as specified by the manufacturer of the reverse osmosis equipment</td> <td>Daily</td> </tr> <tr> <td>Water softener brine tank</td> <td>Level of undissolved salt in tank</td> <td>&nbsp;</td> <td>Daily</td> </tr> <tr> <td>Water softener regeneration cycle</td> <td>Regeneration cycle timer setting</td> <td>&nbsp;</td> <td>Daily</td> </tr> <tr> <td>Carbon beds</td> <td>Product-water total chlorine between the beds</td> <td>&#8804;0.1 mg/L of total chlorine</td> <td>Daily</td> </tr> <tr> <td>Chemical injection system</td> <td>Level of chemical in the reservoir, injector function, value of the controlling parameter (eg, pH)</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Daily (continuous monitoring is preferable)</td> </tr> <tr> <td>Reverse osmosis</td> <td>Product water conductivity, TDS, or resistivity and calculated rejection</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Daily (continuous monitoring is preferable)</td> </tr> <tr> <td>Reverse osmosis system</td> <td>Product and reject flow rates, and calculated recovery</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Daily (continuous monitoring is preferable)</td> </tr> <tr> <td>Deionizer</td> <td>Product water resistivity or conductivity</td> <td>Resistivity &#8805;1 megaohm/cm; conductivity &#8804;1 microSiemens/cm</td> <td>Continuous monitoring</td> </tr> <tr> <td>Endotoxin-retentive filters</td> <td>Pressure drop across the filter at a fixed flow rate or product-water flow rate at a fixed pressure drop</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Daily</td> </tr> <tr> <td>Dialysis water storage tanks</td> <td>Bacterial growth and endotoxins</td> <td>Total viable microbial count less than action level (typically 50 CFU/mL); endotoxin less than action level (typically 0.125 EU/mL)</td> <td>Monthly, or as defined by the results of the validation process for storage tanks supplying a central dialysis fluid delivery system</td> </tr> <tr> <td>Water distribution piping system</td> <td>Bacterial growth and endotoxins</td> <td>Total viable microbial count less than action level (typically 50 CFU mL); endotoxin less than action level (typically 0.125 EU/mL)</td> <td>Monthly, or as defined by the validation process results</td> </tr> <tr> <td>UV irradiators</td> <td>Energy output and/or the lamp lifespan</td> <td>Based on the manufacturer's instructions or measurements of system performance</td> <td>Monthly</td> </tr> <tr> <td>Ozone generators</td> <td>Concentration in the water contact time and residual ozone after disinfection</td> <td>Facility should define an acceptable operating range based on the manufacturer's instruction or system performance</td> <td>During each disinfection</td> </tr> <tr> <td>Hot water disinfection system</td> <td>Temperature and time of exposure of the system to hot water</td> <td>Facility should define an acceptable operating range based on the manufacturer's instructions or measurements of system performance</td> <td>During each disinfection</td> </tr> <tr> <td>Chemical disinfection systems</td> <td>Concentration of germicide in water and contact time</td> <td>Facility should define an acceptable operating range based on the manufacturer's instruction or measurements of system performance</td> <td>During each disinfection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TDS: total dissolved solids; CFU: colony forming units; EU: endotoxin units; UV: ultraviolet.<br />* It is not possible to specify universally acceptable operating ranges for each device listed since some of the specifications will be system specific.<br />¶ The actual interval for monitoring, testing, cleaning, and/or disinfection should be based on the results of the validation process and ongoing trend analysis.</div><div class=\"graphic_reference\">Courtesy of Nicholas Hoenich, PhD.</div><div id=\"graphicVersion\">Graphic 95215 Version 2.0</div></div></div>"},"95216":{"type":"graphic_table","displayName":"Monitoring frequency of water and dialysis fluid","title":"Suggested monitoring frequency of water and dialysis fluid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested monitoring frequency of water and dialysis fluid</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item to monitor</td> <td class=\"subtitle1\">What to monitor</td> <td class=\"subtitle1\">Typical range of values</td> <td class=\"subtitle1\">Typical interval</td> </tr> <tr> <td>Feed water</td> <td>Chemical contaminant levels</td> <td>&nbsp;</td> <td>Yearly, but more frequently if trend analysis demonstrates variability</td> </tr> <tr> <td>Product water</td> <td>Chemical and microbiologic contaminant levels</td> <td>As defined by the AAMI<sup>[1]</sup></td> <td>Six monthly, or more frequently if trend analysis demonstrates variability</td> </tr> <tr> <td>Standard dialysis fluid</td> <td>Bacterial growth and endotoxin concentration</td> <td>Total viable microbial count less than action level (typically 50 CFU/mL); endotoxin less than action level (typically 0.25 EU/mL)</td> <td>Monthly, rotated among machines so that each machine is tested at least once per year, and different machines are sampled on each occasion</td> </tr> <tr> <td>Ultrapure dialysis fluid</td> <td>Bacterial growth and endotoxins in the ultrapure dialysis fluid as it enters the dialyzer</td> <td>Total viable microbial count &#60;0.1 CFU/mL; endotoxin &#60;0.03 EU/mL</td> <td> <p>Before the first use to validate the system and monthly thereafter</p> Bacterial growth and endotoxin tests are not necessary if the system is fitted with a bacteria- and endotoxin-retentive filter validated by the manufacturer and operated and monitored according to the manufacturer's instructions</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The actual interval for monitoring, testing, cleaning, and/or disinfection should be based on the results of the validation process and ongoing trend analysis.</div><div class=\"graphic_footnotes\">AAMI: Association for the Advancement of Medical Instrumentation; CFU: colony-forming units; EU: endotoxin units; ANSI: American National Standards Institute; ISO: International Organization for Standardization.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Association for the Advancement of Medical Instrumentation. Water for hemodialysis and related therapies. ANSI/AAMI/ISO 13959. 2009 Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Nicholas Hoenich, PhD.</div><div id=\"graphicVersion\">Graphic 95216 Version 2.0</div></div></div>"},"95217":{"type":"graphic_picture","displayName":"Gianotti-Crosti syndrome papulovesicles","title":"Gianotti-Crosti syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Gianotti-Crosti syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95217_Gianotti-Crosti_synd_papulo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules and papulovesicles on the extremities of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95217 Version 1.0</div></div></div>"},"95218":{"type":"graphic_picture","displayName":"Gianotti-Crosti syndrome face","title":"Gianotti-Crosti syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Gianotti-Crosti syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95218_Gianotti-Crosti_syndro_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules and papulovesicles on the face of a child with Gianotti-Crosti syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95218 Version 1.0</div></div></div>"},"95219":{"type":"graphic_picture","displayName":"Gianotti-Crosti syndrome eruption","title":"Gianotti-Crosti syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gianotti-Crosti syndrome</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95219_Gianotti-Crosti_synd_erupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular and papulovesicular eruption with a predilection for the face and extremities in a child with Gianotti-Crosti syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95219 Version 1.0</div></div></div>"},"95220":{"type":"graphic_picture","displayName":"Gianotti-Crosti syndrome on extremity","title":"Gianotti-Crosti syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Gianotti-Crosti syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95220_Gianotti-Crosti_synd_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papules and papulovesicles in Gianotti-Crosti syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95220 Version 1.0</div></div></div>"},"95221":{"type":"graphic_picture","displayName":"Gianotti-Crosti syndrome buttocks","title":"Gianotti-Crosti syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Gianotti-Crosti syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95221_Gianotti-Crosti_synd_buttoc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papules and papulovesicles on the buttocks of a child with Gianotti-Crosti syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95221 Version 1.0</div></div></div>"},"95222":{"type":"graphic_table","displayName":"Evaluation of AS","title":"Diagnostic evaluation of patients with aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic evaluation of patients with aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient characteristics</td> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Signs or symptoms of aortic stenosis</td> <td>Transthoracic echocardiogram<sup>[1]</sup></td> <td> <ul> <li>Evaluate valve anatomy </li> <li>Measure valve hemodynamics </li> <li>Evaluate&nbsp;left ventricular&nbsp;size and systolic function </li> </ul> </td> <td>Follow-up transthoracic echocardiogram: <ul class=\"decimal_heading\"> <li>Changing signs or symptoms </li> <li>Stable patients with AS: <ul> <li>Every three to five years for Stage B mild AS (transvalvular velocity 2 to 2.9 m/s) </li> <li>Every one to two years for Stage B moderate AS (transvalvular velocity 3 to 3.9 m/s) </li> <li>Every 6 to 12 months with Stage C severe AS (transvalvular velocity 4 m/s or higher) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Calcified valve with reduced systolic opening, LVEF &#60;50 percent,&nbsp;calculated aortic valve area&nbsp;1.0 cm<sup>2</sup> or less AND transvalvular V<sub>max</sub> &#60;4 m/s </td> <td>Low-dose dobutamine stress echocardiogram<sup>[1]</sup></td> <td>Severe AS is present if velocity increases to 4 m/s or higher (mean gradient 40 mmHg or higher) with an AVA of 1.0 cm<sup>2</sup> or less</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Nondiagnostic&nbsp;echocardigram or discrepancy between clinical and echocardiogram findings</td> <td>Cardiac catheterization<sup>[1]</sup></td> <td> <p>Evaluate transaortic pressure gradient&nbsp;with calculation of valve area&nbsp;as well as&nbsp;pulmonary artery&nbsp;pressures and pulmonary vascular resistance</p> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Asymptomatic severe AS to confirm absence of symptoms&nbsp;</p> </td> <td>&nbsp;Exercise testing<span style=\"font-size: 10px;\"><sup>[1]</sup></span></td> <td> <p>Determine exercise duration and blood pressure response to exercise</p> <p>Determine whether provoked symptoms are equivalent to&nbsp;previously unrecognized or new&nbsp;symptoms</p> </td> <td>Exercise testing is contraindicated in symptomatic severe AS</td> </tr> <tr> <td>Patient being considered for transcatheter aortic valve replacement </td> <td>Computed tomography<sup><span style=\"font-size: 10px;\">[2]</span></sup></td> <td> <p>Evaluation of left ventricular outflow tract and annulus shape and size for valve sizing, leaflet length and calcification, and annular to coronary ostial distance</p> </td> <td> <p>3D TEE is used for this evaluation at some centers</p> TEE is used for intraprocedural guidance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AS: aortic stenosis; LVEF: left ventricular ejection fraction; AVA: aortic valve area; TEE: transesophageal echocardiogram; TTE: transthoracic echocardiogram.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2438.</LI>&#xD;&#xA;<LI>Achenbach S, Delgado V, Hausleiter J, et al. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr 2012; 6:366.</LI></OL></div><div id=\"graphicVersion\">Graphic 95222 Version 5.0</div></div></div>"},"95223":{"type":"graphic_table","displayName":"AHA ACC recommendations for aorta in adults with BAV","title":"AHA ACC recommendations for evaluation and treatment of the aorta in adults with a bicuspid aortic valve","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AHA ACC recommendations for evaluation and treatment of the aorta in adults with a bicuspid aortic valve</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient groups with a bicuspid aortic valve</td> <td class=\"subtitle1\">Test or therapy</td> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>All bicuspid valve patients</td> <td>Transthoracic echocardiography</td> <td> <p>Evaluate valve morphology</p> <p>Measure severity of AS and AR</p> Shape and size of aortic sinuses and ascending aorta</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>When aortic anatomy is not adequately evaluated by TTE</td> <td>CMR or CT angiography</td> <td>Shape and size of aortic sinuses and ascending aorta</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic diameter &#62;4.0 cm</td> <td>Serial evaluation of aorta by echo, CMR, or CT angiography</td> <td>Shape and size of aortic sinuses and ascending aorta</td> <td>Examination frequency determined by degree and rate of progression and family history</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic diameter &#62;4.5 cm</td> <td>Serial&nbsp;evaluation of aorta by echo, CMR, or CT angiography</td> <td>Shape and size of aortic sinuses and ascending aorta</td> <td>Annual evaluation recommended</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic diameter &#62;5.5 cm </td> <td>Operative intervention to repair the aortic sinuses or replace the ascending aorta</td> <td>&nbsp;</td> <td>Strong recommendation</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic diameter &#62;5.0 cm plus a risk factor for dissection</td> <td>Operative intervention to repair the aortic sinuses or replace the ascending aorta</td> <td>&nbsp;</td> <td>Weak recommendation; additional risk factors for dissection are a family history of dissection or a rate of progressive dilation 0.5 cm/yr or greater</td> </tr> <tr> <td>Aortic diameter &#62;4.5 cm in patients undergoing surgery for severe AS or AR</td> <td>Operative intervention to repair the aortic sinuses or replace the ascending aorta</td> <td>&nbsp;</td> <td>Weak recommendation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AHA: American Heart Association; ACC: American College of Cardiology; AS: aortic stenosis; AR: aortic regurgitation; CT: computed tomography; CMR: cardiac magnetic resonance imaging; TTE: transthoracic echocardiography.</div><div class=\"graphic_reference\">Source: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014. [Epub ahead of print]</div><div id=\"graphicVersion\">Graphic 95223 Version 3.0</div></div></div>"},"95224":{"type":"graphic_table","displayName":"Description of stages of AS","title":"Description of stages of aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Description of stages of aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"8%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"21%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Stage</td> <td class=\"subtitle1\" rowspan=\"2\">Description and symptoms</td> <td class=\"subtitle1\" colspan=\"2\">Valve anatomy</td> <td class=\"subtitle1\" colspan=\"2\">Haemodynamics</td> <td class=\"subtitle1\" rowspan=\"2\"> <p>LVEF</p> </td> </tr> <tr> <td class=\"subtitle2\">Ca<sup>++</sup></td> <td class=\"subtitle2\">Mobility</td> <td class=\"subtitle2\">Key criteria</td> <td class=\"subtitle2\">Additional measures</td> </tr> <tr> <td class=\"centered\">A</td> <td>At risk (asymptomatic)</td> <td class=\"centered\">+</td> <td class=\"centered\">Normal</td> <td>Aortic V<sub>max</sub> &#60;2 m/s</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"centered\">B</td> <td>Progressive (asymptomatic)</td> <td class=\"centered\">++</td> <td class=\"centered\">&#8595; to &#8595;&#8595;</td> <td> <p>Mild AS: Aortic V<sub>max</sub> 2.0 to 2.9 m/s or mean&nbsp;&#916;P &#60;20 mmHg</p> Moderate AS: Aortic V<sub><span style=\"font-size: 10px;\">max</span></sub> 3.0 to 3.9 m/s or mean &#916;P 20 to 39 mmHg</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"centered\">C1</td> <td>Asymptomatic severe AS with normal LVEF</td> <td class=\"centered\">+++</td> <td class=\"centered\">&#8595;&#8595;&#8595;</td> <td> <p>Aortic V<sub><span style=\"font-size: 10px;\">max</span></sub> &#8805;4 m/s or mean&nbsp;&#916;P 40 mmHg (severe) <br /> Aortic V<sub><span style=\"font-size: 10px;\">max</span></sub> &#8805;5 m/s or mean &#916;P &#8805;60 mmHg (very severe)</p> </td> <td> <p>AVA typically &#8804;1 cm<sup>2</sup></p> <p>(or AVAi &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup>)</p> </td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"centered\">C2</td> <td>Asymptomatic severe AS with low LVEF</td> <td class=\"centered\">+++</td> <td class=\"centered\">&#8595;&#8595;&#8595;</td> <td>Aortic V<sub><span style=\"font-size: 10px;\">max</span></sub> &#8805;4 m/s or mean &#916;P &#8805;40 mmHg (severe)</td> <td> <p>AVA typically &#8804;1 cm<sup>2</sup></p> <p>(or AVAi &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup>)</p> </td> <td class=\"centered\">&#60;50%</td> </tr> <tr> <td class=\"centered\">D1</td> <td>Symptomatic severe high gradient AS</td> <td class=\"centered\">++++</td> <td class=\"centered\">&#8595;&#8595;&#8595;&#8595;</td> <td>Aortic V<sub><span style=\"font-size: 10px;\">max</span></sub>&#8805;4 m/s or mean &#916;P &#8805;40 mmHg</td> <td> <p>AVA typically is &#8804;1 cm<sup>2</sup></p> <p>(or AVAi &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup>)</p> <p>but may be larger with mixed AS/AR</p> </td> <td class=\"centered\">Normal or &#8595;</td> </tr> <tr> <td class=\"centered\">D2</td> <td>Symptomatic severe low gradient AS with low LVEF</td> <td class=\"centered\">++++</td> <td class=\"centered\">&#8595;&#8595;&#8595;&#8595;</td> <td> <p>Resting AVA &#8804;1 cm<sup>2</sup> with aortic V<sub>max</sub>&#60;4 m/s or mean &#916;P &#60;40 mmHg</p> </td> <td>Dobutamine stress shows AVA &#8804;1 cm<sup>2</sup> with V<sub>max</sub> &#8805;4 m/s at any flow rate</td> <td class=\"centered\">&#60;50%</td> </tr> <tr> <td class=\"centered\">D3</td> <td>Symptomatic severe low gradient AS with normal LVEF</td> <td class=\"centered\">++++</td> <td class=\"centered\">&#8595;&#8595;&#8595;&#8595;</td> <td> <p>AVA &#8804;1 cm<sup>2</sup> with aortic V<sub>max</sub> &#60;4 m/s or mean &#916;P &#60;40 mmHg</p> Measured when the patient is normotensive (systolic BP &#60;140 mmHg)</td> <td> <p>Indexed AVA &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup><strong> and</strong> stroke volume index &#60;35 mL/m<sup>2</sup></p> </td> <td class=\"centered\">Normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">↓: decreased with degree indicated by number of arrows; +: present with severity indicated by number of symbols; ΔP: pressure gradient; AS: aortic stenosis; AVA: aortic valve area; AVAi: valve area indexed for body surface area; BP: blood pressure; Ca<SUP>++</SUP>: calcification; LVEF: left ventricular ejection fraction; V<SUB>max</SUB>: maximum transvalvular aortic velocity; AR: aortic regurgitation.</div><div class=\"graphic_reference\">Reproduced with permission from: Otto CM, Nishimura RA. New ACC/AHA valve guidelines: aligning definitions of aortic stenosis severity with treatment recommendations. Heart 2014; 100:902. Copyright &copy; 2014 BMJ Publishing Group Ltd and British Cardiovascular Society. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95224 Version 6.0</div></div></div>"},"95225":{"type":"graphic_table","displayName":"Doula interview","title":"Doula interview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doula interview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Why did you become a doula? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Describe your philosophy/orientation about labor and the birth process. </li> </ul> </td> </tr> <tr> <td> <ul> <li>What is your training and certification? (If doula is certified, confirm with certifying organization.) </li> </ul> </td> </tr> <tr> <td> <ul> <li>How many births have you attended? How many births do you attend per month? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What are your thoughts about childbirth preparation (eg, Lamaze, Bradley)? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Will you visit our home during my pregnancy? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Will you attend one of my prenatal appointments? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Can I call you with questions before labor begins? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Are you familiar with my doctor/midwife? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Have you worked at my hospital? Are you familiar with the facilities, policies, and nursing staff there? Do you foresee any difficulties? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Will you come to our home when labor begins? </li> </ul> </td> </tr> <tr> <td> <ul> <li>When do you want to be called? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What is your role during labor and birth? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What services do you provide? Are there any tasks that are specifically included or excluded? </li> </ul> </td> </tr> <tr> <td> <ul> <li>How do you view the father's role? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What items do you carry in your \"birth bag\"? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What non-drug measures do you suggest for pain relief? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do you have preferences for labor and/or birth positions? </li> </ul> </td> </tr> <tr> <td> <ul> <li>How long do you stay after birth? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do you offer post-birth care for the mother and/or baby? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Are you available for my due date? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What if you don't make it to the birth or most of the labor? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do you have a back-up doula? </li> </ul> </td> </tr> <tr> <td> <ul> <li>How much do you charge for your services? What is your refund policy? </li> </ul> </td> </tr> <tr> <td> <ul> <li>What services are included in your fee? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Does our insurance plan cover your fee? </li> </ul> </td> </tr> <tr> <td> <ul> <li>When would you like payment to be made? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do you have a written contract that we can sign? </li> </ul> </td> </tr> <tr> <td>It is also desirable to discuss your birth preferences with the doula and discuss her role in this plan, find out whether she is comfortable with your birth preferences and philosophy about labor and birth, and decide whether you are comfortable with her. You may want to interview more than one doula.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Examples of areas for discussion when interviewing a potential doula.</div><div id=\"graphicVersion\">Graphic 95225 Version 2.0</div></div></div>"},"95227":{"type":"graphic_diagnosticimage","displayName":"Ectopic ureter inserting into vagina","title":"Imaging studies of ectopic ureter inserting into the vagina","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Imaging studies of ectopic ureter inserting into the vagina</div><div class=\"cntnt\"><img style=\"width:598px; height:336px;\" src=\"images/RADIOL/95227_Ectopic_ureter_into_vagina.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound images of the right kidney shows a hydronephrotic upper pole moiety (arrow) of a duplex collecting system (panel A) and insertion of an ectopic hydroureter (panel B) posterior to the uterus (UT) and below the bladder (BL) (arrowhead). Magnetic resonance imaging (panel C) shows hydronephrosis of the upper pole moiety (arrow) with insertion of the dilated ureter below the bladder (BL) (arrowhead). Panel D is a retrograde contrast radiographic study of the ectopic ureter performed through the vagina (arrowhead).</div><div id=\"graphicVersion\">Graphic 95227 Version 1.0</div></div></div>"},"95229":{"type":"graphic_picture","displayName":"Laugier-Hunziker lips","title":"Laugier-Hunziker syndrome","html":"<div class=\"graphic\"><div style=\"width: 713px\" class=\"figure\"><div class=\"ttl\">Laugier-Hunziker syndrome</div><div class=\"cntnt\"><img style=\"width:693px; height:510px;\" src=\"images/DERM/95229_Laugierhunzikerlips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple lentigines on the lip mucosa of a 19-year-old woman with Laugier-Hunziker syndrome. Lentigines are also present on the dorsal aspect of fingers.</div><div class=\"graphic_reference\">From: Asati DP, Tiwari S. Laugier-Hunziker syndrome. Indian J Dermatol Venereol Leprol 2011; 77:536. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2011;volume=77;issue=4;spage=536;epage=536;aulast=Asati\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.82422</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2011 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95229 Version 2.0</div></div></div>"},"95235":{"type":"graphic_table","displayName":"CDC HIV surveillance stage","title":"CDC surveillance case definition HIV infection stage based on age-specific CD4+ T-lymphocyte count or CD4+ T-lymphocyte percentage of total lymphocytes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CDC surveillance case definition HIV infection stage based on age-specific CD4+ T-lymphocyte count or CD4+ T-lymphocyte percentage of total lymphocytes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Stage</td> <td class=\"subtitle1\" colspan=\"6\">Age at time of CD4+ T-lymphocyte test*</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&#60;1 year</td> <td class=\"subtitle2\" colspan=\"2\">1 to 5 years</td> <td class=\"subtitle2\" colspan=\"2\">&#8805;6 years</td> </tr> <tr> <td class=\"subtitle3\">Cells/microL</td> <td class=\"subtitle3\">Percent</td> <td class=\"subtitle3\">Cells/microL</td> <td class=\"subtitle3\">Percent</td> <td class=\"subtitle3\">Cells/microL</td> <td class=\"subtitle3\">Percent</td> </tr> <tr> <td>0<sup>&#182;</sup></td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr> <td>1</td> <td>&#8805;1500</td> <td>&#8805;34</td> <td>&#8805;1000</td> <td>&#8805;30</td> <td>&#8805;500</td> <td>&#8805;26</td> </tr> <tr> <td>2</td> <td>750 to 1499</td> <td>23 to 33</td> <td>500 to 999</td> <td>22 to 29</td> <td>200 to 499</td> <td>14 to 25</td> </tr> <tr> <td>3 (AIDS)<sup>&#916;</sup></td> <td>&#60;750</td> <td>&#60;26</td> <td>&#60;500</td> <td>&#60;22</td> <td>&#60;200</td> <td>&#60;14</td> </tr> <tr> <td>Unknown<sup>&#9674;</sup></td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention; HIV: human immunodeficiency virus; NA: not applicable; AIDS: acquired immunodeficiency syndrome.<br />* The CD4+ T-lymphocyte count takes precedence over the CD4 T-lymphocyte percentage; the percentage is considered only if the count is missing.<br />¶ Stage 0 represents early infection and is defined by a negative or indeterminate HIV test within 180 days before the first confirmed positive HIV test. If the criteria for stage 0 are met, the stage is 0 regardless of criteria for other stages (CD4 T-lymphocyte test results and opportunistic illness diagnoses).<br />Δ If the criteria for stage 0 are not met and a stage-3-defining opportunistic illness has been diagnosed, then the stage is 3 regardless of CD4 T-lymphocyte test results.<br /><FONT class=lozenge>◊</FONT> If the criteria for stage 0 are not met and information on the above criteria for other stages is missing, then the stage is classified as unknown.</div><div class=\"graphic_reference\">Adapted from: Selik RM, Mokotoff ED, Branson B, et al. Revised Surveillance Case Definition for HIV Infection - United States, 2014. MMWR Recomm Rep 2014; 63:1.</div><div id=\"graphicVersion\">Graphic 95235 Version 4.0</div></div></div>"},"95236":{"type":"graphic_table","displayName":"CDC HIV surveillance criteria","title":"CDC surveillance case definition laboratory criteria for HIV-1 infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CDC surveillance case definition laboratory criteria for HIV-1 infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Persons &#8805;18 months and children &#60;18 months born to HIV-negative mothers</td> </tr> <tr> <td class=\"subtitle2_single\">HIV-infected (one of the following)</td> </tr> <tr> <td class=\"indent1\">A multitest algorithm consisting of: <ul class=\"decimal_heading\"> <li>A positive HIV antibody or combination antigen/antibody test </li> <li>An accompanying or subsequent positive result from a supplemental test different from the initial test </li> </ul> </td> </tr> <tr> <td class=\"indent1\">A positive result from a multitest HIV antibody algorithm from which only the final result was reported</td> </tr> <tr> <td class=\"indent1\">A positive result or report of a detectable quantity from any of the following HIV virologic tests: <ul class=\"decimal_heading\"> <li>Qualitative HIV nucleic acid test (DNA or RNA) </li> <li>Quantitative HIV nucleic acid test (viral load assay) </li> <li>HIV-1 p24 antigen </li> <li>HIV isolation (viral culture), or </li> <li>HIV nucleotide sequence </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Children &#60;18 months born to mothers with HIV infection or unknown HIV status</td> </tr> <tr> <td class=\"subtitle2_single\">HIV-infected (all three of the following)</td> </tr> <tr> <td class=\"indent1\">Positive results on at least one specimen (not including cord blood) from any of the following HIV virologic tests: <ul class=\"decimal_heading\"> <li>HIV-1 NAT (DNA or RNA) </li> <li>HIV-1 p24 antigen test, including neutralization assay for a child aged &#62;1 month </li> <li>HIV isolation (viral culture) </li> <li>HIV nucleotide sequence (genotype) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">The test date is known</td> </tr> <tr> <td class=\"indent1\">One or both of the following: <ul class=\"decimal_heading\"> <li>Confirmation of the first positive result by another positive result on one of the above virologic tests from a specimen obtained on a different date; or </li> <li>No subsequent negative result on an HIV antibody test, and no subsequent negative result on an HIV NAT before age 18 months </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Definitively HIV-uninfected (both of the following)</td> </tr> <tr> <td class=\"indent1\">No positive HIV NAT (RNA or DNA)</td> </tr> <tr> <td class=\"indent1\">At least one of the following: <ul class=\"decimal_heading\"> <li>At least two negative HIV NATs from specimens on different dates at age &#8805;1 month of age, one of which was obtained at age &#8805;4 months </li> <li>At least two negative HIV antibody tests from specimens obtained on different dates at age &#8805;6 months </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Presumptively HIV-uninfected (all three of the following)</td> </tr> <tr> <td class=\"indent1\">Does not meet criteria for definitively uninfected</td> </tr> <tr> <td class=\"indent1\">Meets at least one of the following four laboratory criteria: <ul class=\"decimal_heading\"> <li>At least two negative NATs from specimens obtained on different dates at age &#8805;2 weeks, one of which was obtained at age &#8805;4 weeks </li> <li>One negative NAT (RNA or DNA) at age &#8805;8 weeks </li> <li>One negative HIV antibody test at age &#8805;6 months </li> <li>If criteria for HIV infection had initially been met by one positive HIV NAT test, then it must have been followed by at least two negative results from specimens obtained on different dates, one of which is: <ul class=\"decimal_heading\"> <li>A NAT test from a specimen obtained at age &#8805;8 weeks, or </li> <li>An HIV antibody test from a specimen obtained at age &#8805;6 months </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">No subsequent NAT</td> </tr> <tr> <td class=\"subtitle2_single\">Indeterminate</td> </tr> <tr> <td class=\"indent1\">Does not meet criteria for HIV-infected or HIV-uninfected (definitive or presumptive)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention; HIV: human immunodeficiency virus; NAT: nucleic acid test.</div><div class=\"graphic_reference\">Selik RM, Mokotoff ED, Branson B, et al. Revised Surveillance Case Definition for HIV Infection - United States, 2014. MMWR Recomm Rep 2014; 63:1.</div><div id=\"graphicVersion\">Graphic 95236 Version 2.0</div></div></div>"},"95252":{"type":"graphic_diagnosticimage","displayName":"Echo of RA thrombus in patient with AP Fontan","title":"Echocardigram showing right atrial thrombus in a patient with prior atriopulmonary Fontan operation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardigram showing right atrial thrombus in a patient with prior atriopulmonary Fontan operation</div><div class=\"cntnt\"><img style=\"width:352px; height:405px;\" src=\"images/CARD/95252_Echo_RA_thrombus_AP_Fontan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Still frame two-dimensional apical transthoracic echocardiographic image in a patient with prior atriopulmonary Fontan operation. The patient presented with atrial arrhythmias and was noted to have dilatation of the right atrium and a large (5.1 x 3.9 cm) thrombus (asterisk) in the right atrium.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 95252 Version 1.0</div></div></div>"},"95253":{"type":"graphic_figure","displayName":"Proposed mechanism for PLE","title":"Proposed mechanism for protein losing enteropathy after the Fontan operation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proposed mechanism for protein losing enteropathy after the Fontan operation</div><div class=\"cntnt\"><img style=\"width:387px; height:339px;\" src=\"images/CARD/95253_Proposed_mechanism_for_PLE.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Rychik J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2007; 2:288.</div><div id=\"graphicVersion\">Graphic 95253 Version 2.0</div></div></div>"},"95254":{"type":"graphic_figure","displayName":"Relative circulation pressures post Fontan","title":"Relative circulation pressures in a patient post Fontan operation compared to a healthy individual with biventricular heart","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Relative circulation pressures in a patient post Fontan operation compared to a healthy individual with biventricular heart</div><div class=\"cntnt\"><img style=\"width:554px; height:360px;\" src=\"images/CARD/95254_Rela_circu_press_pst_Fontan.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic demonstrates the relative circulation pressures in a normal biventricular heart (solid line) and a patient with a Fontan operation (dashed line). In both situations, the systemic and pulmonary circulations are connected in series. The primary difference seen at rest is in the central venous pressure. Without a ventricle pumping blood from the systemic veins to the lungs, the central venous pressure remains elevated.</div><div class=\"graphic_reference\">Adapted from: Gewillig M. The Fontan circulation. Heart 2005; 91:839.</div><div id=\"graphicVersion\">Graphic 95254 Version 1.0</div></div></div>"},"95255":{"type":"graphic_picture","displayName":"Corneal arcus","title":"Corneal arcus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Corneal arcus</div><div class=\"cntnt\"><img style=\"width:590px; height:384px;\" src=\"images/CARD/95255_LCAT_deficiency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corneal arcus is a&nbsp;white or grey arc or ring around the cornea due to deposition of cholesterol.&nbsp;It is&nbsp;commonly seen&nbsp;in older adults (called arcus senelis), but is an abnormal finding&nbsp;in individuals under age 40.</div><div class=\"graphic_reference\">Copyright &copy; 2014 The University of Manchester. Reproduced with the permission of Paul Durrington, MD.</div><div id=\"graphicVersion\">Graphic 95255 Version 3.0</div></div></div>"},"95256":{"type":"graphic_picture","displayName":"Pigmentary demarcation line F","title":"Pigmentary demarcation line type F","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigmentary demarcation line type F</div><div class=\"cntnt\"><img style=\"width:394px; height:524px;\" src=\"images/DERM/95256_PigmentarydemarcationlnF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmentary demarcation line type F appearing as a V-shaped line between the malar prominence and the temple, demarcating a relatively darker zone from a light area on the face.</div><div class=\"graphic_reference\">From: Kathuria S, Khunger N, Ramesh V. Clinical and hormonal evaluation in facial pigmentary demarcation lines: A pilot study. Indian J Dermatol Venereol Leprol 2012; 78:742. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=6;spage=742;epage=744;aulast=Kathuria\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.102371</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95256 Version 2.0</div></div></div>"},"95257":{"type":"graphic_picture","displayName":"Pigmentary demarcation line G","title":"Pigmentary demarcation line type G","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigmentary demarcation line type G</div><div class=\"cntnt\"><img style=\"width:429px; height:528px;\" src=\"images/DERM/95257_PigmentarydemarcationlnG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type G pigmentary lines appear as W-shaped hyperpigmented lines between the malar prominence and the temple.</div><div class=\"graphic_reference\">From: Kathuria S, Khunger N, Ramesh V. Clinical and hormonal evaluation in facial pigmentary demarcation lines: A pilot study. Indian J Dermatol Venereol Leprol 2012; 78:742. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=6;spage=742;epage=744;aulast=Kathuria\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.102371</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95257 Version 2.0</div></div></div>"},"95258":{"type":"graphic_picture","displayName":"Pigmentary demarcation lines H","title":"Pigmentary demarcation lines type H","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Pigmentary demarcation lines type H</div><div class=\"cntnt\"><img style=\"width:727px; height:521px;\" src=\"images/DERM/95258_PigmentarydemarcationlnH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmentary demarcation lines type H appear as linear bands of hyperpigmentation from the angle of the mouth to the lateral aspects of the chin.</div><div class=\"graphic_reference\">From: Kathuria S, Khunger N, Ramesh V. Clinical and hormonal evaluation in facial pigmentary demarcation lines: A pilot study. Indian J Dermatol Venereol Leprol 2012; 78:742. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=6;spage=742;epage=744;aulast=Kathuria\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.102371</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95258 Version 2.0</div></div></div>"},"95259":{"type":"graphic_picture","displayName":"Pigmentary demarcation lines A arm","title":"Pigmentary demarcation lines type A (Futcher lines)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigmentary demarcation lines type A (Futcher lines)</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95259_Pigment_demarc_lines_A_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmentary demarcation line type A (Futcher lines) appearing as a sharply demarcated line running vertically on the anterolateral aspect of the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95259 Version 1.0</div></div></div>"},"95260":{"type":"graphic_picture","displayName":"Pigmentary demarcation lines A chest","title":"Pigmentary demarcation lines type A (Futcher lines)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pigmentary demarcation lines type A (Futcher lines)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95260_PigmentdemarclineAchest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmentary demarcation lines type A (Futcher lines) appearing as sharply demarcated lines running vertically on the anterolateral aspect of the arms and across the pectoral area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95260 Version 1.0</div></div></div>"},"95262":{"type":"graphic_picture","displayName":"Blue nevus","title":"Common blue nevus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Common blue nevus</div><div class=\"cntnt\"><img style=\"width:590px; height:493px;\" src=\"images/DERM/95262_Bluenevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue-black papule on the dorsal hand of a child. This represents a frequent location for blue nevi.</div><div id=\"graphicVersion\">Graphic 95262 Version 2.0</div></div></div>"},"95263":{"type":"graphic_picture","displayName":"Pustular psoriasis response to IL-1 antagonist","title":"Response of generalized pustular psoriasis to treatment with an IL-1 antagonist","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Response of generalized pustular psoriasis to treatment with an IL-1 antagonist</div><div class=\"cntnt\"><img style=\"width:728px; height:304px;\" src=\"images/DERM/95263_Pustular_psoriasis_resp_IL1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dramatic response of severe generalized acute pustular psoriasis to treatment with an IL-1 antagonist.</div><div class=\"graphic_reference\">Reproduced with permission. Image courtesy of XOMA (US), LLC. Copyright &copy; 2014.</div><div id=\"graphicVersion\">Graphic 95263 Version 3.0</div></div></div>"},"95264":{"type":"graphic_picture","displayName":"Spongiform pustule of Kogoj in generalized pustular psoriasis","title":"Spongiform pustule of Kogoj in generalized pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Spongiform pustule of Kogoj in generalized pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:590px; height:397px;\" src=\"images/DERM/95264_Spongif_pustule_Kogoj_pust.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biopsy reveals a central pustule comprised of neutrophils. (Hematoxylin and Eosin original magnification 100x)</div><div id=\"graphicVersion\">Graphic 95264 Version 1.0</div></div></div>"},"95265":{"type":"graphic_picture","displayName":"Spongiform pustule of Kogoj in generalized pustular psoriasis 2","title":"Spongiform pustule of Kogoj in generalized pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Spongiform pustule of Kogoj in generalized pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:590px; height:390px;\" src=\"images/DERM/95265_Spongif_pustule_Kogoj_pust2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examination under high power reveals neutrophils extending into the epidermis with spongiform pustule formation. Eosinophils are absent, helping to exclude a diagnosis of acute generalized exanthematous pustulosis. (Hematoxylin and Eosin original magnification 200x)</div><div id=\"graphicVersion\">Graphic 95265 Version 1.0</div></div></div>"},"95273":{"type":"graphic_diagnosticimage","displayName":"Retained sponge following breast surgery","title":"Retained sponge following breast surgery","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Retained sponge following breast surgery</div><div class=\"cntnt\"><img style=\"width:753px; height:468px;\" src=\"images/RADIOL/95273_Retained_sponge_breast_surg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph performed following lumpectomy (A) shows a surgical sponge in the right lateral chest (arrows). This finding was overlooked. Two weeks later, the patient presented with a breast abscess. Image B is a mammogram and shows the surgical sponge (arrows), surrounding soft tissue abscess (arrowheads), and gas pockets in the abscess (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Priscilla Slanetz, MD.</div><div id=\"graphicVersion\">Graphic 95273 Version 1.0</div></div></div>"},"95274":{"type":"graphic_diagnosticimage","displayName":"Retained sponge following chest surgery","title":"Retained sponge following chest surgery","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Retained sponge following chest surgery</div><div class=\"cntnt\"><img style=\"width:595px; height:480px;\" src=\"images/RADIOL/95274_Retained_sponge_chest_surg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray performed following thoracic aneurysm repair shows a retained sponge in the left chest (arrow).</div><div class=\"graphic_reference\">Courtesy of Priscilla Slanetz, MD.</div><div id=\"graphicVersion\">Graphic 95274 Version 1.0</div></div></div>"},"95276":{"type":"graphic_figure","displayName":"Ureteral stent with extraction string","title":"Ureteral stent with extraction string","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteral stent with extraction string</div><div class=\"cntnt\"><img style=\"width:394px; height:563px;\" src=\"images/SURG/95276_Ureteral_stent_with_extraction_string.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 95276 Version 2.0</div></div></div>"},"95281":{"type":"graphic_algorithm","displayName":"Management of Budd-Chiari syndrome","title":"Management of Budd-Chiari syndrome","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Management of Budd-Chiari syndrome</div><div class=\"cntnt\"><img style=\"width:586px; height:796px;\" src=\"images/GAST/95281_Management_Budd_Chiari_synd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topic reviews on Budd-Chiari syndrome for detailed discussions of treatment and monitoring.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma; TIPS: transjugular intrahepatic portosystemic shunt.<br />* Provided there are no contraindications, including high-risk varices that have not been treated.<br />¶ Present for three to four weeks.<br />Δ Disease progression includes the development of cirrhosis and its complications (portal hypertension, HCC), and progression of an underlying myeloproliferative disorder.<br />​<FONT class=lozenge>◊</FONT> Thrombolytic therapy can be combined with angioplasty in patients in whom there is recent thrombosis of a single hepatic vein.</div><div id=\"graphicVersion\">Graphic 95281 Version 3.0</div></div></div>"},"95285":{"type":"graphic_figure","displayName":"Ramp position illustration","title":"Ramp position illustration","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Ramp position illustration</div><div class=\"cntnt\"><img style=\"width:507px; height:620px;\" src=\"images/ANEST/95285_RAMP_position_for_obese_patient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the ramp position, the patient's head and torso are elevated such that the external auditory meatus and the sternal notch are horizontally aligned (black line). This position allows for a better view of the glottis in obese patients and should be used unless there are contraindications (eg, possible cervical spine injury).</div><div id=\"graphicVersion\">Graphic 95285 Version 4.0</div></div></div>"},"95287":{"type":"graphic_table","displayName":"Resources SMY family members","title":"Resources for parents and family members of sexual minority youth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for parents and family members of sexual minority youth</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Advocates for Youth: LGBTQ Issues Info for Parents</p> <a href=\"http://www.advocatesforyouth.org/index.php/glbtq-issues-info-for-parents\" target=\"_blank\">www.advocatesforyouth.org/index.php/glbtq-issues-info-for-parents</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>American Academy of Pediatrics</p> <p>Gay, lesbian, bisexual teens: Facts for teens and their parents</p> <a href=\"http://www.healthychildren.org/English/ages-stages/teen/dating-sex/Pages/Gay-Lesbian-and-Bisexual-Teens-Facts-for-Teens-and-Their-Parents.aspx\" target=\"_blank\">www.healthychildren.org/English/ages-stages/teen/dating-sex/Pages/Gay-Lesbian-and-Bisexual-Teens-Facts-for-Teens-and-Their-Parents.aspx</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>American Academy of Child and Adolescent Psychiatry</p> <p>Facts for Families: Gay, Lesbian and Bisexual Adolescents</p> <a href=\"http://www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/Facts_for_Families_Pages/Gay_Lesbian_and_Bisexual_Adolescents_63.aspx\" target=\"_blank\">www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/Facts_for_Families_Pages/Gay_Lesbian_and_Bisexual_Adolescents_63.aspx</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>American Psychological Association</p> <p>Understanding sexual orientation and gender identity</p> <a href=\"http://www.apa.org/topics/sexuality/index.aspx\" target=\"_blank\">www.apa.org/topics/sexuality/index.aspx</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Centers for Disease Control and Prevention</p> <p>Electronic aggression: Technology and youth violence</p> <p><cite><span style=\"color: #ff0000;\"><a href=\"https://www.cdc.gov/violenceprevention/pdf/ea-tipsheet-a.pdf\"><span style=\"color: #0000ff; font-style: normal;\">https://www.cdc.gov/violenceprevention/pdf/ea-tipsheet-a.pdf</span></a></span></cite></p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kids Health: Sexual Attraction and Orientation</p> <a href=\"http://www.kidshealth.org/parent/emotions/feelings/sexual_orientation.html\" target=\"_blank\">kidshealth.org/parent/emotions/feelings/sexual_orientation.html</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Parents, Families, and Friends of Lesbians and Gays</p> <a href=\"http://www.community.pflag.org/\" target=\"_blank\">community.pflag.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Sexuality Information and Education Council of the United States</p> <p>Families Are Talking: Why It's Important to Talk About Sexual Orientation</p> <a href=\"http://www.siecus.org/_data/global/images/FAT_Newsletter_V3N2.pdf\" target=\"_blank\">www.siecus.org/_data/global/images/FAT_Newsletter_V3N2.pdf</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Stopbullying.gov</p> <a href=\"http://www.stopbullying.gov/\" target=\"_blank\">www.stopbullying.gov</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Stop Bullying Now</p> www.stopbullyingnow.com</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Supportive Families, Healthy Children: Helping Families with Lesbian, Gay, Bisexual and Transgender Children</p> <a href=\"http://familyproject.sfsu.edu/sites/sites7.sfsu.edu.familyproject/files/FAP_English%20Booklet_pst.pdf\" spellcheck=\"true\" target=\"_blank\">http://familyproject.sfsu.edu/sites/sites7.sfsu.edu.familyproject/files/FAP_English%20Booklet_pst.pdf</a></td> </tr> <tr> <td> <p>The Trevor Project: Education and training for adults</p> <a href=\"http://www.thetrevorproject.org/section/education-training-for-adults\" target=\"_blank\">www.thetrevorproject.org/section/education-training-for-adults</a></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LGBTQ: lesbian, gay, bisexual, transgender, questioning.</div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95287 Version 5.0</div></div></div>"},"95288":{"type":"graphic_table","displayName":"Resources SMY","title":"Resources for sexual minority youth and their friends","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for sexual minority youth and their friends</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Gay-Straight Alliance Network</p> <a href=\"http://gsanetwork.org/\" target=\"_blank\">gsanetwork.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Gay Lesbian Straight Education Network: Information for Students</p> <a href=\"http://glsen.org/students\" target=\"_blank\">glsen.org/students</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>It Gets Better Project</p> <a href=\"http://www.itgetsbetter.org/\" target=\"_blank\">www.itgetsbetter.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Sexuality Information and Education Council of the United States</p> <a href=\"http://www.siecus.org/\" target=\"_blank\">www.siecus.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Stopbullying.gov</p> <a href=\"http://www.stopbullying.gov/\" target=\"_blank\">www.stopbullying.gov</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Stop Bullying Now</p> www.stopbullyingnow.com</td> </tr> <tr class=\"divider_bottom\"> <td> <p>The Trevor Project: Help and Suicide Prevention</p> <a href=\"http://www.thetrevorproject.org/\" target=\"_blank\">www.thetrevorproject.org</a></td> </tr> <tr> <td> <p>Trevor Space: News and Networking</p> <a href=\"http://www.trevorspace.org/\" target=\"_blank\">www.trevorspace.org</a></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95288 Version 3.0</div></div></div>"},"95289":{"type":"graphic_table","displayName":"Resources SMY clinicians","title":"Sexual minority health-related national organizations/coalitions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sexual minority health-related national organizations/coalitions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>American Psychiatric Association - LGBT Sexual Orientation</p> <a href=\"http://www.psychiatry.org/mental-health/people/lgbt-sexual-orientation\" target=\"_blank\">www.psychiatry.org/mental-health/people/lgbt-sexual-orientation</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Gay and Lesbian Medical Association</p> <a href=\"http://www.glma.org/\" target=\"_blank\">www.glma.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Mautner Project of Whitman-Walker Health</p> <a href=\"http://www.whitman-walker.org/mautnerproject\" target=\"_blank\">www.whitman-walker.org/mautnerproject</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>National Association of Lesbian and Gay Addiction Professionals</p> <a href=\"http://www.nalgap.org/\" target=\"_blank\">www.nalgap.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>National Coalition for LGBT Health</p> <p><a href=\"http://healthlgbt.org/\">http://healthlgbt.org/</a></p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>National LGBT Cancer Network</p> <a href=\"http://www.cancer-network.org/\" target=\"_blank\">www.cancer-network.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>National LGBT Health Education Center</p> <a href=\"http://www.lgbthealtheducation.org/\" target=\"_blank\">www.lgbthealtheducation.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>National LGBT Tobacco Control Network</p> <a href=\"http://www.lgbttobacco.org/\" target=\"_blank\">www.lgbttobacco.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Society for Adolescent Health and Medicine Position Statement on LGBT Adolescent Health and Well-being</p> <a href=\"http://www.adolescenthealth.org/Advocacy/Position-Papers-Statements.aspx\" target=\"_blank\">www.adolescenthealth.org/Advocacy/Position-Papers-Statements.aspx</a></td> </tr> <tr> <td> <p>Substance Abuse and Mental Health Services Administration</p> <p>A Practitioner's Resource Guide: Helping Families to Support Their LGBT Children</p> <a href=\"http://store.samhsa.gov/shin/content//PEP14-LGBTKIDS/PEP14-LGBTKIDS.pdf\" target=\"_blank\">http://store.samhsa.gov/shin/content//PEP14-LGBTKIDS/PEP14-LGBTKIDS.pdf</a></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LGBT: lesbian, gay, bisexual, transgender.</div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95289 Version 5.0</div></div></div>"},"95290":{"type":"graphic_table","displayName":"Sexual activity by sexual orientation","title":"Median percentage of US high-school students reporting sexual activities according to self-reported sexual identity and sex of partner*, United States, 2001-2009","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Median percentage of US high-school students reporting sexual activities according to self-reported sexual identity and sex of partner*, United States, 2001-2009</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Unsure</td> <td class=\"subtitle1\">Bisexual identity</td> <td class=\"subtitle1\">Both sex partners</td> <td class=\"subtitle1\">Gay or lesbian identity</td> <td class=\"subtitle1\">Same sex partners</td> <td class=\"subtitle1\">Heterosexual identity</td> <td class=\"subtitle1\">Opposite sex partners</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ever had sexual intercourse</strong></td> <td class=\"centered\">43.0</td> <td class=\"centered\">69.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">67.1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">44.1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>First sexual intercourse before age 13</strong></td> <td class=\"centered\">13.1</td> <td class=\"centered\">14.6</td> <td class=\"centered\">22.9</td> <td class=\"centered\">19.8</td> <td class=\"centered\">15.8</td> <td class=\"centered\">4.8</td> <td class=\"centered\">12.4</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sexual intercourse with &#8805;4 partners</strong></td> <td class=\"centered\">18.8</td> <td class=\"centered\">28.2</td> <td class=\"centered\">44.1</td> <td class=\"centered\">29.9</td> <td class=\"centered\">26.8</td> <td class=\"centered\">11.1</td> <td class=\"centered\">25.8</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sexually active<sup>&#182;</sup> in the last 3 months</strong></td> <td class=\"centered\">32.0</td> <td class=\"centered\">52.6</td> <td class=\"centered\">64.9</td> <td class=\"centered\">53.2</td> <td class=\"centered\">52.4</td> <td class=\"centered\">19.3</td> <td class=\"centered\">59.0</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Used a condom with last intercourse<sup>&#916;</sup></strong></td> <td class=\"centered\">52.7</td> <td class=\"centered\">53.7</td> <td class=\"centered\">44.1</td> <td class=\"centered\">35.8</td> <td class=\"centered\">59.6<sup>&#9674;</sup></td> <td class=\"centered\">65.5</td> <td class=\"centered\">64.2</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Used both a condom and birth control pills or depot medroxyprogesterone with last intercourse<sup>&#916;</sup></strong></td> <td class=\"centered\">7.2</td> <td class=\"centered\">6.2</td> <td class=\"centered\">4.7</td> <td class=\"centered\">4.5</td> <td class=\"centered\">&ndash;&ndash;</td> <td class=\"centered\">7.6</td> <td class=\"centered\">8.4</td> </tr> <tr> <td><strong>Used alcohol or drugs before last intercourse<sup>&#916;</sup></strong></td> <td class=\"centered\">37.9</td> <td class=\"centered\">29.9</td> <td class=\"centered\">35.0</td> <td class=\"centered\">35.1</td> <td class=\"centered\">27.2</td> <td class=\"centered\">18.7</td> <td class=\"centered\">20.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Among students who ever had sexual contact.<br />¶ Had sexual intercourse with at least one person.<br />Δ Among students who were sexually active in the last three months.<br /><FONT class=lozenge>◊</FONT> Male students only.</div><div class=\"graphic_reference\">Data from: Kann L, Olsen EO, McManus T, et al. Sexual identity, sex of sexual contacts, and health-risk behaviors among students in grades 9-12--youth risk behavior surveillance, selected sites, United States, 2001-2009. MMWR Surveill Summ. 2011; 60:1.</div><div id=\"graphicVersion\">Graphic 95290 Version 2.0</div></div></div>"},"95291":{"type":"graphic_table","displayName":"SMY disclosure","title":"Discussing disclosure with sexual minority youth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Discussing disclosure with sexual minority youth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>When?</strong></td> <td>Coming out can be a life-long process. Everyone's timing is different. The person coming out should decide when is best.</td> </tr> <tr class=\"divider_bottom\"> <td>Consider coming out when you: <ul class=\"decimal_heading\"> <li>Are comfortable with your sexual interests, identity and orientation </li> <li>Want to share this with persons that you trust and are close to you </li> <li>Have had a chance to gather information or talk to others to learn from their coming out experiences </li> <li>Have a plan for support&ndash;where could you live, get money for food and clothes, go to school and work if you are not accepted in your home and need to live elsewhere? </li> <li>Are ready to </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Who?</strong></td> <td>You don't have to tell everyone at the same time. Parents and family may be a strong source of support, but also may respond differently than you expect. Sometimes telling a close and trusted friend or professional (eg, teacher, coach, counselor) can be easier and safer the first time you tell someone about your sexuality.</td> </tr> <tr class=\"divider_bottom\"> <td>Choose a person or persons who you: <ul class=\"decimal_heading\"> <li>Know well and expect to be respectful and supportive </li> <li>Trust, feel safe with, and know will keep your information confidential if you ask them to </li> <li>If you are thinking about telling a friend, choose carefully; some may have trouble keeping your information safe and confidential </li> <li>If you are thinking about disclosing to a school staff member, it is important to know whether or not your school's privacy and confidentiality policy requires staff to reveal that information to your parents </li> <li>Be sure to tell the person or persons you tell, who else may be told and who should <strong>NOT</strong> be told </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><strong>How?</strong></td> <td><strong>Planning</strong></td> </tr> <tr> <td class=\"indent1 divider_bottom\">Planning for your disclosure can help to make it a more positive and safe experience. Preparation may include: <ul class=\"decimal_heading\"> <li>Talking to other sexual minority youth or sexual minority adults who have already come out to family and friends; listening and learning from others may provide useful strategies and help you feel confident about when and how to come out </li> <li>Participating in LGBTQ youth groups, support groups, or school groups that can offer advice on coming out </li> <li>Accessing Internet resources that relate other youth's coming out experiences </li> <li>Creating a support network before you come out; professionals (eg, health care providers, mental health professionals, counselors) who work with children and teens may be able to help with this </li> </ul> </td> </tr> <tr> <td><strong>Process</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Disclosing in a letter</strong></td> </tr> <tr> <td class=\"indent2\">Writing a letter gives you time to carefully say what you mean to say. Reading a letter in private gives the other person time to consider how they feel and how they might respond to you.</td> </tr> <tr> <td class=\"indent1\"><strong>Disclosing in person</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Some things to keep in mind if you decide to disclose in person: <ul class=\"decimal_heading\"> <li>Try to choose a quiet and private space where you can talk with one or two people at a time </li> <li>If you have concerns about your parents' reaction (or the reaction of whoever you are telling), try to choose a quiet but public place with other persons around and available to help if needed </li> <li>Disclose when you and the other person are well rested, not dealing with other active stressors, and have time to continue talking </li> <li>Focus on a few issues that are most important to you. Actively listen to what is important to the other person as well. </li> <li>Plan how you might want to end the conversation and how you might plan to talk about it later </li> <li>Avoid using alcohol or drugs; your mental and emotional state should be stable and secure when you have this important conversation </li> <li>Try to avoid coming out because of pressure from others, being angry, or fighting </li> </ul> </td> </tr> <tr> <td rowspan=\"6\"><strong>Safety</strong></td> <td><strong>Be prepared for the possibility of a negative or rejecting reaction.</strong></td> </tr> <tr> <td><strong>Safety first and foremost.</strong> Plan how to keep yourself physically safe at the time of disclosure and afterward. This may be difficult, but it is important to figure out ahead of time where you would go if the disclosure is difficult or threatening.</td> </tr> <tr> <td>Emotional safety is important too. If you think you may be disclosing to a person who will be negative or rejecting, have your support network ready to help you process the negative reaction.</td> </tr> <tr> <td>Some people's first reaction may be more negative than you anticipate. The negative response may be based on the initial shock, surprise, or discomfort. They may need time to process the disclosure. People with negative initial reactions may still accept and support you but have a hard time processing their own feelings.</td> </tr> <tr> <td>Strong negative reactions may reflect personal biases or a background and culture that discriminate against sexual minorities. Issues of religion, morality, and culture have a large impact on how people view sexual diversity. However, there are many social and religious institutions that support civil and social rights of individuals regardless of sexuality or orientation.</td> </tr> <tr> <td>You get to decide if and when to walk away from people who are negative, unsupportive, or harmful.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LGBTQ: lesbian, gay, bisexual, transgender, questioning.</div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95291 Version 2.0</div></div></div>"},"95292":{"type":"graphic_table","displayName":"Sexual history for parents","title":"Strategies for interviewing parents about their child’s sexual attraction, identity, and behaviors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for interviewing parents about their child’s sexual attraction, identity, and behaviors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sample questions regarding sexuality</td> <td class=\"subtitle1\">Developmental goals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For parent(s) of prepubertal or peripubertal adolescents (age &#60;14 years)</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Do you have any questions or concerns about how your child expresses gender or sexuality? </li> <li>What sorts of play, interests, and friends does your child have? </li> <li>Does any of your child's play, activities, or interests concern you or your co-parent? </li> <li>Do you have any concerns about your child's friends, lack of friends, bullying, or other social issues? </li> <li>Do you need information regarding upcoming changes with puberty and adolescence? </li> <li>How do you plan to talk with your child about puberty? </li> <li>What were your experiences with puberty, adolescence and sex? </li> <li>What sort of expectations and plan for communication have you established with your teen? </li> </ul> </td> <td> <ul> <li>Preparing parents to tasks of puberty </li> <li>Preparing parents to talk with children about upcoming puberty changes </li> <li>Prepare parents to have open, honest, supportive communication </li> <li>Give parents skill set to set limits, establish plans, and discuss consequences </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95292 Version 2.0</div></div></div>"},"95293":{"type":"graphic_table","displayName":"Sexuality history middle and late adolescents","title":"Strategies for interviewing middle and late adolescents about sexual attraction, identity, and behaviors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for interviewing middle and late adolescents about sexual attraction, identity, and behaviors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sample questions regarding sexuality</td> <td class=\"subtitle1\">Developmental goals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For middle adolescents (age 15 to 17 years)</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Do you have any romantic interests in your life? </li> <li>Are you dating anyone? </li> <li>Is there anyone with whom you have a sexual relationship, including kissing, touching, or other stuff? Tell me about your partner. </li> <li>Are you sexually active or have you ever had sex*? </li> <li>What do you mean by \"sex\"? </li> <li>What sorts of sex have you had? </li> <li>What parts went where when you were having sex? </li> <li>Has sex been something you have wanted or something you felt emotionally or physically forced into doing? </li> <li>Have you ever paid for sex or been paid for sex? </li> <li>Who have you talked with about sex? </li> <li>What do your parents have to say about sex? </li> <li>What do your parents, family, and friends say about same sex or gay people? </li> <li>Do you have any gay or bisexual people in your life that you can talk with? </li> <li>How do you feel about homosexuality or same sex relationships? </li> </ul> </td> <td> <ul> <li>Safer exploration, experimentation </li> <li>Risk reduction and prevention of: sexually transmitted infections, unintended pregnancy, dating violence, bullying, substance use, mental health concerns, and suicidality </li> <li>Acknowledging and modeling support for diversity </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For late adolescents (age 18 and older)</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Are you sexually active or have you ever had sex*? </li> <li>Why or why not? </li> <li>What benefits or risks does being sexually active bring to a relationship? </li> <li>What sorts of things do you and your partner(s) do when you are sexually active? </li> <li>Do you kiss, touch each other's genitals, put your fingers in your partner's vagina or butt, put your penis in your partner's vagina or butt, receive a penis in your vagina or butt, give or receive oral sex? </li> <li>Has sex been something you have wanted or something you felt emotionally or physically forced into doing? </li> <li>Have you ever paid for sex or been paid for sex? </li> <li>Is sex pleasurable for you? </li> <li>Do you have any concerns about sex, orgasm? </li> <li>Any concerns about premature ejaculation or having a hard time getting aroused, wet, or hard? </li> <li>Do you do anything else that gives you and/or your partner sexual pleasure? Masturbation? Pornography? Drugs or alcohol with sex? Sex games or fantasy? Sadism or masochism? Fetishes or unusual ways to pleasure yourself or partner? </li> <li>(Remember to <strong>leave long and open pauses</strong> for patients to fill in the blanks or report other activities or interests) </li> </ul> </td> <td> <ul> <li>Risk and harm reduction </li> <li>Explore sex for pleasure and pleasurable sex </li> <li>Explore sex's role in intimacy and mature relationship building </li> <li>Prepare for intimate partners, family planning </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For those who are sexually active, it is also important to ask about the number of partners, use of condoms or dental dams, and contraception.</div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95293 Version 2.0</div></div></div>"},"95294":{"type":"graphic_table","displayName":"Sexuality history pre- and peripuberty","title":"Strategies for interviewing prepubertal and peripubertal adolescents about sexual attraction, identity, and behaviors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for interviewing prepubertal and peripubertal adolescents about sexual attraction, identity, and behaviors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sample questions regarding sexuality</td> <td class=\"subtitle1\">Developmental goals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For prepubertal children and peripubertal adolescents (age &#60;10 years)</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Do you have any questions or concerns about what being a boy or girl means? </li> <li>How do you feel&ndash;more like a boy, girl, or somewhere in between? </li> <li>Do you like your body? </li> <li>Do you think your body is healthy? Does your body fit you? </li> <li>What do you wish was different about your body? </li> <li>If you could change anything about your body, what would it be? </li> <li>Have you talked with your parent(s) or at school about puberty? </li> <li>What does puberty mean to you? </li> <li>Do you know what changes are ahead when you start puberty? </li> <li>What sort of plan do you have with your parent(s) for talking about teen issues? </li> </ul> </td> <td> <ul> <li>Prepare children to enter puberty </li> <li>Prepare children to have open, honest, supportive communication </li> <li>Give children permission to ask questions </li> <li>Give children a skill set to ask questions </li> <li>Give children an explicit plan about how to bring up sensitive topics with adults </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For peripubertal and early adolescents (age 10 to 14 years)</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>What do you know about puberty? </li> <li>What sort of conversations have you had about being a teen with your parents, at school, or with friends? </li> <li>How do you feel about the changes in your body? Have your friends' bodies started to change? </li> <li>What changes are occurring with your friends regarding crushes, romantic feelings, dating, or sex? </li> <li>Do you have any crushes or romantic interests in your life? </li> <li>Is there anyone who is extra special and who you would like to get to know or date? </li> <li>Most kids masturbate. Do you get aroused, touch yourself or wonder about having sex? </li> <li>Some kids start experimenting with sex early. Do you have any questions about what sex is? </li> <li>What are your friends doing in regards to sex? </li> <li>What have you done so far about sex? </li> <li>What and how do you and your parent(s) communicate about sex? </li> <li>What is your parent(s) position on being sexually active? </li> <li>Can you talk openly with your parent(s) about sex? </li> <li>Is there anything I can do to help you communicate with your parent about puberty and sex? </li> </ul> </td> <td> <ul> <li>Early education, preparation for puberty </li> <li>Early identification of gender dysphoria, same sex attraction and behaviors </li> <li>Early support for sexual minority youth and early intervention for parents (eg, resources, referrals) </li> <li>Risk reduction and prevention of: anxiety, depression, suicidality and other mood or behavioral concerns </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95294 Version 2.0</div></div></div>"},"95298":{"type":"graphic_table","displayName":"Normal values maximum oxygen uptake","title":"Normal values for maximum oxygen uptake during cycle ergometry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for maximum oxygen uptake during cycle ergometry</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">25-34</td> <td class=\"subtitle1\">35-44</td> <td class=\"subtitle1\">45-54</td> <td class=\"subtitle1\">55-64</td> <td class=\"subtitle1\">&#62;64</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Men</td> </tr> <tr> <td class=\"indent1\">Median VO<sub>2</sub> max (mL/minute per kg)<br /> (5<sup>th</sup>-95<sup>th </sup>percentile)</td> <td>38<br /> (26-51)</td> <td>36<br /> (24-48)</td> <td>35<br /> (23-45)</td> <td>33<br /> (20-40)</td> <td>30<br /> (17-36)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Women</td> </tr> <tr> <td class=\"indent1\">Median VO<sub>2</sub> max (mL/minute per kg)<br /> (5<sup>th</sup>-95<sup>th </sup>percentile)</td> <td>30<br /> (22-41)</td> <td>29<br /> (21-39)</td> <td>27<br /> (20-37)</td> <td>25<br /> (18-32)</td> <td>22<br /> (16-28)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal VO<sub>2</sub> max values, based on incremental bicycle ergometry testing in healthy individuals derived from a population-based cohort.</div><div class=\"graphic_footnotes\">VO<sub>2</sub> max: maximum oxygen uptake during exercise.</div><div class=\"graphic_reference\">Data from: Koch B, Schaper C, Ittermann T, et al. Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur Respir J 2009; 33:389.</div><div id=\"graphicVersion\">Graphic 95298 Version 1.0</div></div></div>"},"95312":{"type":"graphic_figure","displayName":"Exercise training and VO2max","title":"Effect of exercise training on oxygen uptake at peak exercise","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Effect of exercise training on oxygen uptake at peak exercise</div><div class=\"cntnt\"><img style=\"width:718px; height:556px;\" src=\"images/PULM/95312_Exercise_training_VO2max.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel illustrates representative normal values for oxygen uptake at rest, at peak exercise, and at peak exercise following exercise training in a 25-year-old male. The right panel illustrates relative changes in the three components of VO<sub>2</sub> (heart rate, stroke volume, and arteriovenous difference in oxygen content) in response to maximal exercise.</div><div class=\"graphic_footnotes\">VO<SUB>2</SUB>: oxygen uptake; HR: heart rate; SV: stroke volume; C: content.</div><div class=\"graphic_reference\">Courtesy of Gregory D Lewis, MD.</div><div id=\"graphicVersion\">Graphic 95312 Version 1.0</div></div></div>"},"95314":{"type":"graphic_figure","displayName":"Ventilatory efficiency and cardiac prognosis","title":"Ventilatory efficiency predicts risk for major cardiac events","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Ventilatory efficiency predicts risk for major cardiac events</div><div class=\"cntnt\"><img style=\"width:609px; height:467px;\" src=\"images/PULM/95314_Vntltryefficncycrdcprgns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis for two-year major cardiac-related events. Subjects meeting criteria for VC-1 (VE/VCO<sub>2</sub> slope &le;29.9; n = 144) experienced four major cardiac events (including two heart transplants); 97.2% were event-free. Subjects meeting VC-II criteria (VE/VCO<sub>2</sub> slope 30 to 35.9; n = 149) experienced 22 major cardiac events (including three LVAD implantations); 85.2% were event-free. Subjects meeting VC-III criteria (VE/VCO<sub>2</sub> slope 36 to 44.9; n = 112) experienced 31 major cardiac events (including three LVAD implantations and two heart transplants); 72.3% were event-free. Subjects who met VC-IV criteria (VE/VCO<sub>2</sub> slope &ge;45; n = 43) experienced 24 major cardiac events (including two LAVD implantations and five heart transplants); 44.2% were event-free. Log-rank 86.8, p&lt;0.0001.</div><div class=\"graphic_footnotes\">VE: minute ventilation; VCO<sub>2</sub>: carbon dioxide output; LVAD: left ventricular assist device.</div><div class=\"graphic_reference\">From: Arena R, Myers J, Abella J, et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007; 115:2410. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 American Heart Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95314 Version 3.0</div></div></div>"},"95316":{"type":"graphic_figure","displayName":"STOP-Bang OSA risk assessment in the general population","title":"STOP-Bang OSA risk assessment in the general population","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">STOP-Bang OSA risk assessment in the general population</div><div class=\"cntnt\"><img style=\"width:568px; height:470px;\" src=\"images/ANEST/95316_STOP_Bang_OSA_risk_assess.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Yang Y, Chung F. A screening tool of obstructive sleep apnea. Sleep Med Clin 2013; 8:65. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95316 Version 1.0</div></div></div>"},"95317":{"type":"graphic_figure","displayName":"STOP-Bang OSA risk assessment obese pts","title":"STOP-Bang OSA risk assessment for obese patients","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">STOP-Bang OSA risk assessment for obese patients</div><div class=\"cntnt\"><img style=\"width:568px; height:470px;\" src=\"images/ANEST/95317_STOP_Bang_OSA_obese_pts.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea.</div><div id=\"graphicVersion\">Graphic 95317 Version 1.0</div></div></div>"},"95318":{"type":"graphic_figure","displayName":"Minority stress theory","title":"Minority stress theory","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Minority stress theory</div><div class=\"cntnt\"><img style=\"width:564px; height:377px;\" src=\"images/PEDS/95318_Minority_stress_theory.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sexual minority youth (eg, lesbian, gay, bisexual, transgender, etc) may experience stigma related to their sexual orientation or gender nonconformity. This stigma can lead to prejudice, discrimination, and lack of acceptance in society at large or in one's relationships with peers and family members, resulting in \"minority stress.\" Stigmatization and minority stress may increase vulnerability to psychologic distress (eg, anxiety, depression), which may contribute to adverse health and psychosocial outcomes (eg, suicide, substance use, socioeconomic disadvantage, victimization). Psychologic distress and adverse psychosocial outcomes are society-induced and not inherent to being a sexual minority.</div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 95318 Version 2.0</div></div></div>"},"95319":{"type":"graphic_figure","displayName":"Glenn shunt","title":"Bidirectional cavopulmonary anastomosis (Glenn connection)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bidirectional cavopulmonary anastomosis (Glenn connection)</div><div class=\"cntnt\"><img style=\"width:409px; height:524px;\" src=\"images/CARD/95319_Glenn_shunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration demonstrates the bidirectional cavopulmonary anastomosis (\"Glenn\" connection) in a patient with a history of a Blalock-Taussig shunt. The superior vena cava (SVC) has been transected, with the proximal end oversewn and the distal end sewn directly into the pulmonary artery. At the time of the Glenn, the prior Blalock-Taussig shunt is divided. This surgery allows for all SVC blood flow to drain directly to the pulmonary vascular bed; however, the inferior vena cava flow enters the systemic circulation through an atrial septal defect or patent tricuspid valve.</div><div class=\"graphic_reference\">Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95319 Version 2.0</div></div></div>"},"95320":{"type":"graphic_figure","displayName":"Fontan connections","title":"Fontan connections","html":"<div class=\"graphic\"><div style=\"width: 951px\" class=\"figure\"><div class=\"ttl\">Fontan connections</div><div class=\"cntnt\"><img style=\"width:931px; height:388px;\" src=\"images/CARD/95320_AtriopulmonFontanconnect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration demonstrates a classic atriopulmonary Fontan connection (figure A) in a patient with a history of a Blalock-Taussig shunt. The right atrial appendage has been anastomosed to the PA confluence, and the atrial septal defect has been closed. These maneuvers direct venous flow from both of the venae cavae through the right atrium and to the pulmonary vascular bed without the assistance of a ventricular pump. The connection of the main PA to the ventricle has been interrupted to eliminate any residual left-to-right shunting. Figures B and C illustrate modifications of the original Fontan concept. They both utilize a direct, bidirectional anastomosis of the SVC to the right pulmonary artery and a conduit to connect the IVC to the PA. Figure B shows an example of an intra-atrial conduit connecting the IVC to the PA. This modification may still be used when pulmonary venous or other anomalies complicate the placement/use of an extracardiac conduit. Figure C illustrates the anatomy of a patient with an extracardiac Fontan. A nonvalved conduit completes the connection of the IVC to the PA. This conduit is placed within the pericardial space, but outside the heart itself. This type of connection is preferred because it places all of the patient's native atrial volume under the lowest possible distending pressure. In both the intra-atrial conduit and the extracardiac conduit types, a small fenestration can be placed between the conduit and atrium, allowing for a small, persistent right-to-left atrial shunt. An epicardial pacemaker is generally placed during this conversion procedure; the leads are seen attached to the heart in this schematic.</div><div class=\"graphic_footnotes\">PA: pulmonary artery; SVC: superior vena cava; IVC: inferior vena cava.</div><div class=\"graphic_reference\">Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95320 Version 5.0</div></div></div>"},"95321":{"type":"graphic_table","displayName":"Hyperpigmentation disorders histopathology","title":"Key histopathologic findings in selected hyperpigmentation disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key histopathologic findings in selected hyperpigmentation disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Selected disorders</td> <td class=\"subtitle1\">Key histopathologic findings</td> </tr> <tr class=\"divider_bottom\"> <td>Acanthosis nigricans</td> <td> <ul> <li>Hyperkeratosis and papillomatosis of the epidermis </li> <li>Basal layer hyperpigmentation </li> <li>Minimal acanthosis (misnomer) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Actinic lichen planus</td> <td> <ul> <li>Variable with typical findings of lichen planus including hyperkeratosis without parakeratosis, hypergranulosis, irregular acanthosis with \"saw-toothed\" rete ridges, liquefaction degeneration of the basal layer, and band-like lymphocytic infiltrate at the dermal-epidermal junction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Addison's disease<sup>[1]</sup></td> <td> <ul> <li>Increased basal layer melanin, sometimes melanin incontinence </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Becker's melanosis<sup>[2]</sup></td> <td> <ul> <li>Variable papillomatosis, acanthosis, and hyperkeratosis </li> <li>Regular elongation of the rete ridges with or without pilosebaceous unit hyperplasia </li> <li>May have increased hair follicles or smooth muscle </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Caf&#233;-au-lait macules<sup>[1]</sup></td> <td> <ul> <li>Increased melanin in the basal layer </li> <li>Normal number of hyperactive melanocytes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dermal melanocytosis<sup>[1]</sup></td> <td> <ul> <li>Spindle-shaped dendritic melanocytes in the deep dermis with abundant fine granules of melanin </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Diabetes mellitus - diabetic dermopathy<sup>[1]</sup></td> <td> <ul> <li>Dermal hemosiderin, increased papillary dermal blood vessels, sparse perivascular lymphocytes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Diabetes mellitus - necrobiosis lipoidica</td> <td> <ul> <li>Diffuse palisaded and interstitial granulomatous dermatitis with tiers of granulomatous inflammation (includes multinucleated histiocytes) aligned parallel to the surface </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dowling-Degos</td> <td> <ul> <li>Delicate, elongated, hyperpigmented rete ridges </li> <li>Sometimes resembles a reticulated seborrheic keratosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Drug-induced hyperpigmentation<sup>[1]</sup></td> <td> <ul> <li>Variable depending on drug or chemical: <ul> <li>Minocycline: brown dermal pigment that is positive with iron and melanin stains </li> <li>Gold: chrysiasis pigment appears as black particles </li> <li>Bleomycin: basal layer with increased melanin </li> <li>Clofazimine: brown lipofuscin that stains with PAS </li> <li>Amiodarone: brown pigment that stains with PAS </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ephelides<sup>[1]</sup></td> <td> <ul> <li>Increased melanin in basal layer </li> <li>Normal or decreased number of hyperactive melanocytes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Erythema dyschromicum perstans<sup>[1]</sup></td> <td> <ul> <li>Liquefaction degeneration of the basal layer </li> <li>Melanin incontinence </li> <li>Interface changes with perivascular or interface lymphocytes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Erythromelanosis follicularis faciei et colli<sup>[3]</sup></td> <td> <ul> <li>Hyperkeratosis </li> <li>Dilatation of superficial dermal blood vessels </li> <li>Follicular plugging </li> <li>Variable melanin in basal layer </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Exogenous ochronosis<sup>[1]</sup></td> <td> <ul> <li>Yellow-brown \"banana-shaped\" deposits on homogenized collagen bundles </li> <li>Small yellow-brown granules in endothelial cells and sweat glands </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hemochromatosis<sup>[1]</sup></td> <td> <ul> <li>Increased melanin in the basal layer </li> <li>Hemosiderin deposits scattered in the dermis, usually around blood vessels and sweat glands, best seen with Perl's stain </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lentigines<sup>[1]</sup></td> <td> <ul> <li>Hyperpigmented, often elongated rete ridges, usually with increased melanocytes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lichen planus pigmentosus</td> <td> <ul> <li>Similar to erythema dyschromicum perstans with marked pigment incontinence and epidermal atrophy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Melasma<sup>[4]</sup></td> <td> <ul> <li>Increased melanin deposition in all layers of the epidermis </li> <li>Solar elastosis </li> <li>More abundant mast cells </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Nevus of Ota, Nevus of Ito, Hori's nevi<sup>[1]</sup></td> <td> <ul> <li>Normal epidermis </li> <li>Spindle-shaped dendritic melanocytes in the dermis with abundant fine granules of melanin </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Nevus spilus</td> <td> <ul> <li>Lentiginous melanocytic hyperplasia </li> <li>Papular foci represent junctional, compound, blue, Spitz, and/or atypical nevi </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Periorbital hyperpigmentation<sup>[5,6]</sup></td> <td> <ul> <li>Dermal melanocytosis and melanin in upper dermal macrophages (melanophages) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Post-chikungunya pigmentation<sup>[7,8]</sup></td> <td> <ul> <li>Intact basal layer with diffuse hypermelanosis of the entire epidermis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Postinflammatory hyperpigmentation</td> <td> <ul> <li>Increased or normal amount of melanin at basal layer, with or without melanin incontinence based on etiology </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Primary cutaneous amyloidosis<sup>[1]</sup></td> <td> <ul> <li>Macular amyloidosis with subtle amyloid globules in the papillary dermis in areas of melanin incontinence </li> <li>Lichen amyloidosis with small deposits of amyloid in the dermal papillae </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Riehl's melanosis<sup>[1]</sup></td> <td> <ul> <li>Lymphocytic perivascular or interface dermatitis with melanin incontinence </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Smoker's melanosis</td> <td> <ul> <li>Mucosal surface with basal layer melanosis, with or without melanin incontinence </li> </ul> </td> </tr> <tr> <td>Terra firma-forme dermatosis<sup>[9]</sup></td> <td> <ul> <li>Prominent lamellar hyperkeratosis with focal areas having compact orthokeratosis in whorls </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PAS: periodic acid-Schiff.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Rapini RP. Practical Dermatopathology, 2nd ed, Saunders, Philadelphia 2012.</li>&#xD;&#xA;    <li>Cohen PR. Becker's nevus. Am Fam Physician 1988; 37:221.</li>&#xD;&#xA;    <li>Kim MG, Hong SJ, Son SJ, et al. Quantitative histopathologic findings of erythromelanosis follicularis faciei et colli. J Cutan Pathol 2001; 28:160.</li>&#xD;&#xA;    <li>Kang WH, Yoon KH, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002; 146:228.</li>&#xD;&#xA;    <li>Malakar S, Lahiri K, Banerjee U, et al. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol 2007; 73:323.</li>&#xD;&#xA;    <li>Watanabe S, Nakai K, Ohnishi T. Condition known as \"dark rings under the eyes\" in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg 2006; 32:785.</li>&#xD;&#xA;    <li>Khanna N, Rasool S. Facial melanoses: Indian perspective. Indian J Dermatol Venereol Leprol 2011; 77:552.</li>&#xD;&#xA;    <li>Inamadar AC, Palit A, Sampagavi VV, et al. Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India. Int J Dermatol 2008; 47:154.</li>&#xD;&#xA;    <li>Browning J, Rosen T. Terra firma-forme dermatosis revisited. Dermatol Online J 2005; 11:15.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 95321 Version 3.0</div></div></div>"},"95322":{"type":"graphic_table","displayName":"Assessment of impairment due to asthma","title":"Assessment of permanent impairment due to asthma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of permanent impairment due to asthma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Class 0</td> <td class=\"subtitle1\" colspan=\"5\">Class 1</td> <td class=\"subtitle1\" colspan=\"5\">Class 2</td> <td class=\"subtitle1\" colspan=\"5\">Class 3</td> <td class=\"subtitle1\" colspan=\"5\">Class 4</td> </tr> <tr class=\"divider_bottom\"> <td>Whole person impairment rating (%)</td> <td class=\"centered\">0</td> <td class=\"centered\" colspan=\"5\">2 to 10</td> <td class=\"centered\" colspan=\"5\">11 to 23</td> <td class=\"centered\" colspan=\"5\">24 to 40</td> <td class=\"centered\" colspan=\"5\">45 to 65</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"22\">Severity grade</td> </tr> <tr> <td class=\"indent1\">Percent impairment</td> <td>&nbsp;</td> <td class=\"centered\">2</td> <td class=\"centered\">4</td> <td class=\"centered\">6</td> <td class=\"centered\">8</td> <td class=\"centered\">10</td> <td class=\"centered\">11</td> <td class=\"centered\">14</td> <td class=\"centered\">17</td> <td class=\"centered\">20</td> <td class=\"centered\">23</td> <td class=\"centered\">24</td> <td class=\"centered\">28</td> <td class=\"centered\">32</td> <td class=\"centered\">36</td> <td class=\"centered\">40</td> <td class=\"centered\">45</td> <td class=\"centered\">50</td> <td class=\"centered\">55</td> <td class=\"centered\">60</td> <td class=\"centered\">65</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Grade</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"5\">Minimal</td> <td class=\"centered\" colspan=\"5\">Mild</td> <td class=\"centered\" colspan=\"5\">Moderate</td> <td class=\"centered\" colspan=\"5\">Severe</td> </tr> <tr class=\"divider_bottom\"> <td>Clinical parameters (minimum medication need, frequency of attacks, etc)</td> <td>No medication required</td> <td colspan=\"5\">Occasional bronchodilator use (not daily use)</td> <td colspan=\"5\">Daily low-dose inhaled glucocorticoid (&#60;500 mcg per day of beclomethasone or equivalent)</td> <td colspan=\"5\"> <p>Daily medium or high-dose inhaled glucocorticoids (500 to 1000 mcg of beclomethasone or equivalent per day) and/or short periods of systemic glucocorticoids and a long acting bronchodilator</p> Daily use of glucocorticoids, systemic and inhaled, and daily use of maximum bronchodilators</td> <td colspan=\"5\">Asthma not controlled by treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Maximum postbronchodilator FEV<sub>1</sub> percentage predicted*<sup>&#182;</sup></td> <td class=\"centered\">&#62;80</td> <td class=\"centered\" colspan=\"5\">70 to 80</td> <td class=\"centered\" colspan=\"5\">60 to 69</td> <td class=\"centered\" colspan=\"5\">50 to 59</td> <td class=\"centered\" colspan=\"5\">&#60;50</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"22\">Objective tests for degree of airway hyperresponsiveness</td> </tr> <tr> <td class=\"indent1\">PC20 mg/mL*</td> <td class=\"centered\">6 to 8</td> <td class=\"centered\" colspan=\"5\">3 to 5</td> <td class=\"centered\" colspan=\"5\">&#62;0.5 to &#60;3</td> <td class=\"centered\" colspan=\"5\">0.25 to 0.5</td> <td class=\"centered\" colspan=\"5\">0.125 to 0.24</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; PC20: provocative dose of methacholine that results in a 20% decrease in forced expiratory volume in one second.<br />* The \"key\" factor PC20 indicates and measures the degree of airway hyperresponsiveness. Alternatively the postbronchodilator FEV<sub>1</sub> percentage predicted is used as key factor.<br />&para; Percent predicted FEV<sub>1</sub> after albuterol therapy.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Modified from Ranavaya MI. The challenge of evaluating asthma impairment and disability. AMA Guides Newsletter. May-June 1997: 1-4.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted from AMA's Guides to the Evaluation of Impairment, 6th Edition with the permission of the American Medical Association, Copyright &copy; 2008. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 95322 Version 3.0</div></div></div>"},"95326":{"type":"graphic_picture","displayName":"Yellow sac spider","title":"Yellow sac spider (<em>Cheiracanthium spp.</em>)","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Yellow sac spider (<em>Cheiracanthium spp.</em>)</div><div class=\"cntnt\"><img style=\"width:478px; height:275px;\" src=\"images/EM/95326_Yellow_sac_spider.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 95326 Version 1.0</div></div></div>"},"95334":{"type":"graphic_figure","displayName":"Right scapula and clavicle - Glenoid fossa anterolateral view","title":"Right scapula and clavicle: Glenoid fossa (anterolateral view)","html":"<div class=\"graphic\"><div style=\"width: 719px\" class=\"figure\"><div class=\"ttl\">Right scapula and clavicle: Glenoid fossa (anterolateral view)</div><div class=\"cntnt\"><img style=\"width:699px; height:610px;\" src=\"images/EM/95334_Rght_scpl_clvcl_glnd_antrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Originally published in: Sobotta Atlas der Anatomie des Menschen, 22. Auflage, Band 1, Band 2; M&uuml;nchen: Elsevier/Urban &amp; Fischer &copy; 2006. The English translation was undertaken by Lippincott Williams &amp; Wilkins and published in: Anatomy: A Regional Atlas of the Human Body, 6th ed, Clemente CD (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95334 Version 1.0</div></div></div>"},"95345":{"type":"graphic_algorithm","displayName":"Evaluation of hematochezia","title":"Evaluation of patients presenting with hematochezia (excluding those with minimal rectal bleeding)","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Evaluation of patients presenting with hematochezia (excluding those with minimal rectal bleeding)</div><div class=\"cntnt\"><img style=\"width:728px; height:1006px;\" src=\"images/GAST/95345_Evaluation_of_hematochezia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IDA: iron deficiency anemia; CTA: computed tomographic angiography; CT: computed tomographic; GI: gastrointestinal; MR: magnetic resonance.<br />* If hematemesis or melena is present the patient should be evaluated for upper GI bleeding. Refer to UpToDate topics on the evaluation of upper GI bleeding for details.<br />&para; Bleeding associated with signs such as hypotension, tachycardia, or orthostatic hypotension.<br />&Delta; Colonoscopy should be performed once the patient has been resuscitated and an adequate bowel preparation has been given (typically 4 to 6 L of polyethylene glycol). If the initial colonoscopy was inadequate (eg, inadequate visualization, failure to reach the cecum), repeat colonoscopy should be considered.<br /><span class=\"lozenge\">&loz;</span> Consider evaluation with a side-viewing duodenoscope in patients with risk factors for hemobilia or hemosuccus pancreaticus or CT angiography (followed by push enteroscopy if the CT angiography is negative) in patients at risk for an aortoenteric fistula. Conventional transvenous angiography is typically performed if the patient remains hemodynamically unstable despite attempts at resuscitation. If the suspicion for an upper GI source is moderate (rather than high), nasogastric lavage can be performed to look for evidence to support an upper GI source. Refer to UpToDate topics on lower GI bleeding in adults for additional details.<br />&sect; CTA is an alternative but lacks therapeutic capacity. A tagged red blood cell scan may aid with localization prior to angiography.<br />&yen; Refer to UpToDate topic review on suspected small bowel bleeding for details.<br />&Dagger; A Meckel's scan should be performed in younger patients with overt bleeding. Surgical exploration is appropriate if no other studies have revealed a source and significant bleeding continues or if there is high suspicion for a small bowel neoplasm.<br />&dagger; If the deep small bowel enteroscopy was incomplete, a video capsule endoscopy study should be obtained, followed by CT or MR enterography if the capsule endoscopy is negative.</div><div id=\"graphicVersion\">Graphic 95345 Version 6.0</div></div></div>"},"95363":{"type":"graphic_table","displayName":"Evaluation of a neonate with seizures","title":"Evaluation of a neonate with seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of a neonate with seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">First-tier tests</td> <td class=\"subtitle1\">Second-tier tests</td> </tr> <tr class=\"divider_bottom\"> <td>Clinical</td> <td>Complete history, general physical and neurologic exams</td> <td> <p>Dilated ophthalmologic exam</p> Pyridoxine/PLP therapeutic trials*</td> </tr> <tr class=\"divider_bottom\"> <td>Blood</td> <td> <p>Sodium, glucose, calcium, magnesium, liver function tests, ammonia, lactate, pyruvate, amino acids</p> <p>Arterial blood gas, pH, lactate, pyruvate</p> <p>Newborn screen<sup>&#916;</sup></p> TORCH titers (toxoplasmosis, other infections, rubella, cytomegalovirus, herpes simplex)</td> <td> <p>Carnitine, acylcarnitine, carbohydrate deficient transferrin</p> <p>Biotinidase enzyme activity<sup>&#182;</sup></p> Genetic testing for neonatal-onset epilepsies<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Urine</td> <td> <p>Urine culture</p> Toxicology screen</td> <td>Reducing substances, sulfites, organic acids, guanidinoacetate, creatine, alpha-AASA</td> </tr> <tr class=\"divider_bottom\"> <td>Cerebrospinal fluid</td> <td> <p>Cell counts and differential</p> <p>Glucose and total protein</p> <p>HSV1/2 PCR</p> Gram stain and culture</td> <td> <p>Lactate</p> <p>Amino acids</p> Neurotransmitter profile</td> </tr> <tr> <td>Neuroimaging</td> <td> <p>MRI with MR angiography and venography</p> Cranial ultrasound<sup>&#9674;</sup></td> <td>MR spectroscopy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PLP: pyridoxal phosphate; TORCH: toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus; alpha-AASA: alpha-aminoadipic semialdehyde; HSV: herpes simplex virus; PCR: polymerase chain reaction; MRI: magnetic resonance imaging.</div><div class=\"graphic_footnotes\">* Consider in cases of refractory neonatal seizures unresponsive to conventional antiepileptic drugs.<br />¶ If biotinidase deficiency is not included in newborn screen.<br />Δ Composition of the newborn screening panel varies by state and country.<br />§ Consider genetic testing in cases of refractory neonatal seizures unresponsive to conventional antiseizure drugs or with no cause identified on initial evaluation.&nbsp;<br />◊ If available and MRI cannot be obtained in a timely manner.</div><div id=\"graphicVersion\">Graphic 95363 Version 4.0</div></div></div>"},"95374":{"type":"graphic_algorithm","displayName":"ID evaluation algorithm","title":"Algorithmic approach to the evaluation for causes of intellectual disability in children","html":"<div class=\"graphic\"><div style=\"width: 794px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to the evaluation for causes of intellectual disability in children</div><div class=\"cntnt\"><img style=\"width:774px; height:808px;\" src=\"images/PEDS/95374_ID_evaluation_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CMA: chromosomal microarray analysis; GDD: global developmental delay; CT: computed tomography; ID: intellectual disability; FISH: fluorescence in situ hybridization; MRI: magnetic resonance imaging.<br />* If the child has not previously had lead screening performed, a blood lead level should be obtained. Lead is the most common environmental neurotoxin, but an uncommon cause of ID in the United States.<br />&para; Common specific causes of ID include Down syndrome, fragile X syndrome, Rett syndrome, Klinefelter syndrome, Prader-Willi syndrome, DiGeorge syndrome, metabolic disorders, muscular dystrophy, congenital hypothyroidism, and lead poisoning. However, there are many other causes of ID in children. For more details, refer to UpToDate content on ID in children and to UpToDate topics on these specific disorders.<br />&Delta; If CMA is unavailable, G-band karyotype and FISH testing are applied.<br /><span class=\"lozenge\">&loz;</span> Many experts recommend fragile X testing in all children with unexplained ID or autism, since fragile X syndrome often presents with non-specific GDD in young children.<br />&sect; Consultation with a pediatric neurologist may be warranted in these cases. MRI is the preferred neuroimaging modality; however, CT is acceptable if MRI is not available. Potential radiation exposure and risk of sedation should be considered as part of informed decision making. Some abnormal findings on neuroimaging do not lead to a specific diagnosis. Additional evaluation may be warranted.</div><div id=\"graphicVersion\">Graphic 95374 Version 4.0</div></div></div>"},"95375":{"type":"graphic_table","displayName":"Somatic Symptom Scale-8","title":"Somatic Symptom Scale-8","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Somatic Symptom Scale-8</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">During the past seven days, how much have you been bothered by any of the following problems?</td> <td class=\"subtitle1\">Not at all</td> <td class=\"subtitle1\">A little bit</td> <td class=\"subtitle1\">Somewhat</td> <td class=\"subtitle1\">Quite a bit</td> <td class=\"subtitle1\">Very much</td> </tr> <tr> <td>1. Stomach or bowel problems</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>2. Back pain</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>3. Pain in your arms, legs, or joints</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>4. Headaches</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>5. Chest pain or shortness of breath</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>6. Dizziness</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>7. Feeling tired or having low energy</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>8. Trouble sleeping</td> <td><span class=\"primarybox_left\">&nbsp;</span>0</td> <td><span class=\"primarybox_left\">&nbsp;</span>1</td> <td><span class=\"primarybox_left\">&nbsp;</span>2</td> <td><span class=\"primarybox_left\">&nbsp;</span>3</td> <td><span class=\"primarybox_left\">&nbsp;</span>4</td> </tr> <tr> <td>&nbsp;&nbsp;<strong>SSS-8 score</strong></td> <td><span class=\"primarybox_left\">&nbsp;&nbsp;</span>= </td> <td>____ +</td> <td>____ +</td> <td>____ +</td> <td>____</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Gierk B, Kohlmann S, Kroenke K, et al. The somatic symptom scale-8 (SSS-8): a brief measure of somatic symptom burden. JAMA Intern Med 2014; 174:399. Copyright &copy; 2014 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95375 Version 4.0</div></div></div>"},"95380":{"type":"graphic_picture","displayName":"Orbital compartment syndrome","title":"Retrobulbar hemorrhage with orbital compartment syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retrobulbar hemorrhage with orbital compartment syndrome</div><div class=\"cntnt\"><img style=\"width:406px; height:244px;\" src=\"images/EM/95380_Orbitalcompartmentsyndrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had acute onset of decreased vision and periorbital swelling and hemorrhage. Physical examination demonstrated markedly decreased vision, an afferent pupillary defect, proptosis, subconjunctival hemorrhage, chemosis, ophthalmoplegia, tightness of the eyelids, and decreased retropulsion (resistance to attempts to push the eye farther back into the orbit).</div><div class=\"graphic_reference\">Reproduced with permission from: Traumatic retrobulbar hemorrhage. In: The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, 6th ed, Gerstenblith AT, Rabinowitz MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 95380 Version 4.0</div></div></div>"},"95382":{"type":"graphic_picture","displayName":"Common HE chronic hemolytic anemia","title":"Common hereditary elliptocytosis with chronic hemolytic anemia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Common hereditary elliptocytosis with chronic hemolytic anemia</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/HEME/95382_Comm_HE_chr_hemolyt_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral blood smear shows elliptocytes, poikilocytes, microcytes, and red cell fragments. The patient was a compound heterozygote for two different mutations of alpha-spectrin.</div><div class=\"graphic_reference\">Courtesy of William C Mentzer, MD.</div><div id=\"graphicVersion\">Graphic 95382 Version 2.0</div></div></div>"},"95383":{"type":"graphic_picture","displayName":"Hereditary pyropoikilocytosis","title":"Hereditary pyropoikilocytosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hereditary pyropoikilocytosis</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/HEME/95383_Hereditary_pyropoikilocytos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral blood smear shows an abundance of spherocytes as well as elliptocytes and microcytes.</div><div class=\"graphic_reference\">Courtesy of William C Mentzer, MD.</div><div id=\"graphicVersion\">Graphic 95383 Version 1.0</div></div></div>"},"95384":{"type":"graphic_table","displayName":"Severity of intellectual disability","title":"Severity of intellectual disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity of intellectual disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"3\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Severity level*</td> <td class=\"subtitle1\" rowspan=\"2\">Proportion of individuals with ID<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"3\">Adaptive skill domains</td> </tr> <tr> <td class=\"subtitle2\">Conceptual domain<sup>&#916;</sup></td> <td class=\"subtitle2\">Social domain<sup>&#916;</sup></td> <td class=\"subtitle2\">Practical domain<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Mild</td> <td class=\"centered\">85 percent</td> <td>Children require academic supports to learn skills expected for age. Adults may have difficulties with functional academic skills such as planning, reading, and money management.</td> <td>Social skills and personal judgement are immature for age. The individual is at risk of being manipulated by others (gullibility).</td> <td>Most individuals are independent in daily living activities, employable in jobs requiring simple skills, and often able to live independently. They typically need support for making decisions in health care, nutrition, shopping, finances, and raising a family.</td> </tr> <tr class=\"divider_bottom\"> <td>Moderate</td> <td class=\"centered\">10 percent</td> <td>For children, conceptual and academic skills lag well behind those of peers. For adults, academic<span style=\"color: black;\"> skills are typically attainable&nbsp;at an</span> elementary level. Complex tasks such as money management need substantial support.</td> <td>Successful friendships with family/friends are possible using spoken language, but the individual is limited by deficits in social and communicative skills. Social cues, social judgment, social and life decisions regularly need support.</td> <td>Most individuals are capable of personal care activities with sufficient teaching and support, and achieve independent self-care with moderate supports, such as is&nbsp;available in a group home. Adults may be employable in a supported environment.</td> </tr> <tr class=\"divider_bottom\"> <td>Severe</td> <td class=\"centered\">3 to 4 percent</td> <td>Individuals have little understanding of written language, or number, time, and money concepts. Caretakers provide extensive supports for problem-solving.</td> <td>Individuals benefit from healthy supportive interactions with family/familiar people and may use very basic single words, phrases, or gestures pertinent to their direct experience.</td> <td>Individuals are trainable in some basic activities of daily living with significant ongoing support and supervision.</td> </tr> <tr> <td>Profound</td> <td class=\"centered\">1 to 2 percent</td> <td>Individuals may use objects in a goal-directed fashion for self-care and recreation.</td> <td>Although understanding of symbolic communication is very limited, individuals may understand some gestures and emotional cues, and can express themselves non-verbally.</td> <td>Individuals are typically dependent upon support for all activities of everyday living. Co-occurring sensory or physical limitations are common.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table paraphrases the severity levels of ID as outlined by the American Psychiatric Association in the Diagnostic and Statistical Manual, 5<SUP>th</SUP> Edition (DSM-5). The American Association on Intellectual and Developmental Disabilities (AAIDD) uses a scheme that is similar except that it focuses on support needs, which are classified as intermittent, limited, extensive, and pervasive.</div><div class=\"graphic_footnotes\">ID: intellectual disability.<br />* DSM-5-defined categories of severity.<br />¶ Estimates are based on IQ-derived levels of severity (which differ from DSM-5 defined categories of the same name).<br />Δ Examples of the needs and supports of each adaptive domain, with increasing categories of severity.</div><div class=\"graphic_reference\">Adapted from the following sources:&#xD;&#xA;<ol>&#xD;&#xA;    <li>American Psychiatric Association. Intellectual Disability (Intellectual Developmental Disorder). In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association.</li>&#xD;&#xA;    <li>American Association of Intellectual and Developmental Disabilities (AAIDD), Definition of Intellectual Disability, available at: http://aaidd.org/intellectual-disability/definition (Accessed on July 11, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 95384 Version 3.0</div></div></div>"},"95385":{"type":"graphic_picture","displayName":"Southeast Asian ovalocytosis","title":"Southeast Asian ovalocytosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Southeast Asian ovalocytosis</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/HEME/95385_Southeast_Asian_ovalocytos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral blood smear shows ovalocytes, several of which exhibit longitudinal slits or a dense central band (ie, stomatocytic elliptocytes).</div><div class=\"graphic_reference\">Courtesy of William C Mentzer, MD.</div><div id=\"graphicVersion\">Graphic 95385 Version 1.0</div></div></div>"},"95389":{"type":"graphic_table","displayName":"Patient complaints of dysphagia and physiologic counterparts","title":"Patient complaints of swallowing difficulty and their possible physiologic counterparts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient complaints of swallowing difficulty and their possible physiologic counterparts</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient's complaint</td> <td class=\"subtitle1\">Physiological impairment</td> </tr> <tr> <td>Choking on fluids</td> <td> <p>Poor tongue control for oral manipulation</p> <p>Impaired laryngeal closure</p> Delayed onset of pharyngeal swallow</td> </tr> <tr> <td>Protracted meal times</td> <td> <p>Weak chewing</p> Diminished endurance</td> </tr> <tr> <td>Nasal regurgitation of fluids</td> <td>Incompetent velopharyngeal mechanism</td> </tr> <tr> <td>Difficulty getting swallow started</td> <td>Reduced oral and hypopharyngeal sensation</td> </tr> <tr> <td>Dry mouth</td> <td>Reduced or impaired saliva production</td> </tr> <tr> <td>Solids caught in throat</td> <td> <p>Weak tongue-driving force</p> Impaired laryngeal excursion fails to open upper esophageal segment</td> </tr> <tr> <td>Regurgitation or emesis after swallowing</td> <td>Poor esophageal motility or esophageal obstruction</td> </tr> <tr> <td>Sour taste in mouth after eating</td> <td>Gastroesophageal reflux</td> </tr> <tr> <td>Pain on swallowing</td> <td>Esophagitis, mucositis, esophageal obstruction</td> </tr> <tr> <td>Excessive drooling</td> <td>Reduced frequency or efficiency of swallowing</td> </tr> <tr> <td>Food sticking in thoracic or chest region</td> <td>Poor esophageal motility or obstruction</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted by permission of Oxford University Press, USA. Dahlin CM, Cohen AK, Goldsmith T. Dysphagia, Xerostomia, and Hiccups. In: Oxford Textbook of Palliative Nursing, 3rd ed, Ferrell BR, Coyle N (Eds), Oxford University Press 2010. Copyright © 2010. <A href=\"http://www.oup.com/\" target=_blank>www.oup.com</A>.</div><div id=\"graphicVersion\">Graphic 95389 Version 1.0</div></div></div>"},"95391":{"type":"graphic_table","displayName":"Dietary modifications for patients with swallowing disorders","title":"Modifications in food texture and consistency for patients with swallowing disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modifications in food texture and consistency for patients with swallowing disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diet</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Example</td> <td class=\"subtitle1\">Indication</td> </tr> <tr> <td>Pureed diet</td> <td>Blenderized food with added liquid to form smooth consistency; no chewing necessary</td> <td>Applesauce, yogurt, moist mashed potatoes, puddings</td> <td>Reduced tongue function for chewing, impaired pharyngeal contraction, esophageal stricture, reduced laryngeal closure</td> </tr> <tr> <td>Mechanically altered diet</td> <td>Ground, finely chopped foods that form a cohesive bolus with minimal chewing</td> <td>Pasta, soft scrambled eggs, cottage cheese, ground meats</td> <td>Some limited chewing possible but protracted due to impaired tongue control</td> </tr> <tr> <td>Soft, moist diet</td> <td>Naturally soft foods requiring some chewing; food is cut in small pieces; serve with gravy to moisten</td> <td>Soft meats, canned fruits, baked fish; avoid raw vegetables, bread, and tough meats</td> <td>Reduced endurance for prolonged meal due to tongue weakness for chewing, reduced attention span</td> </tr> <tr> <td rowspan=\"2\">Liquids</td> <td>Honey consistency</td> <td>Similar in viscosity to honey; available in ready-to-serve packaging or use thickening agent</td> <td>Reduced oral or lingual control, premature spillage, delayed swallow initiation and airway closure</td> </tr> <tr> <td>Nectar consistency</td> <td>Similar in viscosity to tomato juice; less thick than honey consistency</td> <td>Reduced bolus control, premature spillage, delayed swallow and airway closure</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted by permission of Oxford University Press, USA. Dahlin CM, Cohen AK, Goldsmith T. Dysphagia, Xerostomia, and Hiccups. In: Oxford Textbook of Palliative Nursing, 3rd ed, Ferrell BR, Coyle N (Eds), Oxford University Press 2010. Copyright &copy; 2010. <a href=\"http://www.oup.com/\" target=\"_blank\">www.oup.com</a>.</div><div id=\"graphicVersion\">Graphic 95391 Version 2.0</div></div></div>"},"95403":{"type":"graphic_figure","displayName":"Typical vertebra represented by the 2nd lumbar vertebra","title":"Typical vertebra represented by the 2nd lumbar vertebra","html":"<div class=\"graphic\"><div style=\"width: 685px\" class=\"figure\"><div class=\"ttl\">Typical vertebra represented by the 2nd lumbar vertebra</div><div class=\"cntnt\"><img style=\"width:665px; height:408px;\" src=\"images/EM/95403_Tpclvrtbrprsn2lmbrvrtb.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Functional components include the vertebral body (<em>bone color</em>), a vertebral arch (<em>red</em>), and seven processes: three for muscle attachment and leverage (<em>blue</em>) and four that participate in synovial joints with adjacent vertebrae (<em>yellow</em>).<br />(B) and (C) Bony formations of vertebrae are demonstrated. The vertebral foramen is bounded by the vertebral arch and body. A small superior vertebral notch and a larger inferior vertebral notch flank the pedicle.<br />(D) The superior and inferior notches of adjacent vertebrae plus the IV disc that unites the m form the IV foramen for passage of a spinal nerve and its accompanying vessels. Each articular process has an articular facet where contact occurs with the articular facets of adjacent vertebrae (B-D).</div><div class=\"graphic_reference\">Reproduced with permission from: Back. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 95403 Version 3.0</div></div></div>"},"95404":{"type":"graphic_figure","displayName":"Spondylolysis and spondylolisthesis","title":"Spondylolysis and spondylolisthesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spondylolysis and spondylolisthesis</div><div class=\"cntnt\"><img style=\"width:425px; height:653px;\" src=\"images/EM/95404_Spondylolysisspndyllsths.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Left posterolateral oblique view.<br />(B) Transverse CT.<br />(C) \"Scotty dog sign\" in posterolateral oblique view of lumbar vertebra.<br />(D) Median MRI, spondylolisthesis secondary to spondylolysis of L5.</div><div class=\"graphic_reference\">Reproduced with permission from: Back. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 95404 Version 4.0</div></div></div>"},"95414":{"type":"graphic_diagnosticimage","displayName":"Transverse cerebellar diameter on fetal ultrasound","title":"Transverse cerebellar diameter on fetal ultrasound","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Transverse cerebellar diameter on fetal ultrasound</div><div class=\"cntnt\"><img style=\"width:620px; height:505px;\" src=\"images/RADIOL/95414_Trans_cereb_diam_fetal_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gray-scale fetal ultrasound through the calvarium shows a transverse measurement of the cerebellum of 2.05 cm (20.5 mm), which corresponds to an estimated gestational age of 20 weeks and&nbsp;6 days, concordant with the gestational age based on the last menstrual period.</div><div class=\"graphic_reference\">Courtesy of Lachlan McG Smith, MD.</div><div id=\"graphicVersion\">Graphic 95414 Version 1.0</div></div></div>"},"95416":{"type":"graphic_table","displayName":"Meds for pediatric OCD","title":"Medications for pediatric obsessive compulsive disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications for pediatric obsessive compulsive disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Initial daily dose</td> <td class=\"subtitle1\">Suggested dose titration based upon response</td> <td class=\"subtitle1\">Maintenance daily dose range</td> <td class=\"subtitle1\">Selected characteristics*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective serotonin reuptake inhibitors (SSRIs)*</td> </tr> <tr> <td class=\"indent1\">Fluoxetine<sup>&#182;</sup></td> <td> <p>Children: 5 to 10 mg</p> Adolescents: 10 to 20 mg</td> <td>Increase daily dose by 5 to 10 mg (child) or 10 to 20 mg (adolescent) after 14 days or more</td> <td> <p>Pre-adolescent: 20 to 30 mg</p> Adolescent: 20 to 60 mg</td> <td> <ul> <li>Prolonged half-life </li> <li>Metabolized by and inhibits CYP2D6 </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluvoxamine<sup>&#182;</sup></td> <td>25 mg at bedtime</td> <td>Increase daily dose by 25 mg (child) or 25 to 50 mg (adolescent) after 7 days or more</td> <td> <p>Pre-adolescent: 50 to 200 mg</p> Adolescent: 50 to 300 mg </td> <td> <ul> <li>Girls generally require lower maintenance doses than boys </li> <li>Give in divided doses with meals and bedtime to minimize side effects </li> <li>Metabolized by CYP1A2 and 2D6 </li> <li>Inhibits CYP1A2 and 2C19 </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sertraline<sup>&#182;</sup></td> <td> <p>Children: 25 mg</p> Adolescents: 50 mg</td> <td>Increase daily dose by 25 (child) or 50 mg (adolescent) after 7 days or more</td> <td>25 to 200 mg</td> <td> <ul> <li>Diarrhea more frequent than other SSRIs </li> <li>Metabolized by CYP2D6 </li> <li>Inhibits CYP2D6 with larger doses </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective serotonin reuptake inhibitors (SSRI) - potential alternate*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Paroxetine</td> <td> <p>Children age &#8805;7 years: 5 mg</p> Adolescents: 10 mg</td> <td>Increase daily dose by 10 mg after 7 to 14 days or more</td> <td>10 to 60 mg</td> <td> <ul> <li>Short half-life </li> <li>Mild anticholinergic side effects </li> <li>Metabolized by and inhibits CYP2D6 </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tricyclic antidepressant (TCA)</td> </tr> <tr> <td class=\"indent1\">Clomipramine<sup>&#182;</sup></td> <td>Children &#8805;10 years old and adolescents: 25 mg</td> <td>Increase daily dose by 25 mg every 7 to 14 days or more</td> <td> <p>25 to 200 mg</p> Maximum: smaller of 200 mg or 3 mg/kg per day<sup>&#916;</sup></td> <td> <ul> <li>Only TCA with demonstrated efficacy in pediatric OCD </li> <li>Cardiovascular screening including ECG recommended prior to initiating treatment </li> <li>Anticholinergic side effects may limit usefulness in children </li> <li>Drowsiness, irritability and vomiting may be seen </li> <li>Give in divided doses with meals and at bedtime to minimize side effects </li> <li>Metabolized by CYPs 1A2, 2C19 and 3A4 </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Second generation antipsychotics (SGAs) for SSRI augmentation </td> </tr> <tr> <td class=\"indent1\">Risperidone</td> <td>0.25 mg</td> <td>Increase daily dose by 0.25 mg after 7 to 14 days or more</td> <td>Maximum: 1.5 to 2 mg</td> <td> <ul> <li>Metabolic adverse effects </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinicians should be aware of the potential for activating side effects of antidepressants in younger children and regulatory warnings of potential for an increased risk of suicidality in children. All doses shown are for oral administration.</div><div class=\"graphic_footnotes\">ECG: Electrocardiogram; GI: Gastrointestinal; TCA: Tricyclic antidepressant.<br />* Common generally mild adverse effects of SSRIs seen in children treated for various anxiety disorders may include headache, anorexia, vomiting, sleep disturbance and somnolence.<br />&para; Fluoxetine, fluvoxamine and sertraline are approved for treatment of obsessive compulsive disorder (OCD) in children aged &ge;7, 8 and 6 years respectively in United States. Clomipramine is approved for treatment of OCD in children aged &ge;10 years in United States.<br />&Delta; Dose- related ECG changes have been reported in children and close monitoring is necessary with larger doses. According to the product information approved in the United States, doses &gt;2.5 mg/kg per day are not recommended in children.</div><div class=\"graphic_reference\">Courtesy of authors with additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014; 14:S1.</LI>&#xD;&#xA;<LI>Rynn M, Puliafico A, Heleniak C, et al. Advances in pharmacotherapy for pediatric anxiety disorders. Depress Anxiety 2011; 28:76.</LI>&#xD;&#xA;<LI>Martin A, Scahill L, Kratochvil C. Pediatric Psychopharmacology, Oxford University Press, New York 2010. p.480.</LI></OL></div><div id=\"graphicVersion\">Graphic 95416 Version 1.0</div></div></div>"},"95444":{"type":"graphic_table","displayName":"PHQ-9 PI","title":"PHQ-9 depression questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PHQ-9 depression questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Name:</td> <td class=\"subtitle1_single\" colspan=\"4\">Date:</td> </tr> <tr> <td class=\"subtitle2_left\">Over the last two weeks, how often have you been bothered by any of the following problems?</td> <td class=\"subtitle2_left\">Not at all</td> <td class=\"subtitle2_left\">Several days</td> <td class=\"subtitle2_left\">More than half the days</td> <td class=\"subtitle2_left\">Nearly every day</td> </tr> <tr> <td class=\"indent1\">Little interest or pleasure in doing things</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Feeling down, depressed, or hopeless</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Trouble falling or staying asleep, or sleeping too much</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Feeling tired or having little energy</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Poor appetite or overeating</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Feeling bad about yourself, or that you are a failure, or have let yourself or your family down</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Trouble concentrating on things, such as reading the newspaper or watching television</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual.</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Thoughts that you would be better off dead or of hurting yourself in some way</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\"><strong>Total ___ =</strong></td> <td><strong>___</strong></td> <td><strong>+ ___</strong></td> <td><strong>+ ___</strong></td> <td><strong>+ ___</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">PHQ-9 Score &#8805;10: Likely major depression.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Depression score ranges:</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">5 to 9: mild</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">10 to 14: moderate</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">15 to 19: moderately severe</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8805;20: severe</td> </tr> <tr> <td><strong>If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?</strong></td> <td> <p>Not difficult at all</p> <p>___</p> </td> <td> <p>Somewhat difficult</p> <p>___</p> </td> <td> <p>Very difficult</p> <p>___</p> </td> <td> <p>Extremely difficult</p> <p>___</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc.</div><div id=\"graphicVersion\">Graphic 95444 Version 1.0</div></div></div>"},"95445":{"type":"graphic_table","displayName":"Classification of idiopathic interstitial pneumonias","title":"Revised American Thoracic Society/European Respiratory Society classification of idiopathic interstitial pneumonias: Multidisciplinary diagnoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised American Thoracic Society/European Respiratory Society classification of idiopathic interstitial pneumonias: Multidisciplinary diagnoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major idiopathic interstitial pneumonias</td> </tr> <tr> <td class=\"indent1\">Idiopathic pulmonary fibrosis</td> </tr> <tr> <td class=\"indent1\">Idiopathic nonspecific interstitial pneumonia</td> </tr> <tr> <td class=\"indent1\">Respiratory bronchiolitis-interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Desquamative interstitial pneumonia</td> </tr> <tr> <td class=\"indent1\">Cryptogenic organizing pneumonia</td> </tr> <tr> <td class=\"indent1\">Acute interstitial pneumonia</td> </tr> <tr> <td class=\"subtitle1_single\">Rare idiopathic interstitial pneumonias</td> </tr> <tr> <td class=\"indent1\">Idiopathic lymphoid interstitial pneumonia</td> </tr> <tr> <td class=\"indent1\">Idiopathic pleuroparenchymal fibroelastosis</td> </tr> <tr> <td class=\"subtitle1_single\">Unclassifiable idiopathic interstitial pneumonias*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Causes of unclassifiable idiopathic interstitial pneumonia include (1) inadequate clinical, radiologic, or pathologic data and (2) major discordance between clinical, radiologic, and pathologic findings that may occur in the following situations: (a) previous therapy resulting in substantial alteration of radiologic or histologic findings (eg, biopsy of desquamative interstitial pneumonia after&nbsp;glucocorticoid therapy, which shows only residual nonspecific interstitial pneumonia<SUP>[1]</SUP>); (b) new entity, or unusual variant of recognized entity, not adequately characterized by the current American Thoracic Society/European Respiratory Society classification (eg, variant of organizing pneumonia with supervening fibrosis)<SUP>[2]</SUP>; and (c) multiple high-resolution computed tomography and/or pathologic patterns that may be encountered in patients with idiopathic interstitial pneumonia.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Matsushima H, Takayanagi N, Sakamoto T, et al. Pathologic findings both before and after steroid therapy in a case of desquamative interstitial pneumonia. Nihon Kokyuki Gakkai Zasshi 2001; 39:609.</LI>&#xD;&#xA;<LI>Lee JW, Lee KS, Lee HY, et al. Cryptogenic organizing pneumonia: serial high-resolution CT findings in 22 patients. AJR Am J Roentgenol 2010; 195:916.</LI></OL>Reprinted with permission of the American Thoracic Society. Travis WD, Costabel U, Hansell DM, et al, 2013. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American journal of respiratory and critical care medicine; 188:733. Official Journal of the American Thoracic Society. Copyright © 2014 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 95445 Version 2.0</div></div></div>"},"95447":{"type":"graphic_figure","displayName":"Mensical tear types","title":"Major types of meniscal tears","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Major types of meniscal tears</div><div class=\"cntnt\"><img style=\"width:522px; height:640px;\" src=\"images/EM/95447_Meniscal_tear_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One important factor for determining the appropriate management of a meniscal tear is the type of tear. The most common types are shown above. Degenerative tears, which develop gradually from aging and the cumulative effects of years of trauma, are managed differently than acute meniscal injuries.</div><div id=\"graphicVersion\">Graphic 95447 Version 3.0</div></div></div>"},"95448":{"type":"graphic_table","displayName":"Tumor regression grading rectal CA German Rectal CA Study Group","title":"Tumor regression grading after preoperative chemoradiotherapy for rectal cancer from the German Rectal Cancer Study Group","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumor regression grading after preoperative chemoradiotherapy for rectal cancer from the German Rectal Cancer Study Group</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor regression grade</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Number of patients*</td> <td class=\"subtitle1\">Five-year disease-free survival (percent)</td> </tr> <tr> <td class=\"centered\">0</td> <td>No regression</td> <td class=\"centered\">28</td> <td class=\"centered\">78</td> </tr> <tr> <td class=\"centered\">1</td> <td>&#60;25 percent tumor mass</td> <td class=\"centered\">47</td> <td class=\"centered\">55</td> </tr> <tr> <td class=\"centered\">2</td> <td>&#8805;25 to 50 percent of tumor mass</td> <td class=\"centered\">43</td> <td class=\"centered\">83</td> </tr> <tr> <td class=\"centered\">3</td> <td>&#62;50 percent of tumor mass</td> <td class=\"centered\">186</td> <td class=\"centered\">73</td> </tr> <tr> <td class=\"centered\">4</td> <td>Complete regression</td> <td class=\"centered\">40</td> <td class=\"centered\">86</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not all numbers in the respective variables add up to 344 patients because data with unknown factors were excluded from analysis.</div><div class=\"graphic_reference\">Data from: R&ouml;del C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688.</div><div id=\"graphicVersion\">Graphic 95448 Version 2.0</div></div></div>"},"95449":{"type":"graphic_table","displayName":"Genetic forms of HSP","title":"Genetic forms of hereditary spastic paraplegia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic forms of hereditary spastic paraplegia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Designation</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Predominant phenotype</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">OMIM number</td> </tr> <tr> <td>SPG1</td> <td>Xq28</td> <td>L1CAM</td> <td>Complicated</td> <td>X-linked</td> <td>303350</td> </tr> <tr> <td>SPG2</td> <td>Xq22.2</td> <td>PLP1</td> <td>Complicated</td> <td>X-linked</td> <td>312920</td> </tr> <tr> <td>SPG3A</td> <td>14q22.1</td> <td>ATL1</td> <td>Pure</td> <td>AD</td> <td>182600</td> </tr> <tr> <td>SPG4</td> <td>2p22.3</td> <td>SPAST</td> <td>Pure</td> <td>AD</td> <td>182601</td> </tr> <tr> <td>SPG5A</td> <td>8q12.3</td> <td>CYP7B1</td> <td>Pure</td> <td>AR</td> <td>270800</td> </tr> <tr> <td>SPG6</td> <td>15q11.2</td> <td>NIPA1</td> <td>Pure</td> <td>AD</td> <td>600363</td> </tr> <tr> <td>SPG7</td> <td>16q24</td> <td>SPG7</td> <td>Pure or complicated</td> <td>AR and AD</td> <td>607259</td> </tr> <tr> <td>SPG8</td> <td>8q24.13</td> <td>KIAA0196</td> <td>Pure</td> <td>AD</td> <td>603563</td> </tr> <tr> <td>SPG9</td> <td>10q23.3-q24.1</td> <td>SPG9</td> <td>Complicated</td> <td>AD</td> <td>601162</td> </tr> <tr> <td>SPG10</td> <td>12q13.3</td> <td>KIF5A</td> <td>Pure</td> <td>AD</td> <td>604187</td> </tr> <tr> <td>SPG11</td> <td>15q21.1</td> <td>SPG11</td> <td>Complicated</td> <td>AR</td> <td>604360</td> </tr> <tr> <td>SPG12</td> <td>19q13.32</td> <td>RTN2</td> <td>Pure</td> <td>AD</td> <td>604805</td> </tr> <tr> <td>SPG13</td> <td>2q33.1</td> <td>HSPD1</td> <td>Pure</td> <td>AD</td> <td>605280</td> </tr> <tr> <td>SPG14</td> <td>3q27-q28</td> <td>SPG14</td> <td>Complicated</td> <td>AR</td> <td>605229</td> </tr> <tr> <td>SPG15</td> <td>14q24.1</td> <td>ZFYVE26</td> <td>Complicated</td> <td>AR</td> <td>270700</td> </tr> <tr> <td>SPG16</td> <td>Xq11.2</td> <td>SPG16</td> <td>Complicated</td> <td>X-linked</td> <td>300266</td> </tr> <tr> <td>SPG17</td> <td>11q12.3</td> <td>BSCL2</td> <td>Complicated</td> <td>AD</td> <td>270685</td> </tr> <tr> <td>SPG18</td> <td>8p1123</td> <td>ERLIN2</td> <td>Complicated</td> <td>AR</td> <td>611225</td> </tr> <tr> <td>SPG19</td> <td>9q</td> <td>&ndash;</td> <td>Pure</td> <td>AD</td> <td>607152</td> </tr> <tr> <td>SPG20</td> <td>13q13.3</td> <td>SPG20</td> <td>Complicated</td> <td>AR</td> <td>275900</td> </tr> <tr> <td>SPG21</td> <td>15q22.31</td> <td>ACP33</td> <td>Complicated</td> <td>AR</td> <td>248900</td> </tr> <tr> <td>SPG23</td> <td>1q24-q32</td> <td>&ndash;</td> <td>Complicated</td> <td>AR</td> <td>270750</td> </tr> <tr> <td>SPG24</td> <td>13q14</td> <td>SPG24</td> <td>Pure</td> <td>AR</td> <td>607584</td> </tr> <tr> <td>SPG25</td> <td>6q23-q24.1</td> <td>SPG25</td> <td>Complicated</td> <td>AR</td> <td>608220</td> </tr> <tr> <td>SPG26</td> <td>12p11.1-q14</td> <td>B4GALNT1</td> <td>Complicated</td> <td>AR</td> <td>609195</td> </tr> <tr> <td>SPG27</td> <td>10q22.1-q24.1</td> <td>&ndash;</td> <td>Complicated</td> <td>AR</td> <td>609041</td> </tr> <tr> <td>SPG28</td> <td>14q22.1</td> <td>DDHD1</td> <td>Pure</td> <td>AR</td> <td>609340</td> </tr> <tr> <td>SPG29</td> <td>1p31.1-p21.1</td> <td>&ndash;</td> <td>Complicated</td> <td>AD</td> <td>609727</td> </tr> <tr> <td>SPG30</td> <td>2q37.3</td> <td>KIF1A</td> <td>Pure</td> <td>AR</td> <td>610357</td> </tr> <tr> <td>SPG31</td> <td>2p11</td> <td>REEP1</td> <td>Pure</td> <td>AD</td> <td>609139</td> </tr> <tr> <td>SPG32</td> <td>14q12-q21</td> <td>&ndash;</td> <td>Complicated</td> <td>AR</td> <td>611252</td> </tr> <tr> <td>SPG33</td> <td>10q24.2</td> <td>ZFYVE27</td> <td>Pure</td> <td>AD</td> <td>610244</td> </tr> <tr> <td>SPG34</td> <td>Xq24-q25</td> <td>&ndash;</td> <td>Pure</td> <td>X-linked</td> <td>300750</td> </tr> <tr> <td>SPG35</td> <td>16q23.1</td> <td>FA2H</td> <td>Complicated</td> <td>AR</td> <td>612319</td> </tr> <tr> <td>SPG36</td> <td>12q23-q24</td> <td>&ndash;</td> <td>Complicated</td> <td>AD</td> <td>613096</td> </tr> <tr> <td>SPG37</td> <td>8p21.1-q13.3</td> <td>SPG37</td> <td>Pure</td> <td>AD</td> <td>611945</td> </tr> <tr> <td>SPG38</td> <td>4p16-p15</td> <td>SPG38</td> <td>Complicated</td> <td>AD</td> <td>612335</td> </tr> <tr> <td>SPG39</td> <td>19p13.2</td> <td>PNPLA6</td> <td>Complicated</td> <td>AR</td> <td>612020</td> </tr> <tr> <td>SPG41</td> <td>11p14.1-p11.2</td> <td>SPG41</td> <td>Pure</td> <td>AD</td> <td>613364</td> </tr> <tr> <td>SPG42</td> <td>3q25.31</td> <td>SLC33A1</td> <td>Pure</td> <td>AD</td> <td>612539</td> </tr> <tr> <td>SPG43</td> <td>19q12</td> <td>C19ORF12</td> <td>Complicated</td> <td>AR</td> <td>615043</td> </tr> <tr> <td>SPG44</td> <td>1q42.13</td> <td>GJC2</td> <td>Complicated</td> <td>AR</td> <td>613206</td> </tr> <tr> <td>SPG45</td> <td>10q24.3-q25.1</td> <td>NT5C2</td> <td>Complicated</td> <td>AR</td> <td>613162</td> </tr> <tr> <td>SPG46</td> <td>9p13.3</td> <td>GBA2</td> <td>Complicated</td> <td>AR</td> <td>614409</td> </tr> <tr> <td>SPG47</td> <td>1p13.2</td> <td>AP4B1</td> <td>Complicated</td> <td>AR</td> <td>614066</td> </tr> <tr> <td>SPG48</td> <td>7p22.1</td> <td>AP5Z1</td> <td>Pure</td> <td>AR</td> <td>613647</td> </tr> <tr> <td>SPG49</td> <td>14q32.31</td> <td>TECPR2</td> <td>Complicated</td> <td>AR</td> <td>615031</td> </tr> <tr> <td>SPG50</td> <td>7q22.1</td> <td>AP4M1</td> <td>Complicated</td> <td>AR</td> <td>612936</td> </tr> <tr> <td>SPG51</td> <td>15q21.2</td> <td>AP4E1</td> <td>Complicated</td> <td>AR</td> <td>613744</td> </tr> <tr> <td>SPG52</td> <td>14q12</td> <td>AP4S1</td> <td>Complicated</td> <td>AR</td> <td>614067</td> </tr> <tr> <td>SPG53</td> <td>8p22</td> <td>VPS37A</td> <td>Complicated</td> <td>AR</td> <td>614898</td> </tr> <tr> <td>SPG54</td> <td>8p11.23</td> <td>DDHD2</td> <td>Complicated</td> <td>AR</td> <td>615033</td> </tr> <tr> <td>SPG55</td> <td>12q24.31</td> <td>C12ORF65</td> <td>Complicated</td> <td>AR</td> <td>615035</td> </tr> <tr> <td>SPG56</td> <td>4q25</td> <td>CYP2U1</td> <td>Complicated</td> <td>AR</td> <td>615030</td> </tr> <tr> <td>SPG57</td> <td>3q12.2</td> <td>TFG</td> <td>Complicated</td> <td>AR</td> <td>615658</td> </tr> <tr> <td>SPG58</td> <td>17p13.2</td> <td>KIF1C</td> <td>Complicated</td> <td>AR and AD</td> <td>&ndash;</td> </tr> <tr> <td>SPG61</td> <td>16p12.3</td> <td>ARL6IP1</td> <td>Complicated</td> <td>AR</td> <td>615685</td> </tr> <tr> <td>SPG62</td> <td>10q24.3</td> <td>ERLIN1</td> <td>Complicated</td> <td>AR</td> <td>615681</td> </tr> <tr> <td>SPG63</td> <td>1p13.3 </td> <td>AMPD2</td> <td>Complicated</td> <td>AR</td> <td>615686</td> </tr> <tr> <td>SPG64</td> <td>10q24.1 </td> <td>ENTPD1</td> <td>Complicated</td> <td>AR</td> <td>615683</td> </tr> <tr> <td>SPG72</td> <td>5q31.2</td> <td>REEP2</td> <td>Pure</td> <td>AR/AD</td> <td>615625</td> </tr> <tr> <td>SPG73</td> <td>19q13.33</td> <td>CPT1C</td> <td>Pure</td> <td>AD</td> <td>616282</td> </tr> <tr> <td>SPG74</td> <td>1q42.1</td> <td>IBA57</td> <td>Complicated</td> <td>AR</td> <td>616451</td> </tr> <tr> <td>SPG75</td> <td>19q13.1</td> <td>MAG</td> <td>Complicated</td> <td>AR</td> <td>616680</td> </tr> <tr> <td>SPG76</td> <td>11q13.1</td> <td>CAPN1</td> <td>Complicated</td> <td>AR</td> <td>616907</td> </tr> <tr> <td>SPG77</td> <td>6p25.1</td> <td>FARS2</td> <td>Pure</td> <td>AR</td> <td>617046</td> </tr> <tr> <td>SPG78</td> <td>1p36.1</td> <td>ATP13A2</td> <td>Complicated</td> <td>AR</td> <td>617225</td> </tr> <tr> <td>SPG79</td> <td>4p13</td> <td>UCHL1</td> <td>Complicated</td> <td>AR</td> <td>615491</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li><a href=\"http://www.ncbi.nlm.nih.gov/omim\" target=\"_blank\">Online Mendelian Inheritance in Man</a>.</li>&#xD;&#xA;    <li>Denora PS, Santorelli FM, Bertini E. Hereditary spastic paraplegias: one disease for many genes, and still counting. Handb Clin Neurol 2013; 113:1899.</li>&#xD;&#xA;    <li>Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol 2013; 126:307.</li>&#xD;&#xA;    <li>Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014; 343:506.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 95449 Version 4.0</div></div></div>"},"95450":{"type":"graphic_figure","displayName":"Vena cava anatomy","title":"Vena cava anatomy","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Vena cava anatomy</div><div class=\"cntnt\"><img style=\"width:536px; height:632px;\" src=\"images/SURG/95450_Vena_cava_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 95450 Version 1.0</div></div></div>"},"95451":{"type":"graphic_figure","displayName":"Renal vein anomalies","title":"Renal vein anomalies","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Renal vein anomalies</div><div class=\"cntnt\"><img style=\"width:519px; height:626px;\" src=\"images/SURG/95451_Renal_vein_anomalies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Type I &ndash; Retroaortic left renal vein; normal level of drainage into the IVC.</li>&#xD;&#xA;    <li>Type II &ndash; Retroaortic left renal vein, caudal level of drainage into the IVC (L4/L5).</li>&#xD;&#xA;    <li>Type III &ndash; Circumaortic left renal veins (venous collar), normal level of drainage into the IVC.</li>&#xD;&#xA;    <li>Type IV &ndash; Retroaortic left renal vein, caudal level of drainage into the left iliac vein.</li>&#xD;&#xA;    <li>Other (nonclassified) &ndash; Supernumerary renal veins, which can involve either kidney.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">RLRV: retroaortic left renal vein; IVC: inferior vena cava; LRV: left renal vein.</div><div class=\"graphic_reference\">Korean J Urol. Apr 2010; 51(4): 276-280.</div><div id=\"graphicVersion\">Graphic 95451 Version 2.0</div></div></div>"},"95452":{"type":"graphic_figure","displayName":"Vena cava variations","title":"Vena cava variations","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Vena cava variations</div><div class=\"cntnt\"><img style=\"width:536px; height:709px;\" src=\"images/SURG/95452_Vena_cava_variations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Partial malrotation and left IVC<br />(B) Duplicated IVC with left IVC draining into the left renal vein<br />(C) Azygos communication with the IVC; lack of continuity between the prerenal segment of the IVC and the hepatic segment<br />(D) Circumaortic left renal vein (renal vein collar, double left renal vein)<br />(E) Retroaortic left renal vein<br />(F) Double IVC with hemiazygos continuation of the right IVC<br />(G) Double IVC with retroaortic left renal vein and azygos communication with the right IVC; lack of continuity between the prerenal segment of the IVC and the hepatic segment<br />(H) Circumcaval ureter<br />(I)&nbsp;Absent infrarenal IVC; paravertebral collateral veins communicate via the azygos vein</div><div class=\"graphic_footnotes\">IVC: inferior vena cava.</div><div class=\"graphic_reference\">Modified from: Bass JE, Redwine MD, Kramer LA, et al. Spectrum of congenital anomalies of the inferior vena cava: cross-sectional imaging findings. Radiographics 2000; 20:639.</div><div id=\"graphicVersion\">Graphic 95452 Version 2.0</div></div></div>"},"95453":{"type":"graphic_diagnosticimage","displayName":"Retinal detachment ultrasound","title":"Ultrasound showing retinal detachment","html":"<div class=\"graphic\"><div style=\"width: 659px\" class=\"figure\"><div class=\"ttl\">Ultrasound showing retinal detachment</div><div class=\"cntnt\"><img style=\"width:639px; height:513px;\" src=\"images/EM/95453_Retinaldetachmentultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The detached retina is seen floating in the vitreous (arrows) with tethering at the optic nerve (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Retinal detachment. In: The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, 6th edition, Gerstenblith AT, Rabinowitz MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 95453 Version 3.0</div></div></div>"},"95454":{"type":"graphic_picture","displayName":"Polymorphous light eruption face","title":"Polymorphous light eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphous light eruption</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95454_Polymor_light_eruption_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and plaques on sun-exposed skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95454 Version 1.0</div></div></div>"},"95455":{"type":"graphic_figure","displayName":"Uterine compression sutures to prevent recurrent inversion","title":"Uterine compression sutures to prevent recurrent puerperal uterine inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine compression sutures to prevent recurrent puerperal uterine inversion</div><div class=\"cntnt\"><img style=\"width:442px; height:287px;\" src=\"images/OBGYN/95455_Uterine_compression_sutures_to_prevent_recurrent_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Matsubara S, Baba Y. MY (Matsubara-Yano) uterine compression suture to prevent acute recurrence of uterine inversion. Acta Obstet Gynecol Scand 2013; 92:734.</div><div id=\"graphicVersion\">Graphic 95455 Version 1.0</div></div></div>"},"95479":{"type":"graphic_figure","displayName":"JAK-STAT3 signaling pathway","title":"JAK-STAT3 signaling pathway","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">JAK-STAT3 signaling pathway</div><div class=\"cntnt\"><img style=\"width:514px; height:601px;\" src=\"images/ALLRG/95479_JAKSTAT3_signaling_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IL-6: interleukin-6; JAK: Janus activated kinase; STAT3: signal transducer and activator of transcription 3; p<FONT color=black>: phosphorous;</FONT> STAT: signal transducer and activator of transcription; DNA: deoxyribonucleic acid.</div><div id=\"graphicVersion\">Graphic 95479 Version 1.0</div></div></div>"},"95480":{"type":"graphic_picture","displayName":"Proliferative verrucous leukoplakia gingiva","title":"Oral proliferative verrucous leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Oral proliferative verrucous leukoplakia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95480_Prolif_verruc_leuko_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive, white, verrucous plaques involving the gingival margin in a patient with oral proliferative verrucous leukoplakia.</div><div class=\"graphic_reference\">Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95480 Version 1.0</div></div></div>"},"95484":{"type":"graphic_picture","displayName":"Oral proliferative verrucous leukoplakia histo1","title":"Clinical and pathologic features of oral proliferative verrucous leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Clinical and pathologic features of oral proliferative verrucous leukoplakia</div><div class=\"cntnt\"><img style=\"width:656px; height:386px;\" src=\"images/DERM/95484_Oralprolifverrucoleukopl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Proliferative verrucous leukoplakia of the gingiva with flat and exophytic appearance.<br />(B) On histologic examination, the lesion reveals markedly hyperplastic and papillomatous squamous proliferation. Note the extensive keratinization and the thin band of subepithelial chronic inflammatory cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Gillenwater AM, Vigneswaran N, Fatani H, et al. Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity! Adv Anat Pathol 2013; 20:416. DOI: <a href=\"http://journals.lww.com/anatomicpathology/pages/articleviewer.aspx?year=2013&amp;issue=11000&amp;article=00006&amp;type=abstract\" target=\"_blank\">10.1097/PAP.0b013e3182a92df1</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95484 Version 3.0</div></div></div>"},"95490":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica atrophy","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95490_Necrobiosis_lipoid_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This close-up view of the edge of a lesion of nonulcerated necrobiosis lipoidica demonstrates atrophy with thinning of the skin, a shiny, whitish appearance, and strikingly visible vasculature underlying the lesion. Much of the periphery of the atrophic plaque appears hyperpigmented, but there are areas of active erythema on the left side of the image.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95490 Version 1.0</div></div></div>"},"95491":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica ulceration","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/DERM/95491_Necrobiosis_lipoidica_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A close-up view of ulcerated necrobiosis lipoidica on the anterior shin. There is surrounding atrophy and faintly visible underlying blood vessels in the affected area. The ulcerations themselves are clinically nondescript and can be challenging to distinguish clinically from other causes of ulceration in the absence of surrounding skin changes classic for necrobiosis lipoidica.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95491 Version 1.0</div></div></div>"},"95492":{"type":"graphic_picture","displayName":"Ultrasound probe position for examination of IVC","title":"Ultrasound probe position for examination of IVC","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Ultrasound probe position for examination of IVC</div><div class=\"cntnt\"><img style=\"width:595px; height:795px;\" src=\"images/EM/95492_Ultrsnd_prb_pstn_exmn_IVC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of photographs shows the position of the ultrasound probe after it has been rotated into the sagittal orientation used to examine the IVC. In this position, the probe provides a longitudinal view of the IVC.</div><div class=\"graphic_footnotes\">IVC: Inferior vena cava.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 95492 Version 1.0</div></div></div>"},"95493":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis by CLL treatment regimen","title":"Recommended antimicrobial prophylaxis by CLL treatment regimen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended antimicrobial prophylaxis by CLL treatment regimen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Antibacterial</td> <td class=\"subtitle1\">Antifungal</td> <td class=\"subtitle1\"><em>Pneumocystis</em></td> <td class=\"subtitle1\">HSV/VZV</td> <td class=\"subtitle1\">CMV</td> </tr> <tr> <td>Alkylating agents (eg, chlorambucil)</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td>Bendamustine</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td>Purine analog monotherapy (eg, fludarabine)</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Purine analog &ndash; anti-CD20 monoclonal antibody</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Chlorambucil &ndash; anti-CD20 monoclonal antibody</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Purine analog &ndash; cyclophosphamide</td> <td class=\"centered\">No*</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Purine analog &ndash; cyclophosphamide &ndash; anti-CD20 monoclonal antibody</td> <td class=\"centered\">No*</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Anti-CD20 monoclonal antibodies (eg, rituximab, ofatumumab, obinutuzumab)</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td>Alemtuzumab</td> <td class=\"centered\">No*</td> <td class=\"centered\">No<sup>&#182;</sup></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Weekly PCR monitoring<sup>&#916;</sup></td> </tr> <tr> <td>Lenalidomide</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td>Ibrutinib</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td>Idelalisib</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">CMV monitoring<sup>&#9674;</sup></td> </tr> <tr> <td>Venetoclax</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CLL: chronic lymphocytic leukemia; HSV: herpes simplex virus; VZV: varicella-zoster virus; CMV: cytomegalovirus; PCR: polymerase chain reaction.<br />* The National Comprehensive Cancer Network suggests that fluoroquinolone prophylaxis be considered.<br />¶ When glucocorticoids are used in combination with alemtuzumab, we give antifungal prophylaxis.<br />Δ We give preemptive therapy with valganciclovir to those with a positive CMV PCR result. Some experts prefer giving prophylaxis rather than preemptive therapy.<br /><FONT class=lozenge>◊</FONT> In patients with a history of CMV infection or positive CMV serology receiving idelalisib, regular clinical and laboratory monitoring for CMV infection should be performed<SUP>[1]</SUP>. For patients who develop CMV infection while receiving idelalisib and in whom idelalisib is reinstituted, monitoring with CMV PCR or CMV antigenemia should be done at least monthly.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Zydelig. US Food and Drug Administration approved product information. Revised February 2018. US National Library of Medicine. <A href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50\">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50</A> (Accessed on March 19, 2018).</LI></OL></div><div id=\"graphicVersion\">Graphic 95493 Version 11.0</div></div></div>"},"95494":{"type":"graphic_figure","displayName":"Types of central venous access","title":"Types of central venous access","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Types of central venous access</div><div class=\"cntnt\"><img style=\"width:505px; height:656px;\" src=\"images/SURG/95494_Typesofcentralvenousaccess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term tunneled central venous catheters often include a cuff (B) located&nbsp;just above (cephalad) to the skin exit site. The cuff facilitates tissue ingrowth over a&nbsp;two- to three-week period to anchor the catheter and minimize bacterial migration from the exit site.</div><div id=\"graphicVersion\">Graphic 95494 Version 2.0</div></div></div>"},"95505":{"type":"graphic_table","displayName":"Management of osteoporosis risk during ICS therapy","title":"Management of osteoporosis risk in adults receiving high-dose inhaled glucocorticoid therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of osteoporosis risk in adults receiving high-dose inhaled glucocorticoid therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Measure BMD (DXA) of hip and spine and serum 25-hydroxyvitamin D in the following high-risk patients at baseline</td> </tr> <tr> <td class=\"indent1\">Anyone taking systemic glucocorticoids or high-dose inhaled glucocorticoids for &#8805;3 months</td> </tr> <tr> <td class=\"indent1\">Postmenopausal women</td> </tr> <tr> <td class=\"indent1\">Premenopausal women with amenorrhea</td> </tr> <tr> <td class=\"indent1\">Men with hypogonadism</td> </tr> <tr> <td class=\"indent1\">History of fragility fracture</td> </tr> <tr> <td class=\"indent1\">BMI &#60;18.5 kg/m<sup>2</sup></td> </tr> <tr> <td>Encourage an exercise program to improve strength and balance, including weight-bearing exercise</td> </tr> <tr> <td>Encourage patients to avoid cigarette smoking and excess alcohol intake</td> </tr> <tr> <td>Give calcium and vitamin D supplementation; most individuals require 1200 mg of elemental calcium daily (diet plus supplement) and 800 IU vitamin D daily</td> </tr> <tr> <td>Select therapy based upon fracture risk, determined by BMD (eg, T score &#8804;&ndash;2.5), history of fragility fracture, or Fracture Risk Assessment Tool (FRAX)*</td> </tr> <tr> <td>Measure BMD at the initiation of glucocorticoid therapy and after one year. If BMD is stable or improved, measure BMD less frequently (every two to three years) thereafter.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMD: bone mineral density; DXA: dual-energy x-ray absorptiometry; BMI: body mass index.<br />* Refer to UpToDate topics on the evaluation, prevention, and treatment of glucocorticoid-induced osteoporosis and to the website for the FRAX tool (<a href=\"http://www.shef.ac.uk/FRAX\" target=\"_blank\">http://www.shef.ac.uk/FRAX</a>).</div><div id=\"graphicVersion\">Graphic 95505 Version 5.0</div></div></div>"},"95506":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of second metatarsal stress fracture","title":"Ultrasound of second metatarsal stress fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of second metatarsal stress fracture</div><div class=\"cntnt\"><img style=\"width:425px; height:598px;\" src=\"images/EM/95506_US_metatarsal_stress_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These ultrasound images show the periosteal edema associated with a metatarsal stress fracture. Both transverse and longitudinal views are shown.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 95506 Version 1.0</div></div></div>"},"95520":{"type":"graphic_picture","displayName":"Portable bronchoscope","title":"Portable bronchoscope with monitor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Portable bronchoscope with monitor</div><div class=\"cntnt\"><img style=\"width:381px; height:720px;\" src=\"images/PULM/95520_Portable_bronchoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portable bronchoscope with built-in liquid crystal display (LCD) and light source. It has an outer diameter of 5.1 mm and working channel of 2.6 mm and can be operated without a large monitor or image processor.</div><div class=\"graphic_reference\">Image courtesy of Olympus America Inc. Copyright &copy; 2014 Olympus America Inc.</div><div id=\"graphicVersion\">Graphic 95520 Version 1.0</div></div></div>"},"95521":{"type":"graphic_picture","displayName":"Reprocessing system","title":"Bronchoscope reprocessing system","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Bronchoscope reprocessing system</div><div class=\"cntnt\"><img style=\"width:532px; height:712px;\" src=\"images/PULM/95521_Reprocessing_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscope reprocessing system. A dual chamber unit where the bronchoscope is placed for disinfection after enzymatic cleaning and leak testing is done.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Medivators Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95521 Version 1.0</div></div></div>"},"95522":{"type":"graphic_picture","displayName":"Rotation ring","title":"Bronchoscope with rotation ring","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Bronchoscope with rotation ring</div><div class=\"cntnt\"><img style=\"width:590px; height:609px;\" src=\"images/PULM/95522_Rotation_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexible bronchoscope with the ability to rotate the insertion tube at the handle. The rotation ring allows additional 120 degrees of axial movement to allow increase maneuverability to access subsegmental bronchi and/or upper lobe segments. The outer diameter is 5.5 mm with a working channel of 2 mm.</div><div class=\"graphic_reference\">Image courtesy of Olympus America Inc. Copyright &copy; 2014 Olympus America Inc.</div><div id=\"graphicVersion\">Graphic 95522 Version 1.0</div></div></div>"},"95523":{"type":"graphic_movie","displayName":"Leak test","title":"Leak test","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Leak test</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/95523_Leaktestvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:504px; height:325px;\" src=\"images/PULM/95523_Leaktestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A port on the top part of the bronchoscope is first connected to an air compressor and then submerged in water to determine if there are any air bubbles. Absence of air bubbles suggests that there is no damage. This video shows a positive leak test suggesting a breach of the outer covering near the distal end of this bronchoscope.</div><div id=\"graphicVersion\">Graphic 95523 Version 1.0</div></div></div>"},"95529":{"type":"graphic_diagnosticimage","displayName":"Ultrasound pediatric appendicitis fecalith","title":"Ultrasound  of pediatric appendicitis with fecalith","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ultrasound  of pediatric appendicitis with fecalith</div><div class=\"cntnt\"><img style=\"width:598px; height:335px;\" src=\"images/EM/95529_US_ped_appendicit_fecalith.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Six-year-old girl with RLQ pain. Image A shows a dilated, fluid filled, non-compressible appendix measuring 8 mm in diameter, with a localized peri-appendiceal fluid collection. The echogenic mucosa is discontinuous (arrow) at the site of perforation. Image B shows a calcified fecalith immediately adjacent to the perforated appendix (cross hatches).</div><div class=\"graphic_reference\">Courtesy of George Taylor, MD.</div><div id=\"graphicVersion\">Graphic 95529 Version 1.0</div></div></div>"},"95531":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of a hyperemic appendix with a thickened wall","title":"Ultrasound of a hyperemic appendix with a thickened wall","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ultrasound of a hyperemic appendix with a thickened wall</div><div class=\"cntnt\"><img style=\"width:598px; height:345px;\" src=\"images/EM/95531_US_hyperemic_appendix_thick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute appendicitis: 17-year-old female with RLQ pain. Sagittal power Doppler US image of the appendix (A) shows a markedly hyperemic appendix. Transverse US image of the appendix (B) shows a fluid-filled, appendix with thickened wall (4 mm, arrow). Note echogenic, surrounding fat consistent with peri-appendiceal inflammation.</div><div class=\"graphic_reference\">Courtesy of George Taylor, MD.</div><div id=\"graphicVersion\">Graphic 95531 Version 1.0</div></div></div>"},"95532":{"type":"graphic_diagnosticimage","displayName":"Abdominal computed tomography peri-appendiceal abscess fecalith","title":"Abdominal computed tomography showing a peri-appendiceal abscess and fecalith","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Abdominal computed tomography showing a peri-appendiceal abscess and fecalith</div><div class=\"cntnt\"><img style=\"width:590px; height:409px;\" src=\"images/EM/95532_Abd_CT_peri_append_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 13-year-old boy with peri-appendiceal abscess and fecalith. Contrast-enhanced CT scan through the pelvis shows a large calcified fecalith (arrow) within a large inflammatory mass.</div><div class=\"graphic_reference\">Courtesy of George Taylor, MD.</div><div id=\"graphicVersion\">Graphic 95532 Version 1.0</div></div></div>"},"95534":{"type":"graphic_diagnosticimage","displayName":"Appendicitis on coronal computed tomography","title":"Appendicitis on coronal computed tomography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Appendicitis on coronal computed tomography</div><div class=\"cntnt\"><img style=\"width:598px; height:313px;\" src=\"images/EM/95534_Appendicitis_coronal_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Retrocecal appendicitis. A six-year-old male. Coronal CT reconstruction (A) shows a large, fluid-filled appendix in sub-hepatic, retrocecal location (arrow). Note localized adenopathy (arrowhead).<br />(B) An 11-year-old female. Coronal CT reconstruction (B) shows perforated, fluid-filled, appendix with multiloculated pelvic abscess. Arrow denotes location of perforation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of George Taylor, MD.</div><div id=\"graphicVersion\">Graphic 95534 Version 2.0</div></div></div>"},"95536":{"type":"graphic_diagnosticimage","displayName":"Appendicitis with fecalith on computed tomography","title":"Appendicitis with fecalith on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Appendicitis with fecalith on computed tomography</div><div class=\"cntnt\"><img style=\"width:599px; height:333px;\" src=\"images/EM/95536_Appendicitis_fecalith_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 17-year-old-male. Axial (A) and coronal reconstructed (B) CT scans show a large calcified fecalith (arrows) at the base of a dilated, fluid filled appendix (arrowhead). Note moderate small bowel dilatation and focal mesenteric edema (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of George Taylor, MD.</div><div id=\"graphicVersion\">Graphic 95536 Version 2.0</div></div></div>"},"95551":{"type":"graphic_table","displayName":"Characteristics of the Marfanoid habitus","title":"Characteristics of the Marfanoid habitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of the Marfanoid habitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name of measurement</td> <td class=\"subtitle1\">Value consistent with Marfanoid habitus*</td> <td class=\"subtitle1\">Technique for measurement and for calculation of ratio<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Span/height ratio</td> <td>&#62;1.03</td> <td>The span/height ratio (S-HR) is measured by asking the patient to stand with their back to a wall and in contact with the wall, with the arms out to 90 degrees at the shoulder, and hands and fingers fully extended. The arm span is the measure from the tip of the middle finger of one hand to that of the other. This is then divided by the height to obtain the S-HR.</td> </tr> <tr class=\"divider_bottom\"> <td>Hand/height ratio</td> <td>&#62;0.11</td> <td>The hand/height ratio (H-HR). Hand length is taken to be the distance between the distal palmar crease to the tip of the middle finger. This is then divided by the height to obtain the H-HR.</td> </tr> <tr class=\"divider_bottom\"> <td>Foot/height ratio</td> <td>&#62;0.15</td> <td>The foot/height ratio (F-HR). Foot length is taken to be the distance between the base of the posterior edge of the heel and the tip of the hallux. This is then divided by the height to obtain the F-HR.</td> </tr> <tr class=\"divider_bottom\"> <td>Upper segment/lower segment ratio</td> <td>&#60;0.89</td> <td>The upper segment/lower segment ratio (US/LSR). LS is taken to be the distance from the mid-point of the pubic symphysis and the floor with the patient standing erect. The US is calculated by subtracting the LS from the height. Thus US/LSR = (Height &ndash; LS)/LS.</td> </tr> <tr> <td colspan=\"3\">Other features of the Marfanoid habitus include:</td> </tr> <tr> <td colspan=\"3\"> <ul class=\"decimal_heading\"> <li>Dolichocephaly (skull width/length x 100 &#60;76 percent) </li> <li>Scoliosis (Bunnell Scoliometer &#62;5 degrees) </li> <li>Pectus deformities (excavatum or carinatum) </li> <li>Jaw deformities with overcrowding of teeth </li> <li>High-arched palate </li> <li>Long, flat feet, often with hammer toes, which flatten and pronate on weightbearing </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The cut-off levels for the Marfanoid habitus are based upon the original data collected by McKusick (McKusick VA. The Marfan syndrome. In: Heritable Disorders of Connective Tissue. 4th ed, C.V. Mosby, St. Louis 1972. p.61-223).<br />Δ Equipment needed to perform the necessary measurements comprises an accurate height-measuring scale, a tape measure for measuring the arm span, a Bunnell scoliometer for establishing whether or not a significant scoliosis is present (Bunnell WP. Outcome of spinal screening. Spine 1993; 18:1572-80), and a calculator.</div><div id=\"graphicVersion\">Graphic 95551 Version 1.0</div></div></div>"},"95553":{"type":"graphic_diagnosticimage","displayName":"Double decidual sac","title":"Early IUP with double decidual sac sign","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Early IUP with double decidual sac sign</div><div class=\"cntnt\"><img style=\"width:598px; height:227px;\" src=\"images/RADIOL/95553_Double_decidual_sac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound shows an early&nbsp;intrauterine pregnancy&nbsp;with double decidual sac sign. Image B is a color overlay of the structures that contribute to the appearance, including the gestational sac (GS), surrounded by the decidua capsularis (light pink), partially surrounded by the decidua parietalis (dark pink). In between these two layers is a small amount of fluid (yellow).</div><div id=\"graphicVersion\">Graphic 95553 Version 1.0</div></div></div>"},"95555":{"type":"graphic_diagnosticimage","displayName":"Enthesitis of Achilles tendon in a longitudinal scan","title":"Enthesitis of Achilles tendon in a longitudinal scan","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Enthesitis of Achilles tendon in a longitudinal scan</div><div class=\"cntnt\"><img style=\"width:605px; height:349px;\" src=\"images/RHEUM/95555_Enthesitis_Achill_tndn_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enthesitis of Achilles tendon in a longitudinal scan. Presence of erosion (arrows), enthesophyte (bone spur)&nbsp;(E), hypoechogenicity (A), and Doppler signal (PD) of tendon insertion.</div><div class=\"graphic_reference\">Courtesy of Maria Antonietta D’Agostino, MD, PhD.</div><div id=\"graphicVersion\">Graphic 95555 Version 1.0</div></div></div>"},"95556":{"type":"graphic_diagnosticimage","displayName":"Enthesitis of Achilles tendon with retrocalcaneal bursitis","title":"Enthesitis of Achilles tendon in a longitudinal scan with retrocalcaneal bursitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Enthesitis of Achilles tendon in a longitudinal scan with retrocalcaneal bursitis</div><div class=\"cntnt\"><img style=\"width:590px; height:276px;\" src=\"images/RHEUM/95556_Achilles_tndn_rtrclcnl_brst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enthesitis of Achilles tendon in a longitudinal scan. Presence of erosion (arrow), hypoechogenicity (A), retrocalcaneal bursitis (B), and Doppler signal (PD) of tendon insertion.</div><div class=\"graphic_reference\">Courtesy of Maria Antonietta D’Agostino, MD, PhD.</div><div id=\"graphicVersion\">Graphic 95556 Version 1.0</div></div></div>"},"95571":{"type":"graphic_diagnosticimage","displayName":"Atypical alveolar hyperplasia II","title":"Atypical alveolar hyperplasia II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical alveolar hyperplasia II</div><div class=\"cntnt\"><img style=\"width:404px; height:590px;\" src=\"images/PULM/95571_Atyp_alveolar_hyperplas_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT thorax, coronal reformation, shows one ground glass nodule in the right upper lobe and one ground glass nodule in the superior segment of the right lower lobe (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 95571 Version 2.0</div></div></div>"},"95572":{"type":"graphic_diagnosticimage","displayName":"Atypical alveolar hyperplasia I","title":"Atypical alveolar hyperplasia presenting as multiple ground glass nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical alveolar hyperplasia presenting as multiple ground glass nodules</div><div class=\"cntnt\"><img style=\"width:357px; height:590px;\" src=\"images/PULM/95572_Atyp_alveolar_hyperplas_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT thorax, coronal reformation, shows one ground glass nodule in the right upper lobe and one ground glass nodule in the superior segment of the right lower lobe (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 95572 Version 2.0</div></div></div>"},"95574":{"type":"graphic_table","displayName":"Autoantibodies in SSc","title":"Serum autoantibodies in systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serum autoantibodies in systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antigen</td> <td class=\"subtitle1\">ANA staining pattern</td> <td class=\"subtitle1\">Approximate frequency in all patients (percent)</td> <td class=\"subtitle1\">Clinical associations</td> <td class=\"subtitle1\">Organ involvement</td> </tr> <tr> <td>Scl-70 (topoisomerase-1)</td> <td>Speckled</td> <td>10 to 40</td> <td>dcSSc</td> <td>Lung fibrosis, isolated pulmonary hypertension less likely</td> </tr> <tr> <td>Centromere</td> <td>Centromere (kinetochore)</td> <td>15 to 40</td> <td>lcSSc</td> <td>Pulmonary hypertension, esophageal disease, \"protection\" from lung fibrosis and renal disease</td> </tr> <tr> <td>RNA polymerase III</td> <td>Fine speckled nucleolar</td> <td>4 to 25</td> <td>dcSSc</td> <td>Renal, skin, malignancy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Characteristics and clinical associations of the different autoantibodies that may be seen in scleroderma. dcSSc and lcSSc refer to diffuse and limited cutaneous systemic sclerosis, respectively.</div><div class=\"graphic_footnotes\">dcSSc:&nbsp;diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis.</div><div class=\"graphic_reference\">Adapted from: Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6:112.</div><div id=\"graphicVersion\">Graphic 95574 Version 2.0</div></div></div>"},"95586":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica large patch","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95586_Necrobiosis_lipoid_lrg_ptch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, slightly atrophic patches with visible vasculature and a striking orange hue, characteristic of necrobiosis lipoidica.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95586 Version 1.0</div></div></div>"},"95587":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica atrophic patches","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95587_Necrobiosis_lipoi_atrp_ptch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic atrophy and visible underlying vasculature in necrobiosis lipoidica. Some plaques demonstrate hyperpigmentation (smaller lesions, top-middle of photo), while others show actively inflamed lesions (left side of photo).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95587 Version 1.0</div></div></div>"},"95589":{"type":"graphic_picture","displayName":"Histopathology of necrobiosis lipoidica","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:552px;\" src=\"images/DERM/95589_Histo_necrobiosis_lipoidica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On low power, necrobiosis lipoidica can demonstrate layering of abnormal collagen with inflammatory cells composed of histiocytes, lymphocytes, and plasma cells. This can be referred to as “wedding cake” or “tiramisu” type of layering.</div><div id=\"graphicVersion\">Graphic 95589 Version 1.0</div></div></div>"},"95590":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica collagen degeneration and inflammation","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/DERM/95590_Necrob_lipoidica_degen_infl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The collagen does not look healthy or normal (“necrobiotic” collagen) and is surrounded by histiocytes, lymphocytes, and plasma cells.</div><div id=\"graphicVersion\">Graphic 95590 Version 1.0</div></div></div>"},"95591":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica inflammatory infiltrate","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/DERM/95591_Necrob_lipoidica_infl_infil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inflammatory infiltrate has histiocytes, plasma cells, and lymphocytes, which is characteristic of necrobiosis lipoidica.</div><div id=\"graphicVersion\">Graphic 95591 Version 1.0</div></div></div>"},"95602":{"type":"graphic_table","displayName":"Postural strategies to improve bolus flow in swallowing","title":"Postural strategies to improve bolus flow for patients with swallowing disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Postural strategies to improve bolus flow for patients with swallowing disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder observed on fluoroscopy</td> <td class=\"subtitle1\">Posture applied</td> <td class=\"subtitle1\">Rationale</td> </tr> <tr> <td>Inefficient oral transit (reduced posterior propulsion of bolus by tongue)</td> <td>Head back</td> <td>Utilizes gravity to clear oral cavity</td> </tr> <tr> <td>Delay in triggering the pharyngeal swallow (bolus past ramus of mandible, but pharyngeal swallow not triggered)</td> <td>Chin down</td> <td>Widens valleculae to prevent bolus entering airway; narrows airway entrance; pushes epiglottis posteriorly</td> </tr> <tr> <td>Reduced posterior motion of tongue base (residue in valleculae)</td> <td>Chin down</td> <td>Pushes tongue base backward toward pharyngeal wall</td> </tr> <tr> <td>Unilateral laryngeal dysfunction (aspiration during swallow)</td> <td>Head rotated to damaged side; chin down</td> <td>Places extrinsic pressure on thyroid cartilage, increasing adduction</td> </tr> <tr> <td>Reduced laryngeal closure (aspiration during swallow)</td> <td>Chin down; head rotated to damaged side</td> <td>Puts epiglottis in more protective position; narrows laryngeal entrance; increases vocal fold closure by applying extrinsic pressure</td> </tr> <tr> <td>Reduced pharyngeal contraction (residue spread throughout pharynx)</td> <td>Lying down on one side</td> <td>Eliminates gravitational effect on pharyngeal residue</td> </tr> <tr> <td>Unilateral pharyngeal paresis (residue on one side of pharynx)</td> <td>Head rotated to damaged side</td> <td>Eliminates damaged side from bolus path</td> </tr> <tr> <td>Unilateral oral and pharyngeal weakness on the same side (residue in mouth and pharynx on same side)</td> <td>Head tilt to stronger side</td> <td>Directs bolus down stronger side</td> </tr> <tr> <td>Cricopharyngeal dysfunction (residue in pyriform sinuses)</td> <td>Head rotated</td> <td>Pulls cricoid cartilage away from posterior pharyngeal wall, reducing resting pressure in cricopharyngeal sphincter</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Table 6.1 Reprinted from Evaluation and Treatment of Swallowing Disorders (p. 198), by Jeri Logemann, Austin, TX: PRO-ED. Copyright 1998, 1983 by PRO-ED, Inc. Reprinted online with permission.</div><div id=\"graphicVersion\">Graphic 95602 Version 1.0</div></div></div>"},"95608":{"type":"graphic_algorithm","displayName":"Evaluation of small bowel bleeding","title":"Evaluation of suspected small bowel bleeding in hemodynamically stable patients*","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected small bowel bleeding in hemodynamically stable patients*</div><div class=\"cntnt\"><img style=\"width:648px; height:1244px;\" src=\"images/GAST/95608_Eval_obscure_GI_bleeding.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GI: gastrointestinal; VCE: video capsule endoscopy; CTE: computed tomographic enterography; MRE: magnetic resonance enterography; CTA: computed tomographic angiography.<br />* Small bowel bleeding should be suspected in patients with signs of GI bleeding who have had a negative initial endoscopic evaluation (typically upper endoscopy and colonoscopy). The evaluation of hemodynamically unstable patients is discussed in the context of the specific bleeding manifestations (eg, hematemesis). Refer to UpToDate topic reviews on the evaluation and management of GI bleeding for details.<br />&para; For patients with risk factors for hemobilia or hemosuccus pancreaticus, the upper endoscopy should have included evaluation with a side-viewing duodenoscope. Patients with risk factors for an aortoenteric fistula should also have undergone CTA. If the initial upper endoscopy and/or colonoscopy was inadequate (eg, fair or poor visualization, failure to reach the cecum), repeat examination should be considered before initiating an evaluation for small bowel bleeding.<br />&Delta; VCE should be done as close to the acute bleeding episode as possible to increase diagnostic yield. Patients at risk for capsule retention should undergo small bowel imaging (eg, CTE) or a patency capsule study prior to VCE.<br /><span class=\"lozenge\">&loz;</span> In patients with significant comorbid illnesses with slow rates of blood loss, it may be reasonable to stop the evaluation and treat with iron repletion and/or transfusions as needed.<br />&sect; Push enteroscopy is an alternative if not already done and if deep small bowel enteroscopy is not available. Intraoperative enteroscopy is an alternative if there are contraindications to deep small bowel enteroscopy, such as dense intra-abdominal adhesions.<br />&yen; The choice of test will depend on the rate of bleeding, patient characteristics, and the degree of suspicion for a small bowel lesion. A Meckel's scan should be performed in younger patients with overt bleeding. Angiography or CTA can be obtained if there is active bleeding. Surgical exploration is appropriate if no other studies have revealed a source and significant bleeding continues or if there is high suspicion for a small bowel neoplasm. If the evaluation is still negative, non-GI sources of blood loss should be reconsidered.</div><div id=\"graphicVersion\">Graphic 95608 Version 4.0</div></div></div>"},"95614":{"type":"graphic_movie","displayName":"3D echo mitral valve ring dehiscence","title":"Three-dimensional (3D) echocardiography showing mitral valve ring dehiscence in infective endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Three-dimensional (3D) echocardiography showing mitral valve ring dehiscence in infective endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/95614_Mitrvalringdehiscenvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:579px; height:529px;\" src=\"images/CARD/95614_Mitrvalringdehiscenimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A three-dimensional view from atrium to ventricle shows mitral valve ring dehiscence. The mitral valve leaflets are seen in motion between the lower portion of the ring and the mitral annulus at the four to seven o'clock positions. The mitral valve leaflets do not co-apt completely in systole, consistent with severe mitral regurgitation.</div><div id=\"graphicVersion\">Graphic 95614 Version 1.0</div></div></div>"},"95615":{"type":"graphic_algorithm","displayName":"Pain assessment in older adults with severe cognitive impairment","title":"Pain assessment in older adults with severe cognitive impairment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pain assessment in older adults with severe cognitive impairment</div><div class=\"cntnt\"><img style=\"width:446px; height:603px;\" src=\"images/ANEST/95615_Pn_ass_old_adlt_svr_cgn_imp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">* Grimacing, guarding, combativeness, groaning with movement, resisting care.<br />¶ Agitation, fidgeting, sleep disturbance, diminished appetite, irritability, reclusiveness, disruptive behavior, rigidity, rapid blinking.<br />Δ Toileting, thirst, hunger, visual or hearing impairment.</div><div class=\"graphic_reference\">Reproduced with permission from: Reuben DB, Herr KA, Pacala JT, et al. Geriatrics At Your Fingertips: 2014, 16th Edition. New York. The American Geriatrics Society; 2014. Copyright &copy; 2014 The American Geriatrics Society.</div><div id=\"graphicVersion\">Graphic 95615 Version 1.0</div></div></div>"},"95619":{"type":"graphic_table","displayName":"CLL antimicrobial prophylaxis regimens","title":"Antimicrobial prophylaxis regimens for adult patients with chronic lymphocytic leukemia (CLL)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis regimens for adult patients with chronic lymphocytic leukemia (CLL)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antibacterial</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin 500 mg orally twice daily</td> </tr> <tr> <td class=\"indent1\">Levofloxacin 500 mg orally once daily</td> </tr> <tr> <td class=\"subtitle1_single\">Antifungal</td> </tr> <tr> <td class=\"indent1\">Fluconazole<sup>&#182;</sup> 200 or 400 mg orally once daily</td> </tr> <tr> <td class=\"indent1\">Posaconazole<sup>&#182;</sup> delayed-release tablets 300 mg (three 100 mg tablets) orally every 12 hours on the first day, followed by 300 mg (three 100 mg tablets) once daily starting on the second day</td> </tr> <tr> <td class=\"indent1\">Voriconazole<sup>&#182;</sup> 200 mg orally twice daily</td> </tr> <tr> <td class=\"subtitle1_single\">Antiviral</td> </tr> <tr> <td class=\"subtitle2_single\">Herpes simplex virus and varicella-zoster virus</td> </tr> <tr> <td class=\"indent1\">Acyclovir 400 to 800 mg orally twice daily (for VZV, 800 mg orally twice daily)</td> </tr> <tr> <td class=\"indent1\">Valacyclovir 500 mg orally two or three times daily</td> </tr> <tr> <td class=\"indent1\">Famciclovir 250 mg orally twice daily</td> </tr> <tr> <td class=\"subtitle2_single\">Cytomegalovirus<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Valganciclovir 900 mg orally once daily with food</td> </tr> <tr> <td class=\"indent1\">Ganciclovir 5 mg/kg IV once daily</td> </tr> <tr> <td class=\"subtitle1_single\"><em>Pneumocystis</em></td> </tr> <tr> <td class=\"indent1\"> <p><strong>Preferred regimen:</strong></p> <p>Trimethoprim-sulfamethoxazole one single-strength tablet orally once daily <strong>or</strong> one double-strength tablet orally once daily or three times weekly<sup>&#9674;</sup></p> </td> </tr> <tr> <td class=\"indent1\"> <p><strong>Alternative regimens:&nbsp;</strong></p> <p>Dapsone 100 mg orally once daily or 50 mg orally twice daily</p> </td> </tr> <tr> <td class=\"indent1\">Pentamidine 300 mg by aerosol every four weeks</td> </tr> <tr> <td class=\"indent1\">Atovaquone 1500 mg orally once daily with a high-fat meal</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of many of the agents listed above must be adjusted in the setting of renal insufficiency. Many of the agents listed above can be given IV if the patient is unable to take oral medications. Refer to the Lexicomp drug specific monograph for renal dose adjustments and IV dosing.</div><div class=\"graphic_footnotes\">IV: intravenously; VZV: varicella-zoster virus.<br />* Refer to the associated topic review for indications for antimicrobial prophylaxis.<br />¶ Posaconazole and voriconazole are potent inhibitors of CYP3A4 drug metabolism; fluconazole is a moderate inhibitor. Adjustment of antineoplastic therapy may be required. Readers may use Lexi-Interact, the drug interactions program included with UpToDate to determine specific interactions.<br />Δ Regular cytomegalovirus (CMV) surveillance testing followed by preemptive anti-CMV therapy for a positive result may be preferred over prophylaxis and is discussed in the topic review on prevention of infections in patients with CLL, section on alemtuzumab. Note that the dosing and schedule for preemptive anti-CMV therapy differs from the prophylaxis dosing shown in this table.<br />◊ Trimethoprim-sulfamethoxazole is preferred as it is the most effective regimen for <EM>Pneumocystis</EM> prophylaxis. It also provides activity against <EM>Toxoplasma gondii </EM>as well as certain bacteria (<EM>Nocardia </EM>spp, <EM>Listeria</EM> spp, some pneumococci).</div><div id=\"graphicVersion\">Graphic 95619 Version 3.0</div></div></div>"},"95620":{"type":"graphic_picture","displayName":"Skin hyperextensibility testing","title":"Clinical assessment of skin hyperextensibility","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Clinical assessment of skin hyperextensibility</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/RHEUM/95620_Skin_hyperextensibilit_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin hyperextensibility can be assessed using the \"rubber glove test\"; as the skin fold is gently pulled away from the skin surface, the true nature of the stretching process can be observed. In the joint hypermobility syndrome or the hypermobility type of Ehlers-Danlos syndrome, the characteristic finding is that the whole skin over the dorsal aspect of the hand (up to and beyond the wrist in some cases) is seen to take part in the stretching process as if the patient's skin were a rubber glove. In a normal individual, skin is seen to&nbsp;stretch to a lesser degree and only in the region adjacent to where the fold is raised.</div><div class=\"graphic_reference\">Courtesy of Rodney Grahame, MD.</div><div id=\"graphicVersion\">Graphic 95620 Version 1.0</div></div></div>"},"95621":{"type":"graphic_table","displayName":"Doses of analgesic drugs for older adults","title":"Dosing and selected characteristics of analgesic drugs for treatment of persistent pain in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing and selected characteristics of analgesic drugs for treatment of persistent pain in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Suggested initial dose* and titration</td> <td class=\"subtitle1\">Selected characteristics relevant to older adults</td> </tr> <tr class=\"divider_bottom\"> <td>Acetaminophen (paracetamol)</td> <td>325 to 500 mg orally every four hours or 500 to 1000 mg every six to eight hours (maximum 3 g per day)</td> <td> <ul> <li>Effective analgesic that may decrease opioid requirements; often used in combination with tramadol </li> <li>Clearance is reduced with aging </li> <li>Maximum 2 g per day suggested for older adults who are frail, aged &#8805;80, with significant organ dysfunction, or at risk for hepatotoxicity (eg, regular alcohol use or malnourished) </li> <li>Interacts with warfarin (prolongs INR) and CYP450 inducing drugs (increased risk of hepatic inflammation) </li> <li>Warn patients concerning acetaminophen content in combination prescription analgesics (eg, oxycodone-acetaminophen) and OTC preparations </li> <li>For short-term or one-time use, a total dose of up to 4 g per day may be considered in selected older adults under medical supervision (eg, nursing facility) </li> </ul> </td> </tr> <tr> <td colspan=\"3\"><strong>Opioid analgesics</strong><sup>&#916;</sup><sup>&#9674;</sup><strong>:</strong> Older adults are more susceptible to opioid-induced adverse effects including respiratory depression, hypotension, delirium, constipation, excessive sedation, and drug accumulation. Low doses should be used initially and titrated gradually to decrease risk of accumulation and overdose. The initial dose should be decreased by 25 percent for a 60 year old patient and by 50 percent for an 80 year old patient, from the initial dose that a 40 year old would receive, but administered at the same intervals.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Tramadol</td> </tr> <tr> <td class=\"indent2\">Immediate release<sup>&#167;</sup></td> <td> <p>Start with 25 mg orally once daily</p> <p>May increase daily dose by 25 to 50 mg after 3 to 7 days; give in 3 or 4 divided doses</p> <p>Age &#8804;75 years: Maximum 400 mg daily</p> <p>Age &#62;75 years: Maximum 300 mg daily</p> Renal impairment (CrCl &#60;30 mL/min): Maximum 200 mg daily irrespective of age</td> <td rowspan=\"2\"> <ul> <li>Partial mu-opioid agonist with norepinephrine/serotonin reuptake; associated with analgesic dose-ceiling effect, but may be less likely to cause physical dependence </li> <li>About one-tenth as potent as morphine; wide inter-individual variation in response </li> <li>Metabolized by CYP2D6 (polymorphic) to active metabolites </li> <li>May cause nausea and dizziness; slowly titrate to improve tolerability in older adults </li> <li>Constipation and sedation less frequent than with strong opioids </li> <li>Renally cleared; dose adjust for renal impairment (CrCl &#60;30 mL/min) </li> <li>Can interact with serotoninergic medications (eg, antidepressants and ondansetron) </li> <li>Avoid use in older adults at risk for seizures </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Extended release</td> <td> <p>Start with 100 mg orally once daily</p> <p>May increase daily dose by 100 mg after 5 or more days (maximum 300 mg daily)</p> Avoid use in renal impairment (CrCl &#60;30 mL/min)</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Oxycodone</td> </tr> <tr> <td class=\"indent2\">Immediate release<sup>&#167;</sup></td> <td> <p>Start with 2.5 to 5 mg orally every four hours as needed</p> After 3 to 7 days determine 24-hour dose requirement and convert to extended release</td> <td rowspan=\"2\"> <ul> <li>Metabolized by CYP2D6 (polymorphic) and CYP3A4 to active metabolites </li> <li>Blood levels increased by about 50 percent in older adults with renal insufficiency (CrCl &#60;60 mL/min); reduce dose and titrate gradually </li> <li>Some opioid-tolerant patients may require every eight hour dosing of extended-release forms for effective analgesia; a 12- to 24-hour interval is appropriate for most older adults </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Extended release</td> <td>Divide 24-hour dose requirement for oxycodone immediate release in two doses</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Morphine</td> </tr> <tr> <td class=\"indent2\">Immediate release</td> <td> <p>Start with 2.5 to 10 mg orally every four hours as needed (an oral solution is available for initial low doses; lowest tablet strength available in US is 15 mg)</p> After 3 to 7 days determine 24-hour dose requirement and convert to extended release</td> <td rowspan=\"2\"> <ul> <li>In patients with renal impairment, clearance of active and potentially neurotoxic metabolites is decreased </li> <li>Hydromorphone or fentanyl may be better choices for older adults with renal impairment (CrCl &#60;60 mL/min) </li> <li>For extended-release forms, some patients may require every eight hour dosing for effective analgesia; a 12- to 24-hour dosing interval is appropriate for most older adults </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Extended release<sup>&#916;</sup></td> <td>Divide 24-hour dose requirement for immediate-release morphine in one, two, or three doses (depending on type of preparation)</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Hydromorphone</td> </tr> <tr> <td class=\"indent2\">Immediate release</td> <td> <p>Start with 2 mg orally every four hours as needed</p> After 3 to 7 days determine 24-hour dose requirement and covert to extended release</td> <td rowspan=\"2\"> <ul> <li>Metabolism to apparently inactive metabolites is an advantage over morphine in older adults with renal or hepatic insufficiency </li> <li>Accumulation of a neurotoxic (excitatory) metabolite may become a concern in older adults with severe renal insufficiency or ESRD </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Extended release<sup>&#916;</sup></td> <td>Divide 24-hour dose requirement for immediate-release hydromorphone in one or two doses (depending on type of preparation)</td> </tr> <tr> <td class=\"indent1\">Transdermal fentanyl<sup>&#916;</sup></td> <td> <p>Determine 24-hour dose requirement using an immediate-release oral opioid; after 3 to 7 days convert to an equianalgesic dose of transdermal fentanyl; refer to Lexicomp drug monograph for initial conversion</p> Or start with 12 mcg/hour patch every 72 hours; if ineffective after one week, increase to 25 mcg/hour patch</td> <td> <ul> <li>Metabolized by CYP3A4 to inactive (nontoxic) metabolites and useful in patients with renal and/or hepatic dysfunction </li> <li>Full effect following application of first patch is delayed by 18 to 24 hours </li> <li>Steady state levels may not be reached in older adults until patch is used for six to nine days </li> <li>Avoid in opioid-na&#239;ve patients </li> <li>Some opioid-tolerant patients may require a 48-hour dosing interval for effective analgesia; a 72-hour dosing interval is appropriate for most older adults </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Transdermal buprenorphine<sup>&#916;</sup></td> <td>5 mcg/hour patch every 7 days</td> <td> <ul> <li>Partial mu agonist and weak kappa antagonist actions are associated with analgesic dose-ceiling effect but may be less likely to cause physical dependence than full agonist opioids </li> <li>Metabolized by CYP3A4 and glucuronidation to active metabolites </li> <li>Full effect following application of first patch is delayed by up to 72 hours </li> <li>Limited information on use in renal impairment </li> <li>Avoid or use with caution in opioid-na&#239;ve patients </li> <li>Precise role in treating older adults with painful conditions not well established </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methadone</td> <td> <p>Start with 1 mg orally, buccal, or subcutaneously every 12 to 24 hours</p> <p>Increase daily dose by 1 to 2 mg after 7 or more days</p> Further increases in daily dose of 1 to 2 mg should be made no more frequently than once every 7 days</td> <td> <ul> <li>Consult with a pain specialist prior to prescribing </li> <li>Due to its highly variable half-life and wide inter-individual pharmacodynamics, methadone has the highest risk of accumulation and overdose during initial titration, periodic dose adjustment, and conversion from other opioids </li> <li>EKG should be obtained and monitored as methadone use is associated with QT interval prolongation </li> <li>Due to challenges inherent in safe prescribing of methadone, it is not a first-line analgesic choice </li> <li>For additional information, refer to the UpToDate topic reviews of treatment of chronic pain and cancer pain management with opioids </li> </ul> </td> </tr> <tr> <td colspan=\"3\"><strong>Adjuvant analgesics</strong><sup>&#9674;</sup><strong>:</strong> Includes options for painful polyneuropathies, muscle spasm, and multipurpose analgesics that may decrease opioid requirements.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Serotonin-norepinephrine reuptake inhibitors (SNRIs)</td> </tr> <tr> <td class=\"indent2\">Duloxetine</td> <td> <p>Start with 20 to 30 mg orally per day</p> <p>May increase daily dose to 40 to 60 mg after 1 week</p> Maximum 60 mg per day (CrCl &#8805;30 mL/min)</td> <td> <ul> <li>Effective for painful neuropathies, low back pain, fibromyalgia, and chronic musculoskeletal pain due to osteoarthritis in older adults </li> <li>Titrate gradually over two weeks or more to improve tolerability </li> <li>Avoid in renal impairment (CrCl &#60;30 mL/min) or hepatic impairment </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Venlafaxine (extended release)</td> <td> <p>Start with 37.5 mg orally daily</p> <p>May increase daily dose by 37.5 mg after 7 or more days; then may increase daily dose by 37.5 to 75 mg after 4 or more days</p> Maximum 225 mg per day</td> <td> <ul> <li>Effective for treatment of various painful polyneuropathies but not PHN </li> <li>Titrate gradually over four weeks or more to improve tolerability </li> <li>Dose-related increase in diastolic blood pressure may be seen </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Milnacipran</td> <td>Start with 12.5 mg orally once daily (refer to Lexicomp drug monograph for titration)</td> <td> <ul> <li>Useful for treatment of various painful conditions including fibromyalgia </li> <li>Dose reduction needed for renal impairment </li> <li>Avoid use in older adults with ESRD or significant hepatic impairment </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"indent2\">Nortriptyline</td> <td> <p>Start with 10 mg orally at bedtime</p> <p>May increase daily dose by 10 mg after 7 or more days</p> Maximum 50 mg per night</td> <td rowspan=\"2\">Applies to nortriptyline and desipramine: <ul class=\"decimal_heading\"> <li>Effective for treatment of neuropathies and other painful conditions </li> <li>Metabolized by CYP2D6 (polymorphic) to active and inactive metabolites </li> <li>Dose-related anticholinergic and cardiovascular side effects may be poorly tolerated in older adults relative to SNRIs </li> <li>Titrate gradually over eight weeks or more to improve tolerability </li> <li>Use low maintenance dose of 25 to 50 mg to decrease risk of accumulation </li> <li>Accumulation toxicity in older adults is less likely with nortriptyline and desipramine than other tricyclic antidepressants (eg, amitriptyline) </li> <li>Low doses used for treatment of painful conditions may be insufficient for treatment of depression </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Desipramine</td> <td> <p>Start with 10 mg orally at bedtime</p> <p>May increase daily dose by 10 mg after 7 or more days</p> Maximum 50 mg per night</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Anticonvulsants</td> </tr> <tr> <td class=\"indent2\">Gabapentin</td> <td> <p>Start with 100 mg orally at bedtime</p> <p>May increase daily dose by 100 mg after 7 or more days; give in divided doses</p> Maximum 3600 mg per day (CrCl &#8805;60 mL/min)</td> <td class=\"divider_bottom\" rowspan=\"2\">Applies to gabapentin and pregabalin: <ul class=\"decimal_heading\"> <li>Effective for treatment of neuropathic and other painful conditions (eg, restless legs syndrome, fibromyalgia) </li> <li>Highly dependent upon renal function for clearance </li> <li>Sedation and dizziness may limit usefulness in frail older adults </li> <li>Gradual titration over weeks is suggested to improve tolerability and to decrease risk of overdose due to the delayed onset of effect </li> <li>Maximum maintenance dose is determined by renal function; refer to Lexicomp monograph for detail </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Pregabalin</td> <td> <p>Start with 25 to 50 mg orally at bedtime</p> <p>May increase daily dose by 25 to 50 mg after 7 or more days; give in divided doses</p> Maximum 300 mg/day (CrCl &#8805;60 mL/min)</td> </tr> <tr> <td colspan=\"3\"><strong>Oral nonsteroidal antiinflammatory drugs</strong><br /> Applies to all: <ul class=\"decimal_heading\"> <li>Due to increased side effects in older adults, use should be limited to brief course(s) in selected patients for painful flare-ups at lowest effective dose </li> <li>Avoid use of NSAIDs in older adults with renal insufficiency (CrCl &#60;50 mL/minute), GI bleeding, platelet dysfunction, reduced cardiac output, hypovolemic state, hyponatremia, hepatic impairment, or receiving an anticoagulant </li> <li>Dose- and age-associated risk of gastropathy; pharmacologic gastroprotection may be indicated even with COX-2 selective therapy; refer to UpToDate topic on prevention of NSAID-associated gastroduodenal toxicity </li> <li>Can cause or worsen renal insufficiency, including age-associated decline in renal function </li> <li>Traditional NSAIDs (eg, ibuprofen, naproxen) reversibly inhibit platelet functioning and may alter cardioprotective effects of aspirin </li> <li>Use with serotonin reuptake inhibitor antidepressants (eg, SSRIs, nortriptyline, venlafaxine) additively decreases platelet functioning </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Naproxen sodium</td> <td>220 mg twice daily (equivalent to 200 mg naproxen base twice daily)</td> <td> <ul> <li>Less cardiovascular toxicity than other nonselective NSAIDs </li> <li>Naproxen sodium has better absorption and more rapid onset than naproxen base </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Ibuprofen</td> <td>200 mg three times daily</td> <td> <ul> <li>Short-half life may be advantageous in older adults </li> <li>Avoid combined use with cardioprotective (low-dose) aspirin therapy </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Celecoxib</td> <td>100 mg daily</td> <td> <ul> <li>Relative reduction in GI toxicity compared to nonselective NSAIDs </li> <li>No effect on platelet functioning </li> <li>Patients taking cardioprotective aspirin may still need concurrent gastroprotection (eg, proton pump inhibitor) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Diflunisal</td> <td>250 mg two or three times daily</td> <td class=\"divider_bottom\" rowspan=\"3\">Applies to nonacetylated salicylates: <ul class=\"decimal_heading\"> <li>No effect on platelet functioning at doses shown </li> <li>Generally tolerated by adults with asthma </li> <li>Relatively slow onset </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Choline magnesium trisalicylate</td> <td>500 to 750 mg three times daily</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Salsalate</td> <td>500 mg two or three times daily</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Topical therapies:</strong> Include topical NSAIDs, capsaicin, and topical lidocaine, which may be useful in combination with systemic therapies for reducing medication load and side effects for treatment of localized painful conditions; refer to separate table on topical analgesics.</td> </tr> <tr> <td colspan=\"3\"><strong>Intra-articular glucocorticoids:</strong> Refer to topic review of initial pharmacologic therapy of osteoarthritis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; CrCl: creatinine clearance; OTC: over-the-counter (non-prescription) medicines; NSAID: nonsteroidal antiinflammatory drug; SSRI: selective serotonin reuptake inhibitor; ESRD: end-stage renal disease; PHN: postherpetic neuralgia.<br />* Lowest starting dose shown should be considered in frail older persons with a history of sensitivity to central nervous system&ndash;active drugs, reduced cardiac output, dehydration, low body weight, or poor oral intake. Doses shown are for oral administration except where noted.<br />&Delta; We suggest establishing dose and effects using an immediate-release opioid preparation prior to prescribing a sustained-release opioid for opioid-na&iuml;ve older patients.<br /><span class=\"lozenge\">&loz;</span> In general, dose tapering is recommended prior to discontinuation of anticonvulsants, opioids, and antidepressants.<br />&sect; Also available in combination preparations with acetaminophen (paracetamol).</div><div class=\"graphic_reference\">Courtesy of Drs. Marissa Galicia-Castillo and Debra Weiner with additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>American Geriatric Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57:1331.</li>&#xD;&#xA;    <li>Barkin R, Beckerman M, Blum S, et al. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010; 27:775.</li>&#xD;&#xA;    <li>van Ojik AL, Jansen PA, Brouwers JR, van Roon EN. Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging 2012; 29:615.</li>&#xD;&#xA;    <li>Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly. Drugs Aging 2010; 27:471.</li>&#xD;&#xA;    <li>Drugs for pain. Treat Guidel Med Lett; 2013. 11:31.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 95621 Version 7.0</div></div></div>"},"95624":{"type":"graphic_figure","displayName":"The four dorsal interosseous muscles","title":"The four dorsal interosseous muscles","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">The four dorsal interosseous muscles</div><div class=\"cntnt\"><img style=\"width:466px; height:628px;\" src=\"images/EM/95624_Fourdrslinterosseousmscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal interosseous muscles abduct the fingers, flex the metacarpophalangeal joints, and extend the interphalangeal joints. Observe that the middle finger (III) has two muscles, one abducting the finger toward the radial side and the other abducting it toward the ulnar side. The line of reference for abduction is midway down the middle finger.</div><div class=\"graphic_reference\">Reproduced with permission from: The upper limb. In: Grant's Dissector, 15th ed, Tank PW (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 95624 Version 3.0</div></div></div>"},"95625":{"type":"graphic_figure","displayName":"The three palmar interosseous muscles","title":"The three palmar interosseous muscles","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">The three palmar interosseous muscles</div><div class=\"cntnt\"><img style=\"width:550px; height:621px;\" src=\"images/EM/95625_Threeplmrintrssmscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The palmar interosseous muscles adduct the fingers; the middle finger has no palmar interosseous muscle attaching to it. The palmar interosseous muscles also flex the metacarpophalangeal joint and extend the interphalangeal joints. Observe that the line of reference for adduction is midway down the middle finger.</div><div class=\"graphic_reference\">Reproduced with permission from: The upper limb. In: Grant's Dissector, 15th ed, Tank PW (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 95625 Version 3.0</div></div></div>"},"95629":{"type":"graphic_picture","displayName":"Condylomata lata infant","title":"Condylomata lata","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Condylomata lata</div><div class=\"cntnt\"><img style=\"width:590px; height:384px;\" src=\"images/DERM/95629_Condylomata_lata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal condylomata lata in an infant with early congenital syphilis.</div><div class=\"graphic_reference\">Courtesy of Moise L Levy, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 95629 Version 3.0</div></div></div>"},"95630":{"type":"graphic_table","displayName":"Stages of valvular AS","title":"Stages of valvular aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of valvular aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Valve anatomy</td> <td class=\"subtitle1\">Valve hemodynamics</td> <td class=\"subtitle1\">Hemodynamic consequences</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td class=\"centered\"><strong>A</strong></td> <td><strong>At risk of AS</strong></td> <td> <ul> <li>Bicuspid aortic valve (or other congenital valve anomaly) </li> <li>Aortic valve sclerosis </li> </ul> </td> <td> <ul> <li>Aortic V<sub>max</sub> &#60;2 m/s </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"divider_bottom highlight_green_text\"> <td class=\"centered\"><strong>B</strong></td> <td><strong>Progressive AS</strong></td> <td> <ul> <li>Mild-to-moderate leaflet calcification of a bicuspid or trileaflet valve with some reduction in systolic motion or </li> <li>Rheumatic valve changes with commissural fusion </li> </ul> </td> <td> <ul> <li>Mild AS: Aortic V<sub>max</sub> 2.0 to 2.9 m/s or mean &#916;P &#60;20 mmHg </li> <li>Moderate AS: Aortic V<sub>max</sub> 3.0 to 3.9 m/s or mean &#916;P 20 to 39 mmHg </li> </ul> </td> <td> <ul> <li>Early LV diastolic dysfunction may be present </li> <li>Normal LVEF </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"highlight_red_text\"> <td colspan=\"6\"><strong>C: Asymptomatic severe AS</strong></td> </tr> <tr class=\"highlight_red_text\"> <td class=\"indent1\"><strong>C1</strong></td> <td><strong>Asymptomatic severe AS</strong></td> <td> <ul> <li>Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening </li> </ul> </td> <td> <ul> <li>Aortic V<sub>max</sub> &#8805;4 m/s or mean &#916;P &#8805;40 mmHg </li> <li>AVA typically is &#8804;1.0 cm<sup>2</sup> (or AVAi &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup>) </li> <li>Very severe AS is an aortic V<sub>max</sub> &#8805;5 m/s or mean &#916;P &#8805;60 mmHg </li> </ul> </td> <td> <ul> <li>LV diastolic dysfunction </li> <li>Mild LV hypertrophy </li> <li>Normal LVEF </li> </ul> </td> <td> <ul> <li>None: Exercise testing is reasonable to confirm symptom status </li> </ul> </td> </tr> <tr class=\"divider_bottom highlight_red_text\"> <td class=\"indent1\"><strong>C2</strong></td> <td><strong>Asymptomatic severe AS with LV dysfunction</strong></td> <td> <ul> <li>Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening </li> </ul> </td> <td> <ul> <li>Aortic V<sub>max</sub> &#8805;4 m/s or mean &#916;P &#8805;40 mmHg </li> <li>AVA typically &#8804;1.0 cm<sup>2</sup> (or AVAi &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup>) </li> </ul> </td> <td> <ul> <li>LVEF &#60;50% </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"highlight_yellow_text\"> <td colspan=\"6\"><strong>D: Symptomatic severe AS</strong></td> </tr> <tr class=\"highlight_yellow_text\"> <td class=\"indent1\"><strong>D1</strong></td> <td><strong>Symptomatic severe high-gradient AS</strong></td> <td> <ul> <li>Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening </li> </ul> </td> <td> <ul> <li>Aortic V<sub>max</sub> &#8805;4 m/s or mean &#916;P &#8805;40 mmHg </li> <li>AVA typically &#8804;1.0 cm<sup>2</sup> (or AVAi &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup>) but may be larger with mixed AS/AR </li> </ul> </td> <td> <ul> <li>LV diastolic dysfunction </li> <li>LV hypertrophy </li> <li>Pulmonary hypertension may be present </li> </ul> </td> <td> <ul> <li>Exertional dyspnea or decreased exercise tolerance </li> <li>Exertional angina </li> <li>Exertional syncope or presyncope </li> </ul> </td> </tr> <tr class=\"highlight_yellow_text\"> <td class=\"indent1\"><strong>D2</strong></td> <td><strong>Symptomatic severe low-flow/low-gradient AS with reduced LVEF</strong></td> <td> <ul> <li>Severe leaflet calcification with severely reduced leaflet motion </li> </ul> </td> <td> <ul> <li>AVA &#8804;1.0 cm<sup>2</sup> with resting aortic V<sub>max</sub> &#60;4 m/s or mean &#916;P &#60;40 mmHg </li> <li>Dobutamine stress echocardiography shows AVA &#8804;1.0 cm<sup>2</sup> with V<sub>max</sub> &#8805;4 m/s at any flow rate </li> </ul> </td> <td> <ul> <li>LV diastolic dysfunction </li> <li>LV hypertrophy </li> <li>LVEF &#60;50% </li> </ul> </td> <td> <ul> <li>HF </li> <li>Angina </li> <li>Syncope or presyncope </li> </ul> </td> </tr> <tr class=\"highlight_yellow_text\"> <td class=\"indent1\"><strong>D3</strong></td> <td><strong>Symptomatic severe low-gradient AS with normal LVEF or paradoxical low-flow severe AS</strong></td> <td> <ul> <li>Severe leaflet calcification with severely reduced leaflet motion </li> </ul> </td> <td> <ul> <li>AVA &#8804;1.0 cm<sup>2</sup> with aortic V<sub>max</sub> &#60;4 m/s or mean &#916;P &#60;40 mmHg </li> <li>Indexed AVA &#8804;0.6 cm<sup>2</sup>/m<sup>2</sup> and </li> <li>Stroke volume index &#60;35 mL/m<sup>2</sup> </li> <li>Measured when patient is normotensive (systolic BP &#60;140 mmHg) </li> </ul> </td> <td> <ul> <li>Increased LV relative wall thickness </li> <li>Small LV chamber with low stroke volume </li> <li>Restrictive diastolic filling </li> <li>LVEF &#8805;50% </li> </ul> </td> <td> <ul> <li>HF </li> <li>Angina </li> <li>Syncope or presyncope </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AR: aortic regurgitation; AS: aortic stenosis; AVA: aortic valve area; AVAi: aortic valve area indexed to body surface area; BP: blood pressure; HF: heart failure; LV: left ventricular; LVEF: left ventricular ejection fraction; DP: pressure gradient; V<sub>max</sub>: maximum aortic velocity.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95630 Version 1.0</div></div></div>"},"95631":{"type":"graphic_table","displayName":"Risk assessment combining STS and other factors","title":"Risk assessment combining STS risk estimate, frailty, major organ system dysfunction, and procedure-specific impediments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk assessment combining STS risk estimate, frailty, major organ system dysfunction, and procedure-specific impediments</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Low risk<br /> (must meet ALL criteria in this column )</td> <td class=\"subtitle1\">Intermediate risk<br /> (any 1 criterion in this column)</td> <td class=\"subtitle1\">High risk<br /> (any 1 criterion in this column)</td> <td class=\"subtitle1\">Prohibitive risk<br /> (any 1 criterion in this column)</td> </tr> <tr> <td><strong>STS PROM</strong>*</td> <td>&#60;4% <strong>AND</strong></td> <td>4 to 8% <strong>OR</strong></td> <td>&#62;8% <strong>OR</strong></td> <td rowspan=\"2\">Predicted risk with surgery of death or major morbidity (all-cause) &#62;50% at 1 y <strong>OR</strong></td> </tr> <tr> <td><strong>Frailty</strong><sup>&#182;</sup></td> <td>None <strong>AND</strong></td> <td>1 Index (mild) <strong>OR</strong></td> <td>&#8805;2 Indices (moderate to severe) <strong>OR</strong></td> </tr> <tr> <td><strong>Major organ system compromise not to be improved postoperatively</strong><sup>&#916;</sup></td> <td>None <strong>AND</strong></td> <td>1 Organ system <strong>OR</strong></td> <td>No more than 2 organ systems <strong>OR</strong></td> <td>&#8805;3 Organ systems <strong>OR</strong></td> </tr> <tr> <td><strong>Procedure-specific impediment</strong><sup>&#9674;</sup></td> <td>None</td> <td>Possible procedure-specific impediment</td> <td>Possible procedure-specific impediment</td> <td>Severe procedure-specific impediment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; CNS: central nervous system; CVA: stroke; DLCO<sub>2</sub>: diffusion capacity for carbon dioxide; FEV1: forced expiratory volume in 1 s; GI: gastrointestinal; INR: international normalized ratio; LV: left ventricular; PROM: predicted risk of mortality; RV: right ventricular; STS: Society of Thoracic Surgeons; VKA: vitamin K antagonist.<br />* Use of the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within one standard deviation of STS average observed/expected ratio for the procedure in question.<br />&para; Seven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist required or 5-meter walk in &lt;6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty.<br />&Delta; Examples of major organ system compromise: Cardiac-severe LV systolic or diastolic dysfunction or RV dysfunction, fixed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with FEV1 &lt;50% or DLCO<sub>2</sub> &lt;50% of predicted; CNS dysfunction (dementia, Alzheimer's disease, Parkinson's disease, CVA with persistent physical limitation); GI dysfunction-Crohn's disease, ulcerative colitis, nutritional impairment, or serum albumin &lt;3.0; cancer-active malignancy; and liver-any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy.<br /><span class=\"lozenge'\">&loz;</span> Examples: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95631 Version 4.0</div></div></div>"},"95632":{"type":"graphic_table","displayName":"Capecitabine XRT rectal","title":"Concomitant chemoradiotherapy with capecitabine for rectal cancer in both the adjuvant* and neoadjuvant<SUP>¶</SUP> setting<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concomitant chemoradiotherapy with capecitabine for rectal cancer in both the adjuvant* and neoadjuvant<SUP>¶</SUP> setting<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 5 to 6 weeks (chemoradiotherapy). </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Capecitabine<sup>&#916;</sup></td> <td>825 mg/m<sup>2</sup> by mouth</td> <td>Twice daily; total daily dose 1650 mg/m<sup>2</sup>. Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#9674;</sup></td> <td>Daily, five days per week (Monday through Friday), during entire five- to six-week course of radiation beginning on week 1</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy (50.4 Gy)</td> <td>1.8 Gy for five days a week</td> <td>Begin within 24 hours of beginning chemotherapy.</td> <td>Beginning week 1 and continuing to week 6</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated. </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of capecitabine may be needed for renal impairment.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during chemoradiotherapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function weekly during chemoradiotherapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias) during treatment. </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Doses of phenytoin and of coumarin-derivative anticoagulants may need to be reduced when either drug is administered concomitantly with capecitabine. More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For neutrophils &#60;1200/microL during therapy, hold capecitabine until &#8805;1200/microL, then reduce capecitabine to 620 mg/m<sup>2</sup> twice daily; if recurs, hold capecitabine until neutrophils &#8805;1200/microL, then reduce capecitabine to 465 mg/m<sup>2</sup> twice daily.<sup>[3]</sup> For platelet count &#60;75,000/microL during therapy, hold capecitabine until &#8805;75,000/microL, and reduce subsequent doses of capecitabine to 620 mg/m<sup>2</sup> twice daily; if recurs, hold capecitabine until platelet count &#8805;75,000/microL, and reduce subsequent capecitabine doses to 465 mg/m<sup>2</sup> twice daily. If recovery takes &#62;2 weeks, discontinue chemotherapy. For febrile neutropenia or infection with grade 3 or 4 neutropenia, hold chemotherapy until clinical resolution then resume at reduced dose of capecitabine (620 mg/m<sup>2</sup> twice daily). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold capecitabine for grade 2 vomiting (despite antiemetics) or grade 2 or 3 diarrhea or mucositis, and delay reinitiation until &#8804;grade 1; for first occurrence, reduce capecitabine dose to 620 mg/m<sup>2</sup> twice daily; for second occurrence, reduce capecitabine to 465 mg/m<sup>2</sup> twice daily; for third occurrence, or any grade 4 diarrhea, or grade 3 or 4 vomiting, or if recovery takes &#62;2 weeks, discontinue capecitabine.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hand-foot syndrome</strong></td> <td colspan=\"3\"> <ul> <li>For grade 2 or 3 hand-foot syndrome, hold capecitabine until &#8804;grade 1.<sup>[3]</sup> Resume capecitabine at 620 mg/m<sup>2</sup> twice daily. For second occurrence, hold capecitabine until &#8804;grade 1, and resume capecitabine at 465 mg/m<sup>2</sup> twice daily. For third occurrence or any grade 4 toxicity, discontinue capecitabine. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 2 hepatotoxicity during therapy, hold capecitabine until bilirubin, alkaline phosphatase, and AST are &#8804;grade 1; resume capecitabine at 620 mg/m<sup>2</sup> twice daily.<sup>[3]</sup> Discontinue chemotherapy for grade 3 or 4 hepatotoxicity or if recovery takes &#62;2 weeks. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other clinically significant adverse events</strong></td> <td colspan=\"3\"> <ul> <li>For other grade 3 adverse events, hold therapy until &#8804;grade 1, then resume at a lower dose (620 mg/m<sup>2</sup> twice daily); discontinue chemotherapy for grade 4.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">Gy: gray; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; INR: international normalized ratio; AST: aspartate aminotransferase.<br />* In the adjuvant setting, concomitant capecitabine-based chemoradiotherapy is generally combined with four to six months of fluoropyrimidine-based adjuvant chemotherapy. Chemotherapy options include capecitabine alone, short-term infusional fluorouracil plus leucovorin with or without oxaliplatin, or weekly fluorouracil plus leucovorin, as used for adjuvant treatment of colon cancer. The optimal sequencing has not been established, but the authors generally gave all the radiotherapy first or last, but not in between courses of chemotherapy. Refer to UpToDate topic on \"Adjuvant therapy for resected rectal adenocarcinoma\".<br />¶ In the neoadjuvant setting, concomitant chemoradiotherapy is generally given upfront prior to surgical resection. Following surgery, adjuvant chemotherapy for four to six months may be recommended. Chemotherapy options include capecitabine alone, short-term infusional fluorouracil plus leucovorin with or without oxaliplatin, or weekly fluorouracil plus leucovorin, as used for adjuvant treatment of colon cancer. Refer to UpToDate topic on \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal adenocarcinoma\".<br />Δ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br /><FONT class=lozenge>◊</FONT> Extemporaneous compounding of liquid dosage forms has been recommended, but intravenous therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>O'Connell MJ, et al. J Clin Oncol 2014; 32:1927.</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Dose modifications per NSABP protocol R-04. (Available online at http://www.mtcancer.org/Protocols/R04.pdf, accessed June 6, 2014).</LI></OL></div><div id=\"graphicVersion\">Graphic 95632 Version 12.0</div></div></div>"},"95634":{"type":"graphic_picture","displayName":"Congenital syphilis infant","title":"Congenital syphilis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis</div><div class=\"cntnt\"><img style=\"width:576px; height:796px;\" src=\"images/DERM/95634_Congenitalsyphilisinfant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread erythema and scaling with large, superficial erosions in an infant with congenital syphilis.</div><div class=\"graphic_reference\">From: Gupta R, Vora RV. Congenital syphilis, still a reality. Indian J Sex Transm Dis 2013; 34:50. DOI: <A spellcheck=true href=\"http://www.ijstd.org/article.asp?issn=2589-0557;year=2013;volume=34;issue=1;spage=50;epage=52;aulast=Gupta\" target=_blank>10.4103/0253-7184.112941</A>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright © 2013 Indian Association for the Study of Sexually Transmitted Diseases. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95634 Version 3.0</div></div></div>"},"95637":{"type":"graphic_figure","displayName":"Female genital tract anomalies ESHRE ESGE classification system","title":"Female genital tract anomalies: ESHRE ESGE classification system","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Female genital tract anomalies: ESHRE ESGE classification system</div><div class=\"cntnt\"><img style=\"width:594px; height:438px;\" src=\"images/OBGYN/95637_Fem_gen_trct_anm_ESHRE_ESGE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ESHRE/ESGE classification of uterine anomalies: schematic representation. (Class U2: internal indentation &gt;50 percent of the uterine wall thickness and external contour straight or with indentation &lt;50 percent; Class U3: external indentation &gt;50 percent&nbsp;of the uterine wall thickness; Class U3b: width of the fundal indentation at the midline &gt;150 percent&nbsp;of the uterine wall thickness.)</div><div class=\"graphic_footnotes\">ESHRE: European Society of Human Reproduction and Embryology; ESGE: European Society for Gynaecological Endoscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Grimbizis GF, Gordts S, Di Spiezio, et al. The ESHRE/ESGE consensus on the classification of female genital tract congenital anomalies. Hum Reprod 2013; 28(8):2032. Copyright &copy; The Author 2013. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.</div><div id=\"graphicVersion\">Graphic 95637 Version 1.0</div></div></div>"},"95638":{"type":"graphic_algorithm","displayName":"Intrapartum fever algorithm","title":"Intrapartum fever algorithm","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Intrapartum fever algorithm</div><div class=\"cntnt\"><img style=\"width:744px; height:400px;\" src=\"images/OBGYN/95638_Intrapartum_fever_algorithm.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 95638 Version 1.0</div></div></div>"},"95639":{"type":"graphic_picture","displayName":"Psoriasis infant","title":"Infantile psoriasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Infantile psoriasis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95639_Psoriasis_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and scaling plaques in an infant with psoriasis. Note the involvement of the diaper area, usually spared in infants with atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95639 Version 1.0</div></div></div>"},"95649":{"type":"graphic_table","displayName":"Hereditary causes of chorea","title":"Hereditary causes of chorea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hereditary causes of chorea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autosomal dominant</td> </tr> <tr> <td class=\"indent1\">Benign hereditary chorea</td> </tr> <tr> <td class=\"indent1\">Dentatorubral pallidoluysian atrophy</td> </tr> <tr> <td class=\"indent1\">Huntington disease</td> </tr> <tr> <td class=\"indent1\">Huntington disease-like types 1 and 2</td> </tr> <tr> <td class=\"indent1\">Idiopathic basal ganglia calcification (Fahr disease)</td> </tr> <tr> <td class=\"indent1\">Neurodegenerative disease caused by C9ORF72 repeat expansions</td> </tr> <tr> <td class=\"indent1\">Neuroferritinopathy</td> </tr> <tr> <td class=\"indent1\">Paroxysmal kinesigenic choreoathetosis</td> </tr> <tr> <td class=\"indent1\">Paroxysmal nonkinesigenic dyskinesia</td> </tr> <tr> <td class=\"indent1\">Spinocerebellar ataxia types 1, 2, 3, and 17</td> </tr> <tr> <td class=\"subtitle1_single\">Autosomal recessive</td> </tr> <tr> <td class=\"indent1\">Ataxia with oculomotor apraxia types 1 and 2</td> </tr> <tr> <td class=\"indent1\">Ataxia-telangiectasia</td> </tr> <tr> <td class=\"indent1\">Choreo-acanthocytosis</td> </tr> <tr> <td class=\"indent1\">Friedreich ataxia</td> </tr> <tr> <td class=\"indent1\">Huntington disease-like 3</td> </tr> <tr> <td class=\"indent1\">Neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"indent1\">Pantothenate kinase-associated neurodegeneration</td> </tr> <tr> <td class=\"indent1\">Phenylketonuria</td> </tr> <tr> <td class=\"indent1\">Porphyria</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"subtitle1_single\">X-linked</td> </tr> <tr> <td class=\"indent1\">McLeod syndrome</td> </tr> <tr> <td class=\"indent1\">Lesch-Nyhan disease</td> </tr> <tr> <td class=\"subtitle1_single\">Maternal inheritance</td> </tr> <tr> <td class=\"indent1\">Mitochondrial disorders</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95649 Version 1.0</div></div></div>"},"95650":{"type":"graphic_table","displayName":"Acquired causes of chorea","title":"Acquired causes of chorea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acquired causes of chorea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autoimmune or inflammatory</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid antibody syndrome</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et disease</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Hashimoto encephalopathy</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Primary angiitis of central nervous system</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren syndrome</td> </tr> <tr> <td class=\"indent1\">Sydenham chorea</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"subtitle1_single\">Cerebrovascular</td> </tr> <tr> <td class=\"indent1\">Arteriovenous malformation</td> </tr> <tr> <td class=\"indent1\">Intracerebral hemorrhage</td> </tr> <tr> <td class=\"indent1\">Ischemic stroke</td> </tr> <tr> <td class=\"indent1\">Moyamoya disease</td> </tr> <tr> <td class=\"indent1\">Postpump chorea</td> </tr> <tr> <td class=\"indent1\">Subarachnoid hemorrhage</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Dopaminergic drugs</td> </tr> <tr> <td class=\"indent1\">Many others (refer to&nbsp;UpToDate graphics on&nbsp;drugs that can cause chorea)</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">AIDS-related</td> </tr> <tr> <td class=\"indent1\">Creutzfeldt-Jakob disease</td> </tr> <tr> <td class=\"indent1\">Diphtheria</td> </tr> <tr> <td class=\"indent1\">Encephalitis</td> </tr> <tr> <td class=\"indent1\">Legionnaire disease</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> </tr> <tr> <td class=\"indent1\">Neurocysticercosis</td> </tr> <tr> <td class=\"indent1\">Neurosyphillis</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Tuberculous meningitis</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic or endocrine</td> </tr> <tr> <td class=\"indent1\">Hepatic failure</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Hypo/hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Hypo/hyperglycemia</td> </tr> <tr> <td class=\"indent1\">Hypo/hypernatremia</td> </tr> <tr> <td class=\"indent1\">Hypomagnesemia</td> </tr> <tr> <td class=\"indent1\">Hypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera</td> </tr> <tr> <td class=\"indent1\">Pregnancy-induced (chorea gravidarum)</td> </tr> <tr> <td class=\"indent1\">Pseudohypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Vitamin deficiency (B1, B12, niacin)</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasia</td> </tr> <tr> <td class=\"indent1\">Basal ganglia involvement</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic</td> </tr> <tr> <td class=\"indent1\">Alcohol intoxication or withdrawal</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Glue sniffing</td> </tr> <tr> <td class=\"indent1\">Manganese</td> </tr> <tr> <td class=\"indent1\">Mercury</td> </tr> <tr> <td class=\"indent1\">Thallium</td> </tr> <tr> <td class=\"indent1\">Toluene</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Any lesion of basal ganglia</td> </tr> <tr> <td class=\"indent1\">Edentulous chorea</td> </tr> <tr> <td class=\"indent1\">Kernicterus</td> </tr> <tr> <td class=\"indent1\">Physiologic chorea of infancy</td> </tr> <tr> <td class=\"indent1\">Senile chorea</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95650 Version 2.0</div></div></div>"},"95651":{"type":"graphic_table","displayName":"Drugs that can cause chorea","title":"Drugs that can cause chorea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that can cause chorea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dopaminergic medication</td> </tr> <tr> <td class=\"indent1\">COMT inhibitors with levodopa</td> </tr> <tr> <td class=\"indent1\">Dopamine agonists</td> </tr> <tr> <td class=\"indent1\">Levodopa</td> </tr> <tr> <td class=\"subtitle1_single\">Dopamine blocking agents</td> </tr> <tr> <td class=\"indent1\">Amantadine</td> </tr> <tr> <td class=\"indent1\">Anticholinergics</td> </tr> <tr> <td class=\"indent1\">Atypical neuroleptics</td> </tr> <tr> <td class=\"indent1\">Typical neuroleptics</td> </tr> <tr> <td class=\"subtitle1_single\">Dopamine depleting agents</td> </tr> <tr> <td class=\"indent1\">Reserpine</td> </tr> <tr> <td class=\"indent1\">Tetrabenazine</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> </tr> <tr> <td class=\"indent1\">Lamotrigine</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Valproic acid</td> </tr> <tr> <td class=\"subtitle1_single\">Calcium channel blockers</td> </tr> <tr> <td class=\"indent1\">Cinnarizine</td> </tr> <tr> <td class=\"indent1\">Flunarizine</td> </tr> <tr> <td class=\"indent1\">Verapamil</td> </tr> <tr> <td class=\"subtitle1_single\">Central nervous system stimulants</td> </tr> <tr> <td class=\"indent1\">Amphetamines</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Cyproheptadine</td> </tr> <tr> <td class=\"indent1\">Methylphenidate</td> </tr> <tr> <td class=\"subtitle1_single\">Others</td> </tr> <tr> <td class=\"indent1\">Aminophylline and theophylline</td> </tr> <tr> <td class=\"indent1\">Antihistamines (H1 and H2 blockers)</td> </tr> <tr> <td class=\"indent1\">Baclofen</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Cimetidine</td> </tr> <tr> <td class=\"indent1\">Cyclosporine</td> </tr> <tr> <td class=\"indent1\">Digoxin</td> </tr> <tr> <td class=\"indent1\">Estrogens and oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Levofloxacin</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">Opioids</td> </tr> <tr> <td class=\"indent1\">Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Sympathomimetics</td> </tr> <tr> <td class=\"indent1\">Tricyclic antidepressants</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COMT: catechol-O-methyl transferase.</div><div id=\"graphicVersion\">Graphic 95651 Version 2.0</div></div></div>"},"95658":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris infant","title":"Juvenile pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Juvenile pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95658_Pityrias_rubra_pilar_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and scaling in an infant with pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95658 Version 1.0</div></div></div>"},"95659":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris infant 2","title":"Juvenile pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Juvenile pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95659_Pityrias_rub_pilar_infant_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse follicular erythematous papules in an infant with pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95659 Version 1.0</div></div></div>"},"95668":{"type":"graphic_table","displayName":"Examples of drugs available as orally disintegrating tablets","title":"Medicines available as orally disintegrating tablets (ODTs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines available as orally disintegrating tablets (ODTs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Available ODT strengths</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Analgesic, antiinflammatory, antipyretic, antimigraine</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (paracetamol)</td> <td>80, 160 mg</td> </tr> <tr> <td class=\"indent1\">Ibuprofen (ODT not available in United States)</td> <td>200 mg</td> </tr> <tr> <td class=\"indent1\">Nimesulide (not available in United States)</td> <td>100 mg</td> </tr> <tr> <td class=\"indent1\">Rizatriptan</td> <td>5, 10 mg</td> </tr> <tr> <td class=\"indent1\">Zolmitriptan</td> <td>2.5, 5 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antihistamine</td> </tr> <tr> <td class=\"indent1\">Cetirizine</td> <td>10 mg</td> </tr> <tr> <td class=\"indent1\">Desloratadine</td> <td>2.5, 5 mg</td> </tr> <tr> <td class=\"indent1\">Diphenhydramine</td> <td>12.5 mg (dispersible film)</td> </tr> <tr> <td class=\"indent1\">Fexofenadine</td> <td>30 mg</td> </tr> <tr> <td class=\"indent1\">Loratadine</td> <td>5, 10 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cough and cold</td> </tr> <tr> <td class=\"indent1\">Benzocaine</td> <td>6% (dispersible film, local effect)</td> </tr> <tr> <td class=\"indent1\">Dextromethorphan</td> <td>7.5 mg (dispersible film)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Famotidine (ODT not available in United States)</td> <td>10, 20 mg</td> </tr> <tr> <td class=\"indent1\">Hyoscyamine</td> <td>0.125 mg</td> </tr> <tr> <td class=\"indent1\">Lansoprazole</td> <td>15, 30 mg</td> </tr> <tr> <td class=\"indent1\">Loperamide (ODT not available in United States)</td> <td>2 mg</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> <td>5 mg</td> </tr> <tr> <td class=\"indent1\">Ondansetron</td> <td>4, 8 mg ODT (4 mg dispersible film)</td> </tr> <tr> <td class=\"indent1\">Simethicone</td> <td>40, 62.5 mg (dispersible film)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Alprazolam</td> <td>0.25, 0.5, 1, 2 mg</td> </tr> <tr> <td class=\"indent1\">Aripiprazole</td> <td>10, 15 mg</td> </tr> <tr> <td class=\"indent1\">Asenapine</td> <td>5, 10 mg (sublingual)</td> </tr> <tr> <td class=\"indent1\">Baclofen (ODT not available in United States)</td> <td>10 mg</td> </tr> <tr> <td class=\"indent1\">Carbidopa-levodopa</td> <td>10/100, 25/100, 25/250 mg</td> </tr> <tr> <td class=\"indent1\">Clonazepam</td> <td>0.125, 0.25, 0.5, 1, 2 mg</td> </tr> <tr> <td class=\"indent1\">Clozapine</td> <td>12.5, 25, 100, 150, 200 mg</td> </tr> <tr> <td class=\"indent1\">Donepezil</td> <td>5, 10 mg</td> </tr> <tr> <td class=\"indent1\">Fluoxetine (ODT not available in United States)</td> <td>20 mg</td> </tr> <tr> <td class=\"indent1\">Lamotrigine</td> <td>25, 50, 100, 200 mg</td> </tr> <tr> <td class=\"indent1\">Mirtazapine</td> <td>15, 30, 45 mg</td> </tr> <tr> <td class=\"indent1\">Olanzapine</td> <td>5, 10, 15, 20 mg</td> </tr> <tr> <td class=\"indent1\">Phentermine</td> <td>15, 30, 37.5 mg</td> </tr> <tr> <td class=\"indent1\">Prednisolone</td> <td>10, 15, 30 mg</td> </tr> <tr> <td class=\"indent1\">Risperidone</td> <td>0.25, 0.5, 1, 2, 3, 4 mg</td> </tr> <tr> <td class=\"indent1\">Selegiline</td> <td>1.25 mg</td> </tr> <tr> <td class=\"indent1\">Tramadol (ODT not available in United States)</td> <td>50 mg</td> </tr> <tr> <td class=\"indent1\">Vardenafil</td> <td>10 mg</td> </tr> <tr> <td class=\"indent1\">Zolpidem</td> <td>5, 10 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Orally disintegrating, also known as orodispersible, tablets are designed to dissolve rapidly in saliva and provide a useful alternative to pills for patients with swallowing difficulties.</div><div class=\"graphic_footnotes\">ODT: orally disintegrating tablet.</div><div id=\"graphicVersion\">Graphic 95668 Version 3.0</div></div></div>"},"95677":{"type":"graphic_table","displayName":"Fluorouracil XRT rectal","title":"Concomitant chemoradiotherapy with infusional fluorouracil for rectal cancer in both the adjuvant* and neoadjuvant<SUP>¶</SUP> setting<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concomitant chemoradiotherapy with infusional fluorouracil for rectal cancer in both the adjuvant* and neoadjuvant<SUP>¶</SUP> setting<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 5 to 6 weeks (chemoradiotherapy). </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>225 mg/m<sup>2</sup> per day IV</td> <td>Infuse through a central line as a continuous infusion via a portable infusion device. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.</td> <td>Daily by continuous infusion five days per week (Monday through Friday) during the entire five- to six-week course of radiation beginning on week 1</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy (50.4 Gy)</td> <td>1.8 Gy for five days a week</td> <td>Begin within 24 hours of beginning chemotherapy.</td> <td>Beginning week 1 and continuing to week 6</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated.</li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of FU may be needed for patients with liver impairment.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during chemoradiotherapy.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver function weekly during chemoradiotherapy.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias) during therapy.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant FU and oral coumarin-derivative anticoagulant therapy.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For neutrophils &#60;1200 cells/microL during therapy, hold FU until &#8805;1200 cells/microL, then reduce FU to 175 mg/m<sup>2</sup> per day; if recurs, hold FU until neutrophils &#8805;1200 cells/microL, then reduce FU to 125 mg/m<sup>2</sup> per day.<sup>[2]</sup> For platelet count &#60;75,000/microL during therapy, hold FU until &#8805;75,000/microL, and reduce FU to 175 mg/m<sup>2</sup> per day; if recurs, hold FU until platelet count &#8805;75,000/microL, and reduce FU to 125 mg/m<sup>2</sup> per day. If recovery takes &#62;2 weeks, discontinue chemotherapy. For febrile neutropenia or infection with grade 3 or 4 neutropenia, hold chemotherapy until clinical resolution then resume at reduced dose of FU (175 mg/m<sup>2</sup> daily).</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold FU for grade 2 vomiting or grade 2 or 3 diarrhea or mucositis, and delay reinitiation of treatment until &#8804;grade 1; for first occurrence, reduce FU to 175 mg/m<sup>2</sup> per day; for second occurrence, reduce FU to 125 mg/m<sup>2</sup> per day; for third occurrence or any grade 4 diarrhea, or grade 3 or 4 vomiting, or if recovery takes &#62;2 weeks, discontinue FU.<sup>[2]</sup></li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 2 hepatotoxicity during therapy, hold FU until bilirubin, alkaline phosphatase, and AST are &#8804;grade 1; resume FU at 175 mg/m<sup>2</sup>.<sup>[2]</sup> Discontinue chemotherapy for grade 3 or 4 hepatotoxicity or if recovery takes &#62;2 weeks.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other clinically significant adverse events</strong></td> <td colspan=\"3\"> <ul> <li>For other grade 3 adverse events, hold FU until &#8804;grade 1, then resume at a lower dose (175 mg/m<sup>2</sup> per day); discontinue chemotherapy for grade 4.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">AST: aspartate aminotransferase; CBC: complete blood count; G-CSF: granulocyte colony stimulating factor; INR: international normalized ratio; IV: intravenous.<br />* In the adjuvant setting, concomitant FU-based chemoradiotherapy is generally combined with four to six months of FU-based adjuvant chemotherapy. Chemotherapy options include short-term infusional FU plus leucovorin with or without oxaliplatin, capecitabine alone, or weekly FU plus leucovorin, as used for adjuvant treatment of colon cancer. The optimal sequencing has not been established, but the authors generally gave all the radiotherapy first or last, but not in between courses of chemotherapy. Refer to UpToDate topic on \"Adjuvant therapy for resected rectal adenocarcinoma\".<br />¶ In the neoadjuvant setting, concomitant chemoradiotherapy is generally given upfront prior to surgical resection. Following surgery, adjuvant chemotherapy for four to six months may be recommended. Chemotherapy options include short-term infusional FU plus leucovorin with or without oxaliplatin, capecitabine alone, or weekly FU plus leucovorin, as used for adjuvant treatment of colon cancer. Refer to UpToDate topic on \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal adenocarcinoma\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>O'Connell MJ, et al. J Clin Oncol 2014 (PMID 24799484).</LI>&#xD;&#xA;<LI>NSABP R-04 protocol. (Available online at http://www.mtcancer.org/Protocols/R04.pdf, accessed June 6, 2014).</LI></OL></div><div id=\"graphicVersion\">Graphic 95677 Version 5.0</div></div></div>"},"95678":{"type":"graphic_table","displayName":"ITP therapies advantages and disadvantages","title":"Therapies for immune thrombocytopenia: Advantages and disadvantages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies for immune thrombocytopenia: Advantages and disadvantages</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">High risk of immunosuppression and other side effects&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">First-line therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Glucocorticoids</td> <td> <ul> <li>Effective </li> <li>Oral administration </li> <li>Familiar </li> <li>Inexpensive </li> <li>Short-term toxicities usually tolerable </li> </ul> </td> <td> <ul> <li>Durable response after discontinuation may be uncommon </li> <li>Serious long-term toxicities </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rescue therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IVIG</td> <td> <ul> <li>Rapid </li> </ul> </td> <td> <ul> <li>Cost </li> <li>Frequent side effects </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Second-line and subsequent therapies</td> </tr> <tr> <td class=\"indent1\">Splenectomy</td> <td> <ul> <li>Efficacy </li> <li>Long duration of response </li> </ul> </td> <td> <ul> <li>Surgical risks </li> <li>Infectious risks from asplenia </li> <li>Thrombosis risk </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Rituximab</td> <td> <ul> <li>Familiar </li> <li>Non-surgical </li> </ul> </td> <td> <ul> <li>Less effective than splenectomy </li> <li>Shorter remissions </li> <li>Risks of viral reactivation (especially hepatitis B) </li> <li>Risks of other toxicities (anaphylaxis, pulmonary toxicity) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Thrombopoietin receptor agonists</td> <td> <ul> <li>Efficacy </li> <li>Potential for self-administration </li> <li>Non-surgical </li> <li>No immunosuppression </li> </ul> </td> <td> <ul> <li>Require continuous administration </li> <li>Cost </li> <li>Unclear potential long-term risks (bone marrow fibrosis, thrombosis, hepatotoxicity) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Other immunosuppressive agents or combination therapy</td> <td> <ul> <li>May be effective when other therapies fail to establish a safe platelet count </li> </ul> </td> <td> <ul> <li>High risk of immunosuppression and other side effects </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to the text of UpToDate topics on the management of immune thrombocytopenia for further details and our approach to management.</div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin.</div><div id=\"graphicVersion\">Graphic 95678 Version 3.0</div></div></div>"},"95679":{"type":"graphic_diagnosticimage","displayName":"Dural ectasia","title":"Dural ectasia","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Dural ectasia</div><div class=\"cntnt\"><img style=\"width:600px; height:223px;\" src=\"images/CARD/95679_Dural_ectasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computerized tomography of the pelvis demonstrates (A) normal spinal canal and (B) features of lumbosacral dural ectasia (asterisk). Note dilation of the spinal canal. This may be associated with pain and headaches.</div><div class=\"graphic_reference\">Courtesy of Heidi M. Connolly, MD.</div><div id=\"graphicVersion\">Graphic 95679 Version 2.0</div></div></div>"},"95681":{"type":"graphic_diagnosticimage","displayName":"MRI Grade II carotid traumatic injury","title":"Grade II traumatic injury of the carotid on MRI","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Grade II traumatic injury of the carotid on MRI</div><div class=\"cntnt\"><img style=\"width:656px; height:304px;\" src=\"images/RADIOL/95681_MRI_Grade_II_carotid_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 48-year-old male presents with several weeks of left-sided, retro orbital headache. He sustained blunt trauma two months prior to this presentation. Axial (A) and 3D reconstructed (B) MR angiographic images demonstrate a short segment stenosis (arrow) at the distal cervical segment left internal carotid artery with approximately 40 percent luminal narrowing. Axial fat-suppressed T1-weighted image (C) demonstrates T1 hyperintensity at the vessel wall (arrow), consistent with dissection.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Joe Farnam, MD.</div><div id=\"graphicVersion\">Graphic 95681 Version 1.0</div></div></div>"},"95682":{"type":"graphic_diagnosticimage","displayName":"Imaging Takayasu aortitis MRI","title":"Takayasu aortitis on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Takayasu aortitis on MRI</div><div class=\"cntnt\"><img style=\"width:277px; height:454px;\" src=\"images/RHEUM/95682_Img_Takayasu_aortitis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 33-year-old man with Takayasu aortitis. The MRI shows narrowing of the region of the isthmus (arrowhead) as well as diffuse irregular narrowing of the abdominal aorta (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 95682 Version 1.0</div></div></div>"},"95683":{"type":"graphic_picture","displayName":"Diffuse cutaneous mastocytosis in a newborn","title":"Diffuse cutaneous mastocytosis in a newborn","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Diffuse cutaneous mastocytosis in a newborn</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95683_Cutaneo_mastocytosis_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythematous and thickened skin in a newborn with cutaneous mastocytosis. Numerous confluent papules are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95683 Version 2.0</div></div></div>"},"95686":{"type":"graphic_picture","displayName":"Wiskott-Aldrich dermatitis","title":"Wiskott-Aldrich syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wiskott-Aldrich syndrome</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95686_Wiskott-Aldrich dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eczematous dermatitis with associated purpura of the diaper area in an infant with Wiskott-Aldrich syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95686 Version 1.0</div></div></div>"},"95687":{"type":"graphic_table","displayName":"Supplies for a palliative care home visit","title":"Supplies to bring on a home visit for a patient receiving palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supplies to bring on a home visit for a patient receiving palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Recommended supplies</td> </tr> <tr> <td class=\"indent1\">Directions to the home, including phone numbers for the patient and caregivers</td> </tr> <tr> <td class=\"indent1\">Contact information</td> </tr> <tr> <td class=\"indent1\">Patient medical records</td> </tr> <tr> <td class=\"indent1\">Template or laptop to document visit</td> </tr> <tr> <td class=\"indent1\">Gloves</td> </tr> <tr> <td class=\"indent1\">Stethoscope</td> </tr> <tr> <td class=\"indent1\">Thermometer</td> </tr> <tr> <td class=\"indent1\">Pulse oximeter</td> </tr> <tr> <td class=\"indent1\">Sphygmomanometer</td> </tr> <tr> <td class=\"indent1\">Otoscope/ophthalmoscope</td> </tr> <tr> <td class=\"indent1\">Sharps container</td> </tr> <tr> <td class=\"indent1\">Prescription pad</td> </tr> <tr> <td class=\"indent1\">Advance Directives forms*</td> </tr> <tr> <td class=\"indent1\">Information sheets/educational materials<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Optional supplies</td> </tr> <tr> <td class=\"indent1\">Wound care supplies (bandage scissors, gauze/tape/packing)</td> </tr> <tr> <td class=\"indent1\">Tape measure</td> </tr> <tr> <td class=\"indent1\">Supplies for phlebotomy</td> </tr> <tr> <td class=\"indent1\">Supplies for procedures<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Examples include Health Care Proxy form, Do Not Resuscitate order, Physician Order for Life-Sustaining Treatment.<br />&para; These should explain diagnosis and provide information on services provided. They should be available in different languages as needed for your local coverage area.<br />&Delta; Examples of procedures that might be performed in the home include joint injections, incision and drainage, straight urinary catherization.</div><div class=\"graphic_reference\">Adapted from: Unwin BK, Tatum PE III. House calls. Am Fam Physician 2011; 83:925.</div><div id=\"graphicVersion\">Graphic 95687 Version 3.0</div></div></div>"},"95707":{"type":"graphic_table","displayName":"Approach to VTE prophylaxis in pregnant women w inherited thromb","title":"Approach to VTE prophylaxis in pregnant women with inherited thrombophilias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to&nbsp;VTE prophylaxis in pregnant women with inherited thrombophilias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical setting</td> <td class=\"subtitle1\">Antepartum management</td> <td class=\"subtitle1\">Postpartum management</td> </tr> <tr> <td> <p>Lower-risk thrombophilia* with personal history of previous VTE</p> <p>or</p> <p>Higher-risk thrombophilia<sup>&#182; </sup>without personal history of previous&nbsp;VTE</p> </td> <td>Anticoagulation therapy (intermediate dose)</td> <td>Anticoagulation therapy (intermediate dose)</td> </tr> <tr> <td>Lower-risk thrombophilia* without personal history of VTE</td> <td>Surveillance for VTE without anticoagulation therapy. Anticoagulation may be warranted for individual patients with additional factors that place them at greater risk of thrombosis (eg, prolonged immobility, first degree relative with unprovoked VTE at age &#60;50 years).</td> <td>Postpartum anticoagulation (prophylactic dose)&nbsp;for women who deliver by cesarean</td> </tr> <tr> <td>Higher-risk thrombophilia<sup>&#182;</sup> with previous VTE on chronic anticoagulation</td> <td>Anticoagulation therapy (therapeutic dose)</td> <td>Anticoagulation therapy (therapeutic dose)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Postpartum anticoagulation can generally be started four to six hours after vaginal delivery or 6 to 12 hours after cesarean delivery, unless there&nbsp;is significant bleeding or risk for significant bleeding.</div><div class=\"graphic_footnotes\">VTE: venous thromboembolism.<br />* Lower-risk thrombophilias include women who are heterozygotes for factor V Leiden (FVL) or prothrombin G20210A gene mutation (PGM) and women with deficiencies of protein C or protein S.<br />¶ Higher-risk thrombophilias include women with antithrombin (AT) deficiency, homozygotes for the FVL mutation, homozygotes for the PGM mutation, double heterozygotes for FVL and PGM.</div><div id=\"graphicVersion\">Graphic 95707 Version 4.0</div></div></div>"},"95715":{"type":"graphic_figure","displayName":"Resection of diverticular disease","title":"Resection of diverticular disease","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Resection of diverticular disease</div><div class=\"cntnt\"><img style=\"width:495px; height:474px;\" src=\"images/SURG/95715_Resection_of_diverticular_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-stage procedures are used in emergency situations where there has been peritoneal contamination. Common among the approaches is that the offending segment of diverticular disease is resected at the first operation. Panel A: stage one consists of the Hartmann operation; the diseased sigmoid colon is removed, the fecal stream is diverted, and the rectum is oversewn; in stage two, intestinal continuity is reestablished by a descending colorectostomy. Panel B: in stage one, the diseased sigmoid is removed, and both ends of bowel are brought to the surface, one as an end colostomy and the other as a mucus fistula; in stage two, intestinal continuity is reestablished as in panel A.</div><div id=\"graphicVersion\">Graphic 95715 Version 2.0</div></div></div>"},"95718":{"type":"graphic_picture","displayName":"Laparoscopic hyst positioning","title":"Positioning of patient for laparoscopic hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Positioning of patient for laparoscopic hysterectomy</div><div class=\"cntnt\"><img style=\"width:589px; height:333px;\" src=\"images/OBGYN/95718_Pstn_ptnt_lapr_hysterectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Karen C Wang, MD.</div><div id=\"graphicVersion\">Graphic 95718 Version 2.0</div></div></div>"},"95719":{"type":"graphic_diagnosticimage","displayName":"Grey Turner sign","title":"Grey Turner sign","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Grey Turner sign</div><div class=\"cntnt\"><img style=\"width:586px; height:493px;\" src=\"images/GAST/95719_Grey_turner_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grey Turner sign refers to flank ecchymoses that result from blood tracking subcutaneously from a retroperitoneal or intraperitoneal source.</div><div class=\"graphic_reference\">Reproduced from: Masha L, Bernard S. Grey Turner's sign suggesting retroperitoneal haemorrhage. Lancet 2014; 383:1920. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95719 Version 1.0</div></div></div>"},"95731":{"type":"graphic_picture","displayName":"Laparoscopic hyst uteroovarian ligament","title":"Laparoscopic hysterectomy: Dividing the uteroovarian ligament","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Dividing the uteroovarian ligament</div><div class=\"cntnt\"><img style=\"width:579px; height:395px;\" src=\"images/OBGYN/95731_Lap_hyst_dvdng_utrvrn_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sarah L Cohen, MD.</div><div id=\"graphicVersion\">Graphic 95731 Version 1.0</div></div></div>"},"95733":{"type":"graphic_picture","displayName":"Laparoscopic hyst mesosalpinx","title":"Laparoscopic hysterectomy: Visualizing the mesosalpinx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Visualizing the mesosalpinx</div><div class=\"cntnt\"><img style=\"width:432px; height:326px;\" src=\"images/OBGYN/95733_Laparoscop_hyst_mesosalpinx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95733 Version 1.0</div></div></div>"},"95734":{"type":"graphic_picture","displayName":"Lichen striatus nail","title":"Lichen striatus of the nail","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lichen striatus of the nail</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95734_Lichen_striatus_nail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail ridging and fraying in this child with lichen striatus. Note the subtle, hypopigmented lesions on the dorsum of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95734 Version 1.0</div></div></div>"},"95735":{"type":"graphic_picture","displayName":"Laparoscopic hyst broad ligament","title":"Laparoscopic hysterectomy: Dissecting the broad ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Dissecting the broad ligament</div><div class=\"cntnt\"><img style=\"width:403px; height:597px;\" src=\"images/OBGYN/95735_Laparos_hyst_broad_ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95735 Version 1.0</div></div></div>"},"95736":{"type":"graphic_picture","displayName":"Laparoscopic hyst anterior broad ligament","title":"Laparoscopic hysterectomy: Dissecting the anterior broad ligament across the bladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Dissecting the anterior broad ligament across the bladder</div><div class=\"cntnt\"><img style=\"width:432px; height:327px;\" src=\"images/OBGYN/95736_Lap_hyst_ant_broad_ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95736 Version 1.0</div></div></div>"},"95737":{"type":"graphic_picture","displayName":"Laparoscopic hyst uterine vessels 1","title":"Laparoscopic hysterectomy: Dissecting out the uterine vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Dissecting out the uterine vessels</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/OBGYN/95737_Lapar_hyst_uterine_vessels1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95737 Version 1.0</div></div></div>"},"95738":{"type":"graphic_picture","displayName":"Lichen striatus multiple bands","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95738_Lichen striatus multiple bands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple linear bands of flat-topped, white or skin-colored papules on the buttocks and leg of this child with lichen striatus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95738 Version 1.0</div></div></div>"},"95739":{"type":"graphic_picture","displayName":"Laparoscopic hyst uterine vessels2","title":"Laparoscopic hysterectomy: Ligating the uterine vessels","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Ligating the uterine vessels</div><div class=\"cntnt\"><img style=\"width:590px; height:403px;\" src=\"images/OBGYN/95739_Laparosc_hyst_uter_vessels2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sarah L Cohen, MD.</div><div id=\"graphicVersion\">Graphic 95739 Version 1.0</div></div></div>"},"95740":{"type":"graphic_picture","displayName":"Laparoscopic hyst uterine vessels 3","title":"Laparoscopic hysterectomy: Dividing the uterine vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Dividing the uterine vessels</div><div class=\"cntnt\"><img style=\"width:432px; height:326px;\" src=\"images/OBGYN/95740_Lapar_hyst_uterine_vessels3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95740 Version 1.0</div></div></div>"},"95741":{"type":"graphic_picture","displayName":"Laparoscopic hyst subtotal","title":"Laparoscopic subtotal hysterectomy: Transecting the cervix","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Laparoscopic subtotal hysterectomy: Transecting the cervix</div><div class=\"cntnt\"><img style=\"width:602px; height:211px;\" src=\"images/OBGYN/95741_Lprscpc_ttl_hystrctmy_crvx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sarah L Cohen, MD.</div><div id=\"graphicVersion\">Graphic 95741 Version 1.0</div></div></div>"},"95742":{"type":"graphic_picture","displayName":"Lichen striatus face","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95742_Lichen_striatus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear band of skin-colored papules on the forehead of a child with lichen striatus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95742 Version 1.0</div></div></div>"},"95743":{"type":"graphic_picture","displayName":"Laparoscopic hyst morcellation","title":"Laparoscopic hysterectomy: Power morcellation","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Power morcellation</div><div class=\"cntnt\"><img style=\"width:600px; height:226px;\" src=\"images/OBGYN/95743_Lprscpic_hystrctmy_mrclltn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sarah L Cohen, MD.</div><div id=\"graphicVersion\">Graphic 95743 Version 1.0</div></div></div>"},"95744":{"type":"graphic_picture","displayName":"Lichen striatus face 2","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/95744_Lichen_striatus_face_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear band of erythematous papules on the face of an infant with lichen striatus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95744 Version 1.0</div></div></div>"},"95745":{"type":"graphic_picture","displayName":"Laparoscopic hyst vaginal cuff 1","title":"Laparoscopic hysterectomy: Colpotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Colpotomy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/95745_Laparosc_hyst_vaginal_cuff1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95745 Version 1.0</div></div></div>"},"95746":{"type":"graphic_picture","displayName":"Laparoscopic hyst vaginal cuff 2","title":"Laparoscopic hysterectomy: Occlusion of vaginal incision to maintain pneumoperitoneum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Occlusion of vaginal incision to maintain pneumoperitoneum</div><div class=\"cntnt\"><img style=\"width:432px; height:326px;\" src=\"images/OBGYN/95746_Laparosc_hyst_vaginal_cuff2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95746 Version 1.0</div></div></div>"},"95748":{"type":"graphic_picture","displayName":"Laparoscopic hyst vaginal cuff 3","title":"Laparoscopic hysterectomy: Closing vaginal cuff","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic hysterectomy: Closing vaginal cuff</div><div class=\"cntnt\"><img style=\"width:398px; height:598px;\" src=\"images/OBGYN/95748_Laparosc_hyst_vaginal_cuff3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; MedReviews&reg;, LLC. Reprinted with permission of MedReviews&reg;, LLC. Einarsson JI, Suzuki Y. Total laparoscopic hysterectomy: 10 steps toward a successful procedure. Rev Obstet Gynecol 2009; 2:57. Reviews in Obstetrics &amp; Gynecology is a copyrighted publication of MedReviews&reg;, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95748 Version 1.0</div></div></div>"},"95749":{"type":"graphic_picture","displayName":"Hand dermatitis acute","title":"Acute hand eczema","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Acute hand eczema</div><div class=\"cntnt\"><img style=\"width:783px; height:646px;\" src=\"images/DERM/95749_Hand_dermatitis_acute.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, edema, and confluent vesiculation on the dorsum of the hands in a 49-year-old woman with acute allergic contact dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95749 Version 1.0</div></div></div>"},"95750":{"type":"graphic_picture","displayName":"Hyperkeratotic hand eczema","title":"Hyperkeratotic hand eczema","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">Hyperkeratotic hand eczema</div><div class=\"cntnt\"><img style=\"width:780px; height:525px;\" src=\"images/DERM/95750_Hyperkeratotichndeczema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic, hyperkeratotic, and fissured hand eczema in a 69-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95750 Version 2.0</div></div></div>"},"95752":{"type":"graphic_diagnosticimage","displayName":"Three vessel view","title":"Three vessel view of fetal heart","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Three vessel view of fetal heart</div><div class=\"cntnt\"><img style=\"width:628px; height:540px;\" src=\"images/OBGYN/95752_Three_vessel_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SVC: superior vena cava; Ao Arch: aortic arch; MPA: main pulmonary artery.</div><div class=\"graphic_reference\">Courtesy of Joshua Copel, MD.</div><div id=\"graphicVersion\">Graphic 95752 Version 1.0</div></div></div>"},"95753":{"type":"graphic_diagnosticimage","displayName":"Fetal right ventricular outflow tract","title":"Fetal right ventricular outflow tract","html":"<div class=\"graphic\"><div style=\"width: 715px\" class=\"figure\"><div class=\"ttl\">Fetal right ventricular outflow tract</div><div class=\"cntnt\"><img style=\"width:695px; height:562px;\" src=\"images/OBGYN/95753_Fetal_rght_ventr_outfl_trct.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RV: right ventricle; MPA: main pulmonary artery; RT PA: right pulmonary artery; DV: ductus venosus.</div><div class=\"graphic_reference\">Courtesy of Joshua Copel, MD.</div><div id=\"graphicVersion\">Graphic 95753 Version 1.0</div></div></div>"},"95754":{"type":"graphic_diagnosticimage","displayName":"Fetal left ventricular outflow tract","title":"Fetal left ventricular outflow tract","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Fetal left ventricular outflow tract</div><div class=\"cntnt\"><img style=\"width:688px; height:577px;\" src=\"images/OBGYN/95754_Fetal_left_ventr_outfl_trac.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; Ascend AO: ascending aorta.</div><div class=\"graphic_reference\">Courtesy of Joshua Copel, MD.</div><div id=\"graphicVersion\">Graphic 95754 Version 1.0</div></div></div>"},"95755":{"type":"graphic_table","displayName":"Carbo plus nab-paclitaxel advanced NSCLC","title":"Carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel for advanced non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel for advanced non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Nab-paclitaxel*</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Administer undiluted over 30 minutes.</td> <td>Days 1, 8, 15</td> </tr> <tr class=\"divider_bottom\"> <td>Carboplatin</td> <td>AUC<sup>&#182;</sup> = 6 mg/mL per min IV</td> <td>Dilute in 250 mL normal saline<sup>&#916;</sup> and administer over 30 minutes. The carboplatin should be given immediately after the nab-paclitaxel.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on day 1 (30 to 90%);<br /> LOW on days 8 and 15 (10 to 30%). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedication to prevent hypersensitivity reactions is generally not needed. Premedication may be needed in patients who have had a prior hypersensitivity reaction to nab-paclitaxel. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Nab-paclitaxel can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The incidence of febrile neutropenia with this regimen was 1%.<sup>[1]</sup> Primary prophylaxis with granulocyte colony stimulating factors is not indicated. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose for nab-paclitaxel may be needed for patients with liver impairment.<sup>[2]</sup> Do not administer nab-paclitaxel if AST &#62;10 times ULN or bilirubin &#62;5 times ULN. Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.<sup>&#182;</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelets weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes, renal, and liver function weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for infusion reactions. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for extravasation. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess for changes in neurologic function prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Do not administer carboplatin and nab-paclitaxel on day 1 of each new cycle unless ANC is &#8805;1500 cells/microL and platelet count is &#8805;100,000/microL.<sup>[3]</sup> For patients who develop severe neutropenia or thrombocytopenia, withhold treatment until counts recover to an ANC of at least 1500 cells/microL and platelet count of at least 100,000/microL on day 1, or to an ANC of at least 500 cells/microL and platelet count of at least 50,000/microL on days 8 or 15 of the cycle. Upon resumption of therapy, reduce nab-paclitaxel and carboplatin by 25% each of the first and second occurrences of neutropenic fever, a delay in the next cycle by greater than seven days for ANC &#60;1500 cells/microL, or an ANC of &#60;500 cells/microL for more than seven days. Discontinue treatment for a third occurrence. For intracycle platelet count of &#60;50,000/microL, reduce dose of nab-paclitaxel and carboplatin by 25% upon the first occurrence and discontinue treatment for a second occurrence. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Peripheral neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>In the original trial, all patients had less than grade 2 peripheral neuropathy prior to beginning therapy.<sup>[1]</sup> Withhold nab-paclitaxel for grade 3 or 4 neuropathy. Resume nab-paclitaxel and carboplatin at reduced doses when peripheral neuropathy improves to grade 1 or completely resolves. Upon resumption of therapy, reduce nab-paclitaxel and carboplatin AUC by 25% on each of the first and second occurrence of grade 3 or 4 peripheral neuropathy. Discontinue treatment for a third occurrence.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Reduced starting doses of nab-paclitaxel are recommended for individuals with preexisting moderate to severe hepatic impairment; the need for further dose adjustments in subsequent courses should be based on individual tolerance and clinician judgment.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; AUC: area under the curve; CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate; AST: aspartate aminotransferase; ULN: upper limit of normal.<br />* Do not substitute paclitaxel for nab-paclitaxel.<br />¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert Formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Socinski MA, et al. J Clin Oncol 2012; 30:2055.</LI>&#xD;&#xA;<LI>Paclitaxel protein bound particles for injectable suspension (albumin-bound). United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 30, 2014).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed January 30, 2014).</LI></OL></div><div id=\"graphicVersion\">Graphic 95755 Version 8.0</div></div></div>"},"95763":{"type":"graphic_algorithm","displayName":"Algorithm rectal bleeding in children","title":"Algorithm for the initial evaluation of an infant or child with rectal bleeding","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Algorithm for the initial evaluation of an infant or child with rectal bleeding</div><div class=\"cntnt\"><img style=\"width:455px; height:403px;\" src=\"images/PEDS/95763_Rectal_bleeding_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LGI: lower gastrointestinal tract; UGI: upper gastrointestinal tract.<br />* Rarely, hematochezia (bright red blood per rectum) can be caused by upper gastrointestinal bleeding, especially in an infant (due to short intestinal transit time), or because of a massive UGI bleed in an older individual.<br />&para; The evaluation varies with the age and clinical presentation of the patient. For those with more than minimal bleeding or who are ill-appearing, initial laboratory tests usually include complete blood count (CBC) with differential, erythrocyte sedimentation rate (ESR), albumin and a urine analysis. If diarrhea is present, include a chemistry panel and stool for white blood cells (WBC).</div><div id=\"graphicVersion\">Graphic 95763 Version 3.0</div></div></div>"},"95764":{"type":"graphic_table","displayName":"Differential diagnosis of LGIB in children","title":"Differential diagnosis of the pediatric patient with small to moderate rectal bleeding (hemodynamically stable)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of the pediatric patient with small to moderate rectal bleeding (hemodynamically stable)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"5%\"></colgroup><colgroup span=\"3\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">Typical age group</td> <td class=\"subtitle1\" rowspan=\"2\">Key clinical features</td> <td class=\"subtitle1\" rowspan=\"2\">Primary diagnostic possibilities</td> <td class=\"subtitle1\" rowspan=\"2\">Initial diagnostic steps</td> </tr> <tr> <td class=\"subtitle2\">Neonate</td> <td class=\"subtitle2\">Infants and toddlers</td> <td class=\"subtitle2\">Preschool period</td> <td class=\"subtitle2\">School aged</td> <td class=\"subtitle2\">Adolescent</td> </tr> <tr> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Breastfed; mother's nipples are cracked or bleeding.</td> <td><strong>Swallowed maternal blood</strong></td> <td>Apt test (hemoglobin alkaline denaturation test)</td> </tr> <tr> <td class=\"centered\">x</td> <td class=\"centered\">x*</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Well-appearing; stools with low-moderate blood; with or without diarrhea.</td> <td><strong>Milk or soy protein-induced colitis</strong> (\"allergic\" colitis)</td> <td>Assess diet, and do trial of eliminating milk and soy from the diet</td> </tr> <tr> <td class=\"centered\">x</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Acutely ill (vomiting, abdominal distension, diarrhea, and/or constipation).</td> <td><strong>NEC</strong> (especially in premature)<strong>; malrotation with midgut volvulus; Hirschsprung disease</strong></td> <td>Imaging, surgical consultation</td> </tr> <tr> <td class=\"centered\">x</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Other bleeding symptoms (cephalohematoma, mucocutaneous bleeding, petechiae).</td> <td><strong>Coagulopathy,</strong> eg: VKDB; hemophilia; VWD; maternal ITP</td> <td>Coagulation workup</td> </tr> <tr> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Ill, with abdominal distension, fever, vomiting, diarrhea, in patient with known or suspected Hirschsprung disease.</span>&nbsp;</td> <td><strong>Hirschsprung-associated enterocolitis</strong>&nbsp;</td> <td>Abdominal plain film<sup>&#182;</sup>&nbsp;</td> </tr> <tr> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Typically in child with other vascular lesions (eg, HHT or infantile hemangiomatosis). May have epistaxis or iron deficiency.&nbsp;</td> <td><strong>Vascular malformation</strong>&nbsp;or<strong> hemangioma</strong></td> <td>Endoscopy</td> </tr> <tr> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Variety of presentations, including GI bleeding, infection or intussusception.&nbsp;More common in infants, but may present later.</td> <td><strong>Gastrointestinal duplication cyst</strong>&nbsp;</td> <td>Imaging; most are in the small bowel</td> </tr> <tr> <td class=\"centered\">&nbsp;x</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Diarrhea (with or without blood), poor weight gain and growth, severe perianal disease, recurrent infections, atypical endoscopy or histology findings, skin lesions, and associated autoimmune diseases. </span></td> <td><strong>Infantile and very early onset inflammatory bowel disease (VEO-IBD)</strong></td> <td>Immunodeficiency evaluation; consider whole exome sequencing (in addition to tests listed&nbsp;under \"inflammatory bowel disease\" below). </td> </tr> <tr> <td class=\"centered\">x</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td class=\"centered\">x</td> <td>Loose bloody stools, abdominal pain, fever.</td> <td><strong>Infectious colitis</strong></td> <td>Culture of stool for enteric pathogens; C. difficile testing (toxin or PCR); fecal leukocytes</td> </tr> <tr> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td>Well-appearing; stools with low-moderate blood; often associated with constipation.</td> <td><strong>Anal fissure</strong></td> <td>Examine anus closely</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Sudden onset abdominal pain and lethargy, with or without grossly bloody stools (\"currant jelly\" appearance).</td> <td><strong>Intussusception</strong></td> <td>Abdominal ultrasonography, water-soluble contrast enema, or&nbsp;air enema (for diagnosis and non-operative reduction)</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td>Painless rectal bleeding, especially if recurrent and an anal fissure is excluded; bleeding may be profuse.</td> <td><strong>Meckel's diverticulum</strong></td> <td>Meckel scan</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td>Hemolytic anemia, thromobocytopenia, elevated creatinine, onset 5 to 10 days after diarrheal illness.</td> <td><strong>Hemolytic-uremic syndrome</strong></td> <td>CBC, BUN, creatinine, peripheral blood smear, stool culture</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td>Cutaneous purpura (palpable), abdominal pain, arthralgias.</td> <td><strong>Henoch-Sch<span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\"><strong>&#246;</strong></span>nlein purpura</strong> (IgA vasculitis)</td> <td>Clinical diagnosis if typical features are present; skin or renal biopsy if atypical presentation; abdominal ultrasonography if intussusception is suspected<sup>&#916;</sup></td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td class=\"centered\">x&nbsp;</td> <td>Rectal blood and mucus, tenesmus, sense of incomplete evacuation.&nbsp;</td> <td><strong>Solitary rectal ulcer syndrome&nbsp;</strong>&nbsp;</td> <td>Proctoscopy with biopsy; evaluation to rule out inflammatory bowel disease and infectious proctitis.&nbsp;</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td class=\"centered\">&nbsp;</td> <td>Painless rectal bleeding, often intermittent.</td> <td><strong>Juvenile polyps</strong></td> <td>Examine anus closely to rule out fissure; digital rectal examination for polyp; colonoscopy</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">x*</td> <td class=\"centered\">x*</td> <td>Diarrhea (with or without blood) and abdominal pain, often with growth failure or delayed puberty; may have weight loss&nbsp;or fever.</td> <td><strong>Inflammatory bowel disease</strong></td> <td> <p>CBC, ESR, or CRP, albumin; imaging; colonoscopy and upper endoscopy</p> Additional tests: PT/PTT, AST, ALT, amylase, lipase; fecal calprotectin, stool culture and C. difficile testing; O&#38;P</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NEC: necrotizing enterocolitis; VKDB: vitamin K deficient bleeding; VWD: von Willebrand disease; ITP: immune thrombocytopenia;<FONT color=black> HHT: hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome); GI: gastrointestinal; </FONT><FONT color=black>PCR: polymerase chain reaction; CBC: complete blood count; C. difficle: Clostridium difficile</FONT>; BUN: blood urea nitrogen; IgAV: IgA vasculitis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PT/PTT:&nbsp;prothrombin time/partial thromboplastin time; AST: aspartate transaminase; ALT: alanine transaminase; O&amp;P: ova and parasites.<br />* Relatively common cause in the given age group.<br />¶ On abdominal radiography, signs suggestive of Hirschsprung-associated enterocolitis include absence of air in the distal rectosigmoid colon, with an abrupt cut-off at the level of the pelvic brim (“cut-off” sign).<br />Δ&nbsp;Henoch-Schoenlein purpura may be complicated by intussusception, with the involved bowel serving as a lead point for the intussusception.</div><div id=\"graphicVersion\">Graphic 95764 Version 8.0</div></div></div>"},"95804":{"type":"graphic_picture","displayName":"Candida vulva and thigh","title":"Candida infection involving the vulva and thigh","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Candida infection involving the vulva and thigh</div><div class=\"cntnt\"><img style=\"width:464px; height:307px;\" src=\"images/OBGYN/95804_Candida_vulva_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Candida infection: Bright red patches and plaques with erosion&nbsp;involving the vulva and&nbsp;inner thigh.&nbsp;A slight scale overlies the red patches and plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: Hope K Haefner, MD.</div><div id=\"graphicVersion\">Graphic 95804 Version 1.0</div></div></div>"},"95806":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica early lesion","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95806_Necrobio_lipoi_erly_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thin plaque with a subtle, faint, yellow-orange hue may be a sign of early necrobiosis lipoidica. This image depicts a very early lesion which may be perceived as clinically nonspecific, but shows features of very early necrobiosis lipoidica.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95806 Version 1.0</div></div></div>"},"95807":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica plaque","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/95807_Necrobiosis_lipoid_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical lesion of nonulcerated necrobiosis lipoidica. There is an orange-red patch with visible vasculature hinting at the atrophogenic nature of the disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95807 Version 1.0</div></div></div>"},"95808":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica large plaque","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95808_Necrobiosis_lipoi_lg_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In dark skin, the yellowish hue and erythema of necrobiosis lipoidica can be subtle. Telangiectasias are still visible. Hyperpigmentation is common, as is demonstrated here.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 95808 Version 1.0</div></div></div>"},"95809":{"type":"graphic_picture","displayName":"Vaginal speculums","title":"Vaginal speculums","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal speculums</div><div class=\"cntnt\"><img style=\"width:365px; height:243px;\" src=\"images/OBGYN/95809_Vaginal_speculums.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left to right: Pediatric Pederson, Pederson, and Graves speculums.</div><div class=\"graphic_reference\">Reproduced with permission from: Hope K Haefner, MD.</div><div id=\"graphicVersion\">Graphic 95809 Version 1.0</div></div></div>"},"95810":{"type":"graphic_picture","displayName":"Colposcope","title":"Colposcope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colposcope</div><div class=\"cntnt\"><img style=\"width:415px; height:314px;\" src=\"images/OBGYN/95810_Colposcope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Hope K Haefner, MD.</div><div id=\"graphicVersion\">Graphic 95810 Version 1.0</div></div></div>"},"95811":{"type":"graphic_picture","displayName":"Branching pseudohyphae and budding Candida species","title":"Branching pseudohyphae and budding Candida species","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Branching pseudohyphae and budding Candida species</div><div class=\"cntnt\"><img style=\"width:596px; height:223px;\" src=\"images/OBGYN/95811_Candida_wet_prep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Branching pseudohyphae and budding Candida species.<br />(A) Candida low power.<br />(B) Candida high power.</div><div class=\"graphic_reference\">Reproduced with permission from: Hope K Haefner, MD.</div><div id=\"graphicVersion\">Graphic 95811 Version 1.0</div></div></div>"},"95812":{"type":"graphic_picture","displayName":"Keyes punch for vulvar biopsy","title":"Keyes punch for vulvar biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keyes punch for vulvar biopsy</div><div class=\"cntnt\"><img style=\"width:439px; height:179px;\" src=\"images/OBGYN/95812_Vulvar_punch_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The punch is placed perpendicular to the skin and firm, constant, downward pressure is applied with a circular twisting motion. A definite \"give\" occurs when the punch reaches the subcutaneous fat, indicating that a full-thickness cut has been made.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: Hope K Haefner, MD.</div><div id=\"graphicVersion\">Graphic 95812 Version 1.0</div></div></div>"},"95813":{"type":"graphic_picture","displayName":"Vulvar biopsy using biopsy forceps","title":"Vulvar biopsy using biopsy forceps","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Vulvar biopsy using biopsy forceps</div><div class=\"cntnt\"><img style=\"width:619px; height:411px;\" src=\"images/OBGYN/95813_Vulvar_biopsy_with_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Hope K Haefner, MD.</div><div id=\"graphicVersion\">Graphic 95813 Version 1.0</div></div></div>"},"95841":{"type":"graphic_picture","displayName":"Forces exerted on the elbow during throwing","title":"Forces exerted on the elbow during throwing","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Forces exerted on the elbow during throwing</div><div class=\"cntnt\"><img style=\"width:491px; height:590px;\" src=\"images/SM/95841_Valgusforces.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Powerful repetitive distractive forces (double arrow) and compressive forces (dashed arrows) during overhead throwing are responsible for many baseball-related injuries to the elbow.</div><div class=\"graphic_reference\">Reproduced with permission from: Eyer BA, Crues III, JV. Imaging of the elbow. In: Sports Medicine of Baseball, Dine JS, Altchek DW, Andrews JR, et al (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 95841 Version 5.0</div></div></div>"},"95844":{"type":"graphic_algorithm","displayName":"Unstable pelvic fracture management","title":"Unstable pelvic fracture management","html":"<div class=\"graphic\"><div style=\"width: 669px\" class=\"figure\"><div class=\"ttl\">Unstable pelvic fracture management</div><div class=\"cntnt\"><img style=\"width:649px; height:429px;\" src=\"images/SURG/95844_Unstab_pelvic_fractu_mngmnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ol class=\"numbers_to_nine\">&#xD;&#xA;    <li>Resuscitate with 2 L crystalloid.</li>&#xD;&#xA;    <li>Measure base deficit.</li>&#xD;&#xA;    <li>Rule out thoracic bleeding source (portable chest radiograph).</li>&#xD;&#xA;    <li>Stabilize pelvis (sheet).</li>&#xD;&#xA;    <li>If immediate RBC transfusion required, consider operative pelvic packing.</li>&#xD;&#xA;    <li>Transfuse, FFP:RBC (1:2); platelets:RBC (1:5).</li>&#xD;&#xA;    <li>Perform TEG.</li>&#xD;&#xA;    <li>Notify: trauma surgeon, orthopedic surgeon, blood bank, operating room, interventional radiology.</li>&#xD;&#xA;</ol></div><div class=\"graphic_footnotes\">FAST: focused abdominal sonography for trauma; SBP: systolic blood pressure; RBC: red blood cells; ED: emergency department; REBOA: resuscitative endovascular balloon; HD: hemodynamically; SICU: surgical intensive care unit; CT: computed tomography; FFP: fresh frozen plasma; TEG: thromboelastography.<br />* Normalize coagulation status, abdominal CT scan if no laparotomy done.</div><div id=\"graphicVersion\">Graphic 95844 Version 2.0</div></div></div>"},"95851":{"type":"graphic_table","displayName":"Morphologic definitions for mucocutaneous vulvar lesions","title":"Morphologic definitions for mucocutaneous vulvar lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Morphologic definitions for mucocutaneous vulvar lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Morphology</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Macule</td> <td>Small (&#60;1 cm) area of color change; no elevation and nonpalpable.</td> </tr> <tr> <td>Patch</td> <td>Large (&#62;1 cm) area of color change; no elevation and nonpalpable.</td> </tr> <tr> <td>Papule</td> <td>Small (&#60;1 cm) palpable lesion.</td> </tr> <tr> <td>Nodule</td> <td>Large (&#62;1 cm) palpable lesion; usually dome shaped; margins may be distinct (sharp) or slope shouldered.</td> </tr> <tr> <td>Plaque</td> <td>Large (&#62;1 cm) flat-topped and palpable lesion.</td> </tr> <tr> <td>Vesicle</td> <td>Small (&#60;1 cm) fluid-filled blister; clear fluid.</td> </tr> <tr> <td>Bulla</td> <td>Large (&#62;1 cm) fluid-filled blister; clear fluid.</td> </tr> <tr> <td>Pustule</td> <td>Small or large pus-filled blister; white or yellow fluid.</td> </tr> <tr> <td>Cyst</td> <td>Small or large nodule with epithelial-lined central cavity containing solid, semisolid, or fluid-filled material.</td> </tr> <tr> <td>Erosion</td> <td>Shallow defect limited to epidermis; the base of the defect may be red or covered by yellow crust. Erosions heal without scarring.</td> </tr> <tr> <td>Ulcer</td> <td>Deep defect into or through the dermis; the base may be red or covered by yellow, blue, or black crust. Ulcers heal with scarring.</td> </tr> <tr> <td>Fissure</td> <td>Thin (&#60;2 mm wide), linear erosion into or through the epidermis.</td> </tr> <tr> <td>Scale</td> <td>Grey or silver keratin proteins on the tissue surface that become white when moist; usually feels rough on palpation.</td> </tr> <tr> <td>Crust</td> <td>Yellow, granular material overlying erosions; develops due to solidification of plasma proteins when the water component of plasma evaporates; crusts overlying ulcers may be blue or black due to heme pigment.</td> </tr> <tr> <td>Excoriation</td> <td>Linear or angular erosions due to scratching.</td> </tr> <tr> <td>Lichenification</td> <td>Red or skin-colored plaques with exaggerated skin markings due to chronic rubbing; excoriations are usually also present. The surface may be white when moist.</td> </tr> <tr> <td>Eczema</td> <td>Erythematous, poorly marginated patches and plaques that demonstrate lichenification and/or evidence of epithelial disruption such as erosions or crust.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95851 Version 4.0</div></div></div>"},"95852":{"type":"graphic_table","displayName":"Full Hib and pneumococcal immunization status","title":"Suggested criteria for full <EM>Haemophilus influenza</EM> type b and <EM>Streptococcus pneumoniae</EM> immunization status when considering empiric antibiotics for community-acquired pneumonia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested criteria for full <EM>Haemophilus influenza</EM> type b and <EM>Streptococcus pneumoniae</EM> immunization status when considering empiric antibiotics for community-acquired pneumonia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Current age*</td> <td class=\"subtitle1\">Criteria for full immunization<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><em>Haemophilus influenzae</em> type b</td> </tr> <tr> <td class=\"indent1\">12 to 15 months</td> <td>&#8805;2 doses of Hib conjugate vaccine, with at least one dose at &#8805;12 months of age</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">15 months to 5 years</td> <td>&#8805;2 doses of Hib conjugate vaccine, with at least one dose at &#8805;12 months of age, <strong>or</strong></td> </tr> <tr> <td>&#8805;1 dose of Hib conjugate vaccine at &#8805;15 months of age</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;5 years, not high risk<sup>&#916;</sup></td> <td>Hib immunization not necessary</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">12 to 24 months</td> <td>&#8805;3 doses of PCV at &#60;16 months, with &#8805;1 dose at &#8805;12 months, <strong>or</strong></td> </tr> <tr> <td>2 doses of PCV, both at &#8805;12 months</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">24 months through 5 years</td> <td>&#8805;3 doses of PCV at &#60;16 months, with &#8805;1 dose at &#8805;12 months, <strong>or</strong></td> </tr> <tr> <td>2 doses of PCV, both at &#8805;12 months, <strong>or</strong></td> </tr> <tr> <td>&#8805;1 dose of PCV at &#8805;24 months</td> </tr> <tr> <td class=\"indent1\">&#62;5 years, not high risk<sup>&#9674;</sup></td> <td>PCV immunization not necessary</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Hib: <EM>Haemophilus influenzae</EM> type b; PCV: pneumococcal conjugate vaccine.<br />* Children younger than 12 months are incompletely immunized against Hib and <EM>S. pneumoniae</EM>.<br />¶ Immunizations must be completed at least two weeks before pneumonia diagnosis.<br />Δ Children at high risk for invasive Hib disease include chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, or early component complement deficiency. Please refer to the UpToDate topic on prevention of <EM>H. influenzae</EM> infection for a discussion of full Hib immunization in children at high risk for invasive Hib disease.<br /><FONT class=lozenge>◊</FONT> Children at high risk for invasive <EM>S. pneumoniae</EM> disease include those with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; solid organ transplantation; or congenital immunodeficiency. Please refer to the UpToDate topics on pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccines for a discussion of full <EM>S. pneumoniae</EM> immunization in children at high risk for invasive <EM>S. pneumoniae</EM> disease.</div><div id=\"graphicVersion\">Graphic 95852 Version 5.0</div></div></div>"},"95856":{"type":"graphic_picture","displayName":"Chorioretinitis sclopetaria","title":"Chorioretinitis sclopetaria","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Chorioretinitis sclopetaria</div><div class=\"cntnt\"><img style=\"width:724px; height:308px;\" src=\"images/EM/95856_Chorioretinitissclopetaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 36-year-old man with traumatic chorioretinal rupture in the macula secondary to a bullet in his right orbit. His best-corrected visual acuity is 20/160. There is fibroglial proliferation in the area of the chorioretinal rupture as well as preretinal and vitreous hemorrhage. In addition, there is significant retinal striation in the posterior pole. There was no retinal break elsewhere and his retina was attached.</div><div class=\"graphic_reference\">From: Papakostas TD, Yonekawa Y, Skondra D, Vavvas DG. Traumatic chorioretinal rupture (sclopetaria). Int Ophthalmol Clin 2013; 53:119. DOI: <A spellcheck=true href=\"http://journals.lww.com/internat-ophthalmology/Citation/2013/05340/Traumatic_Chorioretinal_Rupture__Sclopetaria_.12.aspx\" target=_blank>10.1097/IIO.0b013e3182a26f18</A>. Copyright © 2013 Wolters Kluwer Health. Reproduced with permission. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95856 Version 4.0</div></div></div>"},"95864":{"type":"graphic_table","displayName":"Celiac disease phenotypes","title":"Nomenclature for different phenotypes of celiac disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nomenclature for different phenotypes of celiac disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Key characteristics</td> <td class=\"subtitle1\">Classic</td> <td class=\"subtitle1\">Nongastrointestinal*</td> <td class=\"subtitle1\">Silent or subclinical</td> <td class=\"subtitle1\">Potential</td> </tr> <tr> <td>Symptoms of malabsorption (eg, weight loss, steatorrhea, or signs of vitamin deficiency)</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Nongastrointestinal&nbsp;symptoms (eg, liver disease, skin,<sup>&#182;</sup> arthritis, or neuropsychiatric)</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Positive celiac-specific antibody test<sup>&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Characteristic intestinal biopsy (villous atrophy)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Mucosal healing and resolution of symptoms after beginning a gluten-free diet</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In the past,&nbsp;nongastrointestinal celiac disease&nbsp;was termed \"atypical\" because it was thought to be uncommon, but the advent of serologic screening for celiac disease has identified a substantial proportion of patients with this pattern of symptoms. <br />¶&nbsp;Skin lesions may include dermatitis herpetiformis (DH). Many, but not all, patients with DH have intestinal lesions consistent with celiac disease, with or without intestinal symptoms.<br />Δ&nbsp;The celiac-specific antibody tests are tissue transglutaminase (tTG), anti-endomysial antibodies, or deamidated gliadin peptide (DGP). Standard IgG- or IgA-antigliadin antibodies have low specificity and are not sufficient to support the diagnosis of celiac disease.</div><div id=\"graphicVersion\">Graphic 95864 Version 3.0</div></div></div>"},"95868":{"type":"graphic_picture","displayName":"Granuloma faciale inflammatory infiltrate","title":"Histopathology of granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Histopathology of granuloma faciale</div><div class=\"cntnt\"><img style=\"width:468px; height:590px;\" src=\"images/DERM/95868_Granuloma_faci_inflam_infil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse and dense mixed inflammatory infiltrate extending into the reticular dermis.</div><div id=\"graphicVersion\">Graphic 95868 Version 1.0</div></div></div>"},"95870":{"type":"graphic_picture","displayName":"Granuloma faciale Grenz zone","title":"Histopathology of granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histopathology of granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/95870_Granuloma_faciale_Grnz_zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image demonstrating a Grenz zone (a thin zone of uninvolved papillary dermis) in a biopsy specimen from granuloma faciale. A dense inflammatory infiltrate is present beneath the Grenz zone. The overlying epidermis is not involved.</div><div id=\"graphicVersion\">Graphic 95870 Version 1.0</div></div></div>"},"95871":{"type":"graphic_picture","displayName":"Granuloma faciale cellular infiltrate","title":"Histopathology of granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histopathology of granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:446px;\" src=\"images/DERM/95871_Granuloma_faciale_cell_infl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inflammatory infiltrate contains abundant eosinophils and neutrophils. Fibrosis is also present.</div><div id=\"graphicVersion\">Graphic 95871 Version 1.0</div></div></div>"},"95873":{"type":"graphic_picture","displayName":"Granuloma faciale vascular damage","title":"Histopathology of granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histopathology of granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:434px;\" src=\"images/DERM/95873_Granuloma_faciale_vsclr_dam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular damage in granuloma faciale: dense perivascular inflammation, endothelial swelling, and karyorrhexis.</div><div id=\"graphicVersion\">Graphic 95873 Version 1.0</div></div></div>"},"95874":{"type":"graphic_table","displayName":"How to perform nasal irrigation PI","title":"How to perform nasal irrigation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to perform nasal irrigation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Buffered normal saline nasal irrigation</td> </tr> <tr> <td class=\"subtitle2_single\">The benefits</td> </tr> <tr> <td class=\"indent1\">1. Saline (salt water) washes the mucus and irritants from your nose.</td> </tr> <tr> <td class=\"indent1\">2. The sinus passages are moisturized.</td> </tr> <tr> <td class=\"indent1\">3. Studies have also shown that a nasal irrigation improves cell function (the cells that move the mucus work better).</td> </tr> <tr> <td class=\"subtitle2_single\">The recipe</td> </tr> <tr> <td class=\"indent1\">Use a one-quart glass jar that is thoroughly cleansed.</td> </tr> <tr> <td class=\"indent1\">You may use a large medical syringe (30 cc), water pick with an irrigation tip (preferred method), squeeze bottle, or Neti pot. Do not use a baby bulb syringe. The syringe or pick should be sterilized frequently or replaced every two to three weeks to avoid contamination and infection.</td> </tr> <tr> <td class=\"indent1\">Fill with water that has been distilled, previously boiled, or otherwise sterilized. Plain tap water is not recommended, because it is not necessarily sterile.</td> </tr> <tr> <td class=\"indent1\">Add 1 to 1&#189; heaping teaspoons of pickling/canning salt. Do&nbsp;<strong>not</strong> use table salt, because it contains a large number of additives.</td> </tr> <tr> <td class=\"indent1\">Add 1 teaspoon baking soda (pure bicarbonate).</td> </tr> <tr> <td class=\"indent1\">Mix ingredients together and store at room temperature. Discard after one week.</td> </tr> <tr> <td class=\"indent1\">You may also make up a solution from premixed packets that are commercially prepared specifically for nasal irrigation.</td> </tr> <tr> <td class=\"subtitle2_single\">The instructions</td> </tr> <tr> <td class=\"indent1\">Irrigate your nose with saline one to two times per day.</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If you have been told to use nasal medication, you should always use your saline solution first. The nasal medication is much more effective when sprayed onto clean nasal membranes, and the spray will reach deeper into the nose. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pour the amount of fluid you plan to use into a clean bowl. <strong>Do not </strong>put your used syringe back into the storage container, because it contaminates your solution. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>You may warm the solution slightly in the microwave, but be sure that the solution is <strong>not hot</strong>. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Bend over the sink (some people do this in the shower) and squirt the solution into each side of your nose, aiming the stream toward the back of your head,&nbsp;<strong>not</strong> the top of your head. The solution should flow into one nostril and out the other, but it will not harm you if you swallow a little. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Some people experience a little burning sensation the first few times they use buffered saline solution, but this usually goes away after they adapt to it. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Diseases of the Sinuses: Diagnosis and Management. Kennedy DW, Bolger WE, Zinreich SJ (Eds), BC Decker, Hamilton, Ontario 2001. Copyright &copy; Kennedy DW, Zinreich SJ.</div><div id=\"graphicVersion\">Graphic 95874 Version 3.0</div></div></div>"},"95876":{"type":"graphic_picture","displayName":"Granuloma faciale vascular inflammation","title":"Histopathology of granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histopathology of granuloma faciale</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/95876_Granuloma_facl_vascu_inflam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular damage associated with an inflammatory infiltrate composed of eosinophils, neutrophils, histiocytes, lymphocytes, and plasma cells.</div><div id=\"graphicVersion\">Graphic 95876 Version 1.0</div></div></div>"},"95885":{"type":"graphic_table","displayName":"Criteria for NAIT","title":"Criteria for fetal or neonatal alloimmune thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for fetal or neonatal alloimmune thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">All of the following criteria are necessary to diagnose fetal/neonatal alloimmune thrombocytopenia:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Fetal or neonatal thrombocytopenia </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Identification of a paternal, fetal, or neonatal platelet antigen that the mother lacks </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Identification of maternal antibodies to that antigen </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95885 Version 1.0</div></div></div>"},"95886":{"type":"graphic_figure","displayName":"RANK pathway for bone metastases","title":"Receptor activator of nuclear factor kappa B (RANK) pathway for bone metastases","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Receptor activator of nuclear factor kappa B (RANK) pathway for bone metastases</div><div class=\"cntnt\"><img style=\"width:661px; height:466px;\" src=\"images/ONC/95886_RANKL_RANK_bone_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vicious cycle: osteoblasts are activated by PTHrP, leading to increased production of the receptor activator of nuclear factor kappa B ligand (RANKL). RANKL interacts with RANK receptor expressed on hematopoietic osteoclast precursors, resulting in mature active osteoclasts. Mature osteoclasts resorb bone, causing the release by bone and cancer cells of bone-stored minerals and growth factors, including insulin-like growth factor I&nbsp;(IGF-1), transforming growth factor beta (TGF-beta), interleukin (IL)-6, and more parathyroid hormone releasing protein (PTHrP), thus stimulating tumor cell growth. Osteoprotegerin (OPG) can inhibit this process by binding to RANKL.</div><div class=\"graphic_reference\">Reproduced with permission from: Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control 2012; 19:92. Copyright &copy; 2012 H. Lee Moffitt Cancer Center &amp; Research Institute.</div><div id=\"graphicVersion\">Graphic 95886 Version 1.0</div></div></div>"},"95887":{"type":"graphic_algorithm","displayName":"Parental evaluation in suspected NAIT","title":"Parental evaluation in suspected NAIT","html":"<div class=\"graphic\"><div style=\"width: 699px\" class=\"figure\"><div class=\"ttl\">Parental evaluation in suspected NAIT</div><div class=\"cntnt\"><img style=\"width:679px; height:637px;\" src=\"images/OBGYN/95887_Parental_eval_suspect_NAIT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Platelet alloimmunization.</div><div class=\"graphic_footnotes\">NAIT: neonatal alloimmune thrombocytopenia; HPA: human platelet antigen; MACE: modified antigen capture enzyme-linked immunosorbent assay; ELISA: enzyme-linked immunosorbent assay; MAIPA: monoclonal antibody immobilization of platelet antigens.<br />* Examples of sensitive assays include MACE and MAIPA.</div><div class=\"graphic_reference\">From: Pacheco LD, Berkowitz RL, Moise KJ Jr, et al. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011; 118:1157. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2011&amp;issue=11000&amp;article=00027&amp;type=abstract\" target=_blank>10.1097/AOG.0b013e31823403f4</A>. Copyright © 2011 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95887 Version 3.0</div></div></div>"},"95888":{"type":"graphic_algorithm","displayName":"Severity-based approach for prenatal management of NAIT","title":"Severity-based approach for prenatal management of NAIT","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Severity-based approach for prenatal management of NAIT</div><div class=\"cntnt\"><img style=\"width:656px; height:682px;\" src=\"images/OBGYN/95888_Severity_prenatal_mang_NAIT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Platelet alloimmunization.</div><div class=\"graphic_footnotes\">NAIT: neonatal alloimmune thrombocytopenia; HPA: human platelet antigen; PCR: polymerase chain reaction; CVS: chorionic villus sampling; EGA: estimated gestational age.</div><div class=\"graphic_reference\">Adapted from: Pacheco LD, Berkowitz RL, Moise KJ Jr, et al. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011; 118:1157. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2011&amp;issue=11000&amp;article=00027&amp;type=abstract\" target=_blank>10.1097/AOG.0b013e31823403f4</A>. Copyright © 2011 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95888 Version 6.0</div></div></div>"},"95889":{"type":"graphic_picture","displayName":"Hand eczema nails","title":"Nail changes in chronic hand eczema","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Nail changes in chronic hand eczema</div><div class=\"cntnt\"><img style=\"width:781px; height:507px;\" src=\"images/DERM/95889_Handeczemanails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of cuticle, chronic inflammation of the nail folds, and ridging of the nail plate with transversal lines (Beau lines) in this 35-year-old woman with chronic hand eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95889 Version 2.0</div></div></div>"},"95890":{"type":"graphic_picture","displayName":"Hand eczema nummular","title":"Nummular hand eczema","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Nummular hand eczema</div><div class=\"cntnt\"><img style=\"width:783px; height:509px;\" src=\"images/DERM/95890_Hand_eczema_nummular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nummular eczema presenting with well-circumscribed erythematous lesions on the dorsum of the hand in a 23-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95890 Version 1.0</div></div></div>"},"95894":{"type":"graphic_table","displayName":"Criteria for assessment of disease response in bone","title":"WHO and UICC criteria for assessment of disease response in bone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO and UICC criteria for assessment of disease response in bone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Response type</td> <td class=\"subtitle1\">International Union Against Cancer*</td> <td class=\"subtitle1\">WHO<sup>&#182;</sup></td> </tr> <tr> <td>Complete response</td> <td> <p>Disappearance of all known disease</p> Lytic lesions should have radiologic evidence of calcification</td> <td>Complete disappearance of all lesions on&nbsp;plain radiograph or scan for at least&nbsp;four weeks</td> </tr> <tr> <td>Partial response</td> <td> <p>At least 50% decrease in size of measurable lesions</p> <p>Objective improvement in evaluable or nonmeasurable lesions</p> No new lesions or progressive lesions</td> <td>Partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for at least&nbsp;four weeks</td> </tr> <tr> <td>No change (stable disease)</td> <td>Unchanged, or between 25% increase and 50% decrease in size of measurable lesions<sup>&#916;</sup></td> <td>Because of the slow response of bone lesions, the classification of \"no change\" should not be applied until at least&nbsp;eight weeks have passed from start of therapy</td> </tr> <tr> <td>Progressive disease</td> <td> <p>Mixed; some lesions persist while others progress, or new lesions appear</p> <p>Failure; some or all lesions progress and/or new lesions appear</p> No lesions regress</td> <td>Increase in size of existent lesions or appearance of new lesions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; UICC: International Union Against Cancer.<br />* Criteria are based on plain radiography; the duration of response is to be dated from the start of therapy until either new lesions appear or any one existing lesion increases by 25% or more above its smallest recorded size.<br />¶ Occurrence of bone compression or fracture and its healing should not be used as the sole indicator for evaluation of therapy.<br />Δ If lesions that cannot be measured but are otherwise evaluable represent the bulk of disease and these lesions clearly do not respond even though measurable lesions have improved, then the response is considered no change, rather than an objective regression.</div><div class=\"graphic_reference\">From: Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-53. Reprinted with permission. Copyright &copy; 2004 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95894 Version 3.0</div></div></div>"},"95901":{"type":"graphic_figure","displayName":"PVFM PI","title":"Paradoxical vocal fold motion (PVFM)","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Paradoxical vocal fold motion (PVFM)</div><div class=\"cntnt\"><img style=\"width:492px; height:488px;\" src=\"images/PI/95901_PVFM_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normally when you breathe in, your vocal cords open like curtains to allow air into your lungs. In people with paradoxical vocal fold motion, also called PVFM, the vocal cords either stay shut or open only a little. The vocal cords are soft and flexible, so some air can get through, but it is much harder to breathe. PVFM is sometimes confused with asthma, because it can cause many of the same symptoms.</div><div class=\"graphic_reference\">Redrawn from: Hoyte FC. Vocal cord dysfunction. In: Conditions mimicking asthma, Choo EM (Ed), Elsevier, Philadelphia 2013.</div><div id=\"graphicVersion\">Graphic 95901 Version 2.0</div></div></div>"},"95903":{"type":"graphic_picture","displayName":"Stent with string","title":"Stent with string","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Stent with string</div><div class=\"cntnt\"><img style=\"width:590px; height:384px;\" src=\"images/SURG/95903_Stent_with_string.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The extraction string for the ureteral stent is looped through the distal stent (inset) such that pulling on&nbsp;it will&nbsp;unfurl the loop&nbsp;to makes stent removal easier. If the urologist chooses not to leave a string attached to the stent (as in the case when longer indwelling times are required), the string can be cut off and removed .</div><div id=\"graphicVersion\">Graphic 95903 Version 1.0</div></div></div>"},"95904":{"type":"graphic_algorithm","displayName":"CML response monitoring algorithm","title":"Algorithm for monitoring disease response to therapy in chronic myeloid leukemia (CML)","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Algorithm for monitoring disease response to therapy in chronic myeloid leukemia (CML)</div><div class=\"cntnt\"><img style=\"width:581px; height:657px;\" src=\"images/HEME/95904_CML_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm provides an approach to monitoring patients with CML. Cytogenetics are the preferred method for assessment until a complete cytogenetic response is attained.</div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; RT-PCR: reverse transcription polymerase chain reaction; CHR: complete hematologic response.</div><div id=\"graphicVersion\">Graphic 95904 Version 5.0</div></div></div>"},"95908":{"type":"graphic_table","displayName":"Peanut proteins","title":"Peanut proteins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peanut proteins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Allergen</td> <td class=\"subtitle1\">Protein type</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Ara h 1</td> <td>Vicilin (7S globulin)</td> <td>Seed storage protein, stable to heating, major allergen</td> </tr> <tr> <td>Ara h 2</td> <td>Conglutin (2S albumin)</td> <td>Seed storage protein, stable to heating, major allergen</td> </tr> <tr> <td>Ara h 3</td> <td>Glycinin (11S globulin)</td> <td>Seed storage protein, stable to heating, major allergen</td> </tr> <tr> <td>Ara h 4</td> <td>Isoform of Ara h 3</td> <td>&nbsp;</td> </tr> <tr> <td>Ara h 5</td> <td>Profilin (Bet v 2 homologue)</td> <td>Heat labile</td> </tr> <tr> <td>Ara h 6</td> <td>Conglutin (Ara h 2 homologue)</td> <td>&nbsp;</td> </tr> <tr> <td>Ara h 7</td> <td>Conglutin</td> <td>&nbsp;</td> </tr> <tr> <td>Ara h 8</td> <td>Bet v 1 homologue</td> <td>Heat labile</td> </tr> <tr> <td>Ara h 9</td> <td>Lipid transfer protein</td> <td>Stable protein, associated with more severe symptoms as well as oral symptoms in the Mediterranean area</td> </tr> <tr> <td>Ara h 10, 11</td> <td>Oleosin</td> <td>&nbsp;</td> </tr> <tr> <td>Ara h 12, 13</td> <td>Defensins</td> <td>&nbsp;Associated with severe anaphylaxis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ara h: <EM>Arachis hypogaea</EM> (peanut); Bet v: <EM>Betula verrucosa</EM> (birch).</div><div id=\"graphicVersion\">Graphic 95908 Version 3.0</div></div></div>"},"95909":{"type":"graphic_picture","displayName":"Ice cube test","title":"Ice cube test for cold urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ice cube test for cold urticaria</div><div class=\"cntnt\"><img style=\"width:310px; height:596px;\" src=\"images/ALLRG/95909_Ice_cube_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of photographs illustrates a positive ice cube test in a patient with cold urticaria.&nbsp;A plastic&nbsp;bag containing an ice cube and a small amount of water&nbsp;is applied to the volar aspect of the patient's forearm for&nbsp;5 minutes and then removed. The area of application is observed and the response is recorded 10 minutes after removal.&nbsp;It&nbsp;is preferable to use a bag with ice and water rather than applying an ice&nbsp;cube directly to the skin,&nbsp;since&nbsp;some patients can sustain skin damage at temperatures below 0°C. Refer to the UpToDate topic on cold urticaria for further discussion of this test and its interpretation.</div><div class=\"graphic_reference\">Courtesy of Marcus Maurer, MD.</div><div id=\"graphicVersion\">Graphic 95909 Version 3.0</div></div></div>"},"95910":{"type":"graphic_picture","displayName":"TempTest result","title":"Photo of cold testing with TempTest 4.0 in a patient with cold urticaria","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Photo of cold testing with TempTest 4.0 in a patient with cold urticaria</div><div class=\"cntnt\"><img style=\"width:589px; height:275px;\" src=\"images/ALLRG/95910_TempTest_result.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the forearm of a patient with cold urticaria after the application of the TempTest 4.0 testing device. This device contains a U-shaped metallic element that generates differential temperatures (from 4 to 44°C). In this patient, whealing is triggered by temperatures of 24°C and lower.</div><div class=\"graphic_reference\">Courtesy of Marcus Maurer, MD.</div><div id=\"graphicVersion\">Graphic 95910 Version 4.0</div></div></div>"},"95911":{"type":"graphic_picture","displayName":"TempTest device and technique","title":"Temperature testing in a patient with cold urticaria using TempTest 4.0","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Temperature testing in a patient with cold urticaria using TempTest 4.0</div><div class=\"cntnt\"><img style=\"width:540px; height:726px;\" src=\"images/ALLRG/95911_TempTest_device_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT color=black>(A) The TempTest 4.0 is a thermoelectric device that is commercially available. It contains a U-shaped metallic element that is placed against the skin and generates temperatures varying from 4 to 44°C. It is used to diagnose cold urticaria (and heat urticaria) and to determine critical temperature thresholds. Threshold&nbsp;information&nbsp;is useful in monitoring a patient's response to therapy.<br />(B) To perform provocation testing, the volar side of the forearm is laid firmly onto the device along the temperature applicator so that there is no airspace between the device and the forearm and the temperature applicator has close contact to the skin along its entire length. The application time is&nbsp;5 minutes, after which the patient removes the forearm from the device and the marks from the temperature curve (warm end of applicator and cold end</FONT> of the applicator) are noted using a skin marker.<br />(C) The reading is performed 10 minutes after the end of the test procedure. An evaluation template (transparent film) is laid on the patient's forearm based on the position of the temperature applicator so that the markings on the skin and the film are lined up. The contours of the wheal are traced onto the evaluation template using a waterproof permanent marker.<br />(D) The transparent film then serves as a permanent record of the test results. The threshold temperature or the temperature below which symptoms appeared was 18°C in this patient.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Moxie GmbH.</div><div id=\"graphicVersion\">Graphic 95911 Version 3.0</div></div></div>"},"95915":{"type":"graphic_picture","displayName":"Dactylitis sausage digit","title":"Dactylitis (sausage digit)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dactylitis (sausage digit)</div><div class=\"cntnt\"><img style=\"width:427px; height:516px;\" src=\"images/RHEUM/95915_Dactylitis_sausage_digit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of the right hand with dactylitis (sausage digit) of the middle finger.</div><div class=\"graphic_reference\">Courtesy of James Wei, MD, PhD.</div><div id=\"graphicVersion\">Graphic 95915 Version 1.0</div></div></div>"},"95916":{"type":"graphic_table","displayName":"Stages of primary MR","title":"Stages of primary MR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of primary MR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Valve anatomy</td> <td class=\"subtitle1\">Valve hemodynamics*</td> <td class=\"subtitle1\">Hemodynamic consequences</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>A</strong></td> <td><strong>At risk of MR</strong></td> <td> <ul> <li>Mild mitral valve prolapse with normal coaptation </li> <li>Mild valve thickening and leaflet restriction </li> </ul> </td> <td> <ul> <li>No MR jet or small central jet area &#60;20% LA on Doppler </li> <li>Small vena contracta &#60;0.3 cm </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>B</strong></td> <td><strong>Progressive MR</strong></td> <td> <ul> <li>Severe mitral valve prolapse with normal coaptation </li> <li>Rheumatic valve changes with leaflet restriction and loss of central coaptation </li> <li>Prior IE </li> </ul> </td> <td> <ul> <li>Central jet MR 20 to 40% LA or late systolic eccentric jet MR </li> <li>Vena contracta &#60;0.7 cm </li> <li>Regurgitant volume &#60;60 mL </li> <li>Regurgitant fraction &#60;50% </li> <li>ERO &#60;0.40 cm<sup>2</sup> </li> <li>Angiographic grade 1-2+ </li> </ul> </td> <td> <ul> <li>Mild LA enlargement </li> <li>No LV enlargement </li> <li>Normal pulmonary pressure </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>C</strong></td> <td><strong>Asymptomatic severe MR</strong></td> <td> <ul> <li>Severe mitral valve prolapse with loss of coaptation or flail leaflet </li> <li>Rheumatic valve changes with leaflet restriction and loss of central coaptation </li> <li>Prior IE </li> <li>Thickening of leaflets with radiation heart disease </li> </ul> </td> <td> <ul> <li>Central jet MR &#62;40% LA or holosystolic eccentric jet MR </li> <li>Vena contracta &#8805;0.7 cm </li> <li>Regurgitant volume &#8805;60 mL </li> <li>Regurgitant fraction &#8805;50% </li> <li>ERO &#8805;0.40 cm<sup>2</sup> </li> <li>Angiographic grade 3 to 4+ </li> </ul> </td> <td> <ul> <li>Moderate or severe LA enlargement </li> <li>LV enlargement </li> <li>Pulmonary hypertension may be present at rest or with exercise </li> <li><strong>C1:</strong> LVEF &#62;60% and LVESD &#60;40 mm </li> <li><strong>C2:</strong> LVEF &#8804;60% and LVESD &#8805;40 mm </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>D</strong></td> <td><strong>Symptomatic severe MR</strong></td> <td> <ul> <li>Severe mitral valve prolapse with loss of coaptation or flail leaflet </li> <li>Rheumatic valve changes with leaflet restriction and loss of central coaptation </li> <li>Prior IE </li> <li>Thickening of leaflets with radiation heart disease </li> </ul> </td> <td> <ul> <li>Central jet MR &#62;40% LA or holosystolic eccentric jet MR </li> <li>Vena contracta &#8805;0.7 cm </li> <li>Regurgitant volume &#8805;60 mL </li> <li>Regurgitant fraction &#8805;50% </li> <li>ERO &#8805;0.40 cm<sup>2</sup> </li> <li>Angiographic grade 3 to 4+ </li> </ul> </td> <td> <ul> <li>Moderate or severe LA enlargement </li> <li>LV enlargement </li> <li>Pulmonary hypertension present </li> </ul> </td> <td> <ul> <li>Decreased exercise tolerance </li> <li>Exertional dyspnea </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERO: effective regurgitant orifice; IE: infective endocarditis; LA: left atrium/atrial; LV: left ventricular; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension; MR: mitral regurgitation.<br />​* Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95916 Version 1.0</div></div></div>"},"95917":{"type":"graphic_table","displayName":"Stages of secondary MR","title":"Stages of secondary MR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of secondary MR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Valve anatomy</td> <td class=\"subtitle1\">Valve hemodynamics*</td> <td class=\"subtitle1\">Associated cardiac findings</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>A</strong></td> <td><strong>At risk of MR</strong></td> <td> <ul> <li>Normal valve leaflets, chords, and annulus in a patient with coronary disease or cardiomyopathy </li> </ul> </td> <td> <ul> <li>No MR jet or small central jet area &#60;20% LA on Doppler </li> <li>Small vena contracta &#60;0.30 cm </li> </ul> </td> <td> <ul> <li>Normal or mildly dilated LV size with fixed (infarction) or inducible (ischemia) regional wall motion abnormalities </li> <li>Primary myocardial disease with LV dilation and systolic dysfunction </li> </ul> </td> <td> <ul> <li>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>B</strong></td> <td><strong>Progressive MR</strong></td> <td> <ul> <li>Regional wall motion abnormalities with mild tethering of mitral leaflet </li> <li>Annular dilation with mild loss of central coaptation of the mitral leaflets </li> </ul> </td> <td> <ul> <li>ERO &#60;0.20 cm<sup>2</sup><sup>&#916;</sup> </li> <li>Regurgitant volume &#60;30 mL </li> <li>Regurgitant fraction &#60;50% </li> </ul> </td> <td> <ul> <li>Regional wall motion abnormalities with reduced LV systolic function </li> <li>LV dilation and systolic dysfunction due to primary myocardial disease </li> </ul> </td> <td> <ul> <li>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>C</strong></td> <td><strong>Asymptomatic severe MR</strong></td> <td> <ul> <li>Regional wall motion abnormalities and/or LV dilation with severe tethering of mitral leaflet </li> <li>Annular dilation with severe loss of central coaptation of the mitral leaflets </li> </ul> </td> <td> <ul> <li>ERO &#8805;0.20 cm<sup>2</sup><sup>&#916;</sup> </li> <li>Regurgitant volume &#8805;30 mL </li> <li>Regurgitant fraction &#8805;50% </li> </ul> </td> <td> <ul> <li>Regional wall motion abnormalities with reduced LV systolic function </li> <li>LV dilation and systolic dysfunction due to primary myocardial disease </li> </ul> </td> <td> <ul> <li>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>D</strong></td> <td><strong>Symptomatic severe MR</strong></td> <td> <ul> <li>Regional wall motion abnormalities and/or LV dilation with severe tethering of mitral leaflet </li> <li>Annular dilation with severe loss of central coaptation of the mitral leaflets </li> </ul> </td> <td> <ul> <li>ERO &#8805;0.20 cm<sup>2</sup><sup>&#916;</sup> </li> <li>Regurgitant volume &#8805;30 mL </li> <li>Regurgitant fraction &#8805;50% </li> </ul> </td> <td> <ul> <li>Regional wall motion abnormalities with reduced LV systolic function </li> <li>LV dilation and systolic dysfunction due to primary myocardial disease </li> </ul> </td> <td> <ul> <li>HF symptoms due to MR persist even after revascularization and optimization of medical therapy </li> <li>Decreased exercise tolerance </li> <li>Exertional dyspnea </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">2D: 2-dimensional; ERO: effective regurgitant orifice; HF: heart failure; LA: left atrium; LV: left ventricular; MR: mitral regurgitation; TTE: transthoracic echocardiogram.<br />* Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.<br />Δ The measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO due to the crescentic shape of the proximal convergence.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95917 Version 1.0</div></div></div>"},"95958":{"type":"graphic_table","displayName":"Completeness of cytoreduction score for peritoneal mesothelioma","title":"Completeness of cytoreduction (CC) score for peritoneal mesothelioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Completeness of cytoreduction (CC) score for peritoneal mesothelioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>CC-0</td> <td>No visible evidence of residual disease</td> </tr> <tr> <td>CC-1</td> <td>Residual tumors &#60;2.5 mm in diameter</td> </tr> <tr> <td>CC-2</td> <td>Residual tumors between 2.5 mm and 2.5 cm in diameter</td> </tr> <tr> <td>CC-3</td> <td>Residual tumors &#62;2.5 cm in diameter or a confluence of tumor nodules present at any site</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359.</div><div id=\"graphicVersion\">Graphic 95958 Version 1.0</div></div></div>"},"95959":{"type":"graphic_picture","displayName":"Neonatal hyperthyroidism","title":"Neonatal hyperthyroidism","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Neonatal hyperthyroidism</div><div class=\"cntnt\"><img style=\"width:589px; height:332px;\" src=\"images/PEDS/95959_Neonatal_hyperthyroidism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These twins demonstrate clinical features of neonatal hyperthyroidism (thyrotoxicosis), including an anxious-appearing stare and diminished subcutaneous fat.</div><div class=\"graphic_reference\">Courtesy of Dr. Stephen LaFranchi.</div><div id=\"graphicVersion\">Graphic 95959 Version 1.0</div></div></div>"},"95960":{"type":"graphic_figure","displayName":"Overall survival malignant peritoneal mesothelioma CRS HIPEC","title":"Overall survival curve for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 761px\" class=\"figure\"><div class=\"ttl\">Overall survival curve for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy</div><div class=\"cntnt\"><img style=\"width:741px; height:437px;\" src=\"images/ONC/95960_OS_curve_MPM_patients.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier actuarial overall survival (OS) curve for 211 patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS)&nbsp;and hyperthermic intraperitoneal chemotherapy (HIPEC). The median actuarial overall survival was 38.4 months; the actuarial 5 and 10-year survivals were 41 and 26 percent, respectively.</div><div class=\"graphic_reference\">Reproduced from: Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013; 153:779. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95960 Version 1.0</div></div></div>"},"95961":{"type":"graphic_figure","displayName":"Actuarial OS malignant peritoneal mesothelioma CRS HIPEC","title":"Actuarial overall survival curves for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 787px\" class=\"figure\"><div class=\"ttl\">Actuarial overall survival curves for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy</div><div class=\"cntnt\"><img style=\"width:767px; height:456px;\" src=\"images/ONC/95961_Actuarial_OS_curves_MPM_pat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial overall survival in patients with MPM treated with cytoreductive surgery (CRS) and&nbsp;hyperthermic intraperitoneal chemotherapy (HIPEC)&nbsp;was significantly shorter in male versus female patients (graph A), patients 60 years or older&nbsp;versus younger (graph B), patients with high versus low histologic grade tumors (graph C), and patients with suboptimal (CC-2+CC-3*) versus optimal (CC-0+CC-1*) completeness of surgical cytoreduction scores (graph D). All p-values are 0.02. </div><div class=\"graphic_footnotes\">* Completeness of surgical cytoreduction score defined as:<br />CC-0: No visible evidence of residual disease<br />CC-1: Residual tumor &lt;2.5 mm<br />CC-2: Residual tumor 2.5 to 25mm <br />CC-3: Residual tumor &gt;25 mm or confluent tumor nodules</div><div class=\"graphic_reference\">Reproduced from: Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013; 153:779. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95961 Version 1.0</div></div></div>"},"95963":{"type":"graphic_table","displayName":"Considerations in obtaining peanut component tests","title":"Considerations in obtaining peanut component tests for establishing the diagnosis of peanut allergy*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations in obtaining peanut component tests for establishing the diagnosis of peanut allergy*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factors that make component testing LESS likely to be informative</td> <td class=\"subtitle1\">Factors that make component testing MORE likely to be informative</td> </tr> <tr> <td>A recent convincing clinical reaction</td> <td>Mild reactions or no reaction history</td> </tr> <tr> <td>A remote significant clinical reaction in a patient with PN-IgE &#8805;15</td> <td>Remote clinical reaction with development of birch sensitization over time</td> </tr> <tr> <td>PN-IgE &#62;25 or &#60;0.35 kU<sub>&#913;</sub>/L</td> <td>PN-IgE 0.35 to 15 kU<sub>&#913;</sub>/L</td> </tr> <tr> <td>Lack of birch sensitization</td> <td>Birch sensitization</td> </tr> <tr> <td>Younger children</td> <td>Older persons</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PN-IgE: peanut-specific immunoglobulin E.<br />*Obtaining peanut component test results prior to performing a food challenge to peanut is beneficial for risk assessment purposes.</div><div class=\"graphic_reference\">Reproduced from: Sicherer SH, Wood RA. Advances in diagnosing peanut allergy. J Allergy Clin Immunol: In Practice 2013; 1:1. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 95963 Version 2.0</div></div></div>"},"95964":{"type":"graphic_table","displayName":"Red patches and plaques","title":"Differential diagnosis of red patches and plaques on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of red patches and plaques on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Candidiasis</p> <p>Atopic dermatitis (eczema)</p> <p>Lichen simplex chronicus</p> <p>Irritant contact dermatitis</p> Psoriasis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Allergic contact dermatitis</p> <p>Irritant contact dermatitis</p> <p>Lichen planus</p> <p>Tinea cruris</p> <p>Perianal streptococcal infection</p> Vulvar intraepithelial neoplasia (Bowen's disease)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Plasma cell vulvitis</p> <p>Extramammary Paget disease</p> <p>Hailey-Hailey disease</p> <p>Tinea versicolor</p> Pityriasis rosea</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95964 Version 1.0</div></div></div>"},"95971":{"type":"graphic_table","displayName":"Red papules and nodules","title":"Differential diagnosis of red papules and nodules on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of red papules and nodules on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Folliculitis</p> <p>Cherry angioma</p> <p>Angiokeratoma</p> <p>Hemangioma</p> <p>Furunculosis</p> <p>Hidradenitis suppurativa</p> <p>Hemangioma</p> Vestibular papillomatosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Inflamed epidermal cyst</p> <p>Bartholin duct abscess</p> <p>Prurigo nodularis</p> <p>Urethral caruncle</p> <p>Urethral prolapse</p> <p>Crohn disease</p> <p>Vulvar intraepithelial neoplasia and squamous cell carcinoma</p> <p>Molluscum contagiosum (inflamed)</p> Insect bites</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Pyogenic granuloma</p> <p>Kaposi sarcoma</p> <p>Hidradenoma papilliferum</p> <p>Vulvar endometriosis</p> <p>Pseudo warts</p> <p>Langerhans histiocytosis</p> <p>Sarcoidosis</p> Amelanotic melanoma</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95971 Version 2.0</div></div></div>"},"95978":{"type":"graphic_table","displayName":"Brown blue or black macules papules patches plaques","title":"Differential diagnosis of brown, blue, or black macules, papules, patches, plaques on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of brown, blue, or black macules, papules, patches, plaques on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Physiologic hyperpigmentation</p> <p>Postinflammatory hyperpigmentation</p> <p>Human papillomavirus infection (wart)</p> <p>Vulvar intraepithelial neoplasia, usual type</p> <p>Melanocytic nevus</p> <p>Seborrheic keratosis</p> <p>Angiokeratoma</p> Skin tags</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Vulvar melanosis/lentiginosis</p> <p>Lichen planus</p> <p>Atypical melanocytic nevus</p> <p>Varicosity</p> Melanoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Pigmented basal cell cancer</p> <p>Hidradenoma papilliferum</p> Acanthosis nigricans</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95978 Version 1.0</div></div></div>"},"95981":{"type":"graphic_figure","displayName":"MERS-CoV cases","title":"Confirmed global cases of Middle East respiratory syndrome coronavirus – Reported to the World Health Organization as of 10 February 2017 (n = 1905)","html":"<div class=\"graphic\"><div style=\"width: 1150px\" class=\"figure\"><div class=\"ttl\">Confirmed global cases of Middle East respiratory syndrome coronavirus – Reported to the World Health Organization as of 10 February 2017 (n = 1905)</div><div class=\"cntnt\"><img style=\"width:1130px; height:548px;\" src=\"images/ID/95981_MERS-CoV_cases_2017.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Other countries: Algeria, Austria, Bahrain, China, Egypt, France, Germany, Greece, Iran, Italy, Jordan, Kuwait, Lebanon, Malaysia, Netherlands, Oman, Philippines, Qatar, Thailand, Tunisia, Turkey, United Arab Emirates, United Kingdom, United States of America, Yemen.<br />Please note that the underlying data is subject to change as the investigations around cases are ongoing. Onset date estimated if not available.</div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. Emergencies preparedness, response: Middle East respiratory syndrome coronavirus (MERS-CoV) maps and epicurves, 10 Feb 2017. <A href=\"http://www.who.int/emergencies/mers-cov/epicurve-10-february-2017.png?ua=1\" target=_blank>http://www.who.int/emergencies/mers-cov/epicurve-10-february-2017.png?ua=1</A> (Accessed on February 14, 2017).</div><div id=\"graphicVersion\">Graphic 95981 Version 10.0</div></div></div>"},"95983":{"type":"graphic_table","displayName":"White patches and plaques","title":"Differential diagnosis of white patches and plaques on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of white patches and plaques on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Vitiligo</p> <p>Postinflammatory hypopigmentation</p> <p>Lichen sclerosus</p> <p>Lichen planus</p> <p>Lichen simplex (moist)</p> <p>Candidiasis</p> <p>Human papillomavirus infection (wart)</p> Vulvar intraepithelial neoplasia, usual type</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Vulvar intraepithelial neoplasia, differentiated type</p> Squamous cell carcinoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>White sponge nevus</p> <p>Hailey-Hailey disease</p> Verrucous carcinoma</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95983 Version 3.0</div></div></div>"},"95984":{"type":"graphic_table","displayName":"Vulvar erosions","title":"Differential diagnosis of erosions on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of erosions on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Excoriation</p> <p>Fissures</p> <p>Lichen simplex</p> <p>Herpes simplex</p> <p>Candidiasis</p> <p>Erosive lichen sclerosus</p> <p>Erosive lichen planus</p> <p>Impetigo</p> Irritant contact dermatitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Allergic contact dermatitis</p> <p>Post-coital fissures</p> <p>Herpes zoster</p> <p>Stevens-Johnson syndrome</p> <p>Pemphigus</p> <p>Pemphigoid</p> <p>Cicatricial pemphigoid</p> <p>Pemphigoid gestations</p> <p>Eroded malignancy</p> Plasma cell vulvitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Hailey-Hailey disease</p> <p>Extramammary Paget disease</p> Toxic epidermal necrolysis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95984 Version 1.0</div></div></div>"},"95987":{"type":"graphic_table","displayName":"Four box model for medical decisions","title":"Jonsen's four box model for medical decision making","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Jonsen's four box model for medical decision making</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medical indications</td> <td class=\"subtitle1\">Patient and family preferences</td> <td class=\"subtitle1\">Quality of life</td> <td class=\"subtitle1\">Contextual features</td> </tr> <tr> <td class=\"subtitle2\">The principles of beneficence and non-maleficence</td> <td class=\"subtitle2\">The principle of respect for autonomy</td> <td class=\"subtitle2\">The principles of beneficence, non-maleficence, and respect for autonomy</td> <td class=\"subtitle2\">The principles of justice (loyalty and fairness)</td> </tr> <tr> <td> <p>What is the prognosis including survival, function, and quality of life?</p> <p>How certain or uncertain is the prognosis?</p> <p>What are the treatment options?</p> <p>What are the potential benefits and burdens of disease-focused treatment?</p> What are the potential benefits and burdens of palliative-focused treatment?</td> <td> <p>How much information does the patient want about prognosis?</p> <p>How involved does the patient want others (friends, family) to be in decision making?</p> <p>Does the patient have decision making capacity?</p> <p>If the patient does not have decision making capacity, who is the appropriate surrogate decision maker?</p> Has the patient previously expressed preferences in an Advance Directive or physician order for life-sustaining treatment (POLST)?</td> <td> <p>What are the most important things for the patient at this time (eg, survival, pain control, family well-being, etc)?</p> <p>What is the patient hoping for?</p> <p>What is the patient fearful of?</p> <p>What is the patient expecting?</p> <p>If trade-offs between duration and quality of life need to be made, which side should be more heavily weighted?</p> Are there quality of life states (eg, permanent coma) where it would not make sense to continue life sustaining treatment or disease oriented care?</td> <td> <p>Is significant moral distress among staff members present, and how is this affecting care?</p> <p>Are there important family dynamics that must be considered?</p> <p>Are there financial or economic factors that must be considered, such as access to hospice care?</p> <p>Are there religious or cultural factors?</p> <p>Are there problems related to allocation of resources?</p> <p>How does the law affect treatment decisions?</p> Is there any conflict of interest present?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Jonsen AR, Siegler M, Winslade WJ. Clinical ethics: A practical approach to ethical decisions in clinical medicine, 7th ed, McGraw-Hill, New York 2010.</div><div id=\"graphicVersion\">Graphic 95987 Version 1.0</div></div></div>"},"95988":{"type":"graphic_diagnosticimage","displayName":"Aortogram nonocclusive ischemia","title":"Nonocclusive ischemia on aortography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonocclusive ischemia on aortography</div><div class=\"cntnt\"><img style=\"width:440px; height:582px;\" src=\"images/SURG/95988_Celiac_artrio_noncclu_ischm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortogram&nbsp;demonstrating diffuse spasm of all the arteries in the abdomen, including the hepatic, splenic, renals,&nbsp;and mesenteric vessels, with reduced vessel filling consistent with nonocclusive mesenteric ischemia. Small bowel ileus is seen in the left lower quadrant.</div><div id=\"graphicVersion\">Graphic 95988 Version 1.0</div></div></div>"},"95989":{"type":"graphic_diagnosticimage","displayName":"Lateral aortogram nonocclusive ischemia","title":"Lateral aortogram nonocclusive ischemia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lateral aortogram nonocclusive ischemia</div><div class=\"cntnt\"><img style=\"width:590px; height:745px;\" src=\"images/SURG/95989_Lat_aortogram_nonocc_ischem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral aortogram demonstrating narrowing or spasm of&nbsp;the celiac axis and superior mesenteric artery with&nbsp;reduced intramural vessel filling consistent with nonocclusive mesenteric ischemia.</div><div id=\"graphicVersion\">Graphic 95989 Version 1.0</div></div></div>"},"95990":{"type":"graphic_table","displayName":"White papules and nodules","title":"Differential diagnosis of white papules and nodules on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of white papules and nodules on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Fordyce spots</p> <p>Milium (plural, milia)</p> <p>Epidermal cyst</p> <p>Molluscum contagiosum</p> <p>Human papillomavirus infection (wart)</p> Vulvar intraepithelial neoplasia, usual type</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Vulvar intraepithelial neoplasia, differentiated type</p> <p>Squamous cell carcinoma</p> Scar</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Verrucous carcinoma</p> Condylomata lata</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95990 Version 1.0</div></div></div>"},"95992":{"type":"graphic_algorithm","displayName":"Extremity trauma algorithm","title":"Extremity trauma algorithm","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Extremity trauma algorithm</div><div class=\"cntnt\"><img style=\"width:511px; height:770px;\" src=\"images/SURG/95992_Extremitytraumaalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>A</STRONG>: Manual pressure or pressure dressing. A tourniquet is an option for life-threatening hemorrhage that cannot be controlled with other means, but removed as soon as possible. An operative pneumatic type tourniquet is preferred to field type.<br /><STRONG>B</STRONG>: For suspected concomitant intra-cavitary hemorrhage (abdominal or thoracic), two operative teams are an advantage. If only a single team is available, extremity tourniquet may temporarily control hemorrhage until intra-cavitary bleeding can be managed using damage control techniques. Damage control allows the ischemic extremity to be addressed as soon as possible.<br /><STRONG>C</STRONG>: Restoration of alignment alleviates kinking of vasculature and may improve perfusion.<br /><STRONG>D</STRONG>: In patients with multiple injuries, competing priorities for treatment may delay diagnosis of extremity vascular injury. Early vascular assessment minimizes ischemic time.<br /><STRONG>E</STRONG>: Peripheral nerve deficits are not sensitive predictors for failure of functional limb salvage, but it is important to document neurologic findings and factor their presence into decision making.<br /><STRONG>F</STRONG>: Assess factors associated with poor outcome for the mangled extremity, particularly in the context of other injuries or ongoing hemorrhage from the extremity or other sources.<br /><STRONG>G</STRONG>: For hemodynamically stable patients, CTA characterizes the location and extent of vascular injury. If CTA is not available, standard contrast arteriography may be needed, but can often be performed in the operating room, particularly if a hybrid operating suite is available.<br /><STRONG>H</STRONG>: Intraluminal shunts temporarily restore distal perfusion and allow ongoing patient evaluation or restoration of bony alignment. Once the shunt is placed, distal pulses should be documented.<br /><STRONG>I</STRONG>: Assessment of systemic, and extremity skeletal, soft tissue, nerve and vascular factors are weighed against the overall patient injury burden. Limb salvage efforts should not be counter to efforts to sustain life and a good overall patient outcome.<br /><STRONG>J</STRONG>:It is important to include the patients and their family in the decision for limb salvage versus amputation at the earliest possible moment, whenever possible. If they desire to do so, consider bringing family into operating room to view the extremity, if the patient is stable.<br /><STRONG>K</STRONG>:Document the injury with photos placed into the medical record prior to undertaking amputation. The photos may also help the patient and his/her family understand the need for amputation.​</div><div class=\"graphic_footnotes\">OR: operating room; CTA: computed tomographic angiography.</div><div class=\"graphic_reference\">From: Scalea TM, DuBose J, Moore, E, et al. Western Trauma Association critical decisions in trauma: Management of the mangled extremity. J Trauma Acute Care Surg 2012; 72:86. DOI: <a href=\"http://journals.lww.com/jtrauma/pages/articleviewer.aspx?year=2012&amp;issue=01000&amp;article=00012&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/TA.0b013e318241ed70</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2012 American Association for the Surgery of Trauma. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 95992 Version 3.0</div></div></div>"},"95993":{"type":"graphic_table","displayName":"Yellow papules and pustules","title":"Differential diagnosis of yellow papules and pustules on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of yellow papules and pustules on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Candidiasis</p> <p>Folliculitis</p> <p>Furunculosis</p> <p>Hidradenitis suppurativa</p> Molluscum contagiosum</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Keratosis pilaris</p> <p>Epidermal cyst</p> <p>Bullous impetigo</p> Vestibular mucinous cyst</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Fox Fordyce disease</p> <p>Pustular psoriasis</p> <p>Subcorneal pustular dermatosis</p> Condyloma lata</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95993 Version 1.0</div></div></div>"},"95995":{"type":"graphic_table","displayName":"Vulvar vesicles and bullae","title":"Differential diagnosis of vesicles and bullae on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of vesicles and bullae on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Herpes simplex</p> <p>Herpes zoster</p> <p>Impetigo</p> Contact dermatitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Pemphigoid</p> <p>Pemphigoid gestationis</p> <p>Pemphigus</p> <p>Cicatricial pemphigoid</p> Stevens-Johnson syndrome</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Fixed drug eruption</p> <p>Hailey-Hailey disease</p> <p>Lymphangioma/lymphangiectasia</p> <p>Bullous lichen sclerosus</p> <p>Toxic epidermal necrolysis</p> <p>Linear IgA disease</p> <p>Epidermolysis bullosa</p> Acquisita</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 95995 Version 2.0</div></div></div>"},"95996":{"type":"graphic_table","displayName":"Skin-colored papules nodules and plaques","title":"Differential diagnosis of skin-colored papules, nodules, and plaques on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of skin-colored papules, nodules, and plaques on the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Vulvar papillomatosis</p> <p>Skin tag</p> <p>Human papillomavirus wart</p> <p>Molluscum contagiosum</p> <p>Lichen simplex</p> <p>Scar</p> <p>Vulvar intraepithelial neoplasia (usual and differentiated)</p> Epidermal cyst</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Fibroepithelial polyp</p> <p>Bartholin duct cyst</p> <p>Intradermal melanocytic nevus</p> <p>Lipoma</p> <p>Vestibular mucinous cyst</p> Squamous cell carcinoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Syringoma</p> <p>Basal cell carcinoma</p> <p>Hidradenoma papilliferum</p> <p>Fox Fordyce disease</p> <p>Neurofibroma</p> Condyloma lata</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 95996 Version 1.0</div></div></div>"}};